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BACKGROUND Policymakers believe mammography uptake is declining; whether there is a 
decrease, and in whom is not known. There is a wealth of research focussed on single 
predictors of uptake in mammography such as socioeconomic status or ethnicity. However, 
there are limited papers investigating global predictors, particularly with an international 
focus. 
AIM The thesis aims to: identify predictors of (1) mammography uptake worldwide and (2) 
in South-West London; ascertain if patterns of attendance have changed and if so, in whom, 
and; commence questionnaire development to determine influencers of uptake. 
METHODS A systematic search was conducted on six databases in 2016. Two reviewers 
independently examined the articles using pre-defined inclusion criteria. Random-effects 
meta-analyses and sub-group meta-analyses were conducted. Mixed-effects logistic models 
analysed dichotomised cohort data. The questionnaire was developed with a patient and 
public representative prior to testing. Thirteen cognitive interviews were conducted and 
analysed using thematic and content analysis. 
RESULTS Data from 91 studies met the systematic review inclusion criteria. Marital status, 
smoking status, insurance status and number of chronic conditions or primary care visits 
were found to be statistically associated with uptake. Ethnicity, age, socioeconomic status, 
income, education, housing tenure and obesity were not significantly associated. The 
database provided attendance information from 406,015 women. Overall, older women had 
lower odds of attending mammography than younger women. Odds of attending appeared 
to increase with affluence, disability or a previous recall and were lower in minority ethnic 
women compared with White women. Few concerns were identified with the questionnaire 
items. Minor alterations to questions were made in response to data where appropriate. 
CONCLUSION Many variable factors influence uptake. The generalisability of the results to a 
UK population needs establishing. The questionnaire needs further development to establish 
validity before establishing which women make informed decisions. Future research should 
evaluate if personalised information, in line with risk status and other known factors 
associated with uptake, would be beneficial for screening programmes. 
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Chapter 1: Background 
Introduction 
This chapter discusses breast cancer (BC) from a public health perspective and 
describes its risk factors. It explains what health screening is, with particular focus on 
the use of mammography for breast cancer screening (BCS). Predictors of breast 
screening uptake and patterns of attendance are described. Finally, informed choice 
(IC) is examined and discussed with its relevance to screening. 
1.1 Breast cancer 
1.1.1 Epidemiology 
Breast cancer (BC) is the most common cancer in women worldwide with 1.7 million 
new cases diagnosed worldwide in 2012 (1). BC accounts for 18% of all female 
cancers globally (2). BC is the most common malignancy in women in the UK and the 
second most common cause of death from cancer following lung cancer (3, 4). 
There were 55,222 new cases of BC diagnosed in the UK in 2014 which accounted for 
11.39% of all new cancer diagnoses (male and female) (5). In the UK, the incidence 
of BC increased from 66.1 per 100,000 in 1971 to 125.7 per 100,000 in 2010, an 
increase of 90.1% over 39 years, as shown in Figure 1 (4, 6). The gradual increase is 
thought to be related to the introduction of the BCS programme in 1987 and the 
increased prevalence of BC risk factors (7). 
In the UK, a woman’s lifetime risk of developing BC is 1 in 8, and the majority of 
diagnoses (81%) occur in women over the age of 50 (3). Since a peak mortality rate 
in 1986 at 41.7 per 100,000 women, BC death rates have fallen to 24.4 per 100,000 
women in 2011 (all rates are age-adjusted) (4). This reduction in deaths could be 
related to the introduction of BCS, improved treatment options, overdiagnosis or a 




Figure 1. Breast Cancer incidence and mortality rates in England, 1971-2011. Data are taken from 2011 Office for 
National Statistics release, (4). 
1.1.2 Risk Factors 
Understanding the risk factors for BC is important. Identifying which women are at 
higher risk of developing the disease is useful to target public health interventions. 
Increased awareness of these risk factors and their implications is hoped to help, with 
the aid of BCS, diagnose BC earlier and subsequently reduce adverse outcomes such 
as mortality. A number of risk factors have been well reported in the literature as 
discussed below (10-12). 
1.1.2.1 Non-modifiable risk factors 
Non-modifiable risk factors are those factors that cannot be changed. BC risk differs 
by location, with incidence and mortality varying about five-fold between 
populations globally, for instance between North America and China (13, 14). There 
























Breast cancer incidence and mortality rates, women, 
England, 1971–2011 Incidence Mortality
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as seen in Figure 2 (15). Mortality rates also vary globally (Figure 3) (15). High rates of 
mortality are present in countries with seemingly low prevalence of BC whilst the 
developed nations appear to have lower mortality rates (15). 
Among people migrating from low-risk countries to higher-risk countries, individual 
risk tends to increase and becomes similar to those from the new country (13). This 
also suggests that BC risk is related to lifestyle factors. 
 





Figure 3. Estimated Breast Cancer Mortality Worldwide, 2012 (15). 
 Historically, White women have a higher risk of BC (16).  However, in 2012 the rates 
for White and Black African-American women converged in the USA (17). Incidence 
rates have increased among Asian and Pacific Islander women and have remained 
stable amongst non-Hispanic White and White women (17). However, African 
American women still have poor prognosis for BC which may lead to increased rates 
of mortality (18) perhaps due to poor access of services or social stigma in obtaining 
help and treatment.  
Age is a well-known risk factor for developing BC (2, 13, 14) with peak BC incidence 
among those aged 75 to 79 years (19). Women presenting in this age range often 
have BCs that are slow growing and present with smaller tumour masses that may 
be easier to treat (20). 
Age at menarche, the first occurrence of menstruation, is a risk factor for BC. Women 
have an increased lifetime risk of BC if the onset of their first menstruation starts 
before 11 years of age (14). The older a woman is when she starts menstruating the 
lower her lifetime risk of BC (10, 13). For each one-year delay in the onset of 
menarche, the risk of developing BC decreases by 5%. A delay is particularly 
protective if menarche starts after 15 years of age compared with other ages (14, 
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21). Late menopause increases BC risk (10) by approximately 3% for each year of 
delayed start (13, 14, 22). 
Compared with nulliparous women, a woman who has one pregnancy to full-term 
has a 25% reduction in BC risk (10, 13). Additional pregnancies further reduce the risk 
(13). In general, risk of BC increases for women who are older at their first birth (10). 
One study estimated women having a first child before 18 years of age have one third 
the risk of those whose first birth is at 35 years or older (23). Another study compared 
women of different ages at their first birth with nulliparous women. They found if a 
woman is younger than 20 years at the birth of her first child she has a risk ratio (RR) 
of 0.72 (95% confidence interval [CI] 0.60, 0.87) and if a woman is 30 years or older 
she has a RR of 0.93 (0.79, 1.09) compared with nulliparous women (24). 
An evaluation of the links between breastfeeding and BC risk is provided in a pooled 
analysis which reported that the odds of developing BC were 31% lower in women 
who breastfed for one year compared with women who did not breastfeed, odds 
ratio (OR) 0.69 (0.50, 0.96) (25). A different study concluded that breastfeeding 
reduces BC risk by 33% if women have been breastfeeding for 25 months or more 
and has a larger protective effect for younger (13) and African-American women (25). 
A collaborative group conducting a reanalysis of previous data concluded the RR of 
BC is reduced by 4.3% (2.9, 5.8) for each year a woman breastfeeds in addition to a 
7.0% (5.0, 9.0) reduction for each birth (26). 
Family history is strongly associated with the risk of developing BC. However, the 
extent of risk varies depending on factors such as type of relative (e.g. sister, mother, 
grandmother), age of the relative when diagnosed, number of relatives diagnosed 
and the age of the individual (27). Women with a first-degree relative with BC have 
at least double the risk of developing BC themselves (2). Individuals with a relative 
diagnosed at a young age have a higher risk of BC than those with a relative diagnosed 
at an older age (11). 
Mammographic breast density has been frequently found to be a risk factor for BC 
(28, 29). Breast density is a measure of the ratio of fat to tissue in the breast, seen on 
a mammogram. In general, younger women tend to have more dense breasts. 
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Compared with women with a breast density of 10% or less, women with a density 
of 75% or more have higher odds of developing BC, OR of 4.7 (3.0-7.4) (29). Breast 
density is a strong predictor of BC risk, and is useful in the prediction of a woman’s 
risk of BC. 
1.1.2.2 Modifiable risk factors 
Modifiable risk factors are grouped as they are variables that can be altered with a 
subsequent increase or decrease in risk of developing the disease.  
Use of the oral combined-contraceptives is thought to increase BC risk (RR of 
developing BC 1.24 (1.15, 1.33), p<0.00001) (30). However, after ten years cessation 
of the contraceptive, risk of developing BC returns to baseline as if a woman had 
never taken the contraceptive (13). 
Many women opt for hormone replacement therapy (HRT) to reduce symptoms of 
the menopause. Evidence suggests use of exogenous female hormones increases the 
risk of developing BC. The Million Women Study concluded that current and recent 
users of HRT are at increased risk of BC (31). The magnitude of associated risk is 
substantially greater for oestrogen-progestogen types of HRT, RR of BC 2.00 (1.91, 
2.09) p<0.0001 compared with progesterone only HRT-type RR of BC 1.30 (1.22, 1.38) 
p<0.0001 (14). Colditz et al. (32) found a causal relationship in post-menopausal 
women between the use of female hormones such as oestrogens and increased BC 
risk. The magnitude of increase in BC risk per year of hormone use was comparable 
to that of delaying menopause for a year (32). Steinberg et al. (33) conducted a meta-
analysis of 16 papers that found a 30% increase in risk of BC after 15 years of 
oestrogen use post menopause, RR of BC 1.3 (1.2, 1.6), p<0.01 (33), compared with 
no HRT use. This was even more pronounced for those with a family history of BC, RR 
of 3.4 (2.0, 6.0) (33). 
Lifestyle is known to influence BC risk. Evidence indicates that modifiable lifestyle 
factors such as obesity, as measured by body mass index (BMI), diet and exercise, are 
risk factors for BC (11). These three risk factors can be interlinked. 
In post-menopausal women with the smallest waist-to-hip ratio the risk of 
developing BC was 34% lower than in women with the largest waist-to-hip ratio. This 
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association was found by pooling cohort data but not adjusting for BMI or weight. In 
pre-menopausal women however the waist-to-hip ratio was not found to have any 
significant effect on BC risk (34). In post-menopausal women, another study found a 
higher BMI is associated with increased BC risk (10).  
There is a general association between increased exercise and lower risk of BC (35, 
36). White women who report exercising (for at least 30 minutes a day three times a 
week) have a lower risk of BC than White women who do not exercise (37). This effect 
of exercise has been identified mainly in White women of European descent, for 
whom more data is available (38). In America, physical activity (counted as more than 
two hours per week for the previous year) has been linked to a reduction in BC risk 
for African American women. The odds of developing BC were 63% lower for African 
American women with high levels of activity compared to those with low levels, OR 
0.36 (0.16, 0.79) (39). 
Alcohol is classified as a carcinogen for BC by the International Agency for Research 
on Cancer (40, 41). Liu et al. found that compared with women who consume one to 
three alcoholic drinks per weekend, women who consume 10 to 15 alcoholic drinks 
per weekend had a RR of BC of 1.49 (no confidence intervals given), while women 
who drink 16 to 21 alcoholic beverages had a RR of 2.51, (no confidence intervals 
given) (42). This risk is linked to the total amount of alcohol consumed, not the type 
of alcoholic drink. Another study found that compared with non-drinkers, women 
consuming 35-44g of alcohol per day had a RR of BC of 1.32 (1.19, 1.45) and a RR of 
1.46 (1.33, 1.61) for those consuming ≥45g alcohol per day (43). Relative risk 
increases by 7.1% (5.5% to 8.7%) for every additional 10g of alcohol consumed daily 
(43). If this relationship is found to be causal, four percent of BC diagnoses could be 
attributed to alcohol in developed countries (43). 
Alcohol consumption and smoking are profoundly correlated; many studies do not 
account for the confounding of these exposures (44). When limited to analysis of only 
non-drinkers, there was no association found between smoking and BC (43). Other 
papers concluded similar results highlighting the lack of effect of smoking identified 
in the aetiology of BC (2).  
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However, a Canadian paper published in 2015 has found a link between active 
smoking and BC risk (45). Duration, intensity and cumulative exposure are all found 
to increase hazard ratios (HR) of BC development. Those who have been smoking for 
40 years have a HR of 1.57 (1.29, 1.92) compared to non-smokers. Women smoking 
40 cigarettes a day versus non-smokers have a HR of 1.21 (1.04, 1.40) and those with 
a 40 pack-year history vs zero have a HR of 1.19 (1.06, 1.13) (45). 
Some influencing factors can be interlinked and are often confounded with multiple 
different factors. For instance, ethnicity and geography could be interlinked or to 
some extent migration could be explained by personality type. However, for 
demonstration purposes the influencing factors have been presented in the figure 






Figure 4. Summary diagram of risk factors for BC (2, 10, 13, 14, 23, 25, 27-33, 35-39, 42, 44-46). The colours represent varying risk levels, factors shown in red are associated with increased risk 
of BC, those in green are associated with a reduction in risk and those in grey are associated with variable risks. Solid lines represent direct influencing factors. Dotted lines represent those that 
are linked to other influencing factors, for instance parity is a factor on its own but risk also increases with age at first birth.
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1.1.3 Risk prediction modelling 
An individual’s risk can be estimated using their personal information and comparing 
this to statistical averages from the population. A risk prediction model commonly 
uses demographic, lifestyle and personal health information to estimate the 
probability of an individual woman developing BC.  
Trials have begun to investigate the outcomes of predicting risk of BC and adopting 
a more personalised approach. However more work is required to understand how 
risk is understood and perceived by the public. The PROCAS study (Predicting Risk of 
Cancer at Screening) used the Tyrer-Cusick model to explore the effects of their risk 
knowledge on women participating in screening (47, 48). The major limitation of this 
study was that it only used women who attended screening and like with any study 
would therefore be biased in those who participated in the programme. 
Furthermore, due to space restrictions, the questionnaire for risk assessment did not 
collect information on female relatives without BC which can be an important factor 
in risk prediction. No harms were associated with providing women with their 10-
year risk estimate and most women were satisfied with the information provided 
however there was considerable variation in understanding (48). 
Women with high mammographic density were found to have higher risk of BC than 
women with predominantly fatty breasts. Measurement of density has changed 
dramatically in recent years with the advance of technology. However, visual 
assessment of mammographic density requires a skilled worker and is time 
consuming. Automated processes have also become available recently but there are 
concerns for their cost and reliability (49). For these reasons the use of 
mammographic density has never been widely adopted in everyday practice (47, 49). 
Perhaps if an automated system was developed it could be incorporated into the 
NHSBSP system. 
Popular prediction models include the Gail Model (50) and the Tyrer-Cusick (T-C) 
Model (10) which use the additive effect of many different risk factors from personal 
information and hormonal or reproductive factors to personal breast disease and 
family history to create an overarching risk estimate (11). Other risk prediction model 
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options include Claus, BOADICEA or BRCAPRO which do not include as many risk 
factors in their risk assessment and do not appear to perform as well with low 
observed-expected ratios (47). The T-C Model has been chosen for use within this 
thesis as it is the most consistently performing model (11, 46) and this choice of 
model is discussed further in the questionnaire development study section. 
Whilst these risk prediction models are not currently used in the NHSBSP screening 
programme, research is starting to investigate the effect this may have on 
identification of those at higher-than-average risk and for whom a preventative 
intervention or more intensive surveillance may be appropriate (51). This seems to 
be an interesting field for future research to enable them to be used effectively in 
screening programmes. 
1.2 Health screening  
Health screening is a public health tool in which seemingly healthy members of a pre-
defined population are asked questions or invited to complete a test to determine if 
they are at higher than average risk of having a disease/condition (52). Put simply by 
Zavon et al., ‘screening tests sort out apparently well persons who probably have a 
disease from those who probably do not’ [p. 349] and can identify individuals in the 
early or pre-symptomatic stage of the disease (53).  
The ‘Wilson and Jungner’ criteria were developed as fa result of their report for the 
World Health Organisation in 1968 and provided the first clear evidence and 
principles to underpin the practice of screening (52, 54). In the UK, these have since 
been extended to twenty component criteria with which to appraise the validity, 
viability, effectiveness and appropriateness of screening programmes including 
emergence of criteria to ensure informed choice (IC) and respect for patient 
autonomy (54). 
The classic screening criteria proposed by Wilson and Jungner (52) fall into four 
sections: the condition, the test, the intervention and the screening programme. 
They propose the condition should be an important health condition. There should 
also be an accepted treatment for patients with the disease with earlier treatment 
being more beneficial. This treatment should be acceptable to the population. For a 
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screening programme to be implemented there should be a recognisable early 
symptomatic stage and a suitable test or examination to detect this stage that is 
acceptable to the population and there should be an agreed policy on whom to treat 
as patients and the cost of case-finding should be economically balanced. 
There were 1.7 million new BC cases diagnosed worldwide in 2012 making it 
undeniable that BC is an important health condition (1). Whilst the examination and 
treatment appear to be acceptable to most of the population, BC mortality rates have 
not decreased as expected in locations where mammography screening is in place 
(55-57). Furthermore the influence mammography may have on mortality rates has 
likely decreased in-line with increasing efficacy of cancer therapies (58). Whilst 
mammography screening was implemented in review of the current evidence, 
further research has been conducted that may contradict previous thoughts, 
including on the debate about overdiagnosis which shall be discussed in greater 
detail below (58).  
These basic criteria have been further extended to include the requirement that the 
programme ensures informed choice (IC), confidentiality and respect for autonomy 
(52). There should be a defined target population and the programme should have 
quality assurance measures in place to maintain standards. The overall benefits of 
screening should outweigh the harm, some of which have been discussed in Section 
2.5, but this is a controversial matter and still considered debatable (59-61). Further 
work needs to investigate the effect of promoting IC in a screening programme, 
following the example set in Germany, particularly in respect to uptake rates (62).  
1.2.1 Breast Cancer Screening (BCS)  
The Breast Cancer Screening (BCS) programme was introduced in England in 1987 to 
aid the early detection of BC at a population level. It is a mass screening programme 
which aims to reduce mortality from BC by detecting and treating the disease earlier. 
Note, this BCS programme is not the same as the programme for those known to be 
at higher risk, such as women with previous breast disease history or familial BC.  
Women in the UK who are registered with a GP are invited by appointment letter, 
accompanied by a patient-information leaflet which explains the positive outcomes 
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of breast screening and potential harms (63). Results from the mammogram are 
posted to the woman’s home and copied to the GP within two weeks.  
BCS consists of an initial x-ray (i.e. mammogram) taken of each breast. To obtain a 
clear image two views (angles) are taken whilst the breast tissue is compressed 
between two plates. At this first appointment 96% of people receive a negative 
result, indicating no BC is observed, and are not contacted for another three years. 
Four percent of women receive a positive result and are offered further tests and 
procedures to determine whether they have BC. This second set of tests and 
procedures includes either a diagnostic mammogram, ultrasound or guided needle 
biopsy with/without fine needle aspiration. These phases are shown in Figure 5 
below.  
When a woman attends breast screening, there are four possible test results from 
the mammogram: true positive (TP), true negative (TN), false positive (FP) and false 
negative (FN) and these are shown below in Table 2. But there are other outcomes of 
having a mammogram, e.g. positioning or technical failures resulting in recall without 
a result. 
 Approximately four percent of women who attend breast screening are recalled for 
repeat mammography and possible biopsy (64). 
Table 1. Outcome of Screening Tests 
 The “Truth” 
Diseased Not Diseased 
Test Result Positive True Positive (TP) False Positive (FP) 









Figure 5. Sieve and sort process in National Health Service Breast Screening Programme. Eligible population 
consists of women registered with a GP in the UK and aged between 50 and 70 (47 and 73 in some areas). The 
invited population may be smaller than those eligible due to poor records of addresses and contact details (65). 
Coverage = eligible population/whole population X100. Uptake = attended population/eligible population X 100 




A positive result is discussed at multi-disciplinary team meetings to determine if the 
recall is due to a BC and if the patient requires treatment. These meetings use a 
combination of opinions from the physician assessment, mammogram and biopsy 
results to ensure maximum efficiency at discovering all potential BCs. If all three 
indicate cancer, there is a 98-99% likelihood that this is a true BC (64). However, of 
the women recalled, 3.3% are FP results equating to approximately 63,000 women 
annually (67). Alongside the inconvenience and disruption, this has psychological 
consequences such as anxiety, even for those who are given the “all clear” at recall 
(67). For some women, this anxiety about test results persists for up to 12 months 
(68).  
The screening age range in the UK is currently 50-70 years of age but is being 
extended to 47-73 in some regions as part of the age extension trial (NCT01081288). 
A previous ‘Age Trial’, initiated in 1991, evaluated annual screening for women from 
40 years of age until 47-48 years prior to the population screening programme (69). 
The trial did not lead to a significant reduction in mortality in those who attended, 
RR of mortality 0.83 (0.66, 1.04), p=0.11 (65). The current extension of the screening 
age range in the UK is controversial with little evidence promoting its adoption or 
verifying that it is beneficial to screen these additional age ranges, particularly within 
the younger age group (70). 
The popularity paradox indicates ‘the greater the harm through overdiagnosis and 
overtreatment from screening, the more people there are who believe they owe their 
health, or even their life, to the programme’ (p. 68, (54)) and of course those who 
believe they owe their life to screening are avid supporters of it. Because of this, it 
will be extremely difficult to reverse offering population screening to the additional 
age groups even if there proves to be little evidence of benefit (54, 70). 
The ways in which screening programmes are delivered vary around the world, as 
was shown in Chapter 1. Many countries screen women from a younger age and 
screen them more frequently, commonly biennially. For example, Canada screens 
women annually between the ages of 40 and 49 and subsequently biennially for 
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those aged 50 or over.  Many countries, including the United States, begin screening 
women for breast cancer at 40 years of age. This highlights a key difference between 
national programmes. This may be because risk varies worldwide, or it could be 
because there is no clear evidence for an effective regime for BCS. 
1.2.2 The debate about health screening - advantages and limitations  
As with any healthcare procedure there are advantages and limitations. Much of the 
evidence used in the BCS debate relies on randomised controlled trials that were 
conducted decades ago. These trials may not reflect the current screening process 
because they preceded the treatment and healthcare advances which affect BC 
mortality and outcomes today. The benefit observed previously for BCS may be more 
limited now (67, 71). 
1.2.2.1 Early detection 
Screening is beneficial in many ways, its biggest achievement being that it can detect 
BC before symptoms occur. BCS ultimately aims to reduce mortality (72). It is known 
that identifying BC at this early stage improves chances of successful treatment and 
remission (73).  
A meta-analysis of three randomised trials (excluding the Edinburgh trial due to 
issues with reliability (68, 74)) comparing invited women against control women 
calculated an overall RR of 0.80 (0.73, 0.89) for developing BC (67). However, other 
authors have arrived at different risk estimates and conclusions (75). Whether or not 
benefits outweigh the harm is disputed, as there are a number of harms and negative 
aspects to BCS that will be discussed below. In an update of the 2006 Cochrane 
Review, the three trials were re-analysed and did not show a reduction in BC 
mortality at 13 years RR of 0.90 (0.79, 1.02) (76). 
1.2.2.2 Inequalities 
The UK National Health Service Breast Screening Programme (NHSBSP) provides 
nationwide BCS that is free at the point of care. It does this with the aim of reducing 
health inequalities so that every eligible woman in the appropriate age categories 
who is registered with a GP and who wants to be screened, can be screened. 
However, not everyone who wants to attend can attend screening. Some women still 
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struggle to attend due to financial, emotional, accessibility or language barriers (75). 
This can contribute to and exacerbate health inequalities as women who attend 
screening are more likely to take an active role in disease prevention and are 
generally healthier than those who do not (77, 78). This is termed the “healthy 
screenee effect” and is known to make screening appear more beneficial than it 
appears (77).  
Inequalities are present within the NHS healthcare system and early detection of BC 
is no exception (79). Inequalities exist and show an inverse association between 
mortality and social class as discussed in many health inequality papers but especially 
by Marmot et al. (80). Uptake rates in different types of women are discussed more 
below. 
A lower incidence of BC is reported in lower socioeconomic status (SES) groups as 
shown in Figure 6 yet they have a higher rate of mortality (81). The same pattern is 
found in Black and Asian minority ethnic women (82). Despite a lower incidence of 
BC, minority ethnic women have a higher rate of mortality (82, 83). This could be due 





Figure 6.Variation in deprivation status with age at diagnosis for all women diagnosed with breast cancer in 
England, 2007. Source taken from (81).  
 
Decreasing health inequalities is a matter of justice. Marmot recommends not solely 
focussing on the least affluent but increasing the health of all, with a focus on those 
with most need (84). 
1.2.2.3 Overdiagnosis 
Screening sometimes finds BCs that would never have caused a woman harm during 
her life. This is termed overdiagnosis and turns people into patients unnecessarily 
and may lead to treatments that do more harm than good for the individual. 
Overdiagnosis must not be confused with false positive results. 
Overdiagnosis within BCS may be due to one of two things, either the abnormal cells 
meet the criteria for a cancer diagnosis but never progresses (or even regresses 
contrary to expectation), or the cancer progresses slowly enough that the woman 
dies of other causes before symptoms appear as seen below in Figure 8 (85). Thus, 
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even a rapidly growing tumour may be termed overdiagnosed if the woman is near 
the end of her life. With overdiagnosed BCs the diagnosis is correct in that the tumour 
mass, histology and symptoms do reach the criteria for cancer. The challenge is that 
not all BCs end up being detrimental to health and clinicians cannot know at the time 
of diagnosis which tumours are overdiagnosed and subsequently all cancers are 
treated as if lethal (85). 
The diagram below summarises the proportions of events with and without 
screening. This information is not found in the screening leaflet (72). It shows that 
mammographic screening has only small population benefit overall (one fewer 
death) and could instead be risky for the individual (three extra women are treated). 
Furthermore, three women are unaffected by the BC they develop and are not 
treated for in the 200 women who were not screened. 
 
Figure 7. Outcomes of Breast Cancer Screening. Source from (72). 
Rates of overdiagnosis are difficult to estimate and the literature still provides 
conflicting numbers (86). Duffy et al. estimated that for every eleven cases 
diagnosed, two lives were saved and one woman was overdiagnosed (87). The 
Independent UK Panel on Breast Cancer Screening estimated overdiagnosis to be 
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19.0% (15.2, 22.7). This suggested that for those invited for screening over a period 
of 20 years since the age of 50, one life would be saved for every three women 
overdiagnosed (67, 71).  
Arguably, overdiagnosis is the most important harm associated with early detection 
of cancer. As per the NICE guidelines, after a diagnosis of BC the patient is 
commenced on a structured regime of chemotherapy, radiotherapy, endocrine 
therapy and/or surgery depending on the type of BC diagnosed (88). This means 
overdiagnosis can result in overtreatment. This treatment phase is commonly 
accompanied with anxiety which can have significant negative and long-lasting effect 
(85). The harms have become a common issue of debate, ‘the impact is long-lasting 
and affects patients’ sense of well-being, ability to get health insurance, physical 
health and their life expectancy’(85). 
 
Figure 8. Heterogeneity of cancer progression from diagnosis. 'Fast' indicates a fast-growing cancer that often 
quickly leads to symptoms and death. This type is often not detected by mammography screening and is classed 
as ‘interval’ cancer (detected between screening rounds) as seen in length time bias (54). The ‘slow’ arrow 
represents a cancer that leads to symptoms and death but only after many years. The ‘very slow’ is a malignancy 
that never causes a problem because the woman will die of a different reason before this type of cancer is large 
enough to cause symptoms. The ‘non-progressive’ type represents cellular abnormalities that meet pathological 
‘cancer’ definition but never create any symptoms and may even regress back to normality (dotted line). The ‘very 
slow’ and ‘non-progressive’ cancers are termed overdiagnosed cancers. Figure sourced from (85). 
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BCS in the UK was set up shortly after publication of the Forrest Report in 1986. This 
emphasised the need in the UK for BCS (89). This report included evidence from two 
trials at the time (New York and Two-County) which did not fully consider 
overdiagnosis (59). 
A 2005 review by Moss and colleagues investigated overdiagnosis based on data from 
global trials (90). Gotzsche et al. critiques this review claiming it is limited by its 
inclusion of data from studies that were methodologically flawed (59). Duffy et al. 
published five papers between 2003 and 2006 analysing the available data and found 
little or no evidence of overdiagnosis. Rates ranged from 1% in the Two-County trial 
and Gothenburg (8, 91) to 5% in Copenhagen and Florence (9, 92) and 4% in an 
analysis of diagnoses at the incident screen (93). They concluded that these estimates 
are ‘subject to considerable uncertainty’ and that more research is required to 
investigate a more precise estimate of how much overdiagnosis occurs (8). However, 
more recently Duffy et al. have analysed the Swedish Two County Trial of 55,985 
women and argue that at twenty years post screening, the number of lives saved 
outnumbers the number of cases overdiagnosed at 0.88% and 0.43% respectively 
(87) 
Conversely, Gotzsche et al. has published studies showing evidence of overdiagnosis 
in the region of 30% (59, 94).  For every 2000 women invited for BCS over ten years, 
it is estimated that one will have her life prolonged by treatment, but ten healthy 
women will be treated unnecessarily (94). This can be translated into: one out of 
every three BCs detected in a mass screening programme will be overdiagnosed (95). 
A systematic review published in 2009 suggests rates of 52% overdiagnosis in BCS 
(95). A key limitation of this review by Jorgensen and Gotzsche is the limited sources 
examined; the researchers only searched PubMed and this might not necessarily be 
exhaustive. 
The Marmot Review states that BCS reduces deaths but that some overdiagnosis 
occurs, suggesting that it is in the region of ‘one BC death … prevented for every three 
overdiagnosed cases identified and treated’ (96). 
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The Malmö trial was randomised at the individual level, contained 235,000 
participants and was conducted for longer than any other mammography trial. The 
oldest cohorts were not screened and remained as controls throughout the follow-
up period. This provides a reliable control group which is unusual for screening trials. 
Zackrisson et al. indicate, using the Malmö trial data, that there is a 10% rate of 
overdiagnosis found (97).  
Similarly in the UK, as shown in Figure 9, the observed incidence of BCs diagnosed in 
the 50-64 year age group was found to increase after the introduction of screening 
of this group. Gotzsche et al. found the same occurred for the 65-70 year age group 
however this is not shown graphically here (59). This evidence cannot reliably 
discriminate between substantial overdiagnosis or an increase in the incidence of 
breast cancers making them detectable in older women. 
 
Figure 9. Incidence of BC per 100,000 women in the UK by age group. Dashed lines: expected incidence without 
screening. Figure by Gotzsche et al. (59, 95). 
The pattern of increasing BC incidence found in a setting of stable death rates (Figure 
10) and no change in overall mortality reduction is suggestive of overdiagnosis (85). 
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Nevertheless, as the differing systematic reviews suggest, there is no current 
consensus about how much BC overdiagnosis occurs as a result of screening (93). 
 
Figure 10. Incidence of BC in the setting of stable death rates per 100,000 population. Figure sourced from (85). 
1.2.2.4 Pain and psychological impact 
The invitation to mammography that each woman receives briefly mentions that 
‘some women experience pain’. It is important to note that this pain is cited as a 
reason for some women to delay, defer or cancel reattendance (63, 94, 96, 98).  
 As stated above, approximately 4% of women are recalled for repeat mammography 
and possible further investigation such as biopsy. Seventy percent of these women 
will have further imaging and 30% a biopsy, though only 20% of these recalled 
women will eventually have a cancer detected (96). This recall process coupled with 
further, somewhat intrusive, procedures can also cause psychological distress which 
can last for up to 12 months (96).  
Brett et al. found that of women who were recalled for further investigation, 
significant anxiety and adverse psychological impact remains at the three-yearly 
recall. The risk of women experiencing a psychological consequence at one month 
before their recall screen was 107% higher for women who underwent a surgical 
biopsy compared with those who did not, RR 2.07 (1.22, 3.52), p=0.014 (99). 
A UK review in 2012 found that compared to women receiving a negative result, 
women with a false-positive result had a statistically significant reduced likelihood 
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(RR 0.97 (0.96, 0.98)) of returning for further screening rounds as a result of negative 
psychological impact (100). 
In 2016 a review was written to update the US Preventative Task Force (USPSTF) 
recommendations by Nelson et al. (101). This review incorporated four systematic 
reviews and ten observational studies examining the psychological effects of 
screening. Results show that those who had a negative result which was clearly 
communicated to them exhibited minimal anxiety, but those who were recalled 
without clear communication had longer-lasting anxiety and distress (101). It is of 
further concern that although they are not individually possible to identify in 
advance, some of the women undergoing these follow-on tests and treatments will 
have an overdiagnosed cancer and will never obtain benefit from the recall. 
1.2.2.5 Bias 
Any screening programme will have biases. Lead time bias is where cancers are 
detected at an earlier time point, although no treatment benefit is experienced. 
Length time bias is where slow growing, less dangerous cancers are more likely to be 
detected than fast, aggressive tumours due to the intervals between screenings. 
These biases can skew the evidence on the performance of screening programmes 
to suggest more ‘favourable’ results when analysing survival post diagnosis. These 
biases in addition to the “healthy screenee” bias previously described make 




Figure 11. Length time bias. Source adapted from (54). 
 
Figure 12. Lead time bias. Source adapted from (54). 
Additionally, the “popularity paradox” is recognised where the benefits of screening 
are more apparent than the harms. For example, a woman who has a BC detected by 
her mammography screen is likely to have a slower-growing, less-aggressive tumour 
(length time bias). These cancers are more likely to be easy to treat and the woman 
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and her family and friends will notice that she may experience a longer period in 
remission. The woman may then feel, perhaps mistakenly, that she owes her life to 
screening and would thus advocate BCS more strongly to the women in her social 
circle. In reality the tumour that was detected and treated may not have ever caused 
symptoms or caused her harm (85). 
Every public criticism of screening has to be countered with ever more 
positive assertions in order that public confidence is not shaken (102).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
In summary, the decision about whether or not to be screened remains a balancing 
act for each woman, balancing competing conflicting priorities with incomplete 
information. On an individual level, a woman attending screening will not know when 
or whether she has been overdiagnosed and overtreated. Equally if she did not 
attend she will not know whether she would die from a cancer that could have been 
detected earlier by screening, and therefore treated. Problems with this approach 
are discussed later in the section titled Informed Choice (IC). 
In my opinion it is more important to focus on improving knowledge mobilisation and 
transparency of screening information in order to obtain IC from women invited to 
attend. Ultimately, ensuring IC from women will take more effort than providing an 
information leaflet. However, this approach could lead to a personalised approach to 
BCS rather than the “one size fits all” style we have adopted currently (103). For this 
to be implemented more research is required to evaluate who currently attends and 
who does not, who makes an IC now, and whether making an IC influences 
attendance at screening. From these results we can then decide on next steps and 
implementation into personalised practice.  
1.3 Uptake  
1.3.1 Health behaviour theory 
One of the most popular theories used when researching predictors of health 
behaviour (including screening uptake and smoking cessation) is the theory of 
planned behaviour (TPB), seen below in Figure 13. This is an extension of the theory 
of reasoned action (TRA) and attempts to account for personal behaviours. These 
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theories have been used to explore behaviours such as binge drinking, participating 
in more exercise and other screening behaviours (104-107). 
A central component of the theory is the intention to perform the behaviour (as 
discussed below, this is a strong predictor of uptake). This idea that a behaviour 
depends on motivation (intention) and ability (behavioural control) is not new and is 
seen throughout the literature investigating predictors of uptake (108). However, 
this theory relies on the behaviour being rational which is not always thought to be 
the case (109). 
 
  
Figure 13. Theory of Planned Behaviour (TPB). Source recreated from (110). 
The health belief model (HBM), shown below in Figure 14, indicates a health-related 
action relies upon three types of factors which include individual perception, 
modifying factors and likelihood of action (111). The HBM proposes that an individual 
needs to perceive a threat to calculate benefits versus costs involved in participating. 
The HBM also considers that this perception of a threat is dependent on individual 
factors such as demographics, psychosocial influencers and the media, and/or social 
pressure for action or inaction (111). However, the HBM fails to account for self-
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efficacy or whether the individual perceives themselves able to participate in their 
chosen behaviour, and this could be a key limitation of the model.  
 
Figure 14. Health Belief Model (HBM). Source adapted from (112). 
The main behavioural theories incorporate perspectives related to biomedical, 
behavioural, communication, cognition and self-regulation. Each perspective is a 
complex combination and dynamic phenomenon that not only relates to the health 
system and behaviour under consideration but also to the socio-economic and 
demographic contexts each woman is in. 
The HBM bases health behaviour change as a rational appraisal of the balance 
between barriers and benefits to action. Although not explicitly stated, it assumes 
that variables are not moderated by each other and have an additive effect. The HBM 
also assumes that variables remain unmoderated by behavioural intention (113). 
Nevertheless, each model has its strengths and limitations.  
The contributing factors of attendance 
Evidence suggests that non-attendance is not uniformly distributed among the 
eligible population (114). Attendance at screening is an individual’s decision 
(behavioural) which is affected by the accessibility of the service (structural) and by 
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a woman’s immediate surroundings (societal) (115). These factors indicate where 
inequalities in uptake may exist. 
A woman must consider a wide variety of influences on her decision to attend 
mammography. These are discussed further in the sections below. These influences 
include social, psychological and demographic factors that combine into a 
complicated network. Some influences may not manifest themselves as conscious 
decisions and may subliminally sway a woman’s decision or likelihood of 
participating. Variables which have been associated with screening attendance can 
be grouped into a number of categories: 1) socio-demographic characteristics; 2) 
personal health status and history; 3) other health behaviour and use of medical 
services; 4) beliefs, attitudes and knowledge about cancer and screening; 5) intention 
to participate; 6) accessibility and logistics; and 7) social influences and support (115). 
1.3.2 Sociodemographics 
Age has been found to relate to uptake in many studies, with increasing age 
associated with lower uptake (75, 116-123). In 2000, Edwards et al. researched 
factors affecting attendance in a Welsh cohort of women. From a sample of 1,604 
women 16% of those aged 65-69 years attended screening, 6% of those aged 
between 70 and 79 and only 3% of those aged over 80 years attended BCS (118). 
Whilst women over 70 years are not invited to the organised screening programme 
in the UK, they are still encouraged to attend BCS if they suspect a BC but this trend 
needs caution as it might not be generalisable to the UK organised screening 
population. This trend is seen outside the UK. In Lebanon, trends in mammography 
utilisation were studied between 2005 and 2013 and this study found a consistent 
trend. Women aged 50-59 attended most frequently, whilst older women over 60 




Figure 15. Ever-utilisation of screening mammography among women surveyed in Lebanon between 2005 and 
2013. Uptake shown by age group. Source taken from (123). 
An Italian study found that 57.4% of the younger sample attended mammography 
every two years (as recommended by Italian guidelines) compared with only 38.1% 
of those aged between 65 and 69 years (124). 
Lower educational background is also associated with lower uptake (117, 122, 124-
127). A meta-analysis of thirteen studies found the odds of attending were 61% 
higher among women with higher levels of education than those with lower levels, 
OR 1.61 (1.36-1.91), p<0.0001 (127). In Brazil, illiteracy is associated with lower 
uptake; women who are illiterate have an RR for attendance of 0.77 (0.67, 0.90) 
compared with women who were literate (126). This shows that the phenomenon 
appears to be operating across more than one culture or country. 
Aro et al. reported odds of attending that were 91% higher for Finnish women with 
a spouse compared with those without, OR 1.91 (1.51, 2.40), p<0.001 (125). This 
sample was and similar to the Swedish study discussed below which found similar 
results but only had 50% response rate which could indicate an issue with 
generalisability.  A secondary data analysis in Sweden found that when compared 
with women who were married or cohabiting, the odds of not attending BCS were 
significantly higher in women who were single/divorced/separated, OR 2.14 (1.56, 
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2.94) (128). This association between marital status and BCS attendance appears 
consistent worldwide and across study types (116, 123, 129). 
The data for uptake in women with high incomes is difficult to ascertain. If these 
women attend, they are more likely to attend privately either by paying directly or 
through insurance policies which means that the data are not so well recorded as 
part of national or state systems (125). A large study in Australia concluded that late 
or lapsed attendance in the national programme was associated with health 
insurance coverage and higher income (130). It is difficult to ascertain whether those 
women did or did not attend privately as the data are sporadic. In general, and after 
consideration of private screening attendance, studies concluded that those with 
lower income attend screening less (122, 131). If the lower income women do not 
attend the national programme, it is unlikely they would obtain screening elsewhere. 
This lower attendance could be linked to societal influencing factors such as access 
and logistical means of attendance which I discuss in a later section. However, in 
Switzerland the socioeconomic inequality of mammography practice in agreement 
with recommendations has lessened.  The difference between highest and lowest 
income groups here has reduced from 27 percentage points in 1998 to 14 points in 
2012 (132). 
In countries where the screening programme incurs out-of-pocket expenses, those 
with more disposable income will be more able to attend. In other situations, affluent 
women with insurance policies will have BCS access, whereas women with lower 
incomes or from more disadvantaged backgrounds will not be covered by insurance 
for BCS and will be less able to attend. 
Many authors report that women who attend screening are likely to come from more 
affluent areas (79, 122, 133-135). Likewise, studies state that areas of material 
deprivation exhibit less participation (136). A study by Aarts et al. in The Netherlands 
found the odds of attending BCS were 50% higher in the intermediate SES group 
compared with the lower SES women, OR 1.5 (1.5, 1.6) and 80% higher in the higher 
SES group compared with the lower SES women, OR 1.8 (1.7, 1.8) (79). However, 
despite a longitudinal analysis of almost 20 years, the research was only conducted 
on one city which may not be generalisable to the whole country. However, it is 
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encouraging that the trends appear consistent across time periods, countries and 
types of analyses. A large Italian study of over 15,000 women reported odds of 
attending are 77% higher for women of intermediate SES compared with those of 
low SES, OR 1.77 (1.55, 2.03) (124). 
In the UK low uptake rates have been observed among minority-ethnic women (122, 
137). This could be attributed to language problems such as low levels of literacy or 
English fluency, cultural values and beliefs, lack of local access to services and/or poor 
attitudes of GPs as discussed in the literature (137-139). However, the disparity in 
uptake rates, particularly observed in the UK between Asians and non-Asians, is 
narrowing. In round one of the NHSBSP (1989-1992) uptake was 60.8% vs. 75.4% and 
in round five (2001-2004) uptake was 66.8 vs. 77.7% respectively (140). Despite this, 
figures remain low for Muslims (51% in rounds one and five) and other religious 
minorities (139). After adjustments for age and deprivation, uptake remains lower 
for all minority ethnic subgroups compared to White British women (140). In London 
specifically, attendance was lowest for Black women OR 0.47 (0.53-0.56) after 
adjustment for sociodemographics (135). In studies assessing the sole effect of 
ethnicity on behaviours such as uptake it is important, like conducted in this study, 
to have controlled for confounding factors such as socio-economic status and 
geographical variation. However, it does mean that the results of this study need 
consideration whether they are generalisable to the rest of the UK because of the 
specific nature of the analysis. Other evidence suggests foreign-born women 
(migrants) are less likely to attend national screening programmes in the UK (131) 
and so it appears appropriate to consider the results generalisable. Similar results 
have been shown in Sweden, Australia and in the United States (75, 141, 142). 
1.3.3 Health status and history 
The influence of family history of BC on mammography uptake is difficult to 
determine. In some women it deters attendance and in others it encourages uptake 
(119). Family history as a predictor must therefore be interlinked with other 
personality traits such as anxiety, perceived benefits or risks, current health status, 
and ability to access the programme. 
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Previous false positive results are frequently found to be predictors of lower 
reattendance (116, 138). However sometimes this difference can be minimal. In a 
database analysis of over 250,000 women from the UK national screening service, 
ninety-two percent (91.3%, 92.8%) of women with a previous false positive result 
attended subsequent screens versus 92.4% (92.3%, 92.5%) of those with a previous 
normal result (143). These results would be considered reliable as no self-report 
information was used, no study participation biases were introduced and a database 
analysis approach was adopted. 
Rates of reattendance may also be determined by how invasive a re-test was. For 
instance, for reattendance in one study the odds of re-attending were 60% lower for 
women with an open biopsy (+/- needle sampling) compared with women with a 
previous normal screening examination, OR 0.40 (0.25, 0.66), p<0.001 (143). In 
addition the odds for reattendance were lower in all other types of re-testing 
compared with women with previous normal results, for women who had had a 
needle sample only was OR 0.88 (0.84, 0.92), p<0.001, women with no tissue 
sampling had an OR for reattendance of OR 0.99 (0.98, 0.99), p<0.001 compared to 
women with a previous normal result (143). This suggests a dose-response deterrent 
effect may be involved. 
Women with a good current state of health are more likely to attend BCS than those 
reporting poor health (77, 144). A Finnish study of almost a 1,000 women found odds 
of attending BCS were 31% lower in women reporting serious illness compared with 
women with no serious illness, OR 0.69 (0.54, 0.89) p<0.01 (125). A meta-analysis, 
with no geographical restriction, supports this finding as it reported 46% reduced 
odds of screening in those with serious mental illness compared with women 
reporting no mental illness, OR 0.54 (0.45, 0.65), p<0.05 (145). This occurred despite 
increased cancer mortality in this vulnerable population (145-147). 
Nevertheless, a study among older women has found that SES and general health 
factors predict attendance at BCS better than physical and mental health or attitudes 
to health does (148). 
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1.3.4 Health service use 
The healthiest women in the population have been found to be those who tend to 
have a high motivation for health and who are therefore often the attenders at BCS 
(77). Generally, mammography attenders have been found to be women who take 
more conscious care of all aspects of their health in their lives and who commonly 
value health highly. Correspondingly, these women are more likely to have attended 
regularly for their cervical screening as well as other healthcare appointments (77, 
122, 149).  
Women with a current prescription for hormone replacement therapy (HRT) have 
also been found to be more likely to attend BCS (133), as have women who practice 
regular breast self-examination (BSE) (77, 125). 
Previous attendance at BCS is a strongly associated determinant of future 
attendance. One paper found the odds for re-attendance was significantly higher in 
women who had previous attended compared with non-attenders OR 8.17 (4.06, 
20.09), p<0.001 compared to non-attenders (117, 150). 
1.3.5 Beliefs, attitudes and knowledge 
Self-efficacy and personal confidence are associated with whether a woman attends 
BCS or not. Women who report higher self-esteem often have higher rates of 
screening (77). Those with low self-esteem may believe health behaviours such as 
screening for future health benefit is less meaningful or valuable and therefore are 
unlikely to participate (77, 122). Those who feel in control of their health are likely to 
attend health services more frequently (122, 151). 
Risk of BC appears to have opposing effects on different women. Some research says 
attenders are more likely to feel at risk and feel vulnerable about developing BC (77, 
144). However, in 1996, Drossaert et al. found that women with a higher perceived 
risk of BC were less likely to attend screening (152). This research highlights the 
influencing factor of ‘perceived threat’ in the screening decision, as incorporated 
within the HBM (112).  
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There are many psychological factors that influence a decision. Research has found 
that women who exhibit worry about BCS are less likely to attend screening (153) as 
are those who consider BCS embarrassing (154). Similarly, fear is found to be a 
prohibitive emotion to obtaining preventative healthcare such as BCS (137, 155).  
For many women, reassurance is an appealing reason to attend BCS (154). However, 
this is not actually a true representation of what BCS can offer. A negative result is 
only an accurate result for that snap-shot in time and even then it may miss a small 
tumour. Nevertheless, women who want the reassurance about their BC status are 
more likely to attend screening (154). 
For some women the decision whether to attend is a balance between cost and 
benefit. Attenders believe benefits of BCS must outweigh costs of attending (77). 
Despite knowledge of BC and the risks involved, women frequently underestimate 
their own personal risk (155). An optimism bias occurs with a common misconception 
that ‘it will not happen to me’ and the belief that there is no need to attend health 
checks. On the other hand, for women with other and additional health concerns, 
the benefit of BCS becomes smaller and they are therefore less likely to attend (156). 
Women who anticipated pain from mammography were found to be less likely to 
attend (115, 154). However, pain is difficult to measure and study as it is largely 
subjective. The same painful stimuli may influence a woman’s future decision to 
attend BCS differently (98). This adds to the complexity of the pain and discomfort 
phenomenon. A New Zealand study found that 46% women who declined 
reattendance cited pain as their reason (98). 
A study in The Netherlands found that women who attend but then stop participating 
tend to have lower intention, perceive more costs, perceive a lower level of control, 
and expect more difficulties with BCS (157). Mammography attenders appear to have 
more knowledge about BC, including information about risk factors and the 
mammography procedure, compared to non-attenders (138, 158, 159). 
1.3.6 Intention 
Unsurprisingly, intention to be screened is one of the biggest predictors of actual 
attendance within BCS programme (77, 117). A prospective study of attendance in 
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inner London found higher odds of attendance for women who gave a “yes, 
definitely” response to their intention to attend versus those who did not, OR 6.19 
(3.07, 12.50), p<0.001 (154).  
Whether women perceived screening to be important was found to be one of the 
two best predictors of uptake in London by Sutton et al. (154). This gives supporting 
evidence that the decision to attend screening can be influenced by educational 
information such as that provided by a leaflet. 
Despite good intentions, a lack of alternative family care plans may also prevent a 
woman attending. For example, if a woman has child-minding issues she may not feel 
physically able to attend a healthcare appointment for herself. Other factors that 
influence uptake at an individual level may include simply forgetting to attend the 
appointment. Intervention trials have shown simple reminders improve uptake 
(160). A study in America showed that compared to controls, those enrolled in a 
telephone reminder service were more likely to be re-screened at the next round, 
with 35% compared to 24% uptake (161). Another American research team added 
that for women receiving a postal reminder, the uptake rate was 68.1% compared to 
those receiving an email reminder who had an uptake rate of 72.2%. The odds of 
attending BCS were 49% higher for women who received a reminder versus those 
without, OR 1.49 (1.35, 1.65), p<0.01 (162). However, these techniques often rely on 
up-to-date mobile numbers or email addresses which are often not available for the 
entire population.  
1.3.7 Accessibility and logistics 
Distance to the breast screening centre is a known factor influencing the uptake of 
BCS with those who must travel further often having lower uptake (163). A deterrent 
for many women is not having a mode of transport with which to access the 
screening centre (138). 
Factors that influence attendance at an area-level include migration. Regions with 
more transient populations exhibit lower rates of screening (136). This could be due 
to administration error or inaccuracy of the screening registers (139). For instance in 
areas that have a high turnover of population, women do not always register for GP 
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practices or may have left their registered address (154) and therefore some women 
do not receive their invitation. 
Misinformation contributes to some lack of attendance at screening. A common 
reason stated by women for non-participation is that they were not informed by their 
healthcare provider of the opportunity for BCS (155). Further to this, the impact of 
illiteracy on uptake and understanding is of concern. If women do not understand 
the literature or guidance they will not be able to make IC about their screening 
participation (164). 
1.3.8 Societal Factors 
Non-attendance is linked to social isolation implying social support might be 
important for uptake of BCS (151). Compared with non-attenders, participants of BCS 
in the UK are more likely to report at least one close friend and/or know women who 
have participated (117). Likewise, those who have been recommended to attend by 
a friend or family member have been found to be more likely to attend than those 
without any such recommendation (77, 138). Women who lack social participation 
have a higher likelihood of non-attendance with OR of 1.21 (1.10-1.31) (151). 
Nevertheless, the association between social support and attendance is not always 
found to be consistent which may be due to reliance on self-report data (77). Social 
support via the marital bond is linked to higher attendance as attendance is higher in 
women with a spousal partner (115, 117). 
Furthermore, some cultures and traditions prevent or prohibit behaviours that are 
conducive to screening uptake. For example, exposing oneself to a person other than 
a husband is forbidden, speaking about cancer can be a taboo, and cultural norms 
are somewhat prohibitive of BCS for some women (138). 
Media can heavily influence a decision about health, either purposefully or 
unknowingly. This is demonstrated following a celebrity diagnosis or death (165). 
However, a less ‘popular’ public coverage, such as the publication of a report like the 
Marmot Review (96) has less clear impact on preventative uptake (166). 
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1.3.9 Summary of factors believed to influence uptake 
 
Figure 16. Summary of predictors of uptake at screening from the literature. Those highlighted in pink represent 
non-modifiable factors, green represents those that are modifiable and blue those that are external and 
situational but act at the individual level. CBE, clinical breast examination. 
A woman’s sociodemographic factors appear to influence the likelihood of her 
participating in BCS. Being married (122, 125, 126) and having a higher income (125, 
130) are associated with higher attendance, as is higher literacy levels (126) and 
better social support mechanisms (151). Increasing age (118, 123), lower SES (79), 
lower education (124, 127) and being of a minority ethnicity (122, 137, 139, 140) are 
all associated with lower attendance. Women of some cultures and traditions have 
more restrictions on breast screening and have lower uptake (138) as do women who 
live further from the screening centre due to accessibility and logistical issues (163). 
Areas of transient populations also show lower uptake rates (136). 
The influence of health status on breast screening uptake depends on the individual 
as each person reacts to stressors differently (119). Previous false positive results 
appear to reduce reattendance (116, 138), which could be dependent on how 
invasive the test is (143). Women attending breast screening seem to have a good 
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current state of health (77, 144). Women taking HRT are more likely to attend 
screening (133). Those attending screening are the more health-aware women in the 
population (117, 150). 
Beliefs, attitudes and knowledge about screening are important too. Women who 
are self-efficacious tend to attend mammography more frequently (77) as do women 
who desire reassurance (154).  Perceived risk has differing effects on women 
depending how they react to such stresses (152). Women who are worried (153), 
anticipate pain (115, 154), fear the mammogram process itself (155) or are 
embarrassed (154) are less likely to attend. Women must weigh up the benefits 
versus limitations in their cost-benefit analysis whilst making their decision whether 
to attend screening or not (77).  
The biggest predictor of uptake is previous attendance at screening.  Those who 
practice BSE are more likely to attend (77, 125). Intention to attend is another key 
predictor of uptake (77, 117). Women who perceive screening as important often 
participate more than those who do not believe screening to be important (154). 
Media can subtly or purposefully influence the uptake of screening quite dramatically 
(165). 
These influencing factors of uptake interact with each other and are dependent on 
multiple other unknown factors. At the very least, they could look to influence uptake 
as shown in Figure 16. It has been shown that uptake is inequitable and education of 
women in a personalised approach would likely enhance the making of an IC in BCS 
decision making. 
1.4 Patterns of Attendance  
There are natural patterns and fluctuations in women’s attendance at BCS which is 
likely to be because mammography is not a compulsory requirement for healthcare 
provision in the UK. There are four attendance patterns in health screening – 
“consistent” (a woman who regularly attends appointments each three years), 
“dropout” (used to attend regularly but has stopped), “delayed” (used to miss 
appointments but is now participating in mammography) and “refused non-
attenders” (never been screened) (167-169).  
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The study by Drossaert et al. (157) found four differences between consistent and 
dropout attendees. This is consistent with the TPB as proposed by Ajzen in 1991 
(108). The four variables are that women who dropout had a lower level of perceived 
control, had lower intention to attend screening, perceived more costs involved and 
expected more difficulties when compared with women who attended consistently 
(157). Despite high attendance rates at first invitation, participation rates appear to 
decline with each round of invitation (117).  
Furthermore, there is a group of women who are termed “intermittent attenders”. 
These women occasionally miss screening rounds and attend appointments 
infrequently. They are not similar in socio-demographic profile to “refused non-
attenders” and should not be considered in the same way (168). Intermittent 
attenders represent around 15% of those invited and are a distinct subgroup from 
attenders and non-attenders (114).  
The national dataset “KC62” is provided by the Breast Screening Programme to the 
Health & Social Care Information Centre (HSCIC) and shows a possible change over 
time in attendance at BCS. The Forrest Report, written in 1986, resulted in the setting 
up of the breast screening programme with the first women being screened in 1987. 
A sudden rise seen in 1994 ( Figure 17) could be attributed to the initiation of the 
NHSBSP. However, it was only by 1994-95 that most screening units had completed 
the ‘prevalent’ round (66).  It is therefore considered that the graph should be viewed 
as starting from the highest point, at 1994-1995, to minimise the influence of the 
rolling-out phase of NHSBSP. The graph shows the uptake has changed over the last 




Figure 17. Uptake* of breast cancer screening by women aged 50-70 in England, 1993-94 to 2014-15. Data 
taken from KC62 available as report (6) on HSCIC website [http://www.hscic.gov.uk]. *Data excludes short term 
recalls, self/GP referrals and those included within the age extension trial. 
The national minimum uptake standard is 70% with a target of 80% set for cost-
effectiveness and population benefit (69). There is cause for concern regarding this 
changing uptake as its decline approaches the minimum required (70%). If 
attendance drops below this level it may affect whether the programme is 
considered cost-effective for the NHS (6). Data for the previous ten years is provided 







































































Figure 18. Uptake by women aged 50-70 to invitations for breast screening in England between 2005 and 2016. 
Data taken from (170).  
According to data from the national KC62 dataset, there was a change in the number 
of women attending for screening in 2005 as shown in women attending although, 
admittedly, this can be difficult to see amidst the fluctuating trend line. 
There are several explanations for a possible change. For example, the introduction 
of a new administration system for booking appointments may mean that fewer 
women received the correct appointment invitation. Or perhaps there were fewer 
public advertisements about the benefits of screening and perhaps contrariwise 
more media attention was paid to the negative components of screening. 
It is not currently known in whom the changes in attendance patterns are occurring. 
The second study of this research project addresses this literature gap by providing 
evidence using London data. If there is a change in uptake behaviours among the 
screening population of London it is important to understand in which women this 
change occurred (96). Following this research, a wider sample will be needed to 
confirm generalisability across the UK. 
In the UK previous results show attendees are more likely to be younger, married, 
middle class (171) and reside in urban areas (115). This is consistent with profile 
predictions conducted by Canlan et al. of non-attenders being single or widowed and 
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round when invited and are more likely not to attend further screening rounds (114). 
Further, there is geographical variation in uptake over the UK (shown below in Figure 
19) which could be attributed to regional poor access or differences in socio-
demographic profiles. 
Regardless, it is important for the NHSBSP to determine if geographical location has 
an influence on screening uptake. Fifteen Breast Screening Units (BSUs) currently fail 
to meet the 70% national target for uptake and 29 BSUs are within 5% of the target 
(66). 
It is vitally important to know in whom the uptake patterns are changing. Is it the 
older women who are now not participating, or is it a cultural phenomenon 
prohibiting uptake within one ethnic minority? Understanding which women may or 
may not have changed their attendance preferences may highlight important 
inequalities within the screening programme which we can then aim to address. 
Secondary data analysis will be able to answer the question of who participates for 
women in London, from which further research will be warranted. 
 
Figure 19. Uptake* by women aged 50-70 of invitations to screen by reporting region. England, 2012-13 and 
2013-14. *Data excludes short term recalls, self/GP referrals and those included within the age extension trial. 
Graph sourced from KC62 and HSCIC Report (66).  















































1.5 Informed Choice (IC) 
An IC is classified in this research using Marteau et al. (2001) definition as a ‘decision 
where all available information about the health alternatives is weighed up and used to 
inform the final decision; the resulting choice should be consistent with the individual’s values 
and is actively implemented by the person’s behaviours’ (164). Based on this, there are 
three components (knowledge, attitude and uptake) that allow two combinations 
that can be classified as an IC, graphically represented as boxes one and four as 
shown in Figure 20 below. A woman must have sufficient knowledge about the 
consequences of a positive result, the probability of a false positive or negative result, 
and the uncertainty about the screening test etc. as identified by the General Medical 
Council as prerequisites for making an IC. These components should be included 
within the knowledge questionnaire as part of the IC model (172). In addition a 
woman will either have a positive or negative attitude towards mammography and 
these attitudes need to reflect her attendance. For example, a woman with sufficient 
knowledge and a positive attitude to screening must attend screening to have made 
an IC (box one). Similarly, a woman with appropriate knowledge may have a negative 
attitude to screening and therefore in order to make an IC she must not attend 




Figure 20. Classifying informed choices based on knowledge, attitudes and behaviour (164). Boxes ‘1’ and ‘4’ 
represent informed choices. 
 
With Marteau’s definition of IC stated above (164), women are not provided 
sufficient information to make an informed decision without researching further 
information themselves (60). The Patients’ Charter (173), subsequently replaced by 
an updated ‘NHS Constitution for England in 2012’ (174), states that individuals must 
be told if a treatment or investigation has the potential to result in serious adverse 
outcomes, and be told its alternatives, before they agree to participate. Gotzsche et 
al. criticises the ‘Helping you Decide’ breast screening leaflet for its ‘lack of balanced 
information, omission of harms and limitations of screening and exaggerated 
estimations of benefit’ (60, 61).  
The UK breast screening leaflet 
The breast screening information leaflet is the key information source provided to all 
women to help them make a decision about attending screening (175).  
The Independent Breast Screening Review panel recommends that clear information 
should be given to women invited to screening (176). The then current leaflet went 
through vast redesign including advice from women and input from professional 
experts in public engagement, IC and communicating risk. The draft leaflet was then 
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cognitively tested with women before integrating all advice and a final check from 
the advisory committee (176).  
Despite this, the updated leaflet is still heavily criticised for not giving enough 
information to make an IC (59-61, 177). The NHSBSP information leaflet has been 
critiqued by Gotzsche et al. as being ‘not necessarily easy-to-interpret and can be 
misleading’ (60). It has been argued that the current leaflet is confusing and provides 
insufficient information to allow women to make an IC about attending BCS (61). The 
NHS BCS leaflet is considered by some not to contain enough information regarding 
the decision to participate in screening (94, 178). 
A random sample questionnaire study in Oxfordshire was therefore conducted to 
test the levels of knowledge before and after the new leaflet (179). This study found 
that although numerical comprehension of lifetime risk of BC and purpose of 
screening had improved the qualitative interpretation of this risk varied. Additionally, 
some simple messages such as screening does not prevent cancer had not been 
understood by all (179). However, it was only a small sample of women (n=100) in 
one area of the UK and therefore it cannot be assumed that the results are 
generalisable. More research is needed. 
The leaflet often concentrates on the benefits of screening ‘the NHS offers screening 
to save lives from breast cancer’ (63) and it tends to minimise harms or limitations of 
the process ‘screening does have some risks’ (180). Despite undergoing rigorous 
evaluation and expensive renovation, the leaflet still comes under intense scrutiny 
and criticism (61, 63). The leaflet briefly mentions a harm ‘some women find 
mammography uncomfortable or painful’, but in fact this is a widely reported 
phenomenon and a significant deterrent of further mammography uptake so 
deserves more focus than a brief harm (60, 181).  
Furthermore, the balance and measurement of benefits and harms is a personal 
judgement and decision, and their distinct impact will be understood differently for 
each woman. It is not clear from literature if the benefits of screening outweigh the 
harms at a population or individual level (94, 96). Mammography trials have shown 
a reduction in BC mortality but have also shown significant overdiagnosis (87, 96). 
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Technology and treatment options have changed since the trials and the effect this 
has had on the balance of benefits and harms of screening is not known (60, 61, 96). 
These uncertainties are not discussed in the leaflet (63). 
IC is recognised as an important component of personal autonomy and is common 
practice of good medical practice ethics (172, 180, 182, 183). Reflecting this, policy 
has recently changed and the NSC now recognises the responsibility of screeners to 
ensure patients are fully informed and are making a decision that is right for the 
individual (102, 172, 183-185). Policies advise that potential adverse effects should 
be made explicit to potential participants (186). Michie et al. (186) suggests that 
whilst knowledge may not influence a woman’s decision to attend screening, it may 
influence their understanding and reaction to their test results. 
Those who make an IC make value judgements including complex trade-offs between 
potential benefits and harms of BCS. It seems likely that there is a relatively unspoken 
fear held by policy makers that unbiased, clear information may deter people from 
participating in screening programmes (187). The effect of IC on uptake of BCS is so 
far unconfirmed. 
It is not known yet what influence making an IC may have on breast screening uptake 
in the UK. The literature is not consistent, with evidence for both increased and 
decreased uptake rates as a consequence of more IC (102, 174, 183, 185). Accessing 
information relevant to health decisions has become increasingly important as 
women attempt to make informed decisions in BC screening (102).  
Key performance indicators, used as programme targets within the NHSBSP, 
currently rely on uptake rate. This assumes that participation is equivalent to an 
informed decision. Many women trust the healthcare service and welfare state and 
since they are provided with a pre-scheduled appointment they may assume this is 
the ‘correct’ or ‘best’ decision. This process highlights why attendance at the BCS 
appointment cannot be used to determine whether an IC has been made or not. A 
proper, formal, assessment of a woman’s knowledge and attitudes is required to 
evaluate whether they have made an IC. 
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In Australia, a patient decision aid was trialled for use in the bowel screening 
programme in 2008 (188). Participants in the intervention group were given a 
decision aid which comprised an interactive question list and a DVD explaining risk 
and possible outcomes compared with no screening. The control group received 
standard information leaflets. Results suggest those who received the decision aid 
displayed higher knowledge than the controls and less positive attitudes towards 
screening. Participation was lower in the intervention group, with 59% completing 
the faecal occult blood testing compared with 75% of the control group (188). For 
Australia’s bowel screening programme at least, tailored decision aids support 
making ICs but this may come at the expense of uptake. It is not unrealistic to expect 
similar results in the UK within the breast screening programme, as hinted in 
Germany which is discussed below. 
Regardless of its positive or negative influence on uptake, IC is becoming more 
commonly considered in cancer screening programmes. The German health system 
is starting to change and is moving towards informed citizens rather than aiming for 
the highest participation, even at the expense of uptake. IC will be a key indicator of 
quality for their programme (62, 102, 189, 190).  
The factors affecting an IC to attend screening are not known and may depend on 
personal risk of BC or socio-demographic characteristics. Decisions are based on 
many different factors and are complex. It is assumed that women use both intuitive, 
instinctive reactions along with logical reasoning, scientific deliberation and analysis 
to make a decision in health (191).  
The patient information leaflet given to women is considered by some to be biased 
towards screening and insufficient to make an informed decision (184). Even if it was 
clearly explained in detail, it cannot be guaranteed that women will incorporate more 
balanced and detailed information into their decision-making process (186). This is 
particularly true as the benefits of screening are often many years delayed and 
relatively uncommon whilst harms are often misunderstood and viewed with 
minimal concern (192). 
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Balanced sources of information are ethically important in healthcare. However 
simply providing factual information may not substantially increase the proportion 
of women making an IC. Women may not read the leaflet or they may not understand 
what they read (193). The Fuzzy Trace Theory distinguishes between two types of 
understanding, ‘gist’ and ‘verbatim’, in screening information. The theory suggests 
that many people rely on the gist of whether a risk is increased or decreased to make 
their decision (194), therefore more specific information may not be useful (195). 
People who are lower in numeracy capabilities may find it difficult to establish their 
personal risk (187). The ‘Computational Approach’ describes a psychological 
mechanism of personal numeracy, emphasising that poor decision making may be 
the ‘result of information overload and failure to sufficiently process information’, 
which subsequently produces an uninformed choice due to insufficient knowledge 
(194).  
People with lower numeracy may be more likely to overestimate their own personal 
risk of BC, and more likely to overestimate the benefits of screening (196). If it was 
to be introduced, knowledge testing for IC should therefore include both specific and 
general screening questions as well as BC risk knowledge.  
1.6 How to achieve an IC 
For the NHSBSP, achieving an IC is more complicated than simply providing women 
with all the information. Including all information about false positives, 
overdiagnosis, and the full screening procedure would fulfil GMC guidance about 
informed consent (102) and respect individual independence but could be 
overwhelming for women and contain too much detail to allow for extracting the 
relevant and important information. 
Supplying information as a leaflet is low cost as it is simply providing printed 
information with minimal staff time needed. However simple distribution of leaflets 
does not provide sufficient opportunity for an IC to be made (102). Using IC as a 
programme quality indicator would likely increase the amount of time required by 
each staff member to explain and ensure that women are fully informed, at increased 
expense for the NHS. 
50 
 
It is understood that for women to make their own informed decision they need 
sufficient information (164, 186). Despite recommendations for increasing IC (134), 
being open with women about the pros and cons of screening could risk a reduction 
in uptake for the NHSBSP (102). A minimum uptake rate (currently 70% in the UK) is 
required for the NHSBSP to be cost-effective and viable.  
Whilst providing biased or incomplete information focused on the benefits of 
screening may help achieve maximum participation, it does not help achieve 
maximum informed participation (102). 
Chapter Summary 
This chapter discussed the epidemiology of BC and risk factors predisposing women 
to the disease. It explained the basics of screening with a particular focus on 
mammography and debated its advantages and limitations. 
Uptake of screening is dependent on a complicated network of factors and influences 
that have been discussed with different attendance patterns highlighted in different 
subgroups of the population. This is investigated further in later chapters such as the 
systematic review and the secondary data analysis. 
As the NHS moves away from a paternalistic approach in medicine, ensuring women 
make an IC is becoming more important. For an IC to be made, knowledge and 
attitude need to reflect behaviour. Attendance at the appointment cannot therefore 
be a representation of IC. When providing women with transparent information to 
increase knowledge mobilisation a more personalised approach will be necessary to 
ensure each woman is making an IC consistent with her own values. More research 
into IC is described in Chapter Seven during the questionnaire development study. 
Inequalities exist throughout the NHS and are no doubt present in the NHSBSP in 
respect of who attends screening and who makes an IC. It is vitally important to 
ascertain in which women patterns of attendance at mammography is changing. 
From there, research can be conducted about why it is happening and whether 













Chapter 2: Justifications 
Introduction  
In this chapter I describe the gap that my research aims to fill and discuss the 
importance of my research to this field. Firstly I explain the overarching thesis 
research problem and how my work will contribute. I then explain how each of my 
studies will combine to fill the research gap. 
This chapter also describes and justifies the study designs and methodological tools 
used to answer each research objective. Strengths and limitations of the chosen 
methods and approaches used are discussed to determine the appropriateness of 
the findings to answer the objectives. 
2.1 Research questions for thesis 
This PhD has been funded by Collaboration for Leadership in Applied Health Research 
and Care West Midlands (CLAHRC-WM) as part of the NIHR doctoral scheme. After 
significant reading and searching within the literature I identified an important 
literature gap in the field of patterns of mammography attendance and IC within 
uptake. This project contributes to the existing literature and answers some of the 
unanswered questions in the field surrounding changing patterns of attendance. 
In the previous chapter I highlighted how various predictors of uptake are interlinked 
and create a complicated network of influencing factors. I hypothesised that patterns 
of uptake are changing and potentially declining (197). Regardless of any change, it 
is unknown in whom this is occurring. It is vitally important to know this because 
understanding the changes in patterns of attendance will highlight potential 
inequalities in the NHSBSP and consequently have valuable implications for planning 
of services.  
There are clear research gaps in this field which are stated below. There has not been 
a recent global overview of predictors of BCS uptake.  Most studies focus on single 
predictors of uptake and this research needs updating. Globally, each country has a 
different screening programme and therefore diverse categories of predictors of 
uptake. For instance, the screening programme in the USA relies heavily on 
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insurance. Having insurance and the type of insurance held is much more important 
as a predictor of uptake in the USA compared with the UK where mammography is 
provided free at the point of care. In the UK, it is more likely to be factors such as 
age, ethnicity and other health issues which predict whether or not a woman will 
attend breast screening.  
It is unknown whether patterns of mammography attendance are changing over time 
and if so, in whom. Recent data shows a 1% decline in uptake of BCS in the last year 
(197). Furthermore, there are clear literature gaps in understanding what influence 
making an IC has on uptake. It is also unknown if making an IC is dependent on 
personal characteristics of women. In the UK we do not know and cannot identify 
which women make an IC in BCS. 
The research questions, and consequently studies, aim to fill these gaps. The research 
questions of this thesis are: 
1. What are the predictors of BCS uptake worldwide? 
2. What are the predictors of BCS uptake in the London, UK population? 
3. Are patterns of BCS attendance changing in the London, UK population?  
4. In whom are patterns of attendance changing in the London, UK population? 
5. What questions can be asked to explore whether personal characteristics 
and/or personal BC risk, influence making an IC? 
2.2 Rationale, research gap and justification 
From a scoping literature review and background reading it appears that breast 
cancer screening uptake is changing. The underlying reasons for changes in BCS 
uptake are not clear. 
To date, research has often focussed on particular sub-groups of the population. 
Previous studies have examined a small number of predictors for either attendance 
or non-attendance. In 2008 a large systematic review was conducted in America that 
sought to summarise the available literature regarding factors associated with 
mammography uptake (198). However, this 2008 review included self-report data, 
only analysed data from the United States and was conducted ten years ago. Self-
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reported data is consistently villainised for its unreliability in the accurate reporting 
of health behaviours and involves a threat to the validity of the data which weakens 
any inferences or results made from the data (199). This particularly seems true when 
the behaviour under question could be considered by the public as undesirable or if 
the individual is trying to avoid feeling judged for their behaviour (200, 201). The 
systematic review conducted for this research will be a more robust analysis as it 
does not include self-report data, it will be a more inclusive review as it is not 
restricted geographically and it will be an updated review. 
In the UK, the NHSBSP is tightly regulated to adhere to guidelines and standardised 
outcomes. The screening programmes must report data annually on key 
performance indicators. A performance threshold is set for 70% of the population to 
be screened as a minimum and the achievable level is set at 80% (202). Guidelines 
state this percentage of uptake should be of all eligible women who wish to 
participate (203). However, the review has shown that ethnicity, morbidity, 
education and income are predictors of uptake and therefore this may be disrupting 
accessibility and equity of the screening service. 
Therefore it is extremely important to determine which factors are of most 
importance in determining uptake and reflect on how these are influencing 
participation in the UK. 
In London, it is unknown if patterns of attendance at BCS are changing. Although the 
change is unidentified currently, it is hypothesised to be decreasing in certain sub-
groups of the population and not in others. 
One of the public health aims of screening programmes is to ensure access for all by 
providing an equitable service. Provision of clearer information may lead to greater 
inequalities in who decides to attend BCS and who makes an IC about attendance. It 
is possible that the ‘highest risk, concurrently hardest to reach groups may be the 
most easily deterred’ (190). It is therefore imperative to identify in which sub-groups 
uptake is changing to determine the effect this may have on BC rates and long-term 
mortality. Moreover, it is also important to recognise any such changes to minimise 
widening health inequalities. 
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Meanwhile, it is also hypothesised that it is not just demographics that influence 
uptake of BCS. Personal characteristics, women’s own personal BC risk and perhaps 
whether they are making IC are all known to influence uptake as explored above. The 
third study will develop a questionnaire that can be used to investigate how these 
factors are associated with BCS uptake in the UK. 
The NHSBSP has two key aims, to reduce mortality and morbidity from BC. They aim 
to do this by ensuring as many women are screened as possible. In light of modern 
ethical responsibilities to provide patients with clear information to encourage 
women make an IC, there is concern about the incompatibility of these aims with the 
moral obligations. 
To ensure an IC, women must be informed about both the benefits and harms of 
screening. Despite fears that clear information may deter women from participating 
in breast screening (187, 188) the effect on uptake rates is not yet known (102, 174, 
183). If there is an association between making an IC and BCS uptake, it is important 
that research is conducted to identify which women this will likely effect. 
In this thesis I will investigate predictors of uptake internationally, analyse patterns 
of attendance at a breast cancer screening centre in London, and develop a 
questionnaire to evaluate which women are making ICs and analyse if IC or their 
demographic predictors are influencing patterns of attendance.  
2.3 Overall thesis aims and objectives 
Overall, the aims of the thesis are: 
• to identify the predictors of worldwide BCS uptake 
• to recognise if patterns of attendance are changing and if so, in whom  
• To explore women’s views on the drafted questionnaire 
The underlying aim of the research is to contribute new knowledge to the field. I will 
achieve my aims by completing the following objectives for the overall thesis. 
Project 1: Conduct a systematic literature review of worldwide research to identify 
the global predictors of uptake of breast cancer screening.  
• Analyse predictors of uptake using meta-analysis where appropriate 
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• Narratively synthesise data not suitable for meta-analysis  
• Provide an overall summary of the findings of the systematic review 
 
Project 2: Obtain South West (SW) London dataset with the relevant data on uptake 
of BCS to ascertain if patterns of attendance are changing and if so, in whom? 
o Conduct analysis of this dataset to: 
• Identify predictors of uptake within the SW London screening 
centre 
• Analyse whether patterns of attendance have changed over time 
within SW London 
• Further analyse change in attendance over time within specific 
groups of women to identify predictors for any change 
 
 
Project 3: Develop a questionnaire that can be used in the future to understand if 
personal characteristics or personal BC risk influences IC and/or breast screening 
uptake 
• Work with patient and public involvement for the development of the 
questionnaire documentation 
• Use cognitive interviewing to develop the questionnaire 
• Adapt the questionnaire documentation as recommended by results 
of the research 
A key part of this research will be to disseminate research results using publications 
and conferences where appropriate. 
2.3.1 Hypothesis 
There are many predictors that influence BCS attendance and this network of 
influencing factors is complicated. I predict that uptake of BCS has changed over time. 
I am expecting to find uptake of mammography to be lower in older women, in 
women with lower socioeconomic status and in ethnic-minority women. I anticipate 
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finding a complex phenomenon around the effect of false-positive results on 
subsequent uptake. I expect there to be an intriguing pattern of uptake in relation to 
IC. I predict that there will be a subgroup of women (who may be of higher SES) 
making more ICs about breast screening. I hypothesise that this will reduce their 
likely uptake of screening. This will be investigated in future research using the 
questionnaire tool developed as part of this thesis. 
 
2.4 Methodology justification 
2.4.1 Systematic Review 
A systematic review is considered by many to be the gold standard approach to 
evidence synthesis (204). The expression ‘systematic’ review underpins the entire 
method and approach used in order to increase reproducibility and reduce bias. 
For the current review, a formal protocol was written using standardised methods 
for the search, evaluation and selection of primary studies enabling objectivity and 
methodological reproducibility (205). The protocol was uploaded to the PROSPERO 
website for full transparency, as encouraged by the creators of the database (206). 
A broad search was conducted to ensure that all types of predictors of 
mammography uptake were identified. However, this review was undertaken to 
quantitatively evaluate the effect different predictors had on mammography uptake. 
Whilst qualitative studies would provide detailed exploration of why different factors 
influenced uptake and would be extremely useful for future research to establish, 
this was not the purpose of this review and as such they were excluded from the 
review using pre-established screening criteria. 
Where data are unclear, an executive decision needed to be made about how to deal 
with the information. For this review, data were excluded from the analysis where it 
could not explicitly be determined which women participated or did not participate. 
Also, data which did not represent a screening population i.e. which investigated an 
entire sub-group (i.e. all attended) and presented percentages of which women were 
from which demographic were removed. This was stated prior to commencing the 
review using pre-specified inclusion and exclusion criteria (206). 
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My research had a six study overlap of included articles with the American review 
mentioned above. This justifies the purpose of conducting my systematic review on 
the topic.  
A random effects model was chosen to allow for the possibility (and probable) that 
population parameters vary between studies. The assumption made in fixed effects 
models, that these parameters are identical across all studies included in the meta-
analysis would be unrealistic and erroneous (207). Furthermore, where no covariates 
are obvious explanations of the heterogeneity observed in the data, random effects 
meta-analysis is the most appropriate method – some heterogeneity gets explained 
by the variables included in the model and the residual heterogeneity becomes 
modelled (208).  
Where data were dichotomised into groups, data were examined using Mantel-
Haenszel random effects meta-analysis and the effect is presented as an odds ratio 
(OR). Where data were provided in more than two discrete groups, sub-group 
random effects meta-analysis was conducted to compare overall proportion 
attendances. Random effects models were used to allow for differences in the 
underlying proportions of attendance between studies (209, 210). 
2.4.1.2 Quality Assessment 
One of the challenges of systematic reviews is that they rely on the quality of the 
included published research. Additionally, frequently there is no individual data 
provided and the research team have to rely that the summary statistics and data 
included in the studies are accurate and include few errors. To better understand the 
limitations of the available data, I conducted quality appraisal of all included studies. 
In systematic reviews having a tool to appraise quality is a vital part of interpreting 
and synthesising the evidence. It is also a way of ensuring consistency and limiting 
researcher bias when assessing the included data. There are a variety of tools that 
can be used for this process, including the two described below. 
The Quality Assessment Tool (QAT) is used to assess if a study was well conducted. 
This tool can be used for quality assessment (QA) on any quantitative study (211). It 
contains 6 domains: selection bias; study design; confounders; blinding; data 
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collection methods; and withdrawals and dropouts. It is based around the hierarchy 
of evidence used in evidence based practice and therefore tends to rate randomised 
controlled trials as higher quality than descriptive studies or case reports as discussed 
by Tomlin and Borgetto (212). 
Quality in Prognostic Studies (QUIPs) is more focussed on whether the results of the 
study are realistic and believable. It is used only for QA of prognostic studies (213, 
214). This tool also contains 6 domains considered important when evaluating bias 
in prognostic studies, including: participation; attrition; prognostic factor 
measurement; outcome factor measurement; confounding measurement; and 
statistical reporting and analysis.  
The domains are very similar and match well as shown in Table 3. Many of the QA 
questions cover the same detail. However, the ‘blinding’ domain of QAT does not 
affect the overall category score and does not have an equivalent domain within the 
QUIPs and there are no prompt questions within the QUIPs tool for this. 
 
Table 2. Quality assessment domain comparisons 
QAT Domain QUIPs Domain 
Selection Bias  
Study Design 
Study Participation 
Withdrawals & Dropouts Study Attrition 
Confounders Study Confounders 
Blinding (No matching domain) 
Data Collection Method Outcome Measurement 
Prognostic Factor Measurement 




One of the main practical differences between the two tools is how you complete 
them. Using the QAT, you either circle yes/no or the answer such as ‘very likely’ or 
‘somewhat likely’. From this, there are instructions on how to rate the section and 
this translates into an overall summary rating, either strong, moderate or weak study. 
Detailed instructions are given on how to rate each paper (211, 215).  
In the QUIPs tool, each domain is split into multiple questions for which comments 
and/or evidence are required. Following this, the user provides a rating for each 
question and then offers an overall rating of bias either low, moderate or high. This 
method is, by its very nature, more subjective as there are no overarching guidelines 
for assessment and ratings. QUIPs prefers no overall global rating of risk of bias as 
recommendations have been made against a summary score of overall quality, (213), 
so the tool simply provides six ratings of bias.  
Another key difference is the omission of blinding questions in the QUIPs tool. This is 
important for assessment of RCT studies in particular. Not blinding the researchers 
involved in the study could easily bias the trial analysis and results. This is a major 
limitation of the QUIPs tool. 
A significant variation between the tools was the level of detail in the questions 
asked. For example QUIPs asks six questions for both outcome and prognostic factor 
measurement domains, whereas QAT only asks ‘were data collection tools shown to 
be valid?’ and ‘were data collection tools shown to be reliable?’ with simple 
yes/no/can’t tell answer formats. 
QAT uses questions within its assessment to create an objective measure which 
should remain consistent across time and researchers. Indeed, between the 
reviewers CN and RC there was only one discrepancy when using the tool and this 
was due to an initial misunderstanding of the tool’s instructions. Comparatively, the 
QUIPs tool could be considered much more subjective, particularly as there are no 
rules or guidelines how to determine low, moderate or high risk of bias. 
Armigo-Olivo et al. concludes there is no evaluation of ‘reasons for missing data’ or 
the ‘handling of missing data’ in the QAT (216). When they compared the QAT with 
the Cochrane Risk of Bias Tool assessment, they   found that the QAT performed 
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better and had a ‘fair’ inter-rater agreement of 0.60, (presumably it was not high 
because of the level of subjectivity required to complete it)  (216). In a study by 
Hayden et al. the QUIPS tool is found to have a moderate to substantial inter-rater 
reliability of 0.56-0.82 (median, 0.75) (213). However, this study had its own 
limitations such as only using an expert panel who may ‘overestimate usability and 
reliability scores’ (213).  
To further explore the practical differences and some potential limitations of each 
tool, RC took three papers that were included in the final review as examples to 
compare the two tools (Ulcickas, 1999 (169), McCarty, 2003 (217), Zidar, 2015 (163)). 
The acceptability and comparability of both quality measures was compared, both 
tools scored identical ratings for withdrawals/study attrition (scored N/A) and data 
collection methods/PR and outcome measurement (scored low risk). The blinding 
domain was only available in QAT and QA about the analysis component of the study 
was only available in QUIPs due to the nature of the study and the QA questions 
asked. A difference was found in the study design/study participation domain, QUIPs 
scored one paper ‘moderate’ and the others ‘low’ whereas QAT scored them 
‘moderate’ and ‘high risk’ respectively. Likewise in the confounding domain, QAT 
scored all papers ‘low risk’ whereas QUIPs scored each differently (‘moderate’, ‘low’ 












Table 3. Comparison of the two tools using included papers of the systematic review: Ulcickas (169), McCarty 
(217) and Zidar (163). For QAT, scores equate to the following: low = low risk of bias, moderate = moderate risk 
of bias, high = high risk of bias, NA = not appropriate for this study. For QUIPs, scores equate to the following: 1 
= low risk of bias, 2 = moderate risk of bias, 3 = high risk of bias, NA = not appropriate for this study. 
Domain (QAT above QUIPs 
in table heading) 
Study QAT scores QUIP 
scores 





3 & 2 
1 & 2 












































1 & 1 
1 & 1 
1 &1 
(Analysis) 








RC and the second reviewer used the QAT tool to encourage consistency across all 
QA by using the same tool throughout the review. Although it is preferable to use the 
QAT with RCTs, the QAT tool can be used for all quantitative study types within all 
public health topic areas. This proved advantageous as this work incorporates data 
from a wide variety of studies and methodologies (211).  
Meta-analysis has been conducted where three or more studies provide information 
to the identical predictor analyses. Odd ratio forest plots have been provided where 
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the data allowed and if not, sub-group analysis was conducted and proportions 
attending reported. 
To effectively perform a multivariate meta-regression analysis, certain requirements 
must be met. This includes having at least ten studies reporting data on all (or most) 
of the predictor variables (218) and the pooled prevalence of screening attendance 
across all 91 studies must be objectively determined. Without the total number of 
attending and non-attending women reported in each study, irrespective of the 
predictor variables, the second requirement cannot be met. Whilst there are 
methods to be flexible about the first requirement, the second is fundamental 
because we cannot afford to ignore the substantial amount of missing data if the 
attendance was simply pooled based on the predictor category with the largest 
number of attenders. Therefore meta-regression was not conducted. 
2.4.2 Secondary data analysis 
There are many advantages for conducting a secondary data analysis for this study. 
Namely, it is time and financially efficient (219). A statistical analysis plan was created 
to encourage methodological reproducibility.  
Extracts of uptake data are used to answer whether patterns of attendance are 
changing. As the researching team were able to obtain data extracted from the 
database in a previously anonymised format this has further reduced time 
constraints. 
Importantly, South West (SW) London was chosen for two reasons. Partly SW London 
was selected because of personal connections between the breast screening unit 
here and with a previous supervisor of the researcher but primarily as it routinely 
records ethnicity data and ethnicity is a key predictor of uptake required for this 
analysis. 
Using a database for its ease of access has potential flaws – it could be biased or not 
appropriate. However, a requirement for a dataset and the main strength of this 
dataset was its recording of ethnicity. However, ethnicity information is solely self-
reported data which could be considered subjective or less reliable (199). A limitation 
of this dataset is the lack of consistent recording of ethnicity and it was only 
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introduced to the centre in recent years. Where an ethnicity entry has been recorded 
it will be used throughout the woman’s screening data. This will be discussed in the 
relevant chapter below. A further limitation is that using a SW London population 
may not be generalisable to the UK population, this will also be discussed in the 
relevant chapter later. 
A mixed effects model has been selected due to the repeated nature of the 
measurements of the women. The analysis needs to account for any correlation 
between a woman’s previous attendance and her future attendance without interest 
in any specific woman’s attendance compared with another woman. Subsequently, 
random effects modelling was therefore used to account for similarities within 
women but also accounting for the fixed effects of the other covariates. 
Furthermore, mixed effects models are particularly useful when the dataset contains 
varying amount of information for different women, as in this one – some women 
may appear in the data just once, others may appear frequently, some may appear 
every three years, some may appear only twice (220, 221). 
2.4.3 Questionnaire design 
Within this section of the research project I developed a deductive questionnaire to 
measure personal characteristics, risk of BC and levels of IC among women. A 
deductive approach was chosen as it will use information from the previous studies 
and literature to help develop the appropriate questions (222). This was used to 
assess if personal demographics and BC risk profile are associated with either uptake 
of mammography or making an IC.  
A questionnaire was chosen as it is the most practical tool to reach a large sample 
population within a short time frame (222). Some research suggests methods such 
as questionnaires are also the most useful in collecting personal information 
accurately as the researcher is not involved in the completion of the questionnaire 
and therefore the participant has little desire to complete the questions inaccurately 
or to answer with information they believe the researcher is hoping to find (223, 
224). Nevertheless, social desirability bias is still found in some surveys and clearly 
some participants of surveys tend to present a favourable image of themselves (225), 
particularly for behavioural or personality questions (226). This increases the need 
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for indirect questioning on variables that are subject to social influence (227). A 
questionnaire typically has a poor response rate and also has a potential for 
response-bias, for instance only those with strong opinions or interest in breast 
cancer research will likely reply (228, 229). A questionnaire is also limited as there is 
no opportunity to follow up ideas or clarify answers where an interview research 
method would be more appropriate. Despite this, a questionnaire has numerous 
benefits for this research since many more women can be reached in an easy format. 
2.4.3.1 How the items were selected 
The items were selected in relation the literature and in relation to the findings of 
the secondary dataset. For example:  
• The Tyrer-Cuzick (T-C) model was used to estimate a woman’s personal risk 
of developing BC as discussed in the questionnaire chapter below (10). To 
estimate the risk of BC specific information needed to be acquired including 
information to calculate body mass index (BMI), details about menstruation, 
parity and menopausal status, medication use such as HRT and oral 
contraceptives and previous breast disease history including family history. 
• Three sections reflected the components of IC. To ensure ‘sufficient’ 
knowledge, a woman must answer more than fifty percent of the questions 
correctly, meaning she will correctly answer five out of the nine questions 
(230). The questions assessing knowledge and attitude were based on 
previous work conducted by Marteau et al. (164). However they were 
adapted for use with mammography uptake. Behaviour was assessed by 
whether the woman has attended screening within the last three years. 
• Personal characteristics questions were guided by national census survey 
questions deemed suitable and appropriate to ask participants. These 
questions were posed last to maximise participation and relate to predictors 
previously found to be associated with uptake of mammography (231, 232). 
 
Items related to IC were based on the requirements for IC from Marteau et al. work, 
initially conducted in pre-natal screening, as described in further detail in chapters 
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below (164, 233). These items were then validated by Michie et al. (186, 234) before 
being used as part of decision aids in studies about screening programmes by Barratt 
et al. (192). In 2010, Smith et al. (188) used the measure of IC in a bowel cancer 
screening study and Matieu et al. (235, 236) adapted it for use in a BCS decision aid 
tool. These adapted questions have been used as closely as possible in this 
questionnaire.  
2.4.3.2 Cognitive Interviewing 
Cognitive interviewing is a valuable tool in the development of a questionnaire to 
identify and correct problems at an early stage (237). Not all respondents will process 
the questions in an identical manner (238). The cognitive interview will allow the 
researcher to consider how question items will function across a range of 
demographics. 
The process of cognitive interviewing involves an assessment of how people answer 
and think about the questions posed to them during the questionnaire process. It is 
based on the understanding that answering a survey question requires iterative and 
complex information processing – starting with comprehension of the question, 
retrieval of information and then a judgement of motivation to answer the question 
truthfully (232). As a tool, it is useful to gain insight into how a potential research 
participant would answer them and to identify if the questions are being asked in an 
appropriate manner (239). Cognitive interviewing is useful to develop wording that 
is unambiguous and permits a successful response to what the researcher intended 
to ask (240). 
In the interview setting, it was anticipated questionnaire respondents would like to 
offer qualification to their answers on items (241). Whether the comments were 
intentional, direct questions and feedback or incidental this provides important data 
for collection (241). I selected the ‘think-aloud’ technique, based on the origins of the 
Think Aloud Protocol and concurrent verbalisation (239, 242), here as it reduces the 
influence of interviewer bias and is conducted in an open-ended format. 
Furthermore, some research suggests that this concurrent verbalisation technique is 
less invasive and less disruptive than concurrent probing but provides more accurate 
insights than retrospective probing which relied on respondents recall (239). This is 
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important, particularly at the early developmental phase of the questionnaire to 
ensure every possible issue or response is accounted for (239). If the interview 
participant does not ‘think-aloud’ more instruction will be given before direct 
probing questions are used to prevent influencing the cognitive processes (243). If 
anything remains unclear retrospective probes will be used to clarify concurrent 
verbalisations (243). 
Whilst I have not administered the questionnaire myself, the developed 
questionnaire will be of further use in future research on this topic and I hope will go 
on to inform practice. Once developed, this questionnaire could be used with women 
of screening age. Demographics, personal BC risk and IC for each woman could then 
be analysed to answer currently unknown questions about who is attending and who 
is making ICs within the NHSBSP. The results of this research will be vitally important 
for the NHSBSP, as the results will help to determine the future of the screening 
programme’s invitation style and approach. It could be that a personalised invitation 
may be adopted, tailored to personal BC risk, or it could be that more focus is put 
onto ensuring ICs are made by all women attending. All of which will be beneficial for 
the women invited to screening. 
All questionnaire design, development and cognitive interviewing will be conducted 
in English. Whilst this prevents non-English speakers participating in the research and 
potentially minimising the richness of the data obtained, there will be no attempt 
made to ascertain if translation of the materials maintains meaning at this stage, this 
is a limitation that must be acknowledged but one that could not be overcome at this 
timepoint. Further research to establish the effects of different languages and 
cultures would be preferable and important to conduct. 
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2.5 Overview of study flow 
An overview of the study order and research questions is shown below in Figure 21. 
 
Figure 21: Research flow plan 
 
2.4 Contribution to knowledge 
The aim of this doctoral work is to contribute new knowledge to the research field 
through multiple outputs. This information should be used by future policymakers 
and in future research. 
The first study will be a systematic review and analysis of international literature. This 
will combine all previous data on multiple different predictors and influencing 
variables for uptake of breast cancer screening.  
To the authors’ best knowledge, while many previous studies have looked at a small 
number of predictors in a sub-group of the population few have looked at all 
contributing factors to uptake in a worldwide setting.  
A scoping literature search was conducted in Medline, Cochrane Library and EMBASE 
with ‘predictors of attendance’, ‘predictors of non-attendance’, ‘uptake’, 
‘mammogra*’ and ‘breast screening’ used as search terms. This identified a number 
of relevant studies that were likely to be included in the final systematic review. 
However most papers focus on national programmes within Sweden, the UK or non-
national programmes in the USA and this has identified similarities and differences 
in predictors of uptake across the world. Furthermore papers have focused on 
specific groups of women such as the ‘over 65s’ or ethnic minorities.  
This systematic review will add to the previous work in the field of uptake of 
mammography research. It will be more recent and more innovative by firmly 
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establishing worldwide predictors of mammography uptake. My systematic review 
will incorporate and discuss the evidence for all types of women attending or not 
attending. It will not be limited to one single country and will also update the 
previous work which was conducted in the early 2000s. 
The London screening centre data analysis will identify patterns of attendance within 
London and identify if they are changing. More specifically, it will identify predictors 
of attendance (and non-attendance) and will ascertain if these predictors are 
changing over time. This information is not currently known. Little research has been 
conducted using all population subgroups and all predictors in London. This research 
will form the basis of identifying if more research is needed to extend the sample to 
the UK population in order to be more generalisable. 
To the authors’ best knowledge, no questionnaire research has been conducted to 
answer similar questions as the ones posed. For the future literature it will be 
important to identify if there is an association between these factors (personal 
characteristics, demographics, IC and uptake). However, perhaps more importantly 
it will affect future breast screening practice by providing specific information about 
the women and their likelihood of attendance and/or making an IC in BCS. 
To summarise, the review will add to the field of screening uptake research, 
identifying reasons for both attendance and non-attendance, and will provide 
important background information for more detailed investigation of changing 
screening patterns in London, UK. This is important for practice as specifics of who 
attends and who does not is currently unknown. The NHS aims to be equitable to all, 
however the NHSBSP needs answers about this ‘unreached’ group as it currently 
does not know who attends mammography. From this, and the questionnaire results, 
they can tailor information and ensure women are making informed decisions about 
attendance rather than being missed from the system. 
Chapter summary 




This thesis will identify predictors of attendance through a systematic review. The 
review will use international literature identifying predictors of uptake of breast 
cancer screening. Statistical analysis and narrative synthesis will be undertaken to 
indicate if uptake is changing. Summaries of the findings will be provided. 
The results from the systematic review will be further developed within the UK 
context using secondary data from SW London on uptake and its predictors. The 
results of this analysis will identify if patterns of uptake are changing over time, and 
if so in whom.  
Finally, a questionnaire will be developed to investigate whether personal 
characteristics and personal BC risk are associated with uptake of BCS and/or making 
an IC in breast cancer screening. Cognitive interviewing will be used so that the 
questionnaire is designed appropriately. 
This chapter has described the methodology underpinning the research conducted. 
Justifications for each study design have been provided alongside strengths and 
limitations of the approaches discussed.  
The next chapter explains in full detail the first phase of this research, the systematic 












Chapter 3: Systematic Review and 
Meta-Analysis 
Introduction 
This systematic review identifies current literature to provide a comprehensive 
understanding of predictors of mammography uptake. This systematic review is 
similar to a review conducted in 2008 (198) that sought to collate information about 
predictors of mammography uptake. Current literature contains many papers that 
examine predictors of uptake, but these papers tend to analyse individual predictors 
separately and only report influence of predictors individually. This review is not 
restricted by number or type of predictors and therefore provides a detailed 
overview. 
3.1 Research question development 
The research question for the review was ‘What are the predictors of breast cancer 
screening uptake worldwide?’ The sample population includes women invited for 
mammography screening worldwide. The outcome variable of interest is uptake of 
mammography. 
3.2 Aims and Objectives 
I aimed to identify the global predictors of mammography uptake. I performed a 
systematic review to identify, analyse and evaluate the quantitative data available 
for mammography uptake. 
This review had the following objectives: 
• To create a framework of predictors to highlight the different influences on 
uptake of mammography 
• To produce a summary of descriptive statistics regarding predictors of 
mammography uptake 
• To conduct a meta-analysis of available quantitative data, where possible 





My review was conducted in accordance with the protocol published on the 22nd 
November 2016 on the PROSPERO database (registration number: 
CRD42016051597) (206) which can be found in Appendix 8.1. This protocol outlined 
planned search strategies and inclusion criteria. 
This review has been reported using Guidelines for Meta-Analysis and Systematic 
Reviews of Observational Studies (MOOSE) and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) criteria (244, 245). 
3.3.2 Eligibility criteria and definitions  
Quantitative studies that mentioned at least one predictor variable of mammography 
uptake were included. Studies had to quantitatively report uptake, attendance or 
compliance data, either current, previous or changes, to be included. Uptake was 
defined as the active ‘taking up’ of the breast screening invitation, attendance as the 
action of going to the breast screening appointment, and compliance as fully 
participating in the breast screening programme, as the national guidelines 
recommend. 
This study was not restricted by country but was limited to only include studies 
written in the English language. Ninety percent of the study sample had to be within 
the country’s screening programme age range. A publication date cut-off of 1987 was 
imposed to reflect the start of the UK breast screening programme, one of the first 
programmes of its kind (246). Studies that relied on self-report mammography 
uptake were excluded to improve the accuracy and reliability of any results, as some 
evidence has shown inaccuracy of those with average or low perceived BC risk in 
reporting their uptake correctly (247). The full inclusion and exclusion criteria can be 








3.3.3 Search strategy 
A search strategy specialist at the University of Warwick library was consulted in the 
development of the search strategy and review protocol.  
The following MeSH terms were identified. Terms were ‘exploded’ where 
appropriate in this review: 
 
These search terms were used in the search strategy in Medline as depicted in Table 
5 below. The below search strategy was adapted where necessary for the relevant 
database. Searches were conducted on 28th November 2016 for Medline OVID, 
EMBASE and CINAHL, and on 5th December 2016 for PsychINFO, Web of Science and 
Cochrane Library. Reference lists of excluded reviews and meta-analyses were 
searched for relevant articles. Experts in the field were asked to assess the list of 
included studies. This provided additional papers of potential relevance (248-252). 




Table 4: Search strategy used in Medline EMBASE on 28th November 2016 
# Searches Results 
1 Breast*.mp. or exp breast/ 658985 
2 (screen* or “early detection” or mammogram* or 
“mass screening” or “screening program*” or 
“direct to consumer” or “health screen*”).mp. 
[mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword, 
floating subheading] 
1116901 
3 (uptake or adheren* or complian* or “patient 
acceptance of healthcare” or “patient 
acceptance” or “patient access” or attend*).mp. 
[mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword, 
floating subheading] 
1047679 
4 1 and 2 and 3 6254 
5 Limit 4 to humans 5748 
6 Limit 5 to English language 5464 
7 Limit 6 to yr=”1987-Current” 5391 
 
3.3.4 Study selection 
The search initially identified 9,607 unique articles. All articles were assessed by RC 
and independently assessed by a second reviewer, one of nine members of the 
research team. 
A pair of reviewers independently conducted title/abstract assessments. Of these the 
Kappa (211) value was 0.61 before disagreement resolution via discussion or using a 
third reviewer where necessary to raise it to 100% agreement. The remaining 239 
full-text articles were then independently assessed again by a pair of reviewers. Of 
these, the Kappa value was 0.74 (211) before disagreement resolution via discussion 
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or using a third reviewer were necessary to raise it to 100% agreement. The process 
and reasons for exclusion at the full text stage are provided in Figure 22 below. 
There are significant differences in the way breast screening is organised in different 
countries (253). For instance, in the UK women are invited to screening every three 
years. The screening programme is run by the NHS and is free at the point of delivery. 
Other countries screen alternate years, some require insurance policies, and some 
rely on opportunistic presentation to clinicians. These differences impose a difficulty 
in the evaluation of worldwide trends in BCS. However, it is important to obtain an 
international perspective on the uptake of mammography. A perspective of each 





Figure 22: PRISMA diagram of included studies (254)
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3.3.5 Data extraction 
All data extraction was conducted by a single reviewer (RC) and checked by a second 
reviewer. Four authors were contacted where data were ambiguous (116, 121, 140, 
255). 
In the paper by Scaf-Klomp (116) the reported percentage values did not match the 
calculated actual numbers of attendees/non-attendees. Therefore, the author was 
contacted (25th October 2017) with no reply. Another paper (Tatla, 2003 (255)) has a 
similar issue where the reported data do not equal the calculated values and again 
the author was contacted (25th October 2017) with no reply.  The paper by Szczepura 
et al. reported uptake from multiple screening rounds and it was uncertain whether 
data from women may be repeated in the study as they attended each round or each 
woman studied was unique. Szczepura was contacted on the 21st June 2018 with no 
reply. A typographical reporting error was identified in a paper by Freitas et al. as the 
numerator 805 of 13,951 participants did not equal the given 57.7% whereas a study 
sample of 8050 would have. Freitas was contacted on the 2nd July 2018 with no reply. 
The reported values have been used in any analysis or summary because the table 
may have accounted for missing data that has not been reported.  
The extracted information is summarised in Appendix 8.1.4. Percent of uptake was 
extracted or calculated where necessary for both attending and non-attending 
women within each sub-category. 
3.3.6 Quality assessment tool 
As described in Section 3.4.1.2 above, the Quality Assessment Tool (QAT) was used 
as it provides a standardised means to assess study quality and an overall quality 
rating. It contains six domains: selection bias; study design; confounders; blinding; 
data collection methods; and withdrawals and dropouts. The QAT tool has been 
evaluated for content and construct validity and inter-rater reliability and meets 
accepted standards (256).  
All QA appraisals were conducted by RC and were reviewed and checked by CN or 
LA. Assessors were not blinded for this process. Full description and guidance on how 
to use the tool has been published previously (215, 256).  
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3.4 Analysis Methods 
Quantitative analysis for the systematic review was conducted using the statistical 
programme ‘Stata 15.1’ (257) and ‘Review Manager 5.3’ (258) at the University of 
Warwick. Review manager was used where data were dichotomised, Stata was used 
where sub-group meta-analysis had to be performed. 
3.4.1 Data analysis 
A narrative summary of the included studies was undertaken and is provided in 
Section 3.6.4. All studies had data extracted in the same manner, using the data 
extraction sheet as displayed in Appendix 8.1.4. The sample sizes for the narrative 
analyses ranged significantly with the smaller studies having approximately only 30 
women included. More detail about the findings from the narrative analysis can be 
found in Appendix 8.1.5. 
Random effects meta-analysis was conducted on predictors in each case where data 
were available from at least three studies (259). For predictors with fewer than three 
contributing studies or where quantitative data could not be meta-analysed, data 
were summarised narratively for each predictor of uptake. 
Where data were dichotomised into groups, data were examined using Mantel-
Haenszel random effects meta-analysis and the effect is presented as an odds ratio 
(OR). Where data were provided in more than two discrete groups, sub-group 
random effects meta-analysis was conducted to compare overall proportion 
attendances. Random effects models were used to allow for differences in the 
underlying proportions of attendance between studies (209). 
3.4.2 Pooling data 
In order to effectively meta-analyse data, certain information needed to be pooled 
into a wider sub-group to incorporate the maximum available data. For instance, the 
age group bandings presented in papers were merged into <50years, 50-59years, 60-
69years and >70years. This was selected as a common age banding cut-off in the 
literature and incorporated the majority of the review data.  
Country data were combined into North America, UK, ‘other western’ and non-
western. This was chosen to create wider groups than the country level but to retain 
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key differences in data such as the requirement for insurance in North American 
screening programmes versus the UK. 
Insurance records were pooled into three insurance types: private insurance, free 
insurance or uninsured. This minimised the number of differences to allow for 
grouping. Smoking information was combined into never versus ever (minimising the 
need for an occasional smoking category that only occurred in one paper). Some 
predictors were pooled into just two categories. For example, BMI groups were 
categorised as BMI<30 or >=30kg/m2. This grouping was used as BMI=30kg/m2 is the 
cut-off used by NHS for obesity in adults. Women were pooled into either ‘White’ or 
‘other’ ethnicity to maximise the data. Similarly, marital status data were pooled into 
‘married and cohabiting’ or ‘other’. Married and cohabiting women were combined 
replicating previous literature which had pooled the groups in the same manner. 
Extracted income data were merged into ‘low’, ‘middle’ and ‘high’ incomes. Some 
papers already provided the information in this way, others were combined 
manually. SES was also pooled into high, medium and low categories. Caution was 
needed as different studies would have classified ‘high SES’ differently to one 
another or used different scales. However, every effort was made to ensure 
consistency across the review. 
Education was grouped into high, medium, low and no education as detailed in the 
provided studies.  
3.4.3 Quantitative analysis 
Forest plots were created to combine all data extracted for the systematic review by 
subgroup where appropriate. These showed significant heterogeneity (in the region 
of I2=68.0% to 99.9%). Funnel plots were used to assess for publication bias. All 
results are shown in Appendix 8.1.8. 
A Bonferroni correction was used when several independent (or dependent) 
statistical tests were performed on a single dataset (260). In order to minimise the 
likelihood of wrongly rejecting the null hypothesis that there is no significant 
difference in uptake of mammography between groups of women (a type one error) 
the alpha value needed adapting. The alpha value for the entire set of n comparisons 
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is equal to taking the alpha value for each comparison α/n. The advantage of using 
this method to make the p-value more stringent is that it allows a reduced likelihood 
of type one errors. However, it may also make it harder to detect real associations 
within the data (261). Data for thirty-three predictors of uptake have been extracted 
and analysed for these results. The Bonferroni correction uses the typical level of 
significance (p=0.05) and divides it by the number of statistical tests you conduct on 
the data, in this case it is thirty-three. Therefore the Bonferroni adjusted p-value 
significance level is: 𝑝𝑝 = 0.05
33
= 0.00152 (3 𝑑𝑑𝑑𝑑𝑑𝑑𝑖𝑖𝑚𝑚𝑚𝑚𝑚𝑚 𝑝𝑝𝑚𝑚𝑚𝑚𝑑𝑑𝑑𝑑𝑝𝑝 (𝑑𝑑𝑝𝑝)) (260). 
3.5 Results 
Study Characteristics 
There was a trend towards more papers being published more recently (within the 
last 10 years with the exception of 2009) as seen in the table below. 
  
Figure 23. Graph to show the number of included studies per year published between 1989 and 2016 
 
Twenty-six studies were found in the USA, closely followed by the UK (n=21). Thirty-
nine studies were undertaken within European countries (excluding the UK). Studies 

























Figure 24. Number of included studies per country within the review. A table of country characteristics in terms of 
their screening program can be found in Section 1.1. 
The majority of papers were retrospective cohort studies, followed by (prospective) 
cohort analyses and randomised controlled trials. 
  







































Types of studies included
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Inconsistencies of the included papers 
The majority of the included papers reported attendance data for national groups of 
women or large sub-sets of women. Most data reported were for general attendance 
at BCS programmes. A minority of papers were looking at re-screening of women. 
For instance they would report predictors of attendances of women who re-screened 
within the recommended guidelines (255) or participation following a false-positive 
result (262). Although they were included by the selection criteria these papers have 
purposefully been kept separate from those assessing general attendance and will 
be analysed independently. 
 
Appendix 8.1.4 lists the studies in detail, organised by author.
84 
 
3.5.1 Quality assessment results 
An overall weak rating was given to 4/91 (4.40%) studies. These studies were all given 
‘weak’ ratings in the sub-section “selection bias” meaning they were unlikely to have 
a representative sample of the population or a large number of invited participants 
did not participate. Results from these papers should be interpreted with caution. An 
overall moderate rating was given to 10/91 (10.99%) of studies. Five domains were 
rated as being of weak methodological quality in at least one study: selection bias = 
9.89% of studies (9/91); confounders = 7.69% of studies (7/91); blinding = 1.10% of 
studies (1/91); data collection = 2.20% of studies (2/91); withdrawals = 2.20% of 
studies (2/91). Particular problems were encountered with study design as the 
majority of studies were not randomised controlled trials and therefore rated as 
being of moderate quality. The blinding domain was also often non-applicable. 
Table 5: Quality Assessment Summary Table. QAT Rating key: 1 = STRONG = no weak ratings, 2 = MODERATE = 



































































Aarts 2011 (79) 1 2 1 NA 1 1 1 
Andersen 2008 (262) 1 2 1 NA 1 NA 1 
Aro 1999 (125) 1 2 1 NA 1 NA 1 
Banks 2002 (133) 1 2 1 NA 1 NA 1 
Bansal 2012 (248) 1 2 1 NA 1 NA 1 
Beaber 2016 (263) 1 2 1 NA 1 NA 1 
Berens 2014 (264) 1 2 1 NA 1 NA 1 
Blanchard 2004 (55) 1 2 1 NA 1 NA 1 
Bourmaud 2016 (265) 1 1 1 2 1 1 1 
Bulliard 2004 (266) 1 2 1 NA 1 NA 1 
Carney 2005 (267) 1 2 1 NA 1 NA 1 
Chiarelli 2003 (249) 1 2 1 NA 1 NA 1 
Chouliara 2002 (158) 3 2 1 NA 1 2 2 
Coyle 2014 (114) 1 2 1 NA 1 NA 1 
Euler-Chelpin 2008 (167) 1 2 1 NA 1 NA 1 
Ferrante 2006 (268) 1 2 2 NA 2 NA 1 
Fitzpatrick 2011 (269) 1 2 1 NA 1 NA 1 



































































Freitas 2011 (121) 3 2 1 NA 1 NA 2 
Gandhi  2010 (270) 2 1 1 NA 1 NA 1 
Gatrell 1998 (271) 1 2 3 NA 1 NA 2 
Giordano 2008 (272) 1 2 1 NA 1 NA 1 
Giorgi 2000 (273) 3 2 3 3 1 2 3 
Gregory-
Mercado 
2007 (274) 1 2 1 NA 1 NA 1 
Hurley 1994 (275) 1 1 1 2 1 NA 1 
Hyndman 2000 (276) 1 2 1 NA 1 NA 1 
Jean 2005 (277) 1 2 1 NA 1 NA 1 
Jensen 2012  (278) 1 2 1 NA 1 NA 1 
Jensen 2012  (279) 1 2 1 NA 1 NA 1 
Jensen 2015 (144) 1 2 1 NA 1 NA 1 
Jensen 2015  (280) 1 2 1 NA 1 NA 1 
Kee 1993 (281) 2 2 2 NA 3 NA 2 
Kinnear 2010 (282) 1 2 1 NA 1 NA 1 
Kinnear 2011 (283) 1 2 1 NA 1 NA 1 
Lim 2010 (284) 1 2 1 NA 1 NA 1 
Liu 2014 (250) 2 2 1 NA 1 NA 1 
Lagerlund 2015 (285) 1 2 1 NA 1 NA 1 
Lagerlund 2002 (75) 1 2 1 NA 1 NA 1 
Leung 2015 (286) 1 2 2 NA 1 NA 1 
Makedonov 2015 (287) 1 2 1 NA 1 NA 1 
Matson 2001 (288) 1 2 1 NA 1 NA 1 
Maxwell 2013 (143) 2 2 1 NA 1 NA 1 
May 1999 (289) 1 2 1 NA 1 NA 1 
Mayer 1998 (290) 3 2 2 2 1 2 2 
McCann 2002 (291) 1 2 1 NA 1 NA 1 
McCarthy 1996 (292) 1 2 1 NA 1 NA 1 
Meguerditchian 2012 (293) 1 2 1 NA 1 NA 1 
Meldrum 1994 (294) 3 1 3 2 1 2 3 
Moss 2001 (295) 2 2 1 NA 1 NA 1 
Norum 2012 (296) 2 2 1 NA 1 NA 1 
O'Byrne 2000 (141) 1 2 1 NA 1 1 1 
Offman 2013 (297) 2 1 3 NA 1 2 2 
Oh 2011 (298) 1 2 1 NA 1 NA 1 
Ore 1997 (299) 2 2 3 2 1 2 2 
O'Reilly 2012 (300) 1 2 1 NA 1 NA 1 
Otten 1996 (301) 1 2 1 NA 1 NA 1 
Page 2005 (302) 2 1 1 2 1 1 1 
Peeters 1989 (303) 1 2 2 NA 1 NA 1 
Peeters 1994 (304) 2 1 1 1 1 2 1 
Pelfrene 1998 (305) 1 2 1 NA 1 1 1 



































































Renshaw 2010 (135) 1 2 2 NA 1 1 1 
Rodriguez 1995 (306) 1 2 1 NA 1 NA 1 
Rutten 2014 (307) 1 2 1 NA 1 NA 1 
Rutter 1997 (308) 1 2 1 NA 1 2 1 
Scaf-Klomp 1995 (116) 2 2 1 NA 1 NA 1 
Seeley 1994 (309) 2 2 1 NA 1 2 1 
Segnan 1998 (310) 3 1 1 2 1 2 2 
Shippee 2012 (311) 2 2 1 NA 1 NA 1 
Simon 2001 (312) 1 2 1 NA 1 1 1 
St-Jacques 2013 (313) 1 2 1 NA 1 NA 1 
Szczepura 2008 (140) 1 2 2 NA 1 NA 1 
Taplin 1994 (314) 1 1 1 1 1 1 1 
Tatla 2003 (255) 1 2 1 NA 1 NA 1 
Taylor  1999 (315) 3 1 3 2 1 2 3 
Taylor-Phillips 2013 (166) 1 2 1 NA 1 1 1 
Tornberg 2005 (316) 1 2 1 NA 1 NA 1 
Ulcickas 1999 (169) 1 2 1 NA 1 NA 1 
Vaile 1993 (171) 2 2 1 NA 1 NA 1 
Valanis 2003 (317) 1 2 1 NA 1 NA 1 
Vermeer 2010 (252) 1 2 1 NA 1 NA 1 
Vidal 2014 (318) 2 2 1 NA 1 NA 1 
Visser 2005 (319) 1 2 1 NA 1 NA 1 
von Euler-
Chelpin 
2008 (320) 1 2 1 NA 1 NA 1 
Wilf-Miron 2011 (321) 1 2 1 NA 1 NA 1 
Werneke 2006 (322) 3 2 3 NA 1 NA 3 
Williams 1989 (323) 2 2 1 NA 1 NA 1 
Woodhead 2016 (324) 1 2 1 NA 1 NA 1 
Yarnall 1992 (325) 3 2 2 NA 1 NA 2 
Zackrisson 2004 (131) 1 2 1 NA 1 NA 1 





Figure 26. Overall summary of QAT scores. 
The majority (81.6%) of studies were rated as ‘strong’ quality on the QAT tool which 
was considered reliable. ‘Moderate’ methodological quality was given to 12.6% of 
the studies (with one weak rating in one section of the QAT tool). Six studies (5.8%) 
were given an overall ‘weak’ quality rating as they had been given more than one 



































Figure 27. Percent of quality assessment ratings as 'strong' (n=77/91), 'moderate' (n=10/91) or 'weak' (n=4/91) 
for the included studies. 
As shown in Table 7 most of the papers included multiple predictors. Many papers 


















3.5.2 Constructs of the review 
Table 7 below shows the frequency of studies identifying different overarching groups 
of predictors in BCS. A Venn diagram and the number of studies containing each of 
the combinations of the four constructs is provided below.  
The construct coded for each article was assessed by myself and was dependent on 
the type of data extracted for the article in question. For instance, if data about 
uptake dependent on age was extracted then this would be coded as ‘demographics’ 
data. If data about uptake dependent on the use of oral contraceptives, this would 
be coded as ‘health status or medication’. 
Table 6. A table of the number of studies containing each of the combinations of the four constructs of 
predictors of BCS uptake. The constructs consist of factors as shown in Appendix 8.1.3. 
One Two Three Four N 
Demographics    36 
Healthcare 
system 
   2 
Health status or 
medication 
   7 
Interventions    13 
Demographics Healthcare 
system 
  6 
Demographics Health status or 
medication 
  16 
Healthcare 
system 
Health status or 
medication 
  2 
Demographics Healthcare 
system 
Health status or 
medication 
 7 
Demographics Health status or 
medication 
Interventions  1 
Demographics Healthcare 
system 







Figure 28. Venn diagram depicting the number of included studies for each overarching construct of predictors. 
Individual included predictors are defined in Appendix 8.1.3 
Findings 
Overall methodological ratings ranged between weak (if study had been given two 
or more ‘weak’ section ratings), moderate (if study had been given one ‘weak’ rating) 
and strong (if no ‘weak’ ratings were allocated). 
Where appropriate, the number of women included in a study has been provided in 
brackets. For instance, a percentage may be provided as a rate of uptake, the number 
of women in absolute terms is given in the brackets (n=x) immediately afterwards for 
completeness. 
A summary table is presented at the end of this section. For all meta-analysed data, 
funnel plots were conducted and are accessible in Appendix 8.1.7.2. For each 
predictor, the points did not solely lie within the 95% confidence interval plot and 
therefore publication bias is present. 
Heterogeneity was high for all meta-analyses, between 68% and 99% meaning 
significant variation across the included studies was due to heterogeneity rather than 
chance. However, due to the large sample size of the included studies this is 
understandable as each estimate is extremely accurate yet quite disparate from 
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another estimate likely causing the high heterogeneity score. Instead, these tests 
provide evidence that there is significant variation across BCS programmes. 
Some predictors did not provide enough data to quantitatively analyse their effect 
on mammography uptake and instead data have been appraised narratively. Each 
contributing study or group of studies is briefly described as an overall summary with 
more detailed narrative analysis found in Appendix 8.1.5. 
Some papers could not be combined with the quantitative data. Studies that used 
data which sums to 100% (i.e. giving characteristics of the attendee population rather 
than attendance rates for the invited population) are presented in Appendix 8.1.6. 
3.5.1 Demographics 
 













Marital status groups were combined based on similarities between groups to 
investigate if being married/living with a partner was a significant predictor of 
attendance at BCS. Groups were therefore divided into ‘married or cohabiting’ and 
‘other’. Data were pooled based on the hypothesis that marital status influences 
uptake by means of social support.  
The odds of attending BCS for women who are married or cohabiting were 60% 





Figure 30. Meta-analysis results for marital status data. Cohabiting includes married women also.
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Four studies provided quantitative data on ethnicity that could be meta-analysed (55, 
248, 289, 292). There was no significant difference found between attendance of 
White and non-White women, OR 1.08 (0.87, 1.35), p<0.000152. 
 
Figure 31. Meta-analysis results for ethnicity data 
Age 
After removing data that were inconsistent with the specific research question, 
quantitative analysis was conducted on the remaining studies (62, 79, 131, 133, 135, 
140, 144, 166, 255, 279, 283, 296, 300, 301, 303, 304, 306, 309, 326). 
The meta-analysis found, on average, 79% (75, 83%) of women aged under fifty 
attended BCS compared with 75% (68, 81%) of women aged 50-59 years, 71% (64, 
78%) of women aged 60-69 years and 63% (47, 78%) of those aged over seventy. 









Ten studies provided data on SES for the purpose of this analysis (79, 133, 135, 140, 
141, 171, 255, 266, 276, 287). Any data that could be merged into three groups, high, 
medium and low SES, were used for the quantitative part of the analysis. Attendance 
by women of lower SES was 60% (48, 71%) compared with 73% (61, 84%) for women 
of medium SES and 73% (54, 88%) for women of high SES. There was no significant 




Figure 33. Proportion attending mammography by socioeconomic status 
Income 
Income data were extracted from eight studies (75, 125, 169, 263, 278, 279, 327, 
328). Of women who have a low income, 64% (54, 74%) attended BCS compared with 
73% (63, 82%) of women with a medium income and 73% (62, 82%) of high income 




Figure 34. Proportion attending mammography by income level. 
Housing tenure 
Four studies offered data on housing tenure (75, 278, 283, 300). Data were merged 
into women who either own or rent their homes (privately or socially). 
Forest plots were constructed as shown in Figure 35. On average, 85% (77, 91%) of 
women who owned their own house attended screening compared with 71% (62, 
80%) of women who rented privately and 61% (60, 63%) of women who lived in social 
rented accommodation. Based on overlapping confidence intervals, this indicates no 
statistically significant difference in uptake between the group of women who rented 
their housing privately and the other groups. A statistically significant difference was 
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observed between women who own their own house and those who live in social 
rented accommodation. 
 
Figure 35. Proportion attending mammography by housing tenure data. 
Education 
Level of education was analysed as a potential predictor using data from nine studies 
(75, 121, 125, 144, 158, 168, 266, 268, 326). Data were combined into high, average 
or low levels of education. Women who had up to secondary school education were 
defined as ‘low education’, those who had more than secondary school education 
but less than university education were classified as ‘average education’ and women 
with university education were classed as having ‘high education’. 
100 
 
Of highly educated women 71% (66, 77%) attended BCS. Of women who had an 
average education, 75% (70, 80%) attended, and amongst those with low education 
71% (63, 78%) attended. Of women without education 75% (60, 88%) attended. This 
suggests that education level is not a significant predictor of BCS uptake. 
 





Data from seven studies provided data on insurance and mammography uptake (55, 
263, 268, 284, 298, 315, 321). 
 
Figure 37. Proportion attending mammography by insurance status. 
Of women who had free or national health insurance, 53% (38, 68%) attended BCS 
compared with 51% (23, 78%) and 12% (8, 18%) of women with private insurance 
and no insurance respectively. Unsurprisingly women without health insurance 
showed significantly lower rates of uptake. Data from other included papers that 
could not be analysed quantitatively with the above data also supports the argument 
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that women with insurance are more likely to attend than women without insurance 
(284, 298, 315, 321). 
3.5.1.2 Narrative analysis findings 
Marital status 
Two papers provided data about marital status and uptake that could not be 
combined into the meta-analysis (299, 329). These papers suggest that the majority 
of women who attended screening were married (56.3% in the Israel paper (299) and 
64.1% in the USA study (329)). 
SES 
Overall the narrative data supports the idea that uptake increases with affluence, 
whether that be measured by deprivation level or by employment status. 
Additionally, two studies found SES to be significantly associated with uptake of 
mammography. However, our meta-analytic findings did not find a significant result. 
This could be because SES definitions varied considerably between papers (75, 140, 
166, 276, 278, 283, 288, 299, 321, 330). 
Ethnicity 
The narrative data highlights lower uptake in minority ethnic women, this is 
contradictory to my meta-analytic findings which found no significant difference 
between women of different ethnicities (329). The narrative data found increased 
uptake in women whose preferred language is English (255). One study investigated 
the impact of religion and found lower uptake in atheist women (331). Six of the 
seven papers that provided data about nationality state uptake is higher in native 
women (140, 141, 169, 299, 320, 321). The exception found in Germany, uptake was 
highest among women of Turkish origin (264). 
Insurance 
Two studies from Israel (321) and USA (263) found lower uptake in uninsured women 
which is directly comparable to the significantly lower uptake in uninsured women 
found by my meta-analysis. Contradictorily, lowest uptake was observed in Korean 




The data available about the effect of age on uptake is inconsistent. This finding was 
also observed in the meta-analysis results where a non-significant finding was found 
between age groups (140, 144, 158, 163, 167, 171, 267, 272, 284, 285, 299, 300, 302, 
307, 313, 315, 317). 
3.5.1.3 Summary 
The meta-analysis results found women who were married were more likely to 
attend BCS. Uninsured women were significantly less likely to attend compared with 
women who were insured. Surprisingly, meta-analyses showed that age, SES, 
ethnicity, income, housing tenure and education were not found to be significant 
predictors of mammography attendance.  
The narrative analysis found similar results in so much as married women were more 
likely to attend and minority ethnic or uninsured women were less likely to attend. 
The narrative paper did go on to suggest a lower uptake in atheist women, something 
the meta-analysis did not investigate due to limited data. There were inconsistent 
findings for age which is comparable to the non-significant result from the meta-
analysis. Additionally, uptake was found to increase with affluence, something that 
was not supported with my meta-analysis results. 





Figure 38. In this section health related predictors of mammography attendance are discussed 
3.5.2.1 Meta-analysis 
Data from studies reporting smoking status were extracted (125, 266, 268). 
A meta-analysis was conducted to compare smoking status groups and is shown in 
Figure 39. Women who smoke have 38% lower odds of attending [OR 0.62 (0.45, 
0.86), p<0.000152] compared to women who do not smoke. 
 
Figure 39. Meta-analysis results for smoking data. 
Data regarding general illnesses and chronic health conditions were extracted for this 
review (125, 144, 250, 293, 308, 322, 324, 326). 
Women who had chronic conditions were 30% less likely to attend BCS than women 
who did not have chronic conditions, OR 0.70 (0.61, 0.81), p<0.000152 as seen below 




Figure 40. Meta-analysis results for chronic conditions data. 
Data from studies providing information on primary care visits were extracted (121, 
263, 268). Groups were categorised as ‘0-2 visits’ or ‘3 or more’ within the last year. 
This review found women with 0-2 primary care visits in the last year were 73% more 
likely to attend BCS, OR 1.73 (1.06, 2.84), p<0.000152 compared with women who 
attended 3 or more times.  
 
Figure 41. Meta-analysis results for primary care visit data 
The quantitative data available for BMI were extracted from (263, 266, 268). There 
was no significant difference in attendance between obese and non-obese women, 
OR 0.86 (0.71, 1.05), p<0.000152. 
 




3.5.2.2 Narrative analysis findings 
Comorbidity 
Five studies investigated attendance in relation to comorbidity suggesting mixed 
results (144, 322, 324, 326, 332). On balance it appeared that other illnesses do not 
necessarily affect BCS attendance. This is contrary to my meta-analysis results above 
which suggested that women with chronic conditions were less likely to attend BCS. 
HRT  
The narrative results are mixed with studies reporting the opposite effects of HRT on 
uptake. However, these studies are conducted in disparate settings (Australia and 
UK) and perhaps there are other influencing factors that cannot be accounted for 
here (141, 309). 
Family history 
The results about the effect of family history on uptake are variable and further 
research needs conducting (141, 168, 268, 306). 
Previous health behaviours 
Previous attendance at cervical or breast screening and breast self-examination has 
been associated with variable rates of mammography uptake (125, 166, 171, 255, 
289, 292, 293, 295, 298, 306, 308, 332, 333). 
Psychosocial 
Uptake was found to be higher in women who knew the preventative role of BCS 
(306) and in women who believed BCS did more good than harm (281). Uptake was 
also reportedly higher in women who believed their risk of BC was moderately higher 
compared to women who did not think their risk was higher (125, 306). Of women 
who expected BCS to be painful, uptake was lower (125). 
Attenders were found to be more likely to have social support – either instrumentally 






Of women who experienced intimate partner violence, victims were more likely to 
be up-to-date with mammogram screening (270).  
3.5.2.3 Summary 
From my meta-analysis results, women who had never smoked, had no chronic 
conditions or had three or more primary care visits annually were found to be more 
likely to attend BCS than women who had smoked. BMI was not found to be a 
significant predictor of mammography uptake. 
Narratively, there were mixed reports about the effect of co-morbidity, HRT and 
family history on mammography uptake. Women who had attended other 
preventative services were more likely to attend mammography. Women who knew 
the role of BCS, believed their risk to be moderately high or believed BCS did more 
good than harm were more likely to attend. Women who expected mammography 
to be painful or those who worried about mammography were less likely to attend. 
For more detail, please see Appendix 8.1.5.2. 
3.5.3 Other Predictors 
 






The odds of attending BCS were 28% higher for women who were care-givers for 1-
19 hours per week compared with women who were not care-givers, OR 1.28 (1.19, 
1.38) (282). There was no significant difference found in attendance for women who 
spend more hours per week as a care-giver (282).    
GP 
Data about physician characteristics were extracted to investigate if this was 
associated with uptake of BCS. Overall, 37.9% of women attended if they had a 
female physician compared with 41.7% of those with a male physician (279, 293). 
82.0% of women with a physician with a positive attitude attended compared to 77.5% of 
women with a physician with a negative attitude (279). 24.3% of women whose GP 
graduated less than ten years ago and 25.6% of women whose GP graduated ten or 
more years ago attended BCS (287). 
Urban-rural 
The majority of studies found uptake was higher in women living in rural settings 
(141, 168, 171, 286, 300). Only one study reported higher uptakes in urban-dwelling 
women and this study was conducted in Australia where distances are vast. However, 
in the case of rural women attending more it could be due to a confounding factor 
such as they are more likely to own a car, which was associated with uptake below 
or they may be different women to those living in urban settings, such as more 
affluent women. 
Screening site 
The studies reviewed narratively suggested that uptake is higher in women who live 
close to the screening site. Uptake is also increased for women who can attend a 
mobile screening site. This may be because of increased convenience for the woman 






Interventions that included a decision aid resulted in no significant difference in 
uptake (265). Uptake was higher in women who received a reminder (either by 
postcard, letter or text-message) (302, 318, 323, 334, 335). Uptake was also higher 
in groups who received an appointment time (275) and those who received tailored 
information – either to address barriers to attendance or by using their previous 
screening history (294, 317). Incentivised uptake studies did not find a significant 
difference in uptake behaviour between those who received an incentive and the 
control groups (332). 
Car 
Uptake was found to be higher for women who had access to a car (121, 278, 300). 
Children 
The results of studies investigating the effect of children on uptake was variable (75, 
158). 
3.5.3.3 Summary 
There are no meta-analytic findings to summarise for this section. 
Narrative analysis findings suggest that women who were caregivers for between 1-
19 hours a week were more likely to attend mammography. Women with a GP who 
is female, has a positive attitude or graduated more than ten years ago were more 
likely to attend BCS. Women living in rural settings or invited to mobile clinics were 







3.5.4 Summary of predictors 
To summarise, the following figure presents all the predictors of BCS uptake that 




Figure 44. Predictors of BCS uptake in the review 
 











Table 7 A summary of meta-analysed odd ratio comparisons 
Predictor Number of 
studies included 




cohabiting v other) 
17 1.60 (1.38, 1.85) Married 
Smoking status 
(Ever smoker v never 
smoker) 
3 0.62 (0.45, 0.86)  Never smoker 
Chronic conditions 
(yes v none) 
8 0.70 (0.61, 0.81) No chronic 
conditions 
Primary care visits 
(3+ vs 0-2) 
3 1.73 (1.6, 2.84) 3+ visits 
Ethnicity 
(White v Other) 
4 1.09 (0.83, 1.42) No significant 
difference 
BMI 
(obese v non-obese) 






Figure 45. Summary of the sub-group meta-analyses conducted in Stata. The proportion attending 
mammography for each group are provided in one figure for reference and comparability.
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Below is a summary of the extracted, non-meta-analysed predictors only. 
Table 8. Summary of the lowest and highest reported uptake rates for each predictor. This data does not include re-screening data. 
Predictor Lowest 
attendance 
reported (%) (ref) 
Highest 
attendance 
reported (%) (ref) 
Comments 
Demographics (none to report)    
Health    









A mixed effect of HRT on uptake was found. Studies were conducted 


















92.6 (308)  
75.5 (171) 
Previous attendance at cervical screening appears to be associated 
with the uptake of mammography 









Breast self-examination appears to be associated with the uptake of 
mammography.  








Only Gandhi et al. (270) reported data on victims of abuse and uptake 
of BCS. Of women who experienced intimate partner violence, 















reported (%) (ref) 
Highest 
attendance 
reported (%) (ref) 
Comments 









Freitas et al. (121) used data from Portugal whereas Rodriguez et al. 
(306) used Spanish data. Both countries screen every two years 
from 45 years of age. Rodriguez et al. only provided information 
about women with knowledge. 












Uptake appears higher in women who knew the role of BCS. 








Of women who expected BCS to be painful, uptake was lower. 
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 The effect of having children on uptake of mammography appears 
variable 









 The majority of studies found uptake was higher in women living in 
rural settings. 









Uptake was higher in women who lived closer to the screening site 
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Uptake was higher for women who had a female physician 










Uptake was higher for women who had a physician with a positive 
attitude to BCS 















3.5.5 Sensitivity analyses 
Due to the large amount of heterogeneity in the meta-analyses, sensitivity analyses 
were conducted. The predictor age was used to base sensitivity analyses on as it had 
the largest number of studies included and also allowed the greatest number of 
sensitivity analyses. 
Firstly, sensitivity analysis was conducted based on year the data were published 
(pre- or post-2000) as the UK screening programme changed significantly during 
2000; the programme was expanded to include women aged 65-70 years and it 
introduced the use of two views to all screens (336). Heterogeneity remained high at 
I2>98.0%. Compared with the combined meta-analysis, the sensitivity analysis using 
only data published before 2000 changed the pooled attendance rates as can be seen 
in Table 10 below.  
There were only three studies in the oldest age group post-2000 analysis which all 
had high attendance across all ages. It is therefore difficult to identify if the observed 
effect of age is due to a real-life difference in age groups or simply a difference 
between the included studies. However, two of the included studies did show a lower 
attendance in this older age group relative to their younger age groups so it is likely 
that this effect is still a problem. 
Table 9. Sensitivity analyses age meta-analysis data by year published. 




<50 years 0.79 (0.75, 0.83) 0.87 (0.87, 0.88) 0.75 (0.69, 0.80) 
50-59 years 0.75 (0.68, 0.81) 0.79 (0.65, 0.90) 0.72 (0.64, 0.79) 
60-69 years 0.71 (0.64, 0.78) 0.76 (0.66, 0.85) 0.70 (0.61, 0.78) 
70+ years 0.63 (0.47, 0.78) 0.36 (0.35, 0.37) 0.77 (0.67, 0.86) 
 
Subsequently, only studies that scored ‘strong’ on the QAT assessment were included 
but heterogeneity values remained consistently high. Thirdly, a further subgroup 
meta-analysis was conducted using geographical location within the age data. The 
heterogeneity consistently remained high at I2>90.0%. There were some differences 
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between pooled attendance rates at different geographical locations as shown in 
Table 11. 
Table 10. Sensitivity analyses age meta-analysis data using geographical location. 




USA and Canada UK 
<50 years 0.79 (0.75, 0.83) 0.86 (0.83, 0.89) 0.48 (0.26, 0.70) 0.77 (0.65, 0.86) 
50-59 
years 
0.75 (0.68, 0.81) 0.81 (0.76, 0.85) 0.54 (0.38, 0.71) 0.78 (0.71, 0.84) 
60-69 
years 
0.71 (0.64, 0.78) 0.77 (0.71, 0.84) 0.57 (0.37, 0.77) 0.73 (0.68, 0.77) 
70+ years 0.63 (0.47, 0.78) 0.68 (0.40, 0.91) 0.57 (0.40, 0.74) No data 
 
Finally, sub-group analyses were conducted using only data that did not sum 
attendees or non-attendees to 100% and another using only data that did not 
included re-attendance.  
Removing any particular group of studies did not result in a reduction of 
heterogeneity to any desirable level. These analyses are shown graphically in 
Appendix 8.1.7. 
3.6 Discussion 
This study has reviewed the current evidence about predictors of breast screening 
uptake using worldwide data. It has collected and collated information in order to 
provide an overarching summary of associations with BCS attendance. 
Fundamentally these studies are very heterogeneous and cannot always be reliably 
combined in analysis. Despite this it remains important to attempt to identify 
predictors of BCS uptake. 
Data were obtained from studies published within a twenty-nine year timeframe 
from 1987 to 2016. There are likely to be different rates of uptake from these 




Data were collected from a wide range of countries including USA, UK, Korea, Israel, 
Spain. The sample was heavily influenced by studies coming from the UK and USA 
(43.7% of included papers) with minimal input from non-western countries (7.8% of 
included papers). Healthcare practices vary widely from free at point of care to 
insurance-based policies. Nonetheless, data were pooled to obtain an overall 
estimate of the predictor and its association with uptake. 
It must be noted that the majority of data (61% of included papers) came from 
retrospective cohort studies. To increase accuracy and reliability, papers that used 
self-report data for uptake were excluded. However, some studies will have used 
self-report data in terms of SES and ethnicity and this should be considered when 
interpreting the results.  
SES is defined as the social position or class of an individual or group, in this instance 
it is used to measure which group a woman is thought to belong. SES is often 
measured as a combination of education, income, occupation and/or access to 
resources (337). Each of these individually has its own strengths and limitations but 
in combination they are thought to provide a reasonable assessment of ones material 
situation (338). The advantage of using this type of analysis is that the information is 
often readily available and easy to analyse (338). Someone may be classified as ‘poor’ 
if they are rated low on any scale of SES measurement. Furthermore there are some 
key limitations with how SES is often measured. For instance, in the UK a woman’s 
SES was measured by the occupation of the male earner in the household until 2000, 
despite who had the more advanced job or income (338).  
Of note here is the dissimilarity of reporting of SES between studies. Some reported 
SES as high, medium or low. Other papers reported SES in quintiles. O’Byrne et al. 
used the ‘socioeconomic index for areas’ from Australia, of which the two most 
affluent groups were merged (141). If data could not be merged into three distinct 
groups as described, they were not analysed quantitatively in this review. SES data 
as proxy of occupation, community income or education were analysed narratively 
as reported Appendix 8.1.5.  
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3.6.1 Do my results agree with other studies? 
3.6.1.1 Demographics 
The included papers reported age categories differently. Consequently, I combined 
data into four age groups that allowed the maximum amount of data to be used. The 
meta-analysed age data showed non-significant differences. However, conclusions 
are difficult as the effect of age may be lessened as age increases masking effects 
such as media exposure and changing social attitudes (cohort effects, discussed more 
in chapter 5 below) and previous experience as women are re-invited for screening 
every three years in the UK but more frequently elsewhere (339). This finding for age 
is contrary to the hypothesised outcome found in previous literature and an 
important issue for future research, to understand whether particular age groups of 
the population have different attendance patterns and this will be investigated in 
more detail in Chapter 5 on predictors of attendance at a London, UK breast 
screening centre. 
My meta-analytic findings indicated there was no significant difference in attendance 
between women of different SES groups. This is not consistent with previous 
literature which indicates that more affluent women are more likely to attend 
screening (79, 133, 135, 340). 
Results of this review also demonstrate that women with low income are no less 
likely to attend screening than women of higher incomes. It is, again, a surprising 
finding because it is logical that in countries where attendance requires out-of-
pocket expense, income may be closely associated and/or influence uptake. We may 
need to take into account that women with high income may be able to afford private 
screening, and this information would unlikely be included in this review. 
Again, a consequence of analysing data from a heterogeneous sample of countries 
means that high income in one country may not equate to the same level of income 
in another country. Being considered ‘poor’ in the USA is likely very different from 
being ‘poor’ in Sweden. Additionally, each country has its own protocol of how 
women can access screening programmes and therefore material deprivation may 




Again, this review found no significant difference between White women and women 
of other ethnicities, OR 1.09 (0.83, 1.42). Previous literature has indicated a lower 
BCS uptake among women of minority-ethnic backgrounds (122, 137). This is 
investigated further in Chapter 5. The pooling of this data is a cause of concern, the 
ethnic minority in one country may be the ethnic majority in another and thus 
countering each effect. Analysis without the study from North Korea was conducted 
in order to assess for this effect due to its large sample size of over a million women 
but no observable difference was found. 
Lower educational background has previously been associated with lower uptake of 
BCS (127, 341) which is not consistent with results of this review. Surprisingly, this 
review found the highest rates of attendance averaged 75% (67, 84%) for women 
with no education. However a meta-analysis conducted in 2015 on papers published 
between 2000 and 2013 found the odds of attending were 61% higher for women 
with higher education compared with lower education, OR 1.61 (1.36-1.91), 
p<0.0001 (127). Despite this, Anagnostopoulos et al. acknowledge that the 
differences in the literature about the influence of education on mammography 
could be accounted for by the type of BCS programme such as national or 
opportunistic (342). 
Previous research has found that attendance at BCS was higher in women who were 
single, divorced or widowed compared with women who were married or cohabiting 
(128, 129, 278). My results do not support this, consistent with other research which 
suggests being married is a predictor of attendance (116, 125, 154, 169, 343). The 
difference in findings could be due to a confounding factor such as social support 
which has been associated with uptake separately (280). Simply because a woman is 
married does not ensure she has more support than a woman who is not married. 
Women who were insured were significantly more likely to attend BCS than those 
who were uninsured. This is consistent with the anticipated hypothesis as in 
countries with national screening programmes that incur an out-of-pocket expense 
it is somewhat unlikely that low income women would attend unless they had 
insurance to cover the expense. 
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Women who owned their property were found to be more likely to attend BCS than 
women who socially rented their housing. This may be interlinked with SES, location 
in relation to screening site accessibility site distance and location or other factors 
such as car access. It could also be the case that women who rent their home are 
likely to move house more frequently and consequently may not register with health 
services or receive invitations to screening. This was suggested previously as an 
explanation for lower attendances in cities with transient populations (139, 154). 
3.6.1.2 Health 
Attendance of women defined as obese (BMI≥30) was not significantly different from 
women who were not obese, OR 0.86 (0.71, 1.05). This is not consistent with work 
conducted by Damiani et al. who found that obese women in Italy (as measured using 
BMI) were less likely to attend BCS compared to women who are not obese, OR 0.87 
(0.77, 0.98) (2dp) (124).  
There are multiple factors that influence a decision within the realms of 
‘psychosocial’ determinants. Women in this review who perceived their BC risk to be 
lower than average were associated with lower uptake of BCS. This is concordant 
with previous research on this topic by Drossaert et al. (152) which highlighted 
‘perceived threat’ as important in the HBM for screening decisions (112). 
‘Expectation of pain’ was only reported as a predictor of uptake from one study. 
Uptake was found to be higher in women who did not expect pain (125). This is 
consistent with previous literature suggesting pain expectation or previous 
experience of pain is a deterrent to participation (98, 181). 
It is difficult to ascertain what may be happening in the case of the predictor 
‘knowledge’. It is likely a factor that influences each woman differently depending on 
other interacting predictors. For instance, for some women, understanding the risks 
and limitations may be preventing attendance at BCS. Equally, for others who 
understand the risks and limitations they may still attend BCS for different reasons. 
Smoking appears to be associated with women’s attendance at BCS. My meta-
analysis estimates that women who have ever smoked are less likely to attend 
screening than women who never smoked. This is consistent with results from 
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previous survey data that found smoking was associated with a decreased probability 
of attendance (344). 
Previously, research has found women with a current prescription for HRT are more 
likely to attend BCS (133). Reported uptakes of this review also estimate attendance 
is higher in women who have ever used HRT. This could potentially be linked to a 
confounding factor as the number of contacts made with a healthcare professional 
as an increased number of primary care visits was statistically found to be a predictor 
of uptake in the meta-analysis. However, further research is warranted to confirm or 
refute this hypothesis. 
The healthiest women are generally found to be those with highest attendance at 
BCS (77). This review has not demonstrated this as women with 3+ primary care visits 
have higher attendance compared with women with 0-2 visits. There was no 
reported data on the reasons why women had attended primary care and so the data 
may not accurately differentiate between healthy patients and non-healthy patients 
and so conclusions from this are to be interpreted tentatively. 
A more accurate representation of this information may be in that analysed as 
‘chronic conditions’, where women were categorised based on the number of 
chronic conditions, defined as those that “regularly affect daily living”. The review 
found that for women with no chronic disease they were 30% less likely to attend 
BCS than those with a chronic disease, OR 0.70 (0.61, 0.81). This is supportive of 
research conducted by Selvin et al. who reported a similar effect size, OR 0.72 (0.53, 
0.98) p<0.05, for women with self-reported health status as excellent/very 
good/good compared with those who reported their health as fair/poor (344). Again, 
these women who have chronic disease(s) were likely have more frequent contact 
with healthcare professionals and perhaps therefore have a better understanding of 
the BCS programme or have more opportunity to discuss their attendance. For 
women who had mental health related conditions, results appear to show uptake 
rates are lower, ranging between 30.6% and 50.8%, compared with the reference 
population of non-serious mental health patients (322, 324). Uptake of BCS was 
lower in hospitalised women also.  
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As with other predictors, the influence of family history of BC on uptake of BCS is 
difficult to estimate. Previous research has found conflicting outcomes with both 
increased and decreased uptake (119). In this review, reported uptake was higher in 
women with a family history of BC. 
Previous attendance has been strongly associated with future attendance (150). This 
review found women who have previously attended BCS were more likely to attend 
subsequent rounds.  
Women who practice BSE at least once a month were found to be attending BCS 
more frequently than those that do not, consistent with previous literature (77, 125, 
171, 306, 345). This may be for a variety of reasons including worry or conforming to 
societal ‘rules’ of attending preventative services. 
Consistent with previous research (77), this study found women with previous 
cervical screening history were more likely to attend BCS than those without a 
screening history (171). In the analysis of a nation survey in 1998 conducted by Selvin 
et al., having a usual source of care was the most important factor underlying uptake 
of both breast and cervical screening invites (344). 
Despite mounting evidence suggesting IPV has long-lasting negative effects on the 
health of the victim (346), this review found that women who were victims of abuse 
were more likely to attend BCS than women without any abuse experience. However, 
there is insufficient data in this review to conclude how such an association may be 
influencing uptake and further research is warranted. 
3.6.1.3 Other 
In this review the findings were variable as to whether women with children were 
more commonly found to be higher attenders at BCS than women without children. 
This is not consistent with the anticipated findings as previous research has cited 
childcare as a barrier to attendance (75, 347-349). 
No meta-analytical assessment was made on housing location. However, from the 
narrative summary of included studies it can be observed that higher reported 
uptakes were found in women living in rural locations. Perhaps this is due to a 
fundamental difference between women who live in urban and rural settings which 
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cannot be accounted for in this review. It is important to note the heterogeneity of 
locations the data were sampled from – living in a rural setting in Canada or Australia 
is very different to living in a rural setting in the UK, and this needs to be considered 
in interpretation of the results. 
Car access appears to be associated with BCS uptake. Uptake of BCS was higher in 
women with access to a car. This is also likely due to a combination of other 
confounding factors. Women with car access are more likely to be affluent members 
of the population (138) which was associated with higher attendance in previous 
literature but not in my review (133). Additionally, women with access to a car are 
less likely to have logistical barriers in travelling to the screening site. 
Distance to screening site is known to be an influencing factor in the uptake of 
mammography, with uptake often being lower in women who have larger distances 
to travel (138, 163). In this review, women who lived ‘close’ to the screening site 
were more likely to attend BCS. However, from data included in this review, the type 
of screening site does not appear to be associated with uptake. 
The extracted data suggests the GP is a predictor of attendance at BCS. In line with 
expectations, results suggest women with a female physician are less likely to attend 
than those with a male. Only one paper reported the influence of GP attitude on 
uptake and those with a positive attitude had higher rates of uptake. Associations 
between GP attitude and BCS attendance are not always found to be significant in 
previous work (350). Reported data estimates women under the care of a GP who 
graduated fewer than ten years ago were slightly less likely to attend. This is perhaps 
reflective of more up-to-date understanding of evidence-based practice. Again, only 
one paper included in this review reported on this predictor (287). 
The anticipated hypothesis was to find lower uptake in women who were considered 
to be caregivers due to preventative barriers such as time, money or worry (351). 
This review found that uptake was higher for women who are caregivers’ than those 
who are not caregivers. This finding was contrary to the hypothesis and could be 
because I combined any amount of caregiving into one category and analysed carer 
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versus non-carer rather than non-carer, part-time carer and full-time carer. However, 
there was insufficient data available to answer that more specific question. 
The results of this review suggest interventions have increased uptake. In the USA, 
women receiving a letter endorsed by a physician showed higher uptake rates 
compared to women receiving no endorsement; the same was observed in Italy (43, 
144). Furthermore, this review found interventions of simple reminders were shown 
to increase likelihood of attendance (314). This is consistent with previous research 
suggesting reminders improve uptake (161). However, the type of reminder and 
other factors such as method of reminder and distance to screening site appear to 
have impact. Similarly, women who received tailored invitations to BCS were more 
likely to attend than those who did not (84, 124). Another intervention that has 
produced increased uptake at BCS include invites with the option of an out of office 
hours appointment. Uptake for women receiving this invite was 76.4% compared 
with 69.1% for women who did not have this option (297). 
3.6.1.4 Summary 
The meta-analysis had some unexpected results. It was hypothesised that women 
who were older, of minority ethnicity, had a lower income or were less affluent, 
lower educated or lived in rental accommodation would be found to be less likely to 
attend. However, the review found non-significant results for these factors. This is 
perhaps due to the heterogeneity of the screening programmes or between women 
invited to screening programmes in different countries. However, it is an important 
finding that influencers of uptake are likely to differ across programmes. 
Surprising findings among the narrative analysis include an increased uptake in 
women who live in rural settings. However, study settings are so diverse this needs 
further investigation. Secondly, increased uptake was observed in women who were 
reported as care-givers contrary to expectation. It could be due to a mis-
categorisation of the caregiving hours which may hide a true effect. More research 
is required to investigate this phenomenon fully. 
It was unfortunate that there were not sufficient articles with comparable data to 
quantitatively analyse all predictors. However, of those that are comparable it is 
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interesting to note that not all predictors found similar results across the meta-
analysis and the narrative review. For instance, there was no difference found 
quantitatively for SES whereas narratively affluence was associated with increased 
uptake. This could be due to the definition of SES used in each study. Being married 
was associated with increased uptake in all analyses and similar results were found 
across ethnicity and age. The meta-analysis found different results to the narrative 
analysis for co-morbidities and chronic health conditions. However, this could be due 
to the severity or variety of health conditions analysed and the definitions were 
slightly different from the outset (number of co-morbidities compared with 0-3 or 3+ 
chronic conditions). 
3.6.2 Comparison with other reviews 
In this section I compare the findings of other systematic reviews with my findings. 
A review conducted in a UK setting which investigated BCS uptake in Black women 
found the perceived risk of BC and perceived importance of BCS was variable 
amongst Black women. In particular, Black women gave quotes about BC being “a 
Caucasian disease” despite known family history connections and the review also 
suggested a general understanding of breast health was negligible in the population 
studied (352). A significant knowledge deficit may underpin some stigma of BCS for 
Black women. Spirituality and religion were also found to be of relative importance 
in the influence of Black women’s BCS behaviour (352). My review found knowledge 
about screening is to be associated with uptake so a link between a lack of 
knowledge, particularly in minority communities, and uptake appears feasible and 
consistent with my results interpreted above. 
Another review found South Asian (SA) immigrants regularly have low BCS uptake 
despite their risk increasing post-migration to that of the non-Asian native population 
(248). Some SA participants included in this qualitative review had low perceived risk 
of BC and again, some women believed BC was a “White person disease” (353). A 
lack of knowledge was evident here as some women were stating a lack of symptoms 
was their reason for not requiring BCS. Language was consistently quoted and loss of 
social support upon immigration was cited as other barriers to uptake; this aligns 
with the results of my review. 
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As with all the evidence included in my review, common barriers such as time, 
money, children, work and transport were cited as reducing the likelihood of 
attending BCS. This supports evidence provided above that these factors are 
associated with uptake. However these reviews have highlighted that particular 
subgroups may be affected by predictors in different ways than others in this 
complicated network of predictors (352, 353). 
A review conducted by Damiani et al. found a positive association between level of 
education and adherence to mammography guidelines (127). It found evidence that 
higher educated women have a greater awareness about their risk of BC, tend to 
have more interest in health issues and have better access to resources for health 
improvement. This is likely mediated by their SES and their level of health literacy as 
defined as capacity to “obtain, process and understand basic health information and 
services needed to make appropriate health decisions” [p. 286] (127). The major limitation, 
and consequently how I found different results, was that it relied on self-report data 
which, as discussed above, is unreliable and were not included in my own review. 
Despite guidelines and national protocols for participation targets for BCS, there are 
subgroups that are still underrepresented in mammography uptake. The one group 
of variables that is consistently associated with increased participation in 
mammography is participation in other preventative healthcare practices such as 
cervical screening (78). 
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3.6.3 Implications  
Each decision to attend BCS or not includes the complex network of factors mentioned above. The influencing factors analysed in this 
review have been summarised below in Figure 46.   
 
Figure 46. Summary of predictors of BCS uptake investigated in this review
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To summarise the meta-analytic findings, women who are married or cohabiting, never 
smokers, have no chronic conditions, have three or more primary care visits annually are 
more likely to attend BCS. Women living in socially rented housing were found to be less likely 
to attend screening than women who owned their house or rented housing privately. Women 
who were uninsured were significantly less likely to attend compared with women with 
insurance. Ethnicity and BMI were not found to be statistically associated with mammography 
attendance. Sub-group analysis found no significant difference between women of different 
ages, SES, income or education.  
Narratively, reported uptake was higher in women who used HRT, had access to a car, had 
children, lived in rural locations, lived close to the screening site, had family history of BC, had 
attended cervical screening, conducted BSE, had higher perceived risks of BC, had no 
expectation of pain, were caregivers, had knowledge about BCS, were victims of abuse, had a 
female physician or who had graduated more than ten years ago. No difference in reported 
uptake was found between types of screening site or between women under the care of a 
physician with a positive or negative attitude. 
To the best of my knowledge this review is the only one which encompasses exploration of 
all possible predictors of uptake worldwide. Whilst it was important to investigate worldwide 
predictors of uptake to minimise bias, update the literature, obtain a holistic and wholesome 
view of predictors of uptake and to establish what needs to be researched further, it was 
surprising to find no significant difference between uptake of women of different ages, 
affluence or ethnicities. This was perhaps due to the comprehensive scale of the review and 
that any significant findings were countered in opposing countries. It is important to 
investigate this further using individual countries and/or studies as sub-group analyses. 
This review has shown that there are many different factors influencing attendance and 
uptake of BCS. Perhaps the NHS should adapt its screening service to include some of the 
information obtained by this review. For instance, providing sensitive material alongside the 
invite letter to women who have either bad experiences at previous appointments or 
logistical barriers prohibiting them from currently attending may encourage more openness 
and support towards BCS from these women and their families.  
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Moreover, policies involved in dealing with a woman with a false positive result or a previous 
false positive experience need looking at in detail in order to minimise anxiety or worry and 
enhance re-attendance (99). There appears to be a lack of research investigating how and 
why false positive results affect uptake. Future research could be conducted using a more 
exploratory approach to consider how and why the false positives affect BCS uptake. 
Sex of GP was found to be associated with the uptake of BCS. Re-training GP’s and healthcare 
professionals may improve knowledge transition between professionals and patients, 
subsequently increasing IC on uptake. Besides printed literature, providing opportunity for 
women to discuss their BCS decision with a GP or nurse may encourage IC and perhaps even 
increase uptake. 
Further research needs to investigate the effect of the perplexing results above. For instance, 
this review found caregivers were more likely to attend screening compared with women who 
are not caregivers which was not anticipated from the background literature. In-depth 
reviews investigating predictors such as these using a worldwide view could be useful to see 
if the overall effect masks differences in some countries. 
Secondary data analysis of this research further investigates some key predictors of uptake 
using a UK urban sample of the population. Questions that remain unsolved include ‘have 
differences in attendance always been the case or have these inequalities increased over 
time?’ The same can be asked of ethnicity, age and SES differences in uptake. 
Another future development this review supports is the need for tailored information and 
invitations. Every woman is affected by different influencing factors in her decision whether 
or not to attend screening, which has been pointed to already. In particular, it appears 
important that tailored information spans a wide range of factors including ethnicity, 
education, false positive experiences and personalised risks and psychosocial factors. How 
realistic this would be for the NHS is a matter for further research. The questionnaire that I 
am developing as part of this thesis will explore how personal risk of BC and IC influence 
uptake. It would be unfeasible to further develop this idea within this PhD. However, it is 
possible to use the results of this doctoral research to ground future research to investigate 




Variance of methodological, statistical or clinical origin will exist when combining data in a 
meta-analysis. Throughout this meta-analysis there was significant heterogeneity with I2 
values between sixty-eight and ninety percent meaning a high proportion of the variation 
across studies was due to heterogeneity rather than chance. Whilst some of this was 
anticipated due to the large sample sizes and accuracy yet disparity of many of the included 
studies used, it has provided some concern for the analysis and interpretation of the data. 
The statistical heterogeneity may have been caused by clinical differences between the study 
types, for instance pooling of RCT data with cohort data or unknown study characteristics. 
The I2 value has not taken into account the clinical heterogeneity that must be present in this 
analysis. Studies have been combined from twenty different countries which have distinct 
screening programmes and guidelines.  
3.6.5 Pooling of data 
A major advantage of pooling the quantitative data obtained is that it allows a summary 
estimate of the overall effect of predictors associated with the uptake of BCS. It is argued that 
pooled data analysis has the maximum reliability as it provides a holistic framework and 
allows the presentation of data in respect to all available knowledge. The pooled data 
provided a larger sample size on which to conduct analyses and subsequently enhanced 
statistical power to detect statistical differences between subgroups. 
The main source of uncertainty whether this was the correct approach is that considerable 
heterogeneity is present, discussed above. The pooled data may become meaningless if 
heterogeneity is too large. To help overcome some of the methodological flaw in pooling data, 
random-effects modelling was utilised to account for both between-study and within-study 
variability. By pooling data one combines information of different quality which may bias the 
result. 
3.6.6 Different methods 
As mentioned previously, meta-regression as an extension of the subgroup analysis or a 
Bayesian approach to the data would have been preferable, if the data were sufficient. 
However, this was impossible due to the type of data we had. Some data provided prevalence 
estimates by different subgroups but did not have crude or adjusted association measures 
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such as odds ratios. Additionally, a meta-regression would need many more studies where 
each reported its results split by various subgroups of interest.  
A major limitation of the meta-analysis is that the study effects are not accounted for, for 
instance there is no account for the similarity of age group one in study A to age group two in 
study A. They are currently treated as if they came from separate studies. To account for this 
a two level mixed-effects model for dichotomised outcome (attended or not attended) was 
conducted with the study being a separate level. Odd ratio results suggest the odds of 
attending were 14% higher for women aged 50-59 compared with women under fifty years, 
OR 1.14 (1.12, 1.15); 8% higher for women aged 60-69 years compared with women under 
fifty, OR 1.08 (1.06, 1.10); and 31% lower for women aged over seventy compared with 
women under fifty, OR 0.69 (0.67, 0.70), p<0.001. 
For future research, the same analyses could be conducted on all predictors reported to 
influence uptake of mammography to provide an overall odds ratio estimate of its association 
with BCS. 
3.7 Strengths and limitations of the review 
The four ‘weak’ papers remain in the quantitative analysis and this is a limitation of the 
review. However, the majority of the data came from ‘strong’ rated articles. In hindsight it 
would perhaps have made more methodological sense to remove these four papers from the 
analyses and is often suggested in the literature however, the concern about this approach is 
that it could remove and exclude studies that provide valid information (354). Another 
approach, in hindsight, may have been to assign a weighting to the study according to its 
quality assessment score although this has methodological flaws too (354). However, a 
sensitivity analysis with and without the ‘weak’ papers found no significant difference in the 
results and therefore I can be confident in the analyse conducted. 
Having published the protocol prior to commencing the review improves the reproducibility 
and transparency of the research and researcher involved. This has safeguarded against 
subjective inclusions and against the selective reporting of findings (355). This public record 
has also encouraged compliance with PRISMA reporting statements (356). 
A search strategy was written and developed that searched a wide platform of potential 
literature databases to include as much data as possible from a worldwide perspective. It has 
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been discussed that using terminology to confine the search further at this initial search 
strategy would be counter-productive. Restricting the search would return insufficient 
relevant material and narrowing of the results would miss a large proportion of the pertinent 
literature. Instead, stringent inclusion criteria were used. The vast, varied breadth of studies 
is an important advantage of this review as a large body of evidence was searched, sifted and 
included. The large sample (n=91) in this review increased statistical power within the meta-
analysis and allowed a narrower confidence interval for the final results (357). Conversely by 
using such a large sample and having sufficient data to test multiple hypotheses, it may have 
inadvertently introduced type one bias. The risk of this was minimised by using the Bonferroni 
p-value statistic but this possibility still needs to be considered (260). 
A study investigating the accuracy of self-report data for mammography claims has shown 
how unreliable this data is with sensitivity of 93% (90, 95%) and specificity of 54% (49, 59%) 
(358). Furthermore, this study found a systemic overestimation of uptake when using self-
report which could affect any associations drawn from the data and potentially could bias 
results. It was therefore considered important to exclude self-reported uptake data. In 
hindsight, perhaps more research to investigate the self-reported uptake data by sensitivity 
analysis with and without these data would be beneficial to determine if they had any 
significant effect on the results. 
By excluding self-report uptake data it could have influenced which variables appeared most 
important in the review or even biased which variables appeared altogether (359). Variables 
such as stress levels, drug use, caffeine consumption and others which are often established 
using self-reported information would have been interesting to analyse but will unfortunately 
have been excluded. Most importantly, it is likely that qualitative studies with self-reported 
attitudes and levels of IC will have been excluded from this review which is a main limitation 
meaning that results cannot be used to aid the development of the questionnaire in the later 
study.  
Two reviewers were used for all components of the review sifting and data extraction 
processes which will have increased reliability and decreased bias. Nevertheless, this data 
only used published sources of evidence which may exaggerate previous positive findings and 
contribute to any publication bias on the subject.  
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Quality assessment of the included studies was conducted using a tool that was tested for its 
construct and inter-rater reliability. Its reliability was also assessed with agreement kappa 
scores of 0.74 and 0.61 (256). However, currently all evidence is included in the overall 
analysis and synthesis including studies rated ‘weak’ in the overall methodological ratings 
from the QA tool. As mentioned by Juni et al. study quality should be incorporated into the 
analysis and to simply exclude those which are assessed as ‘weak’ cannot be justified without 
further elaboration into the methodological techniques they used (354). Of the studies 
included in this review, 81.6% were assessed to have a ‘strong’ methodological rating using 
the QAT, 12.6% ‘moderate’ and 5.8% ‘weak’. It would be interesting to conduct a sensitivity 
analysis excluding the papers rated ‘weak’ to assess the impact these papers have on the 
overall results. 
Despite a search strategy to contain worldwide papers in the review, all of those included 
were from the developed world. This is a significant flaw of the literature as it does not 
provide a completely encompassing view of BCS uptake. However, this is likely because 
developing countries have less organised screening programmes and more opportunistic 
programmes were present which were excluded from the review as part of the exclusion 
criteria (Appendix 8.1.1). 
Due to the nature of this research question, the included papers were extremely 
heterogeneous. Although expected due to the large sample size and the variation across 
global BCS programmes, data pooling may not be the most appropriate method. Forest plots 
and their I2 statistic for both age and marital status as predictors of uptake clearly show this 
high level of variation across included studies is due to heterogeneity rather than chance. The 
associated funnel plots also suggest that some publications may be missing from the review. 
Meta-regression would have been conducted if the data was more homogeneous. Instead, 
sub-groups of papers were analysed in different sectors as discussed above, relating to the 
predictors mentioned and results presented. 
Furthermore, data was included from a worldwide vantage point and therefore heterogeneity 
cannot be overcome. The data came from different studies, countries, time, healthcare 
systems and cultures so there was vast diversity. However, it was necessary in order to obtain 
the answer to the research question posed. It has been an important review to establish the 
predictors of uptake and a variety of studies was necessary to do this work. 
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Narrative analysis is often considered subjective and less reliable than quantitative methods. 
However, for this review it was the only available approach as a proportion of the data was 
unable to be pooled either due to its subgroups or because it provided information about a 
unique predictor. 
Table 12 summarises the advantages and limitations of this review which have been discussed. 
Table 11. Summary of the advantages and limitations of this systematic review 
Advantages Limitations 
Published protocol  
• PRISMA reporting 
Significant heterogeneity 
No self-reported uptake data was used No papers from the developing world were 
included 
Inclusive search strategy Multiple hypotheses may have introduced 
type one bias (attempted to reduce this risk 
by using Bonferroni p-value statistic) 
Two reviewers assessed all stages Only papers written in English were included 
Quality assessment of all included papers 
was conducted 
Second reviewers were not blinded for data 
extraction 




The purpose of the systematic review was to determine the predictors of breast screening 
uptake worldwide. Ninety-one studies were included in the systematic review with data 
analysed quantitatively and narratively.  
This review has found many different predictors to be significantly associated with uptake. 
Predictors found to increase the odds of attending mammography include being married, ever 
smoked, having no chronic conditions, and visiting primary care three or more times per 
annum. Being uninsured was found to be negatively associated with attendance at BCS. No 




My review has found results that are inconsistent with previous literature, perhaps due to the 
heterogeneity of screening programmes examined. The most surprising results were that 
ethnicity, age and SES were not found to be significant predictors of attendance. Whilst we 
do not have a dataset that includes all variables examined in this review, predictors of 
attendance will be further investigated in the next chapter. 
The review has provided evidence about different predictors that will inform the remaining 
work of the research. For instance, the secondary data analysis will explore in more depth the 
patterns of attendance in London, UK screening data. It will investigate if these predictors of 
attendance have changed over time. The questionnaire study will begin the development of 

















Chapter 4: Predictors of Mammography 
attendance over time (PaMaT).                    
A secondary data analysis 
Introduction 
In this chapter I will explore predictors of BCS uptake within a South West (SW) London 
population in greater detail. First, I will demonstrate the methods used. After that I go on to 
provide quantitative results, both descriptive and analytical. The chapter will conclude by 
contrasting results with the outcomes of the systematic review described above, exploring 
the strengths and limitations of the work, and determining the impact of the research. 
Context 
The data analysed in this chapter come from a cohort in SW London screening centre. Each 
year approximately 40,000 women attend this SW London centre. Women aged between 47 
and 73 and who are registered with a GP in the UK are invited to screening every three years. 
If women attend they come to a hospital or mobile van in their area for the x-ray of each 
breast. Women are either given a negative result or asked to return. If asked to return due to 
a suspicious lesion the screening procedure will be repeated and her results will be assessed 
by a clinical team to determine if the lesion is cancerous or not. If not, the woman is said to 
have received a false positive result as detailed later in this chapter. 
4.1 Research questions and study aims  
The key aim of this study was to ascertain patterns of BCS in a SW London population. 
Analysis was conducted on this dataset to answer the research questions: 
1. What factors influence uptake of BCS in the SW London population? 
2. What factors are associated with uptake of BCS at the first episode in SW London 
population? 
3. Are patterns of attendance changing in the London, UK population? 




4.2 Study sample 
Data between 1987 and 2017 were extracted directly from the National Breast Screening 
Service (NBSS) software before being anonymised at the SW London site and sent to me 
securely. Three separate constituent databases were received comprising 406,015 women, 
1,283,671 episodes and 1,521,309 appointments respectively. The datasets required linking 
using key identifier variables (psuedonymised NHS number and/or episode identification 
number) that remained consistent across three datasets as shown in Figure 47. The final 
database was organised into a hierarchical structure as shown in Figure 48. Each woman was 
invited at least once per screening round (episode) unless she had officially and permanently 
withdrawn from the screening programme. Within each episode a woman may have multiple 
appointments due to technical failures or non-attendance as shown in Figure 48. The final 
database used for further analysis used data from 302,690 unique women. 
 





Figure 48. Representation of the database hierarchy. 
Appointment data prior to 2000 were removed (n=345,301) from the database due to 
inconsistency of matching of episodes to appointments (Appendix 8.3.5). Sensitivity analyses 
were conducted on the multilevel models with and without this data and no discernible 
difference was noted. It is possible these earlier data could be biased e.g. due to changes in 
data management or changes in methods of data extraction. It was therefore decided to 
exclude these data from the analysis. 
4.3 Methods 
4.3.1 Study setting 
The secondary data analysis was designed and conducted solely at The University of Warwick. 
Data from the SW London screening centre were chosen as this centre records ethnicity which 
was hypothesised to be a key predictor of mammography uptake. As with all secondary 
research, data were not collected for this study. Instead, data were routinely collected at the 
time of the mammography appointment by hospital screening staff (who record what 
happened at each appointment) and using NHS medical record notes. SW London uses the 
National Breast Screening Service (NBSS) database to record each screening appointment. 
Each screening centre must submit quality assurance reports to the NHSBSP annually and 
these are comprised of extractions from this NBSS database. The dataset used for my analysis 
was an extraction from this NBSS database which ensures the reliability and trustworthiness 
of the data and means data quality is high. 
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The London boroughs included in the catchment area for SW London screening service 
include Croydon, Kingston, Richmond, Sutton and Merton and Wandsworth. These boroughs 
rank between 91 and 296 (with a rank of one being the most deprived and 32,482 being the 
least deprived nationally) (360).  
4.3.2 Ethical approval 
Sponsorship was obtained from BSREC at the University of Warwick. Full HRA approval was 
obtained on the 16th October 2017. Research and development approval from St Georges 
Hospital, South West London was obtained on the 17th October 2017 to commence on the 
23rd October 2017. Full copies of approval documentation are provided in Appendix 8.3.1. 
4.3.3 Obtaining the data 
After ethical approval was granted, data were extracted from NBSS database by Rani Nair and 
Louise Wilkinson using code written by Sue Hudson that linked the woman to their Index of 
Multiple Deprivation (IMD) decile. IMD allows the measurement of multiple deprivation and 
identification of need at small area levels. IMD comprises distinct measurement of 
deprivation separately for income, employment, health and disability, education, skills and 
training, barriers to housing and services, living environment and crime. IMD combines these 
to give a single score. It is an area-based measure rather than for an individual – women within 
any area will not necessarily have the same level of deprivation.  
IMD here is represented in deciles. The deciles are calculated by the Government by ranking 
the 32,844 small area ‘boroughs’ in England from most deprived to least deprived and 
separating them into 10 equal groups (360).  








Table 12. Variables extracted from the NBSS SW-London for use in this analysis 





nhscryptic Unique identifier of each woman in the database. Used to link the 
databases 
episodeid Unique identifier of each episode for each woman 
gpcode The GP the woman is registered at 
ageatfoa Age at the first offered appointment within an episode. This was 
the age used for the analyses. 
datefirstappt Date of the first appointment. This was used to ensure sequential 
data was correct. 
dateapptmade Date the first appointment was made. This was used to ensure 
sequential data was correct. 
episodecharacter Whether the screen was the first screening or a routine recall 
pistatus Whether the episode was the incident or prevalent screen 
episodeclosed Identifies if the screening round is still ongoing for this woman 
episodereason Reason for episode closure 
attendappt Identifies if the woman attended the appointment 
episodeendcode The reason for closure of the episode 
episodeend The series of events that were undertaken in that episode 
finalactionepisode Identifies the final action in the episode 








apptnr Unique identifier of each appointment for each woman 
screenapptnr Unique identifier of each screen within an appointment for each 
woman 
clinic Clinic code 
dateclinic Date of the clinic 
timeclinic Time of the clinic 
apptstatus Status of the appointment: attended, booked, did not attend and 
whether notice was given 
canceltype Reason given for cancellation where appropriate 
bookcanceldate Date the appointment was booked or cancelled 




Level Variable  Description 





gpcode GP code 
ethnicity Ethnicity 
ethnicold Old version of ethnicity 
specialappt Requirement of a special appointment 
specialreason Reason for requiring a special appointment (such as for disability 
or breast implants) 
callrecall Status of the appointment, whether a woman has attended 
previously 
yob Year of birth 
lsoacode Code used to identify IMD 
lsoaname Name of region woman lives 
imdrank IMD rank 
imddecile IMD decile 
 
4.3.4 Pre-analysis tests 
Ethnicity is defined within this study as the self-reported social group the woman feels she 
most closely belongs and aligns to with the groupings set out in Table 14. Descriptive results 
maintained these sub-groups, but the for the quantitative analysis it was necessary to 
combine the sub-group ethnicities into the following broader ethnicities: White, Black, Asian, 
Mixed or Other.  
4.3.4.1 Missingness 
Six hundred and seventy-three (n=673/1,445,754; 0.047%) of the age entries were missing 
from the age variable with an additional 3,828 (0.26%) ages that were inappropriate (ranging 
from 12 to 87 years) as they were outside the screening invitation ages of 47 to 73. These 
were removed from the dataset. Only three entries (0.00021%) had missing date information 
and therefore were simply removed from the dataset. 
Ethnicity had the highest missing data (265,869 women had no ethnicity data which equates 
to 18.39% of the dataset) but these observations were not removed from the dataset as 
collecting ethnicity information is a recent phenomenon and missingness was anticipated 
from the outset. 
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The first assumption was to test that missing data was missing completely at random (MCAR). 
This was checked in order to determine the dependence of missing data on the other variables 
in the dataset in order to decide how to treat the missing data (361). To confirm this trend, 
logistic regression models were conducted to predict missingness of ethnicity data. It showed 
that age, requiring a special appointment and IMD were associated with missing ethnicity 
data.  Full results can be found in Appendix 8.3.5. 
IMD had 2,467 missing entries which was unexpectedly high. Therefore the association of IMD 
data being non-missing data was estimated. Similar predictors appeared associated with the 
likelihood of IMD information being missing. 
The majority of missing data (i.e. pre-2000) were MCAR due to a technical fault of the 
extraction methods. However, for initial analyses with the remaining data I considered groups 
with missing ethnicity and IMD data as separate sub-categories for each variable in the first 
analysis as demonstrated by Howell et al. before assessing the influence these ‘missing’ sub-
groups had on the dependent variable (362). As no difference in attendance between these 
and the non-missing groups were identified, it was not fundamentally necessary to use 
multiple imputation or another statistical technique to generate the missing values. The lack 
of imputation is a limitation of this research, and there is potential that this may have 
introduced bias into the analysis (361). I acknowledge that a sensitivity analysis of complete 
and available cases analysis may be good avenues for further research. 
4.3.4.2 Assumption testing 
Scatter plots were produced to assess for associations between continuous variables and are 
provided in Appendix 8.3.6. Subsequently, the result of correlation test between age and IMD 
was 0.0134 (363). The predictor variables were tested for between-predictor correlations and 
with the outcome variable (attendance at BCS appointment) using Pearson’s correlation tests. 
The predictors were considered independent from each other. This lack of association was 
reassuring. 
Chi-square tests of association were conducted to test for correlation between non-
continuous variables. No correlation was found between special appointments, 
socioeconomic status and ethnicity as all tests were non-significant. 
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Another key assumption for linear regression models is the independence of responses. 
However, this dataset fails this assumption as each woman has multiple observations due to 
the hierarchy of the data as shown in Figure 48. Accordingly, a mixed effects model was fitted 
to adjust for this. 
4.3.5 Multilevel modelling 
A mixed-effects logistic model (otherwise known as a multilevel model) was performed for 
analysis of the binary outcome of attendance (dichotomised to yes or no), using melogit 
command in Stata v15.1. A mixed effects model contains both fixed effects that are estimated 
directly like standard coefficients and random effects which are those not directly estimated 
but are summarised from estimated variances and co-variances. 
The dataset has a hierarchical structure as repeated measurements are nested within only 
one individual-level structure, as shown in Figure 48. Each woman could have attended 
multiple mammography appointments within each episode depending on the type of 
experience she had. For instance, she may have had to re-schedule the first given 
appointment, then after being screened she was recalled due to a technicality and therefore 
appears three times in this episode. Furthermore, each woman will reappear in the database 
every three years unless she opted out of BCS. Therefore, these repeated measures are 
correlated with each other and are not independent and this is why a nested multilevel model 
is necessary. Since the outcome used was attendance within an episode, a two-level random-
intercept model was used to account for women featuring multiple times within the data. 
Level one was episode and level two was woman. 
The dataset spans seventeen years of screening data. The model was run as both time variant 
and time invariant to account for predictors that do and do not change over time. Variables 
at the woman level which were constant over time include ethnicity, IMD, special 
appointment requirement. The other variables were at the episode level and were more 
variable. 
4.4 Model building and analyses 




Level one of the multilevel mixed-effect model contained the episode level data including the 
dependent variable. The second level incorporated the data at the level of the woman, which 
did not vary across episodes. All potential variables were included in the initial model but 
removed if the variable was either not significant or if the subgroups were small enough to 
result in perfect prediction by Stata. 
Variables of potential interest within each model are: age, IMD, special appointment, date, 
time, ethnicity, being previously recalled, and year (where appropriate). Intraclass correlation 
coefficients (ICC) were also produced subsequent to each model to determine the level of 
variance explained by each of these factors. 
Whilst building the models, widely accepted statistical tests were used to confirm if specific 
variables should be entered into the model. Likelihood ratio (LR) tests were used to confirm 
if there was a significant difference in the nested models with and without certain variables 
(364, 365). A significant LR test result proved that a more complex model was most 
appropriate. Akaike’s information criterion (AIC) and Bayesian information criterion (BIC) 
were also considered when non-nested models were compared (365). 
This method was also adopted for exploring possible interactions. Any interaction effects that 
perfectly predicted the attendance outcome were dropped automatically by Stata. The 
following interactions were removed by Stata due to high collinearity: ethnicity with IMD, 
requiring a special appointment with IMD, ethnicity or age and previous recall with age. This 
was likely due to small numbers within subgroups, particularly for those requiring special 
appointment which was only 17,878 episodes. The only interaction that remained in any 
model was that between age and IMD. Nonetheless, upon testing of the nested models using 
LR tests as above, the model without the interaction effect was preferred. The effects of 
removing the interactions from the model will be discussed later 
Using initial results of the first model output which investigated factors influencing 
attendance, the odds ratios associated with IMD as a predictor of uptake were approximately 
linear and therefore IMD could be treated as a continuous variable (as shown in Figure 49). 
However, IMD itself is not explicitly linear – the difference between decile one and decile two 
is not necessarily equivalent to the difference between decile three and four. This sensitivity 
analysis is shown in 9.1.6. For simplicity of explanation, and use in the real world, IMD was 
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entered into the model as a categorical variable with IMD(1) (most deprived) used as the 
baseline comparator. 
 
Figure 49. Odd ratio output graphically presented for the odds ratios in the first model building exercise. 
After models were selected, post-estimation receiver-operator curves (ROC) were used to 
assess the applicability of the model built. A few, random, women were selected from the 
database based on their different characteristics and the estimated likelihood of attendance 
compared. 
Whilst building models, all variables were included but were removed in a backward stepwise 
elimination based on their significance and effect  
4.5 Results 
All odds ratio (OR) results will be reported with their ninety-five percent confidence interval 
in parentheses unless otherwise stated. Similarly, all results have been rounded to two 


















Odds ratios for IMD
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4.5.1 Descriptive statistics 
The number of episodes of screening that fell into each sub-category of each variable are 
shown below in Table 14. 
Table 13. Number of mammography screening episodes between 2000 and 2017 by each included predictor variable. 
Percentage column may not sum to 100% due to rounding. 
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Asian – Bangladeshi 
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Black – Caribbean 
Mixed – Other 
Mixed – White and Asian 
Mixed – White and Black African 
Mixed – White and Black Caribbean 
Other – Any other 
Other – Chinese 
White – Other 
White – British 
White – Irish 





























Learning Difficulties - Other 
Learning Difficulties – Wheelchair user 
Learning Difficulties 
Other – Physical restriction 
Other – Registered disabled 
Other – Wheelchair user 
Other 
Physical restriction – Wheelchair user 















































































































































































Attended at any point within each episode 915,546 N/A 
Attended the first appointment within the episode 915,546 N/A 





Appendix 8.3.5 presents a more detailed summary of each variable included in the dataset. 
Whilst preparing the dataset for analysis, it was noted that there were up to twelve 
appointments within a screening episode round as detailed in Table 15. The mean number of 







Table 14. Frequency of maximum number of appointments invited per episode. 














4.5.2 Representativeness of the sample 
To assess the generalisability of the findings it is important that the dataset could be 
compared with statistics on the general population. Census data from 2011 that described 
the female composition of England and Wales by ethnicity as shown below (366). A larger 
proportion in the routine SW London dataset came from minority ethnic women compared 
with the census data. 
Census data (of women aged between 47 and 73) from 2014 (as a projection from 2011 
census data) were used to describe differences in the age composition of the sample used 
compared to the national average and this is shown in Figure 51. There is a large difference 
in the age composition of the samples. The routine SW London dataset had a much larger 
representation of women from 50-59 year group and 60-69 year group compared with the 
census data which had more women in the lower and higher age groups (367).   
Twenty-two percent of London’s boroughs fall within the most deprived 20% of the UK but 
simultaneously more than two thirds of London have deprivation levels above the national 
average (360). London scores poorly due to its high levels of deprivation such as crime, 
housing barriers and its environment despite having low levels of unemployment and high 
levels of education and training (360). 
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In the routine SW London dataset, there is a large proportion of women from affluent groups 
of the population. However, in the census dataset the distribution across deprivation levels is 




Figure 50. Ethnicity composition of the sample (routine SW London dataset) compared with female only Census data (2011). In general, minority ethnicities are over-represented whilst White 
British are under-represented compared to the general population (366). 
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Figure 51. Age composition of the sample (routine SW London dataset) compared with female only data of women aged 47 to 73 years (Census data is projections of 2014 composition) (367). 
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Overall, 590,047/915,546 (64.45%) of episodes were attended between 2000 and 2017. 
The number of women attending and not attending were calculated for each group of the key 
predictor variables and are presented with the percentages in Table 16.  
Table 15. Number of mammography screening episodes attended and not attended between 2000 and 2017 by each included 
predictor variable. Row percentages are calculated. 
Categorical Variable Attended 
N (%) 
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Other – Physical restriction 
Other – Registered disabled 
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Other 
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N (%) 

















It is hypothesised by policymakers at SW London breast screening centre and Coventry breast 
screening centre, with whom I initially discussed plans for this thesis, that rates of attendance 
are decreasing. The raw percentages of numbers of women attending by year are shown in 
Table 17 below. In this dataset, there appears to be a decreasing trend by year, except in 2006. 
It was also hypothesised that certain periods of the year would have higher rates of non-
attendance than others. As shown, December has a lower attendance rate compared with 
the other months of the year. 
Table 16. Number of women attending and not attending mammography screening episodes between 2000 and 2017 by 
each included predictor variable. Row percentages are calculated. Data from 2018 appears to be a selection of the 




































































































































































































































































































































The number of women who attended the following scenarios was calculated and is presented 
below: 
Table 17. Number of women attending and not attending as per the specific situation specified. 




Attended at any point 
within each episode 
590,047 64.45 325,499 35.55 915,546 
Attended the first 
appointment within the 
episode 
369,766 40.39 545,780 59.61 915,546 
Recalled for further 
assessment and 
subsequent attendance 
191,515 62.28 116,014 37,72 307,529 
 
However, I am interested in the relative effects of these variables and influences and 
subsequently multivariable modelling was necessary. 
4.5.3 Factors influencing uptake of mammography for any episode 
For this question, all data in the final database were used for the analysis to answer what 
factors were associated with uptake of mammography. 
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As discussed in Chapter four above a Bonferroni adjustment needed to be made to account 
for multiple testing of a single dataset. Here, three different models were tested so the 
appropriate adjustment was considered to be a Bonferroni adjustment, α/n = 0.05/3 = 0.0167 
(260).  LR tests were used to compare models. 
Compared with women aged under 50 years, the odds of older women attending were 
significantly lower as shown in Table 19. The odds of attendance for women who did not 
require a special appointment were 96% higher compared with women who did require a 
special appointment, OR 1.96 (1.82, 2.12). Women who had previously been recalled for 
further assessment had 21% higher odds of attending than women who had not been 
recalled, OR 1.21 (1.19, 1.24). Apart from the deprived end of the IMD scale where no 
significant difference was observed between IMD deciles one and two (p=0.126) or between 
one and three (p=0.017), the odds of attending BCS increased with affluence compared to the 
lowest IMD women with odds of attending 64% higher for affluent women (IMD=10) 
compared with deprived women (IMD=1), OR 1.64 (1.45, 1.84). Women of all minority 
ethnicities had lower odds of attendance when compared with White British women. ICC was 
34.48% (33.99, 34.97) meaning that even individual women exhibit some variability as to 
whether or not they will attend screening. Unless specified all p-values were <0.001. 
Table 18. Odds ratio for each predictor of attendance included in the final model for any episode. Fully adjusted data. 
Unknown ethnicity data was classed as ‘Other’. Figure 52 depict these associations. 
Predictor Sub-group Odds ratio (95% confidence interval) p-value 
Age categorical <50 years 1  
50-59 years 0.78 (0.74, 0.82) 0.000 
60-69 years 0.83 (0.79, 0.87) 0.000 
70+ years 0.61 (0.57, 0.65) 0.000 
Special 
appointment 
No 1  
Yes 1.98 (1.83, 2.13) 0.000 
Previous recall No 1  
Yes 1.22 (1.19, 1.24) 0.000 
IMD 1 1  
2 1.10 (0.97, 1.24) 0.126 
3 1.16 (1.03, 1.31) 0.017 
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Predictor Sub-group Odds ratio (95% confidence interval) p-value 
4 1.29 (1.14, 1.45) 0.000 
5 1.32 (1.17, 1.49) 0.000 
6 1.39 (1.23, 1.56) 0.000 
7 1.40 (1.25, 1.58) 0.000 
8 1.46 (1.29, 1.64) 0.000 
9 1.55 (1.38, 1.75) 0.000 
10 1.64 (1.45, 1.84) 0.000 
Ethnicity White 1  
Asian 0.69 (0.66, 0.71) 0.000 
Black 0.78 (0.76, 0.82) 0.000 
Mixed 0.72 (0.67, 0.78) 0.000 






Figure 52. Graphical representation of the odds ratio results for attendance at any episode as discussed above. 
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Date of episode was not considered in the model as it is not clinically relevant for this research 
question as multiple appointments (with different dates) are analysed. Interaction effects 
were explored in this model but most resulted in perfect prediction or offered no significant 
improvement to the model. The only interaction that may have remained in the model, 
according to a LR test, was the interaction of age and ethnicity. However, some of the 
resulting subgroups contained small numbers of participants, and the estimates for baseline 
ethnicity (White) became non-significant, making interpretation of the interaction terms 
difficult. Sensitivity analyses were conducted on models including and not including an 
interaction between age and S IMD ES which showed little difference on estimates except 
IMD became non-significant. Therefore the interaction term was removed. 
Using post-estimation statistics for clarity, a highly affluent (defined as the highest level of 
IMD which is ten) White woman, aged between 50-59 years, requiring no special 
appointment, who had no previous recall had a probability of attending of 
Pr(attending)=0.895 (3dp). A different highly affluent White women, aged between 50-59 
years, requiring a special appointment, with a previous recall had a probability of attending 
of Pr(attending)=0.840 (3dp). 
Receiver-operator curves (ROC) provides a summary measure of accuracy of the model to 
discriminate between attenders and non-attenders. An AUC value below 0.5 is considered 
non-informative, with increasing values indicating increasing accuracy (less accurate 
(0.5<AUC≤0.7), moderately accurate (0.7<AUC≤0.9), highly accurate (0.9<AUC≤1) and perfect 
(AUC=1)) (368). The area under the curve (AUC) is 0.908 (0.908, 0.909) meaning the model is 





Figure 53. ROC curve for research question one: what influences attendance at any point in the episode. 
4.5.4 Factors influencing attendance at first episode 
There were 205,433 episodes that were relevant for this analysis as they involved the first 
time women were invited to screening and were analysed here. Of these episodes, 121,973 
(59.37%) attended screening within their first episode and 83,460 did not (40.63%). The oldest 
a woman can be when invited to her first screening appointment is 53 years. 
Overall, four different models were compared to identify the best selected model for 
attendance at the first episode. Again, to reduce the likelihood of a type one error in this 
analysis, a Bonferroni statistic of p=0.0125 was used for each model’s individual significance 
value (260, 261). The inclusion of covariates in nested models were verified using LR tests as 
described above. 
The final model for the first episode attendance included age, special appointment status, 




Table 19. Odds ratio estimates with 95% confidence intervals and p-values for the predictors included in the final model. 
Predictor Sub-group Number of 
episodes 
OR (95% confidence 
interval) 
p-value 
Age 47 5,028 1  
48 5,302 0.61 (0.44, 0.86)* 0.004 
49 27,043 0.15 (0.11, 0.19) 0.000 
50 54,863 0.15 (0.12, 0.20) 0.000 
51 52,042 0.16 (0.12, 0.12) 0.000 
52 40,255 0.14 (0.10, 0.18) 0.000 
53 20,900 0.08 (0.06, 0.10) 0.000 
Special 
appointment 
No 202,274 1  
Yes 3,159 0.49 (0.43, 0.56) 0.000 
IMD 1 (low) 1,787 1  
2 14,248 1.25 (1.01, 1.55) 0.040 
3 16,875 1.22 (0.98, 1.50) 0.070 
4 23,016 1.26 (1.02, 1.55) 0.032 
5 17,811 1.25 (1.01, 1.54) 0.041 
6 23,663 1.29 (1.05, 1.59) 0.016 
7 21,431 1.36 (1.11, 1.69) 0.004 
8 26,084 1.33 (1.08, 1.64) 0.007 
9 36,860 1.35 (1.10, 1.66) 0.004 
10 (high) 23,272 1.44 (1.17, 1.78) 0.001 
Ethnicity White 85,751 1  
Asian 11,630 0.75 (0.71, 0.79) 0.000 
Black 11,117 0.83 (0.78, 0.89) 0.000 
Mixed 2,551 0.81 (0.71, 0.91) 0.000 





Figure 54. Graphical representation of the odd ratio results for research question two as discussed above. 
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As age increased odds of attendance were at least 30% lower compared with the youngest 
women. Odds of attending ranged from OR 0.67 (0.48, 0.92) for women aged 48 compared 
with 47 to OR of attendance 0.08 (0.06, 0.11) for women aged 53 compared with 47. For 
women requiring a special appointment, the odds of attending were lower than women not 
requiring a special appointment, OR 0.50 (0.43, 0.57). All minority ethnic women had lower 
odds of attending than White British women, for instance Asian women were 25% lower than 
White women, OR of 0.75 (0.70, 0.79). The odds of affluent women attending were 
significantly higher than those of lower socioeconomic status women. Only IMD categories 
seven to ten were significantly different from baseline (IMD one, low IMD). The odds of a 
highly affluent women (IMD 10) attending BCS were 44% higher than a socially deprived 
woman of IMD 1, OR 1.44 (1.17, 1.77).  
Using post-estimation statistics a White affluent woman (IMD 10), aged 49 years, who did not 
require a special appointment and who had no previous recall had a probability of attending 
0.920. A 50 year old Asian woman, IMD 3, not requiring a special appointment and who had 
no previous recall had a probability of attending of 0.812. A woman with the same 
characteristics but with IMD 10 had a probability of attending 0.886. 
The AUC for the ROC was 0.99 (0.99, 0.99) and is shown below. This means the model is very 




Figure 55. ROC graph for question two: what influences attendance at first episode 
Data for the month of December were removed subsequently from this analysis to conduct a 
sensitivity analysis to account for the festive period. No significant differences were observed 
in the OR results and it made no difference which predictors were or were not significant. 
4.5.5 Have influences of mammography attendance changed over time? 
For this research question, only data in 2001 or 2016 were used for analysis. 40,516 women 
were present in the 2001 analysis and 64,678 women in the 2016 analysis. 
Year of the episode was found to be a significant predictor of attendance at any point within 
an episode. The odds of attending BCS were 2% lower per each additional year from 2000, OR 
0.98 (0.97, 0.98). Therefore, year was investigated further, in particular whether there were 
any noticeable changes in factors influencing attendance in 2001 compared to 2016. I used 
two different cohorts (2001 and 2016) that were well apart in terms of screening round cycle 
so as to investigate the effects of year as far as possible separately from the effects of 
attendance by individual women. 
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Variables found to be significant predictors of uptake in the first research question 
(investigating predictors of attendance) were used again here as I had established they are 
important and associated with uptake. 
Two-by-two cross tabulations were used to highlight potential differences between years. 
Overall, uptake was similar across both years for IMD. Large differences were observed for 
previous recall and requirement of a special appointment where both trends as shown below 
in Figure 56. The percentage attendance was very high for the oldest women in the database in 
2001. However, I believe this is an anomalous result as numbers were very small (there was 
only one woman who was a non-attender whereas there were fifty-three attenders). Ignoring 
that age group, percentage attendance between 2001 and 2016 is broadly similar. Ethnicity 
appears to have changed the most over time. Attendance (and therefore non-attendance) 
appears to remain constant over the time-period examined for White women. All other 
ethnicities have lower percentages of uptake in 2001 compared with 2016 with the most 
noticeable change shown in women of Mixed ethnicity where attendance increases from 





Figure 56. Cross tabulation results for changes in attendance by year. 
Univariate models were used to capture differences in predictors of uptake between the 






Table 20. Comparison of odds ratios of univariate predictors of attendance in 2001 and 2016. *=indicator of a significant 
result at the 95% significance level. Data for the 70+ years group has been included for reference and transparency. 
However, this group represents a very small sample size and therefore the confidence interval estimates are large. 





(95% confidence interval) 
Age <50 years 1 1 
50-59 years 1.02 (0.90, 1.15) 1.19 (1.12, 1.26)* 
60-69 years 0.98 (0.86, 0.11) 1.33 (1.25, 1.41)* 
[70+ years] [25.82 (3.56, 187.40)*] [1.15 (1.06, 1.25)*] 
Special 
appointment 
No 1 1 
Yes 0.65 (0.59, 0.73)* 0.87 (0.75, 1.01)* 
Ethnicity White 1 1 
Asian 0.66 (0.58, 0.74)* 0.84 (0.77, 0.92)* 
Black 0.69 (0.60, 0.79)* 0.92 (0.84, 1.00)* 
Mixed  0.54 (0.42, 0.69)* 0.88 (0.74, 1.05) 
Other 0.74 (0.57, 0.95)* 0.96 (0.82, 1.13) 
Previous 
recall 
No 1 1 




1 (deprived) 1 1 
2 1.06 (0.81, 1.39) 1.06 (0.83, 1.34) 
3 1.08 (0.83, 1.42) 1.14 (0.90, 1.45) 
4 1.22 (0.93, 1.58) 1.26 (0.99, 1.60) 
5 1.34 (1.03, 1.75)* 1.37 (1.08, 1.74)* 
6 1.40 (1.07, 1.82)* 1.36 (1.08, 1.73)* 
7 1.58 (1.21, 2.06)* 1.56 (1.22, 1.98)* 
8 1.72 (1.32, 2.24)* 1.69 (1.33, 2.14)* 
9 1.72 (1.32, 2.23)* 1.73 (1.37, 2.19)* 




It is worth acknowledging that whilst trying to build the best model, the “true model” that 
exists in the real world, with multiple other confounding variables, will never be achievable 
with this dataset. The aim of model selection is to find the best way of explaining a high 
proportion of variance. Model selection is a balance between an ‘Occam’s razor’ approach 
where the simplest solution is the best and the idea that by adding more parameters we can 
obtain a better explanatory model (369). 
Mixed effects multilevel models were used to assess predictors of attendance using data from 
a SW London screening centre. Odd ratio results were compared between 2001 and 2016 to 
assess if predictors of uptake had changed.  
Furthermore, comparison of these results with the findings of the systematic review have 
been discussed in Chapter 7. 
4.6.1 My results compared with previous research 
A more detailed comparison of the results from the review and the secondary data analysis is 
provided in Chapter 7. 
4.6.1.1 Factors influencing uptake of mammography at any episode 
A study by Banks et al. found no significant difference in attendance between women of 
different ages (133). Here, older women were significantly less likely to attend BCS as 
supported by previous research (295, 370), and also specifically in research in London, UK 
which also found lower attendance in older age groups (148). This may be due to competing 
health complaints or the lack of expected benefits from screening for older patients. 
This trend is also true for minority-ethnic women. Lower uptake in this group has been 
frequently reported in the literature as a major source of health inequality (55, 131, 137, 140, 
248, 252, 263, 292, 319, 321). Decreasing odds of attendance were found with increasing 
social deprivation by Maheswaran et al. in North Derbyshire and this is reflected in the results 
we found for this research question (371). 
Women requiring a special appointment, due to disability or breast implants also had higher 
odds of attending BCS than women who did not require a special appointment as did women 
with a previous recall compared with those without a previous recall. Previous research has 
found conflicting results and so this finding is extremely important in the field of re-
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attendance following a false positive result. Brewer et al. (372) in America and Sim et al. (373) 
in Australia found lower re-attendance rates following a false positive result but Andersen et 
al. in Denmark found no significant difference (262). In Ireland, Fitzpatrick et al. found re-
attendance rates differed by type of recall procedure type and whether the recall was on the 
incident or prevalent round of screening (269). Our data did not have sufficient detail to 
identify types of recall appointment and therefore we cannot support or refute that 
association. Regardless, it is important and interesting that women with previous recalls have 
higher odds of attending BCS in this dataset. 
4.6.1.2 Factors influencing attendance at the first episode 
This model has predicted that the likelihood of attending at the first invited episode decreases 
with age when compared to women aged 47. This is similar to attendance at any episode, 
however the differences are more extreme. 
The odds of attending BCS at the first episode were 50% lower amongst women requiring a 
special appointment compared with women who do not, OR 0.50 (0.43, 0.57). As found in the 
first research question (that minority ethnic women are less likely to attend mammography 
at any point), minority ethnic women are less likely to attend the first episode compared with 
White British women. IMD became a significant predictor of attendance at first episode for 
women of IMD7 and above compared with IMD4 for attendance at any point within an 
episode. However, this may be an artefact of the sample size more than a difference in 
attendance. 
Despite lower than normal attendance overall in the month of December it was found that 
there were no differences in a model with or without the December data included. This 
perhaps is because for a women’s first screening appointment the women who attend will 
aim to attend regardless of other commitments as it is such an important milestone in one’s 
life. 
4.6.1.3 Have influences of mammography attendance changed over time? 
As I am using a much smaller sample size for each year compared with the overall database, 
any difference in terms of significance of variables may be due to lack of data, rather than a 




Logistic regression was used for this research question as multilevel modelling was 
inappropriate for the type of data as there was no repetition of women (each woman was 
only invited once). The variables found in the previous models to be significantly associated 
with attendance were used in the logistic model. 
Age 
Even after removing women aged over seventy where the data are unreliable, non-
attendance is higher (or similar) in 2016 compared with 2001 for all age groups. Care was 
taken to ensure women were not double counted in both datasets and consequently different 
media influences will have been apparent on each cohort that can make comparisons 
challenging. Odd ratios results were found to be very different between the year groups. In 
2016 odd ratios for all ages were found to be significant compared with the youngest group. 
In 2001 only odd ratios for 70+ age group were significant when compared with the women 
aged under fifty years and the result was considered somewhat unreliable due to the large 
confidence interval. Therefore, only in 2016 was age found to be a significant predictor of 
uptake with older women having higher odds of attending BCS. 
Special appointment 
In 2016 both groups (women who did and did not require a special appointment) had lower 
rates of attendance than 2001. This is fitting with the overall trend that attendance is 
decreasing over time. Women requiring a special appointment had a higher rate of 
attendance than women without a special appointment requirement in 2016, perhaps this is 
due to better access to services and more inclusivity of the programme. As shown in Table 22 
the odds of attending BCS were only significantly lower in women requiring a special 
appointing in 2001 compared with women who did not require one, OR 0.65 (0.59, 0.73). In 
2016, odds of attending mammography were not significantly different depending on the 
requirement of a special appointment, OR 0.87 (0.75, 1.01). 
Ethnicity 
Cross-tabulations show decreasing inequality in rates of attendance across ethnicities. This 
may be due to many public health campaigns targeted at reducing inequalities of access in 
these minority groups (352). The database had a wide range of ethnicities reported which is 
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useful and has significant advantages compared with many research studies which often 
under-represent ethnic minorities (352). However, this decreasing inequality may not be 
generalisable to the rest of the UK due to the heterogeneous population in this SW London 
sample.  
Despite this, uptake of mammography in the UK is consistently found to be lower in women 
of ethnic minority compared to White British women (135). When compared with attendance 
of White women only the OR of Asian and Black women remained significant in both years 
analysed. However, the relative effect size (OR) was approximately 20-30% lower in 2001. As 
is shown by the lower attendances of women with ‘missing’ ethnicity data, this comparison 
may be biased by the sample used, ethnicity is more likely to be recorded in women who 
attend screening. Furthermore, the changes in uptake of ethnicity could have been influenced 
by improvements in the recording of ethnicity data rather than a definite sign of increased 
attendance of ethnic minorities.  
Previous studies have also found this trend. Szczepura et al. reported in 2008 that rates of 
BCS uptake were increasing for South Asians at a faster rate than other ethnic minorities and 
the majority population (140). Furthermore, inequalities are reported to have narrowed 
elsewhere. In the USA the increase in uptake between 1991 and 1994 was larger among low-
income Black women when compared against low-income White women. This difference is 
unaccounted for by confounding factors such as region or insurance (374). This is a good 
illustration of the changing trend of ethnic women’s screening behaviour. 
Previous recall 
Higher rates of non-attendance were found in 2016 for women who have experienced a 
previous recall. Different women react to this experience differently but perhaps a change in 
the procedure occurred during this time frame that has deterred re-attendance. While both 
odd ratio estimates were significant, those for 2016 were larger, OR 0.53 (0.40, 0.66) meaning 
women with a previous recall in 2016 had higher odds of attending BCS than those without a 
previous recall. The effect of a false positive result in the literature is mixed (143, 249, 251, 
372, 373, 375). Some suggest that re-attendance may vary depending on type of recall 
assessment, type of woman, and skills in information delivery by healthcare staff. However, 
177 
 
any change in trend has not explicitly been analysed to the best of my knowledge but it 
remains important in determining uptake patterns. 
The analysis found an increasing trend of attendance in both year groups with increasing 
affluence. This finding is well documented throughout the literature (79, 124, 135, 136, 371). 
The difference between attendance in 2001 and 2016 appears inconsistent amongst different 
IMD groups. Odd ratios suggest approximately equal likelihoods of attendance across years 
with only odds ratios for groups IMD5 and above (more affluent women) being found 
significant as shown in Table 21. 
4.6.2 Interaction effects 
Interaction effects occur when the effect of one variable on an outcome is dependent on 
another variable. Including interaction effects can improve the fit of a statistical model output 
in a real-world setting, but sometimes at the cost of interpretability. Failing to include 
interaction terms means each variable is assumed to have an independent effect on the 
outcome, which may or may not be true. The interaction between age and IMD was 
considered in the model building process but was not included in the final model due to a lack 
of statistical significance. Hence no interactions were included in the final model. 
4.7 Strengths and limitations 
The largest strength of this study is the size of the database used. Data from 304,616 women 
were collected and analysed over an eighteen year timeframe. A large database is important 
as it provides sufficient power to identify smaller associations with the outcome variable. 
However, it gave a complicated picture of attendance as many variables were found to be 
significantly associated with attendance at mammography. The large number of variables 
being investigated also increases the chance of a type one error, as the large number of 
observations increases the chance of detecting a statistically significant, but clinically 
unimportant effect size. To counter the use of multiple model testing on the data a Bonferroni 
adjustment was used to reduce the likelihood of a type one error. 
Multilevel modelling is a valuable method to modelling hierarchically organised data and 
outperforms the more basic logistic regression in predictive accuracy. As women are invited 
to screening every three years it was anticipated that women could have up to seven episodes 
between 2000 and 2018. Multilevel modelling accounts for the repeated measurements of 
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women and relaxes the assumption of independence of the observations. After fitting the 
best model to the data it also allows a prediction of each women’s likelihood of attendance 
at mammography which is useful to provide a real-life estimate of attendance. 
By using a secondary dataset there was no bias incorporated into the data by the researcher 
and this was a cost-effective means of collecting such a large amount of data. The data were 
routinely collected information by hospital staff at screening centres. However, this means 
that the analysis relied upon self-report for ethnicity and so for women who did not attend 
any appointments ethnicity data remained missing. Whilst there is no perfect way to obtain 
ethnicity information where the person themselves is unable to provide it, use of name 
recognition software (376) was not undertaken and the work relied upon self-reported 
information at attendance. 
As with any large dataset previously collected for a different purpose, my analysis had to rely 
on the variables available and may therefore potentially miss important information that 
could be associated with the outcome of interest such as car access, marital status, 
employment status, distance travelled to the screening site etc. Furthermore, as mentioned 
earlier, the database was incomplete, particularly within the ethnicity domain which may 
have biased interpretation and results. 
The data included in this dataset are not entirely representative of the ethnic diversity of 
England. The analysis was comprised of a larger proportion of ethnic minority women 
compared to the national average. This routine SW London database also favoured the middle 
age groups (50-59 years and 60-69 years) and had a larger proportion of affluent women than 
the census data. Therefore, it appears that the dataset is not generalisable to a nationwide 
scale. On the other hand, the population screened is more likely to reflect the London 
population from which it is drawn which has a higher proportion of ethnic minority women 
(135). This is discussed more in Section 5.8. 
Analysis of this sort using an observational design can only ever identify associations not 
causality. There may be other confounding variables that are not included in this dataset but 
which are extremely important for determining association with uptake of mammography. 
Such confounding variables may include personality characteristics (such as propensity to 
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attend appointments, or fatalism, or health beliefs) or may be other structural characteristics 
which are as yet undescribed. 
 
 
4.8 Representativeness of the data 
Figure 50 shows the composition of this database (routine SW London dataset) compared 
with census data of 2011. It shows that this sample contains fewer White British women and 
more ethnic minority women than the national population. This could explain why the dataset 
is presenting a lower than average attendance overall (64.45%) compared with the national 
average (71.1%) (377) as much literature has previously reported lower uptakes in women of 
ethnic minority (137, 140, 248). 
Routine SW London data used also had a larger representation of women from the 50-59 year 
old age group and 60-69 year group compared with census data which had a less extreme 
distribution of ages. This may have biased any analyses into not finding significant results in 
the 70+ groups or under 50 year old groups. 
In the Census data, distribution across employment groups was fairly consistent (ranging from 
20% to 30%) whereas the distribution of the routine SW London data was skewed towards 
the affluent end of the population. Again this may have biased analyses. 
The comparisons above were made between the routine SW London dataset and census data 
for England and Wales. Whilst it is useful to compare the dataset to a wider national 
population it is anticipated that the composition of SW London would be different from the 
census data. The composition of London nationalities is shown below with a large majority 
comprised of UK nationals. This allows us to be more certain to say the secondary dataset is 




Figure 57. Diversity of nationalities in London population (367). 
As discussed above a general decreasing missingness of data has been observed as age 
increases and is highlighted in Appendix 8.3.6. I cannot be entirely sure why this is the case 
but it could be due to a number of factors. Perhaps that older women were more comfortable 
discussing their ethnicity or because older women will have had more opportunities to 
provide this information as they will have been invited to more appointments and potentially 
had more opportunity to present this information. Again, whilst there are slight trends in the 
missingness of IMD data, there is no clear reason why age would meaningfully predict IMD 
missingness. The association of appointment status with missing data is perhaps about the 
complexity of the appointment meaning less time and/or pressure to ask about ethnicity or 
IMD and therefore this information is not obtained. However, no clear reasons or trends have 
been found and therefore imputation would not be useful. For these reasons, it was 
appropriate to treat ethnicity and IMD data as MCAR in the final analyses.  
 
4.9 Future research recommendations 
When comparing the results of the systematic review with these results it is evident that 
similarities are present. Uptake appears to decline with older age, increase with affluence and 
is lower in women of ethnic minority. This is true for attendance at first screening round and 
throughout. However, despite similarities, the data from the review were found to be not 
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It is unfortunate that the routine SW London data did not have appropriate data on other 
variables such as education, marital status, chronic conditions, housing tenure and number 
of primary care visits as the review found these to be associated with uptake. Future research 
should investigate this, perhaps by collecting more detailed relevant data rather than relying 
on secondary data. 
Unfortunately we did not have time to fully develop a model to look at attendance patterns 
at the first mammography appointment due to the time and financial constraints of the 
doctoral researcher position. This would be interesting to have analysed as there are perhaps 
particular sub-groups of women who attend at the first appointment regardless of its 
convenience for them. In addition it would be fascinating to establish if women who attend 
at the first appointment are more likely to be compliant with subsequent appointments at 
the three-yearly interval. 
What was interesting and observed in the overall descriptive statistics was that attendance 
at a first appointment in December was lower than attendance in other months. As 
hypothesised, general attendance appeared approximately equally distributed across the 
days of the week. However further investigation needs to be undertaken before drawing 
conclusions from these observations. Caution needs to be taken as these data do not account 
for women who needed to re-schedule appointments either due to work commitments, 
holidays or other reasons.  
Much research has looked at the time trends of breast cancer mortality and mortality in 
women who underwent mammography. To the best of my knowledge little research has 
analysed time trend data for determinants of uptake to see if these have changed. It is 
extremely important as a key requirement to achieve cost-effectiveness of the programme 
that attendance remains above 70%. This analysis has started to contribute to the lack of 
understanding of attendance patterns over time. However, much more can be done. 
Ascertaining which women are likely to attend, re-schedule or not attend their first 
appointment would likely highlight key differences between types of women and therefore 
more personalised information could be gathered. 
Despite collecting the data for screening appointments prior to 2000, regrettably I had to 
remove them from the dataset due to the reliability of the information. It is therefore 
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recommended that the issue with the collection of the data be rectified for future use so that 
a wider timespan of uptake information can then be analysed. 
Further research conducted as part of the thesis includes the development of a questionnaire 
in order to further investigate these predictors of uptake. The questionnaire I developed 
collects self-reported information about age, IMD and ethnicity. It also collects information 
about previous attendance, marital status and chronic conditions. These items have been 
found to be associated with uptake of mammography in the systematic review. Furthermore, 
the questionnaire provides information to estimate a woman’s risk. Once collected it would 
be fascinating to combine this questionnaire information with the secondary data analysis to 
understand which types of women are most likely to be at risk from BC compared to who is 
most likely to attend mammography (or not). 
As NHS staff are now directed to collect more data on demographics (including ethnicity) it 
will be intriguing to conduct these same analyses later using a more complete dataset for 
ethnicity. 
Chapter summary 
This chapter has discussed predictors of uptake using a database of appointment attendances 
for 304,616 women from SW London. It found that older, minority ethnic or women from 
deprived areas were significantly less likely to attend BCS and women requiring a special 
appointment or who had had a previous false positive result were more likely to attend BCS 
than their counter-parts. 
This is interesting because previous literature has found that a previous false positive result 
reduces likelihood of returning, whereas my study suggests false positives may increase the 
likelihood. (100). Further research needs to explore this interaction.  
Screening centres should be informed of the results of this study to tailor their services to the 
women they are inviting to comply with ethical guidelines. For instance it is positive and 
reassuring that requiring a special appointment, often believed to be a barrier to attending 
healthcare, meant they were more likely to attend screening at SW London. 
Similar predictors were found to be influencing uptake at the first round of screening except 
that requiring a special appointment was associated with a lower likelihood of attending BCS. 
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This research suggests that more could be done by the screening centres to encourage first 
time attendance in those requiring a special appointment who wish to be screened. 
Year was found to be associated with uptake with an overall lower attendance in 2016 
compared with 2001, with relative effects of covariates being generally maintained across the 
two separate year periods. There appeared to be a higher attendance of ethnic minorities in 
2016 compared to 2001, but it is unclear whether this is the result of an improved attendance 
or from changes made to the recording of ethnicity data.  
The secondary data analysis has found ethnicity, IMD, age and previous recall to be 
statistically associated with uptake whereas the systematic review found no significant 
difference between groups. The integration of study findings will be discussed further in 
Section 7.2. 
The next chapter focusses on the use of individual demographic information and using 



























Chapter 5: Questionnaire Design 
Introduction 
As discussed in previous chapters, personal and demographic predictors are 
positively associated with the uptake of breast screening. The predictors of uptake 
found in my systematic review to be statistically associated with uptake of 
mammography included marital status, smoking status, insurance status, chronic 
conditions and primary care visits. My secondary data analysis also independently 
identified age, SES, ethnicity, requiring a special appointment and previous recall to 
be statistically associated with uptake of mammography. The review did not find age, 
ethnicity or SES to be statistically significantly associated with uptake. 
Further research may identify additional predictors of uptake of breast screening in 
the UK that were not able to be examined in these previous studies. In this chapter I 
develop a questionnaire to examine personal demographics and predictors of uptake 
further. Results of these questionnaires will allow the future measurement of 
associations between personal predictors of BC and uptake. It will also allow 
researchers to determine which women are making an IC about BCS and whether this 
is another predictor of uptake. This interplay of predictors and measures is shown 
below in Figure 58. 
As no previously validated questionnaires met the criteria for obtaining the relevant 
information I will begin by explaining the need for this questionnaire. This chapter 
will explain the methodology of tool selection and elaborate how the questionnaire 







5.1 Research questions, aims and objectives 
The aim of this study was to develop a questionnaire that can be used in future 
research that will allow researchers to answer the following questions (as displayed 
in Figure 58): 
1. Do personal characteristics influence whether a woman attends/not attends 
BCS? 
2. Does personal BC risk influence whether a woman attends/not attends BCS? 
3. What are the characteristics of women who make ICs? 
4. What influence does making an IC have on BCS uptake? 
However, these questions will not be answered in this chapter as the questionnaire 
is only taken to the design stage. 
 
Figure 58. Questionnaire components for analysis. 
 
This chapter describes the development of the questionnaire. A PPI advisor was 
invited to give their opinions on the length, depth, content and design of the 
questionnaire and cognitive interviews were conducted that focussed on the 




• Are there specific questions that raise issues? 
• Are there any mistakes or omissions identified in the questionnaire? 
• Is the questionnaire appropriate for women aged 47 to 73? 
 
Objectives of the questionnaire development study included to: 
o Design the questionnaire to be used at a later stage having obtained ethical 
approval for questionnaire development 
o Write the accompanying documentation including participant information 
leaflet (PIL) and consent form 
o Consult with PPI representatives for advice on writing style, content, layout, 
order, appropriateness and readability and/or factors to improve likely 
response rates 
o Conduct cognitive interviews (until data saturation) with women within the 
target age range to ensure the questionnaire is suitable, feasible and asking 
the right questions 
 
This questionnaire has been drafted for future use. Once fully tested and validated 
its primary future purpose is to explore the associations between IC, personal BC risk, 
personal demographics and mammography uptake. The need for which will be 
described below. Whilst this could just be used for academic purpose (perhaps simply 
to explore the interactions further or to evaluate a re-designed screening leaflet) it 
could be used in a screening programme that will need to be adapted slightly for full 
purpose.  
In a screening programme, the new process would involve women being sent the 
questionnaire alongside the BCS leaflet and asked to complete the questionnaire 
before posting back to the screening centre. It will not explicitly be stated the 
answers can be found from the leaflet. Results (levels of IC and personal BC risk) will 
be used to assess if the woman needs more, specific information to make an IC. This 
will be tailored to her demographics and personal BC risk. Only if the woman has 
made an IC then she will be invited (or not) depending on her preferences. If she still 
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does not make an IC, an appointment should be made to discuss the screening 
process further with her before making an appointment for a mammogram. 
Whilst this proposal contains details that have not been the primary focus of this 
research, this is the concept and end-goal for the questionnaire. 
5.2 Questionnaire design 
Questionnaire design involves the development of clear, unambiguously worded 
questions that allow accurate answers to the question posed (378). However, 
problems of completion frequently encountered include difficulty with 
interpretation or comprehension of questions, retrieval of answers, social desirability 
bias and judgement as to whether the respondent is comfortable disclosing certain 
information (240). These may result in the respondent failing to answer the question 
posed, giving obviously incorrect answers, missing questions (or sections) or not 
following instructions. I aimed to reduce this by including a ‘don’t know’ or ‘prefer 
not to say’ option where questions might be uncomfortable for the respondent. 
In this section the methods used throughout the questionnaire development process 
will be described. 
5.2.1 The current literature 
The current literature was searched to identify potential contributing factors to BCS 
uptake prior to conducting the systematic review study and found a variety of 
predictors have been associated with uptake of mammography. Some of these 
factors were acknowledged as risk factors in the systematic review (see Figure 59) 
and secondary data analysis also and some are new, interesting and important 
factors such as the movement towards IC in screening decisions (265, 305, 345). 
These influencing factors are grouped into health and family history (379), personal 
demographics and other (380) including attitude towards BC risk or BCS (379, 381) 
and previous health-related behaviour. 
Whilst not all of these were to be included in the questionnaire, key data required 
for a comprehensive questionnaire were agreed (by the researcher and her 
supervisors) based on these findings and the relevant predictors and measurements 
identified were included or adapted for use as recommended (382, 383). 
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Decision aid questionnaires currently available are not designed or tested for the UK 
or mammography populations (188). Although it is important to conduct research to 
investigate the effectiveness of the decision aids for screening in the NHSBSP, the 
NHSBSP appears far from adopting this practice to encourage IC due to concern over 
potentially reducing uptake (265). This is despite other countries changing their 
guidance to adopt IC, for instance in Germany (62). Consequently, assessment of 
whether an IC affects uptake decisions and if those decisions are affected by personal 
BC risk or demographics is vital information that the screening programme needs to 
obtain and be able to prepare for the eventuality that encouraging IC is essential 
(184, 235). 
From this assessment of the literature, three topics were found to be of importance 
to explore in further detail. IC (as discussed above) is assumed to be associated with 
rates of uptake and this needed additional investigation. Personal demographics are 
associated with uptake frequently. It is important to assess the effect of personal 
demographics in the UK mammography screening population.  Finally, IC may reduce 
uptake of BCS, but it is important to determine if those who are deciding not to 
attend are those who have higher risk of BC. A risk prediction model was needed to 








5.2.2 Model choice 
Whilst recent research suggests the further addition of factors associated with BC 
risk such as genetic status or mammographic density, the search for an appropriate 
model had to align with factors readily available to the population if the 
questionnaire was going to be effective in the public domain (384-386).  
There are over forty risk prediction models that have been peer-reviewed by 
qualified scientists for use in research and are published in scientific and medical 
journals (387). Whilst the peer review process is not without its own set of flaws and 
biases it does encourage transparency of methods, rigour and increases the reliability 
of the information presented when compared with data that does not come from 
peer-reviewed manuscripts (388).  Eight of these prediction models, which have been 
independently validated in previous research and are discussed earlier in this 
chapter.  
The risk prediction model for this study needs to be one that is suitable for the 
general UK population of women of average risk and aged between 47 and 73 years. 
Those requirements immediately rule out ‘Asian Pacific Islander American Women’ 
(389), the ‘CARE’ model for African American women (390) and the ‘Breast Cancer 
Risk Assessment Tool (BCRAT)’ which can predict only for women of those stated 
ethnicities who are examined annually (391). The Gail model only uses a small 
selection of the available predictors (age, age at menarche, age at menopause, 
personal history of breast disease and only first-degree relations with BC) – 
furthermore the Gail model has been shown to considerably underestimate risk of 
BC diagnosis which means it has been eliminated for use in this research (392). 
The Breast Cancer Surveillance Consortium model by Tice et al. was well calibrated 
but with an observed-expected ratio of 1.03 (0.99, 1.06) meaning that no significant 
difference was found between the model and real life diagnoses (393). However, the 
c-statistic (the proportion of pairs where the woman with the disease has a higher 
predicted risk estimate than the woman who does not have the disease) was lower 
than other models at 0.613 (0.604, 0.622) and was therefore unfavourable (394). The 
model is only ‘modestly able to discriminate between women who will develop breast 
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cancer and those who will not’ and the fact the model was calibrated on major race 
and ethnic groups in the USA means that it is not suitable for use in this study within 
the UK (393). 
Whilst the Barlow et al. Risk Estimation Dataset (384) could have been used here, 
other models had more intuitive interfaces and better c-statistics (the proportion of 
pairs where the woman with BC has a higher predicted risk estimate than the woman 
who does not have the disease) a crucial determinant for a risk prediction model. 
Furthermore the Barlow separated pre- and post-menopausal women into different 
models which would complicate future research in the design of this questionnaire. 
Despite this being advantageous as pre-menopausal and post-menopausal women 
have different risks, the model eventually chosen for our research does account for 
this factor too but in a different manner. 
Two of the remaining options (based on the Nurse’s Health Study) are an update of 
the same model (395, 396). The authors admit an overestimation of risks in certain 
subgroups such as younger parous women. No c-statistics or observed-expected 
ratios were provided meaning no comparison can be made and the model will not be 
used (394). 
To summarise, the above risk prediction models have been discounted for the 
following reasons: 
• Asian Pacific Islander American Women’ – wrong ethnic make-up compared 
with UK 
• Breast Cancer Risk Assessment Tool – USA data, limited predictor section, 
underestimation of risk 
• Breast Cancer Surveillance Consortium – poor c-statistic, different ethnicities 
to UK, based on USA data 
• Barlow et al. Risk Estimation Dataset – unintuitive interface, poor risk 
estimation 
• Two models based on the Nurse’s Health Study – admit to overestimation of 




The Tyrer-Cusick (known as IBIS) model 
The IBIS model was developed in the UK and combines an extensive network of 
hormone related, personal and familial risk factors (n=13). A meta-analysis included 
work by Amir et al. (392) who compared some of the available models and found the 
IBIS to have the highest c-statistic 0.762 (0.700, 0.824) meaning discrimination 
performance of the model was the best. The expected-observed ratio of IBIS model 
was also close to one, 1.09 (0.85, 1.41) meaning it is considered a well-fitting model 
(394). 
Moreover, the IBIS model accounts for a comprehensive set of variables including 
genetic BRCA1/2 factors, environmental factors such as BMI and parity, and 
hormonal-related factors such as use of HRT, age at menarche and menopause (11). 
Research has shown that adding mammographic density information would improve 
accuracy further (397). However, as breast density is not routinely measured in the 
UK, few women would know their mammographic density making the additional risk 
factor unusable in a questionnaire setting. 
The IBIS model out-performed the Gail model in a cohort whose risks span the 
continuum of BC risks. However, this experiment was conducted on a US sample and 
may not be generalisable to the UK population. Despite not being independently 
validated in the family history setting, IBIS model remains popular and most useful. 
The area under the ROC was 0.762 (0.700, 0.824) and was the most accurate of all 
models tested (392). 
The decision was taken to use the Tyrer-Cuzick prediction model “International 
Breast Cancer Intervention Study” (IBIS) (10). 
5.2.3 Structure of the questionnaire 
The first section (marked A) asks specific questions about medical history to calculate 
a personal risk of BC. It starts with questions that should be easy to complete and 
which will not feel too personal for the participants to answer. Section B asks 
questions to measure individual levels of IC and attitudes towards BCS. Section C asks 
about personal characteristic, considered by some as mundane, and by others as 
slightly more intrusive so these were saved until the end of the questionnaire. This 
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section includes questions such as postcode, year of birth and marital status. This is 
done after the bulk of the questionnaire following recommendations by Burns et al. 
as initial presentation of demographic questions may dissuade participants from 
completion (398). 
Balancing important questions with encouraging response rates is always 
complicated in questionnaire design. The questionnaire needed to be detailed to 
obtain sufficient medical information to enter the relevant information into the IBIS 
model variables to obtain a BC risk prediction for each woman. Detailed questions 
about parity, breast disease, family history of cancer and menopausal status are 
therefore included. Not all known risk factors are included in the questionnaire 
including many lifestyle factors, such as smoking, alcohol consumption or physical 
activity thought to be related to BC but are not relevant for completion of the IBIS 
model (10). 
In the aim of reducing repetition of questions which could lead to boredom and 
attrition, some of this information is found in the personal characteristics section of 
the questionnaire instead (C) (399, 400). 
Section A 
This section is designed to allow for estimation of a probability that an individual will 
develop BC over a given timeframe. Risk prediction models for BC use individual’s 
information on variables known to be associated with BC. Examples include age, 
family history, breast density, menarche, BMI, physical activity, use of HRT, history of 
tobacco use and genetics, among others. The risk prediction model used (IBIS) only 
incorporates data on personal and familial risk factors and does not consider others 
such as physical activity or history of tobacco use (10). These are factors that are 
often more well known by the individual and therefore it is anticipated that accurate 
completion of the questions related to these factors is more likely to be achieved.  
Whilst it is difficult to recommend one model over another, as no model consistently 
out-performs the others on all tests, IBIS has been chosen as it has a high c-statistic, 
its observed-expected ratio was close to one and it was developed and tested on a 
population similar to the UK (394). Precise knowledge of individual risk is a 
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prerequisite for tailored information based on risk. Whilst the risk prediction models 
need fine tuning, research can be conducted on the use and implementation of such 
processes ready for when the prediction models improve in accuracy. 
Section B 
Whilst answers to these questions can be answered by consulting the mammography 
leaflet, the leaflet will be sent in conjunction with the screening leaflet, but the 
women will not be advised to complete the questionnaire using the leaflet directly. 
This will enable a clearer understanding of whether a respondent has the 
understanding and knowledge, rather than being able to cite information from a 
leaflet.  
Knowledge 
As discussed in Chapter 2, IC is measured using a combination of knowledge, 
attitudes and behaviour (235). Figure 59 displays this interlinked phenomenon. 
 
Figure 60. Three dimension of informed choice includes knowledge (good/poor), attitudes (positive/negative) and 
uptake (yes/no). Combination 1 and 4 are considered informed choices only. Figure taken from (234). 
To have made an IC, a woman must have sufficient knowledge about screening and 
BC and have either (1) a positive attitude reflected by uptake or (2) a negative 
attitude to BCS echoed by non-attendance at screening (186, 235). Only these 
combinations are considered ICs.  
Whilst that choice may be informed or not, decision making is an essential 
component of healthcare, not only from the physician’s perspective but from the 
patients’. Primarily, the patient has to determine if they are willing to seek 
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healthcare. To make this decision (in this instance whether or not to attend BCS) the 
patient must first decipher the information presented to her before deciding 
whether or not it is something she wants to do.  
The Fuzzy Trace Theory suggests more people rely on gist information compared with 
verbatim reproduction of the information (194). Gist and verbatim are defined in the 
same way as in everyday terms, people who recall the gist of the information 
remember the bottom-line meaning, whereas those who remember information 
verbatim can remember and recall the specific details (194). Gist information is 
considered a subjective interpretation based on emotions, education, experience 
and culture (194). Gist based reasoning is associated with improved health outcomes, 
increased adoption of behaviours to reduce risk and improved decision making (194, 
401). After retrieval of any information however, people assess this against their 
values and principles before applying it to their situation (194).  
Alongside recall of information, health numeracy in terms of judging relative risks 
and benefits of medical interventions is long recognised as a key component of 
ensuring an IC. Individuals with a marked lower literacy ability appear to be at a 
disadvantage. Previous research has found literacy to be connected with greater 
health knowledge and understanding, expertise to self-manage disease and its 
treatments and importantly better health outcomes overall (187, 402-406). 
It is apparent that health numeracy and both gist and verbatim knowledge are 
important in any medical decision making. Sufficient knowledge is a key component 
of the ability to make an IC in a medical decision. In the IC section of the questionnaire 
it tests both gist and verbatim knowledge, as per the Fuzzy Trace Theory (187, 194). 
Consequently, there are two types of questions in this section, numerical and 
conceptual. 
The questions measuring knowledge are adapted from work conducted in Australia 
(164) and the UK (233). As the work conducted by Marteau et al. (164) and Dormandy 
et al. (233) investigated Down’s syndrome screening and low literacy populations 
respectively, questions were adapted to reflect BCS in a general population for this 
questionnaire. Questions used were as similar as possible to increase reliability and 
197 
 
validity by using previously validated questions from questionnaires (407). However 
these sections would need further assessment during the next questionnaire testing 
phase.  
Attitudes 
Likert scales were developed as a five-point bipolar scale in 1932 and are frequently 
used for assessing opinions or attitudes (408). Using a five-point Likert scale and a 
scale of agreements to statements, participants were asked about their attitude to 
BCS. Ethically, questions should be easily interpreted and a five point scale for 
responses was considered appropriate here (409). 
Following research by Dormandy et al. (410) respondents with scores above the mid-
point are classified as having positive attitudes and those with scores on or under the 
mid-point negative attitudes. These positive and negative attitudes have been 
calculated to align with previous research (233, 236). Despite a positive attitude to 
BCS there may be other factors preventing uptake such as childcare, cultural or 
logistical barriers. 
Section C 
The majority of questions regarding personal demographics were taken from the 
Health Survey for England 2012 as they have been previously validated and published 
(411). These questions were left until the end of the questionnaire as recommended 
by previous literature to reduce incompletion of the survey due to tediousness (407). 
5.2.4 Item selection 
Discussion between the student and supervisory team were held regarding item 
selection. 
Items were based on similar questions available in the literature as described above. 
Items were written to be comprehensible to the target population using no jargon 
and simple sentences. Terms were unambiguous and were specific where possible. 
Each item only contains one question and remains neutral. All items are weighted 
equally as each item represents a different dimension. 
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Items within section A are data that will be entered into the IBIS risk prediction model 
as shown in Appendix 8.4. All items were written to account for each component of 
the risk prediction model. Some data for the model are obtained from section C.  
Section B comprised a variety of question types to establish the extent of a woman’s 
knowledge about BCS. There were simple questions that asked women to select the 
answer they felt was correct. These are to be marked as either correct or incorrect. 
Other questions, namely the numerical ones, required more verbatim recall of 
information provided in the BCS leaflet. It is anticipated that the majority would be 
likely to score incorrectly on these (188). However, these statistics are key 
information which the leaflet hopes to portray and are considered important 
information which women should be taking into account when making an IC in BCS. 
Attitude questions were asked using Likert scales. The use of Likert scales is one of 
the most frequently used tools (412). The purpose was to understand the opinion of 
the respondent to the phenomenon of interest (the question posed) and as such their 
opinion was expressed as the response on the Likert scale (412). The main flaw, as 
discussed by Jamieson et al. is that the intervals between the Likert values are 
presumed equal and yet are unlikely to be equal (413). Despite this, the response 
categories have an inherent rank order and as such can be analysed accordingly, in 
this case with an appropriate cut-off set for ‘positive’ attitudes (414). 
In the final version ‘positive’ answers were not all down the right-hand side of the 
page and instead I varied the format to ensure respondents were not biased to one 
end of the scale. However, providing the middle option as ‘3’ may mean we end up 
with a lot of neutral responses with no particular opinion. Therefore, attitudes must 
be more than fifty percent to be considered positive.  
Section C is comprised mainly of questions that should be familiar to respondents as 
they are often presented in questionnaires. They require women to select an option 
that is most appropriate to their own current situation. 
Personal information, not relating to the completion of the IBIS model included 
partial postcode, ethnicity, marital status, a range of questions related to 
socioeconomic status (income, employment, education), housing tenure and health 
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status. These were included based on previous literature searches that indicate these 
factors are important and associated with the development of BC.   
5.2.5 Drafting the questionnaire 
What information? 
Guidance from Boynton et al. was followed throughout the phases of questionnaire 
design (407). The questionnaire was designed to measure three constructs which 
could be used in a future risk prediction model. Section A: medical history and factors 
relevant to a BC risk estimation; Section B: knowledge and attitudes about BCS 
allowing a calculation of IC and; Section C: personal information. 
Is it appropriate? 
A questionnaire allows feedback from a large audience with little cost or intrusion 
into their daily life. The structured, closed questions allow for answers to questions 
in a less cognitively demanding manner whilst the open-ended questions allow for a 
deeper, qualitative exploration into the meaning of the answers (415). Questionnaire 
data generally allows quick analysis using processing software packages but this is 
minimised with the increased use of open ended questions which require different, 
qualitative analysis (222, 378). Feedback from questionnaires is generally anonymous 
(and is in this instance) and therefore the respondents are more likely to be honest 
with their answers compared with other information gathering techniques such as 
interviewing where the respondent is in close proximity with the researcher involved 
(416-418).  
In consideration of these points, a questionnaire was considered appropriate to 
answer these research questions as it is the best tool to use to obtain the large 
number of responses in a structured manner. Additionally, cognitive interviews were 
used to ensure that questions were as appropriate and clear as possible. 
Is there an existing tool? 
There is no single tool that captures data on personal demographics, personal risk of 
BC, and IC. For some components of the tool, previous research has been conducted.  
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For example, Marteau et al. created a measurement of IC and reported key questions 
assessing knowledge of the condition and the screening procedure. However, this 
was conducted for Down’s syndrome rather than BCS and therefore needed adapting 
accordingly (164).  
Michie et al. have also reported key constructs of the knowledge component of the 
MMIC model (Figure 59). These included the ‘purpose of screening, likelihood of 
positive and negative findings, uncertainties and risks attached to the screening 
process and implications of screening’ (234). This model was used to develop the 
knowledge questions about mammography.  
Furthermore, Evans et al. have conducted research investigating whether the use of 
individualised risk in the NHSBSP was feasible and useful (419). This research focused 
on the incorporation of mammographic density and genetic factors to identify high 
risk women before exploring the opportunity to counsel them to reduce their risk. 
Whilst it is acknowledged that using these additional risk factors in the risk estimation 
model might be helpful, it is unfeasible in this research to focus on those predictors. 
Items related to IC were based on the requirements for IC from Marteau et al. work, 
initially conducted in pre-natal screening, as described in further detail in chapters 
below (164, 233). These items were then validated by Michie et al. (186, 234) before 
being used as part of decision aids in studies about screening programmes by Barratt 
et al. (192). In 2010, Smith et al. (188) used the measure of IC in a bowel cancer 
screening study and Matieu et al. (235, 236) adapted it for use in a BCS decision aid 
tool. These adapted questions have been used as closely as possible in this 
questionnaire.  
The questions relating to attitudes towards the screening test were based on work 
conducted by Dormandy et al. (233). Respondents with scores above the mid-point 
were classified as having positive attitudes and those with scores under the mid-point 
as having negative attitudes. 
Questions regarding personal demographics were taken from the Health Survey for 
England 2012, as they have been previously validated and published (411).  
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How to present the questions 
A variety of different question styles were used in this questionnaire. The majority 
used tick boxes for the respondent to select the appropriate answer or left a blank 
space for her to fill in the answer (for example when asked how old she is). Rating 
scales were used to assess a woman’s attitude to BCS and to determine her perceived 
risk of BC. Open-ended questions were used to allow elaboration of negative 
consequences of BCS, or if there were not any negatives to discuss why she felt this 
was the case. Other open-ended questions include the opportunity to expand on an 
answer or to give additional information when an answer is inappropriate. 
Layout 
The layout of the questionnaire is particularly important. Previous literature has 
found that low response rates are often due to respondents being unable to follow 
or read the questionnaire (383, 400, 407). It is preferable that questions are short, 
concise and straight-forward. However, it has been suggested that sensitive material 
requires longer question wording in order not to come across as too abrupt (407). 
Ethical approval 
To develop this questionnaire and conduct cognitive interviews BSREC ethical 
approval was sought. BSREC approval (REGO-2017-2118 AM010) for the cognitive 
interviews at University of Warwick was granted on the 3rd January 2018. 
Checklist (supplementary material (407)) 
Boynton et al. provided a checklist for the development of a questionnaire (407). The 
majority of the suggested components of a questionnaire study have been met. The 
recommendation considered of particular importance was to provide a participant 
information leaflet for participants to take away after completing the questionnaire.  
5.3 Patient and Public Involvement (PPI) 
5.3.1 What is PPI? 
PPI is the use of patients or members of the public, who are not medically or 
academically trained to conduct the research to provide their opinion and ideas 
towards improving the research study. PPI is becoming increasingly common in the 
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design many research projects to ensure that the research is relevant, effective, 
focusses on patient needs and is desirable for the NHS (420-422). INVOLVE (an 
initiative established in 1996 by the NIHR) is a government funded programme to 
actively support public involvement in the NHS (423). 
The process often involves actively collaborating with a PPI advisor throughout the 
design and development of the initial stages of the study – to ensure the design is 
effective to recruit as many as required. The role of the PPI advisor is to bring insight, 
experience in the field of public involvement with research and aims to advance the 
research, the way it is designed, conducted and disseminated (423). 
As part of the CLAHRC team within the University of Warwick I was fortunate to have 
access to a female PPI representative. She was selected based partly on her 
experience with the breast screening service and partly for her experience and 
training within the CLAHRC team. The PPI partner was asked to represent the average 
citizen who may be invited to complete this questionnaire in the future and to view 
the questionnaire as a potential screenee. They had not personally had any 
experience with BC or with a recall result but knew many female friends and/or 
colleagues who had had these experiences. 
5.3.2 Why is PPI needed? 
There is a growing body of literature that highlights discrepancies between aspects 
defined by clinicians to be considered important and those defined by patients as 
important to them (424). PPI is used as a representative of the patient body in 
consideration of what is important to include in the questionnaire and how the 
questionnaire will be perceived by the women completing it. If the questionnaire had 
little content considered important to the public in a questionnaire about breast 
screening then perhaps response rate would decrease. 
5.3.3 PPI Methods 
The PPI representative was provided with a draft copy of the questionnaire and 
associated PIL and was asked to ensure readability, to determine if questions were 
acceptable to the general population and to establish whether the questions would 
provide the desired outcomes. The PPI representative had as much time as she 
needed to complete this task, there was no time pressure set. The PPI representative 
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then provided written feedback and suggested changes alongside a long 
conversation with the researcher about the reasons why and implications of 
particularly concerning components such as the addressing to the participant 
familiarly rather than formerly. 
A detailed discussion with the PPI representative was had regarding the initial draft 
of the questionnaire and the PIL. However, despite never being asked to complete 
the questionnaire themselves through discussion we did effectively go through each 
question as if it were being completed by a future participant. 
5.3.4 PPI outcome and improvements 
The PPI representative highlighted a few concerns with the terminology and 
approach of the first draft questionnaire. Specifically, the PIL was to be made more 
personable and friendlier; as I was asking for participants’ time and contribution to 
the study I should be addressing them more familiarly. Along these lines I also needed 
to be referring to myself in the first person, especially as it was I who was conducting 
the interviews for the questionnaire development. 
Importantly, it was to be emphasised that I was not able to provide individual 
predictions of BC development to the participants. Finally, it was important to 
accentuate that not all risk factors for BC were included in this questionnaire and that 
the questionnaire aims to obtain more information about risk factors for BCS 
development. 
Within the questionnaire itself, an additional introductory paragraph with general 
information was to be added to the start of each section highlighting why these 
questions are necessary to increase saliency and therefore completion rates (409). A 
sentence highlighting that I was only interested in the cancer history of blood 
relatives was also added to the start of relevant questions to serve as a reminder to 
respondents. 
Despite acknowledging that this was not a test, the PPI representative highlighted 
that it did appear to be a knowledge test. To ensure that participants did not feel as 
if they were being judged as to whether they had given right or wrong answers within 
the knowledge section, questions were re-worded so that they reduce the sense that 
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women were being tested. For instance, a question that was previously worded ‘do 
screening mammograms detect every breast cancer?’ became ‘do you believe every 
woman with a ‘positive’ mammogram result has breast cancer?’ The underlying 
assumption therefore changes from testing the respondent to asking an opinion, 
whilst still obtaining the same information about the woman’s knowledge about BCS. 
Acknowledging the limitations of the PPI used 
Whilst I am extremely grateful to have had the opportunity to use the expertise of a 
PPI representative in my research I must acknowledge the limited extent of 
involvement they had on this questionnaire. I only involved a single PPI partner and 
some views may have been her own. Furthermore the PPI representative was only 
involved in a small component of the process, rather than being included throughout 
the process and in the design and concept of the questionnaire which, with hindsight, 
may have been extremely useful. 
5.4 Cognitive Interviews 
Self-report data has been debated for a long time now. “If there is no certainty on 
whether survey items are interpreted as intended, how do we assess if we elicit 
answers to what we really ask?” [p. 524] (425). Without the confidence of the correct 
interpretation of a survey question how do we establish measurement validity? 
Ultimately, that is why questionnaires should undergo rigorous development prior to 
being distributed. 
A cognitive interview is a method of pre-testing the questionnaire on a small subset 
of the population in order to identify problems, comprehension of the questions and 
to gain a general understanding how the questionnaire would be perceived to the 
general sample population. Cognitive interviews are helpful to reduce respondent 
error in large surveys, to highlight potential mistakes in questionnaires such as 
inappropriate response options and to establish people’s opinions of the 
questionnaire. Here, cognitive interviews were used on a sample population prior to 








Participants for this component were recruited via personal connections as per the 
ethical approvals in place (Appendix 8.4.4). An advertisement was placed in the 
Warwick Medical School newsletter publicising the request for recruitment for 
cognitive interviews. This contained my university email address. If anyone receiving 
that newsletter was interested in participating in the cognitive interviews they were 
invited to contact me for more information. At this point I would send them the PIL 
and ask them to read it and if they were still interested in proceeding with the 
interview then we would arrange a mutually convenient appointment with which the 
interviewee was content with.  
At the appointment I provided them the PIL again and a consent. Informed consent 
was collected after the participants had had time to read and digest the PIL and ask 
questions. 
It was anticipated that a sample size of twenty would give enough likelihood of 
detecting problems with the interview given that they were not considered complex 
questions and that previous research suggests a sample size of 20 would identify 
approximately 100 problems with the questionnaire (426). Thirteen participants 
were interviewed. This was fewer than the twenty planned because data saturation 
had been reached. 
5.4.2 Interview 
The cognitive interviews comprised semi-structured interviews alongside completion 
of the draft questionnaire with the intent to identify problems with the questionnaire 
that might arise in prospective research (240). A major component of the interviews 
was to ensure that participants understood and interpreted the questions in the 
same way as the researcher did (427). For example if a question is interpreted 
incorrectly by all cognitive interview participants the issue can be rectified before the 
next phase of the questionnaire (382). Another priority of the cognitive interview 
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phase was to ensure that the questions were correctly designed and that all potential 
answers were accounted for. 
Despite a higher respondent burden, the participant was asked to concurrently ‘think 
aloud’ for the purpose of the interview to encourage participants to explore their 
answers (240, 427). At the start of each interview, the researcher prepared the 
interviewee by saying the following: “This is a questionnaire that I am developing as 
part of my thesis to identify different predictors of uptake in breast screening. I’m 
interested in what you’re thinking while you’re responding to the questions and what 
you understand the meaning of each question to be. So, I’m going to ask you to think-
aloud as you answer each question in each section. Please complete the questionnaire 
and think aloud as if I’m not here. You might think about things that aren’t directly 
related to the questions and that’s fine. Don’t worry if anything doesn’t make sense 
to you, we can talk about it after you complete the questionnaire.” 
This method allowed the interviewer to obtain detailed notes and insight into the 
respondents’ cognitive process when answering questions. However, when this 
provided insufficient detail, pre-planned scripted probe questions were used for 
anticipated difficult questions to obtain missing information (237). Spontaneous 
concurrent and/or retrospective probes were used where necessary and were 
helpful as they allowed exploration of unexpected reactions (240). 
Probes such as ‘what does that question mean to you?’ or ‘what does the term 
screening mean in this question?’ were used to investigate topics such as 
comprehension of the question; ‘how did you get to that answer?’ for retrieval of 
information; ‘was this easy for you to remember?’ for confidence in the answer and 
‘did you feel comfortable answering that question?’ to check for respondents’ 
embarrassment or difficulty with a particular question as suggested in previous work 
(382). 
Interviews were conducted face-to-face only at the University of Warwick except for 
two which were conducted in a neutral environment. Interviews were audio-
recorded (where permission was granted) and additional notes written where 
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necessary. I interviewed, transcribed and analysed all data collected at the 
interviews. 
One of the purposes of the cognitive interview is to explore issues that may appear 
from any stage of cognitive processing: reading; comprehension – the process of 
making sense of the question and developing a response; interpretation – is the 
interviewee understanding the same thing as the researcher; memory retrieval – of 
relevant information to enable a response; formulation of answers – whether the 
interviewee feels it appropriate to provide that information; and judgement - to 
determine if memory retrieval is accurate and complete (428). This relates to the 
analysis section which shall be discussed later. 
There were minimal inclusion/exclusion criteria associated with the cognitive 
interview. Simply, the participants had to be female, within the age of 47 to 73 and 
have received at least one invitation to mammography screening. Of those who 
participated, all were aged between 50 and 70 years, were White ethnicity, one 
woman had previously been diagnosed with BC and one woman had a significant 
family history of BC in her family. The mean duration of the interviews was 
approximately 25 minutes with a range between 13-45 minutes. The longest 
interview was for the woman who had a significant family history which is logical as 
she had more detailed questions to answer than the rest of the cohort. 
5.5 Qualitative Analysis 
One person was responsible for all analysis and coding of the qualitative data. 
A deductive approach was taken to look for similarities and differences between the 
data. Transcripts were coded to be grouped and compared with other similar or 
related pieces of information. These were then assembled into themes or categories. 
The analysis process was a circular, iterative progress. Text summary methods were 
used to describe dominant themes and problems identified within the questionnaire 
using the researchers observations throughout the interviews (429). 
Conventional content analysis was used for the purpose of classification, 
summarisation and tabulation of results (430). It meant the data were described for 
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what it contained and suggestions for future development of the questionnaire could 
be made using participant data rather than pre-conceived ideas from the researcher. 
Codes were derived from the data during analysis. This helped reduce bias. 
Data were organised into six domains as below. These closely resemble the important 
stages of cognitive processing. 
1. Structural Any comment about the physical structure or 
organisation of the survey, e.g. skip instructions, 
ordering or questions 
2. Recommendations Any recommendations suggested by the 
participants 
3. Sensitivities Any comment that suggests that questions are 
insensitive or that they might elicit inappropriate 
feelings or emotions 
4. Response difficulty Items where there were insufficient answer options 
for the participant’s response 
5. Linguistic Any indication of problems with comprehension of 
the question or interpretation of word meaning 
6. Cognition Any issues arising in relation to the mental act of 
acquiring the knowledge or information used to 
answer the question and the process involved in 











Two early interviews identified a vital mistake in the drafting of the questionnaire in 
that there were not appropriate responses to the menopause question. This was 
noted and altered after the first two interviews to improve ease of completion for 
the rest of the interviewees as suggested by Levin et al (431). 
Key quotes were identified in the transcript before being combined into an overall 
summary for each questionnaire item. An analysis table was created that 
summarised the interviewer’s perspective of the interview, using quotes from 
interviewees and another column highlighting whether this finding was found 
consistently or not. This is provided below.
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Table 21. Content analysis and researcher summary of interview transcripts. The question topic is provided in the first column. The full original draft of the questionnaire is provided 
in Appendix 8.4.2. 
Question 
Number/Topic 
How the item 






Most women would 
admit it was too long 
and they skipped 
reading this. 
“[I didn’t read it as] I’ve assumed that’s included in 
the participant information leaflet” (B) 
Most women did appear to skim read the 
introduction section to the questionnaire 
“it’s a little long” (M) 
1 
Height 
Most women answered 
in feet and inches but 
liked that there were 
options for both 
depending which you 
preferred 
“I’m glad you’ve got feet and inches because I saw 
centimetres and was like ooo” (H) 






This question may 
appear quite sensitive to 
some 




“ooo a personal question” (J) 
“People will always underestimate what 
they weigh or round down. I don’t know, 
they might do” (D) 
 




Some identified that the 
question does not 
specify between 
miscarriages or number 
of pregnancies. It was 
simple to answer for 
most. 
“or would you say ‘have you had any children’? I 
guess ‘have you given birth’ allows for any 




Age at first 
birth 
Generally well. There 
was a minor response 
difficulty identified as 
“So, I gave birth to twins so the question should read 
children not first child” (D)  
 
No difficulty in answering the questions 





How the item 




the question does not 
account for twins. Some 
cognitive difficulty in 
recall. 
 
“Erm she was born in 1994 so… these are taking me 
a minute to remember, but other than that I am over 
50 so it is a long time ago. But I don’t find them 
difficult and I don’t find them over-intrusive or 
anything like that” (E) 
question is being asked in relation to 
breast cancer:  
“I’m just thinking does that have 
relevance obviously to breast cancer” (A) 
5 
Age at first 
menstruation 
A lot of inconsistency 
about whether this 
information was easily 
recalled (and accuracy of 
recall). 
“Period information is easily recalled – my mum was 
crying that ‘this is it for the rest of your life’” (K) 
“I have a very good memory of that” (M) 
 
“I don’t know how old I was…I’m gonna 
guess I was 13” (F) 
“…difficult just because it’s such a long 
time ago. I can’t be precise but I think it’s 
about that.” (C) 
6 
Date of last 
period 
Some response difficulty 
with answer options was 
witnessed. It appears 
some women have clear 
recollection and some 
women do not. 
“So I’m going through the menopause so it has been 
a while since I had a period but because I’m on HRT I 
do have a regular monthly bleed with that but it’s 
hormone induced. I will put last month but so long as 
you’re aware of that” (J) 
“I think it was an answer that doesn’t fit within those 
options as it was more than two years ago” (B) 
 
“We’re now perimenopause you see so we have a 
period and then a week later you start so next one…I 
guess that’s within the last month isn’t it” (L) 
“I can pinpoint because of my age, it becomes rather 
significant that I haven’t gone a year yet” (M) 
“Oh goodness gracious (sighs) err…let me 
see. Gosh. Right. I’m nearly 59 so I think 
it’s more than five years ago” (G) 
 
“How old am I now? (laughs) need to stop 
and think. Probably about 52” “I’m just 
trying to think, it’s difficult to remember 
accurately but probably the first signs of it 
were a good few years ago when periods 
come and go well a bit more sporadic to 
the normal routine” (H)  
“You just forget really because it’s such a 
long time ago and of course obviously 
when you start the menopause you don’t 
know that’s going to be your last period 
so you don’ take any sort of note of it…so 





How the item 









The definition of 
menopause caused 
some difficulty. Another 
issue was about the 
recall of information. 
Two women found skip 
instructions confusing 
(from question 6) 
“this depends on their definition of the menopause” 
(D) 
 
“how old were you…errr that’s difficult to pin point 
the start of the menopause…because it’s very 
gradual. Looking back you think oh that was 
probably the start of it…didn’t realise at the time but 
looking back”  (G) 
 
“Right so I miss this one out? It presumes that I’m 
going through the menopause if I haven’t. That 
wasn’t clear.” (I) 











“yes it’s good to have it right next to the 
question” (C)  
 
8 
Use of HRT 
Response difficulty for a 
woman who had had 
breast cancer treatment. 
Another thought the 
potential answer may 
induce anxiety in some 
women. 
“I had breast cancer treatment at 50 years old so 
HRT isn’t an option for me” (K) 
 
“I’m thinking how is this relevant” (A) 
This was only identified by one participant 
who had had breast cancer treatment. 
 
This was only a concern for one woman. 
9 
Date of HRT use 
For women that have 
used HRT this did not 
provoke a reaction – 
either positive or 
negative. 
Comprehension of HRT 
“HRT is HRT. Unless you want to define it even more 







How the item 




was sufficient for this 
question. 
10 
Length of HRT 
use 
Same issue with recall 
but did not appear to be 
as much of an issue, 
potentially as it is more 
recent. 
“I think I’ve been on it two to three years, yeah I’ll 





Definition and therefore 
understanding of terms 
was a common issue 
shared by all. 
Instructions could have 
been clearer. Should 
clarify that the  
question is asking about 
breast biopsies. 
“I don’t know what they are” (D) 
“I don’t know what they mean” (H) 
 
“it made me re-read this question, that’s all. For me 
if none applied I wouldn’t be expecting to tick a ‘no’ 
box” (C) 
“So tick, I don’t need to tick any of them. Actually if 
they were on the same page maybe I’d have skipped 
down and seen breast cancer” (E) 
 
“So all these things you’re asking people if they’ve 
been diagnosed with is this any biopsy or breast 
biopsy” (D) 
 
This was identified by almost every 
woman interviewed as an issue. “I know I 
haven’t been diagnosed with any of these 
as I would know that but I don’t know 





These items appear to 
perform well. However, 
they can only capture 
information about 
relatives that is known 
to the participant. 
The tables appeared to 
confuse some people 
“Not ones [relatives] I’ve known anyway” (G)   
13 
Details 
“what do you do if you have multiple relatives” (D) 
 
“Only because I’m assuming only on what my mum 




“I do know that partly because I’ve been 
doing a lot of family tree searching so I 





How the item 




(although they did not 
have to complete it). 
“trying to think now isn’t that awful. I’ve got a 
massive family so this is actually quite hard for me” 
(A) 





“I don’t know what they are other than they’re a link 
to breast cancer” (B) 
“Explain the terms” (K) 
“I know what those two genes are but it 
maybe needs clarifying again”(E) 
15 
Details 
“Why have you suddenly asked about male relatives 
now? Seems a bit weird” (D) 
“You’re asking people to do this anyway I guess the 
question is whether it’s worth capturing how many 
people had a male relative and it gives them the 
opportunity to fill that in so they don’t feel 
excluded” (D) 





“So I get to skip to question 18 but then I need to 




“It was all shrouded with secrecy” (D)  
“This is presuming people tell each other” (I) 




Options not suitable to 
some women. 
“I’m just re-reading the options because they’re not 
what I would have put…I was expecting to see the 
definition of screening there as an option” (C) 
“I think to give an answer about deserving 
treatment is bizarre. It might put into 
people’s minds that this could be the 




Most women answered 
with no issue. However 
one guessed rather than 
saying ‘don’t know’ 
“I really don’t know. I think I’ll say maybe C) it means 






How the item 







Item performed well in 
general. One woman did 
not know. 
“No because they do say that in all the leaflets that if 
it’s positive don’t panic” (H)  






Answers did not seem 
appropriate for many 
women. 
“hmm…see I would say it means not that she doesn’t 
have cancer that can be detected at the moment but 
that it’s not thought that she has cancer that can be 
detected at the moment. Because actually it could 
be a false negative” (D) 
“I mean they’re not usually confirmatory so to check 
for signs of suspected cancer. It’s not confirmed by 
the mammogram it’s confirmed with the pathology” 
(J) 
“I suppose could there be an option ‘she 






A lot of women 
struggled to answer this 
question. 
“I don’t know. That’s slightly ambiguous. I don’t 
know, I don’t really understand that. I don’t know 
why one of them would be higher than the other.” (I) 
“I was thinking initially when I read it I 
was thinking which groups do you believe 
have the highest rates of BC detection 
whether that was going to be a general so 
smokers or non-smokers that kind of 
thing” (E) 
“I know it happens but I have not got a 
clue on the amounts. I know there are 
positives negatives if that makes sense 
but I really don’t know the statistics” (M) 
“I think I’d tick don’t know because I really 




A lot of women 
struggled to answer this 
question. 
“I honestly don’t know, haven’t got a clue” (G) “I’m thinking it’s a test and I should know 
this” (A)  
“oh gosh I really don’t know that [re-reads 





How the item 







Most women appeared 
to have a stable opinion 
and answered the 
question easily. 
“I’ve read that and I think it depends what you mean 
by negative consequences” (A) 
 
“For me there aren’t any. But I suppose 
there may be negative consequences of 
having an x-ray. There may be negative 
consequences in that people get anxious 
about it. But I don’t so I’m trying to think 





Item appeared to be 
answered easier than 
the previous ‘numbers’ 
question 
“I would say….[pause] hmmm…how many…oh right I 
need to read that again…[reads again] so what 
percentage? I would say about five. Oh I really don’t 
know. I’m going to guess” (E) 
“Don’t know the answer to that one” (D)  
“Now funnily enough I think I might, 
whereas the other one I didn’t know the 
percentage on this because I’ve got 
friends who I know, if that makes sense, 
I’m going to say ermm I’m going to have 
to guestimate at C” (M) 
“See here I’d say it’s 1 in 4 do have or 
would have cancer detected so that’s 





One woman was 
confused about the 
question meaning. 
“is that asking if the government are insisting or is 
that me thinking that it should be” (M) 
No-one else appeared to have an issue 
with understanding the question was 
asking whether the screening programme 




Some of the opposing 




“That’s an interesting question as you’re willing to go 
because you feel you have to do it…I’m not sure 
they’re two opposites” (A) 
“Something I feel I have to do and I’d be willing to 
go. They don’t quite match for me. So the opposite 
or that would be something I don’t feel I have to do. 
So I’m definitely willing to go but it’s not quite the 







How the item 




same as saying…because the opposite to that would 
be I don’t feel I have to go.” (E) 
28 
Previous use of 
screening 
Loose interpretation of 
the timescales identified 
in one interview. This 
could happen 
frequently. 
“PPTT: probably just over three years 
RESEARCHER: why did you tick no there? 
PPTT: because I hadn’t done any of the above 
RESEARCHER: but you said it’s been more than three 
years since your previous one 
PPTT: but only slightly” (L) 
 
29 
Recent use of 
screening 
Most women correctly 
identified the question 
was about a previous 
mammogram. 
“now that ‘a previous breast screening appointment’ 





Women have different 
recall capabilities about 
these events. 
“I haven’t done any of the above I can relate that to 
my experience quite happily” (E) 
“I don’t think I have but then I’ve been 
having them since I was 50 so my minds 




A few women had 
difficulties with this 
question – what it was 
actually asking and also 
with some of the 
options. 
“I don’t know if receive is the right word…when I first 
read that then I thought oh it’s about when I receive 




“I’m comfortable in terms of being with the staff. But 
I’m uncomfortable in the sense it’s physically a bit 
uncomfortable” (E) 
“does that mean physically uncomfortable or that 
it’s a procedure?” (L) 
 
“For this one I’m thinking do you mean 
when you receive it or when you attend 
the mammogram and have the 
actual…because I’m thinking is that the 
invitation in which case I’d feel that’s 
different to actually going along” (E) 
 
 
32 Women either found it 
difficult as “it’s not 
“who knows? It’s not something you can predict” (F) 
“that’s quite difficult isn’t it” (A) 
“If I had a family history of breast cancer 





How the item 




Risk of breast 
cancer in five 
years 
something you can 
predict” or they used 
known risk factors to 
estimate using their best 
knowledge. 
 
Most women didn’t like 
to be too optimistic and  
commented that you 
could never know. 
probably feel differently. I don’t think I’m 
invincible I just think there’s probably 
other things that will get me first. But you 
never know do you” (C) 
 
“on family history I’d say unlikely but then 
I don’t know on the sort of me bit I have 
no idea. I’d say (pause) I’d put it at a two 
maybe” (L) 
 
“in my mind it’s what are the risk factors” 
(A) 
 
“I have other cancers in my family that 
might make me think more but breast 
cancer…I don’t have any blood relatives 
that have had it so probably in the next 
five years pretty unlikely. Most women 
are older when they get it anyway.” (E) 
33 
Risk of breast 
cancer in 
lifetime 
Again, women either 
were hesitant to “tempt 
fate” or used known risk 
factors to estimate. 
“I guess the longer you live the risk of developing 
breast cancer is more likely. I’ll just put the middle 
one again as I’m not sure” (I) 
 
“again I’ll put a two largely on the family 
history side of things…it’s so difficult to 
quantify it. Because you don’t feel like you 
want to say unlikely because it’s almost 
like tempting fate. And it’s what you base 
it on. So far as I know, going back to 
grandparents there hasn’t been a single 
relative who has breast cancer and all 
family members are ok and most are 





How the item 




must be relatively low risk but you think 
ooo with the lumpiness and over the 
years I’ve had a few checks makes me 
uneasy about it” (L) 
34 
Date of birth 
Structural issue with the 
questionnaire. 
“You cannot promise someone if you’ve asked for 
their date of birth and postcode that this 
information will be anonymous. You keep assuring 
them but it’s very identifiable data…could you not 
just have their year …or you can simply ask how old 
people in brackets…and first three parts of the 
postcode?...I would get cross with you if I saw that 
and I was filling it in as I’d just think you were lying” 
(D) 
One woman found an issue with the 









Preference of answer 
options. 
“I hate it, I’m divorced but if you ask me I say I’m 
single” (D) 
“This annoys me. Why can’t people just be going out 
with someone? Why do we have to say we’re single 
when we might have a boyfriend?” (D) 
“I’m currently single. Oh wait, I’m 




Preference of how to ask 
the question in the 
simplest format. 
“So that’s me and partner…so I’m quite happy with 
that. I like those categories actually, I like the last 
one [laughs]” (E) 
 
“I think I’d rather say it like ‘how would 
you describe your living arrangements’ 




No reported issues.   
40 
Employment 
Some reported issues 
with answer options. 
“You haven’t got an option for education” (D) 
“I think some people might like to be able to say 
they’re employed but they’re also a carer because 
“I think you should combine question 40 





How the item 




some people also care and look after a home and 
family. Someone’s working part time maybe. Maybe 
you put an option” (I) 
question so they can fit into multiple 




See above – questions to 
be combined in future 
questionnaire. 
“I don’t know I could tick all of those to be honest. I’ll 






of ‘take home’ confused 
one woman. There may 
be a cultural 
appropriateness issue of 
asking about income but 
this was only raised by 
one woman. 
“It’s difficult because my partner’s income is 
variable, but it’s usually around that” (K) 
 
 
“[researcher: would you be comfortable stating that 
on a questionnaire?] PPTT: yes because I’m not 
specifically stating how much we earn” (B) 
 
 
“So take home is the right phrase but 
some people interpret it better. I could 
tell you my top line not my bottom line” 
(D) 
 
“what is this gotta do with you doing…I 
don’t get that. I think you doing this, it’d 
piss a lot of people off you having that in 
there…I just can’t see the relevant of you 
doing a survey on breast screening asking 
that sort of question. Yes age, health, 
married and working…but what’s salary 




Most women were 
unsure how to answer 
this by the time they’d 
read question 44. 
“I answered no without looking at the options. If I’d 
seen the list before the question I might have 
thought oh well I sometimes do have a problem with 
my memory” (C) 
 
“I think you should combine question 43 
and 44 and just have an option ‘none of 
the above’. That way no-one would skip 
over it accidentally. (D) 
 
And it might focus people’s minds. They 
might not realise what types of conditions 
you’re thinking about until you ask them 





How the item 




have missed. I’d also specific [specify] for 







“[re-reads] well actually I have I don’t consider it to 
be…well I guess I do…I am partially sighted, I only 
have sight in one eye but I don’t consider myself to 
be visually impaired” (I)  
“I suppose the reason I’ve gone on to this question is 
chronic pain in back and neck as it affects me but not 
in these ways in daily life” (B) 
“I have partial sight, I wear reading glasses, but I’m 
not sure that constitutes it” (A) 
“Do you count partially sighted as I wear glasses? (L) 
 
“Oh maybe I should have read that 
question first” (C) 
“I’ve got an underactive thyroid. So I put 
that as a ‘yes’ [previous question] but 
then the things you’ve got here are… 
[putting me off] because the things it 
causes isn’t listed so it makes me think 
have I done it wrong. I suppose fatigue is 
included” (H) 
 
“I must have read that wrong. I think it 
would probably be better to read the 
conditions listed before ticking the box 
saying that it affects you” (H) 
“perhaps swap them [questions] over and 
say ‘do you consider yourself to be 
struggling with any of these things’ and 
then ask ‘do they affect your work life, 
your home life, your daily activities’ (I) 
 
 
A general observation was noted by the researcher that where questions slipped onto a subsequent page there was much page flipping 
back and forth which appeared to distract multiple participants. This has been rectified in the updated draft. 
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Subsequently, an ‘action’ point table (Table 23) was created to highlight problems identified with each item and what action was 
appropriate to take. The justification is in the final column. Revision of an item is not based on the number of times a question was 
considered problematic but the nature of the problem and a logical judgement was undertaken. 
Table 22. Action point summary 
Question 
Number 
Problem identified Action to be taken Justification 
Introductory 
paragraph 
Women skipped the 
introductory text as it was 
too long 
Make it more concise To be read by more women. 
1 
Height 
None – women liked that 
there were options for feet 
and centimetres 
None Doesn’t take too much space on the 




Women are likely to 
estimate the answer if they 
believe it too personal or if 
they genuinely do not know 




Miscarriages or number of 
children not asked 
Unsure  To ask if a woman gave birth only to a live 
foetus could be upsetting to the 
participant. The risk calculator only asks 
about the woman’s parity. 
4 
Age at birth 
Twins Change the wording to include the birth of twins Simple and easy 
5 
Age at first 
menstruation 
Some women found this 
information easy to recall, 
others did not and had to 
estimate 
None Cannot make this question any easier to 
recall. Women either know this 
information or not. 
6 
Date of last 
period 
Response difficulty with 
appropriate answers 
Additional options added. Need to add an HRT-










Definition of menopause 
may be different for each 
woman and therefore they 
could be answering 
different questions 
Either add a definition of menopause (“You 
might want to have a free text that says what is 
your view? What was the trigger for the start of 
menopause for you?” (D)) to the question or add 
another question asking about their trigger for 
menopause or ask about their definition of 
menopause. 
Adding a definition would likely be simpler 
but you cannot ensure that everyone 
reads and understands it. By asking 
women to complete a subsequent 
question you can base their answer on 
this information. 
8 
Use of HRT 
An additional answer box is 
required 
Add “HRT isn’t an option for me” as an answer For women who have had breast cancer 
treatment they do not have the option to 
use HRT. 
9 
Date of HRT use 
Recall None  
10 
Length of HRT 
use 
Recall Answer options should be changed to grouped 
answers such as 1-6 months, 6-12 months, 1 
year, 2 years, 3 years, 4 years, 5+ years. 
Some women may not have used it for a 
year so the current option to have X years 
is inappropriate. Having the grouped 
answers may make it easier to recall in 
which category they belong rather than 




Definition of terms 
Instructions and structure 
Clarify asking about breast 
biopsies 
Clarifying ‘breast biopsies’ is simple quick and 
easy.  
Fibroadenosis needs to be added. Define terms. 
Change ‘no’ to ‘none of these apply to me’. 
Ensure all the options are one page so a woman 
can easily scan the answers 
Definition of terms should go on the same 
page but needs to be in layman terms. 
12 
Family history 
of breast cancer 
The question can only 
capture information that is 




The question can only 
capture information that is 
known to the participant 
Make it clearer in the table how to complete it 
with multiple relatives: “I’d put a line in and 
probably leave a couple of lines as they might 
have more than one sister” (D) 
Use the term ‘both breasts’ rather than 
bilateral because ‘“Are people likely to 
know what bilateral breast cancer is? The 





Problem identified Action to be taken Justification 






The question can only 
capture information that is 
known to the participant 
 
The term BRCA1 and BRCA2 
need explaining 
Explanation of the terms in layman English needs 
updating as identified by multiple participants 
“Explain the terms” (K). 
I will add to the question further instruction 
about how to complete: “You could add ‘please 
only tick no if you definitely know you haven’t 
had it” (D) 
By adding ‘please only tick no if you 
definitely know you haven’t had it’ means 




An error has been identified 
in the questionnaire 
Male relatives (father and brother only) should 
be added to the breast cancer table (question 
13) 
There are options to enter this into the 
risk calculator and therefore should have 





Skip instructions Make the instruction ‘skip to the next section 
KNOWLEDGE ATTITUDES AND BEHAVIOUR’ 
rather than question 18  




The question can only 
capture information that is 





Two women did not 
approve of the answer 
options 






People guessing rather than 
selecting the ‘don’t know’ 
option 
Add a ‘both’ option. Define ‘population 
screening’. 




Different thought processes, 
ranged from don’t know to 
definite answers to even 
more accurate than the 
options 
No need to change anything.  It is acceptable for a woman to tick ‘don’t 









Most women identified that 
the answers were too 
concrete compared to what 
the screening results letter 
would say 
Need to add ‘to the best of the screeners 
knowledge’ and/or ‘that can be detected at this 
time’ 
It is fair and appropriate to add this in. No 




A few women commented 
that this was a good 
question 
None Despite a lot of women feeling ambiguous 
or confused by the question, it does ask 
what I need it to ask and to answer ‘do 




Women did not know the 
answer. They also felt like it 
was a test. 
Change the options to 2/5 or 4/5. Emphasise that 
this is only breast cancer.  
Justified as other women suggested this 
change too: “I’d have guessed at 2/5 or 
3/5” (D) 
“So does this question refer to all cancers? 
Or just breast cancer?...because I’m 





Confused responses by 
women who ticked no. 
Comprehension of negative consequences 
should be explored further in a subsequent 
question. 
Further exploratory work needs 
conducting on this as many women would 
tick ‘no’ but then go on to qualitatively 
describe the negative consequences I was 
originally thinking about when writing the 
question. 
Answers were made clearer ‘yes – there 
are negative consequences’ and ‘no-there 




The answers were split. 
Some women still did not 
know and found it hard to 
work it out. Others based it 
on their personal experience 
with friends and family 
Follow up with further questions in 
questionnaire exploring their baseline – i.e. their 
experience with friends and family and breast 
cancer and screening (see other comments) 
In order to understand where a woman is 
basing her judgement it is interesting and 
important to understand her influences. 










Comprehension issue Elaborate that I am asking if breast screening is 
something that is compulsory (by the 
government) for you to attend 
Otherwise this may be influenced by a 
woman’s opinion of breast screening and 
that she may believe it’s compulsory in 




Problem with the opposite 
ends of the scale 
Something I feel I have to do ….. Something I feel 
I don’t have to do 
Most women picked up on this point so it 
is justified to change it 
28 
Previous use of 
screening 
If interviewee is dishonest 
then there is no way of 
determining this on the 
questionnaire 
Nothing that can be done. Have to rely on 
trustworthiness 
Add ‘screening’ mammogram to the question 
Adding ‘screening’ mammogram is likely 
to make the question less ambiguous 
29 
Recent use of 
screening 
Problem with interpretation 
of terminology 
Change ‘previous breast screening appointment’ 
to ‘previous mammogram’ 





This is the problem with 
using questions that rely on 
recall 




Need the question to be 
clearer. Would also be 
interesting and important to 
understand deterrent 
reasons for screening too. 
Add options for women that have not previously 
had a mammogram in order to determine their 
reasons why etc. 
 
Add definition of uncomfortable – physically. 
 
Justified by this woman’s suggestion: “This 
is for people that have had mammogram. 
This is about people’s perception. People 
who haven’t had it may also perceive 
things like it being painful” (D) 
 
“To make it easier …you might ask them 
to fill it in on the basis of what they think 
it will be” (D)  
 
32 
Risk of breast 
cancer in five 
years 
Some women think 
differently in terms of 
numbers. A lot of women 
Change to include the recurrence information for 
women with previously diagnosed breast cancer 






Problem identified Action to be taken Justification 
are hesitant to put down 
their estimate. 
“So that’s a scale of where you think your 
risk lies. Would that be equivalent to a 
percentage between zero and ten” (J) 
 “Should include recurrence for women 
being diagnosed ‘In the next five years, 
how likely do you think it is that you will 
be diagnosed with breast cancer or a 
breast cancer recurrence?’” (K) 
 
33 
Risk of breast 
cancer in 
lifetime 
A lot of women are hesitant 
to put down their estimate. 
Change to include the recurrence information for 
women with previously diagnosed breast cancer 
 
34 
Date of birth 
Anonymity issue Change to include year of birth and first four 
digits of postcode rather than entire postcode 
Cannot ensure anonymity with entire 
postcode and date of birth in smaller 




No reported issues Remove ‘other’ for ethnicity groups to improve 




Preference of answer 
options for divorced women 
Add additional option: “In a relationship, not 
cohabiting” 
Adds additional detail and is less 





Question format simplicity Reword it to: “How would you describe your 
living arrangements?” and then give the current 
options 
Re-wording the question makes it simpler. 




No reported issues   
40 
Employment 
Answer options of question 
40 and 41 to be combined in 
order to encompass it all 
How would you describe your current 
employment role (over the last seven days) 
(please tick all that apply) 
- Full time work 
“oh I didn’t notice it [RESEARCHER: maybe 
because of where the skip instruction is on 






Problem identified Action to be taken Justification 
- Part time work 
- Self employed 
- In education full time 
- In education part time 
- Permanently unable to work due to long-
term sickness or disability 
- Retired completely 
- Working intermittently 
- Looking after home and/or family 
- Never been employed 
- Other (please specify) 




Different women had 
different opinions 
Define household term. As only one woman disliked having to 
enter her salary (additionally, one rightly 
ticked the ‘prefer not to say’ box) no 
changes will be made 
43 
Illnesses 
Bias of responses Combine question 43 and 44: 
Do you suffer from any of these conditions? 
- Specify partial sight not correctable by 
reading glasses 
Then ask a follow-up question about how they 
affect you – home life, work life, daily activities, 
social life and love life. 
People were answering either yes or no 
and finding the list not to be satisfactory 
for their ailment or realising that they 
should have ticked yes and then believing 
that they’d answered the questionnaire 
wrong. The suggested follow-up question 






Some additional questions were entered into the final draft to aid understanding of 
the woman’s interpretation of some terms, for instance menopause. Further 
questions were added to obtain qualitative information about the negative 
consequences of BCS as this will help identify a woman’s perspective of 
mammography in these terms. The majority of the interviewees selected no negative 
consequences but then went on to describe the negative consequences I was 
interested about in the interview. It is interesting to explore this further as it 
comprises a key part of IC. The scoring system for Likert scales for the experiences 
about mammography have been inverted for some questions in order to help reduce 
response bias and to reveal any basic underlying pattern of response unrelated to 
the actual questions/answers through inconsistencies (432). 
The results of the interviews suggest that the majority of items (n=41/44) were 
acceptable and raised no issues about sensitivity. Two questions (about income and 
marital status) caused concern for one participant each. However, this appeared to 
be due to personal preference as the remaining twelve interviewees did not raise any 
issues with these questions. Furthermore, the income question has the option to 
‘prefer not to say’ if women do not want to answer and the marital status question 
has been re-worded to include dating and non-cohabiting to be more inclusive to 
potential respondents. 
The other question that caused a little concern was about weight. Many respondents 
commented in a comical manner “I’m thinking do I give an honest answer” (G) and 
highlighted that many women may estimate “I’ll estimate about 11 and a half stone” 
(C) or underestimate “… will always underestimate what they weigh or round 
down…” (D).  
Linguistically, a few questions were challenging for some of the participants, so some 
questions have been modified. Specifically, the interpretation of ‘menopause’ for the 
purpose of this questionnaire has been defined and additional questions have been 
added, for example it now asks if a monthly bleed was hormone induced. There is an 
additional question asking if the woman believes herself to be peri-menopausal 
(alongside a definition) which was previously not included in the questionnaire. 
230 
 
Every woman struggled with at least one of the definitions of previous diagnoses of 
breast conditions. Originally, I had assumed that if a woman had been diagnosed with 
one of the breast conditions they would know and remember what it was called. 
However, after analysing the transcripts, and almost all women agreeing that “I don’t 
know what they are” (D), the question was adapted to include definitions alongside 
each option. This was similarly edited for the question asking about BRCA testing. I 
also removed the ‘no’ tick box after one participant highlighted “it made me re-read 
this question, that’s all. For me if none applied I wouldn’t be expecting to tick a ‘no’ 
box” (C). 
Question eighteen and nineteen asked about ‘screening’. Women’s interpretation of 
what ‘screening’ meant ranged from “screening programme in general” (G) to “just 
the mammogram” (F) and “that’s the same thing isn’t it, no? The screening 
programme is the mammogram as far as I’m aware” (L). It was therefore deemed 
appropriate to highlight that those questions were asking about the population 
screening programme not just the mammogram. 
Asking about the negative consequences of breast screening gave some interesting 
responses. Most women ticked no, but qualitatively went on to describe the negative 
consequences of breast screening that the question was asking about. When probed 
about this reaction most women were of the opinion “there may be negative 
consequences in that people get anxious about it. But I don’t so I’m trying to think 
from my perspective” (B). So even though these women were aware of some negative 
consequences they were ticking that there were none. This could have been because 
of the question wording as it asks “Do you think…” and if women emphasised the 
‘you’ this may be how they interpreted it differently from me. Therefore, additional 
probing exploratory questions have been inserted afterwards in the final 
questionnaire. Depending on a woman’s answer they will probe what they think the 
negative consequences are or why they think there are no negative consequences. 
This will help capture women’s true thoughts about this issue rather than a simple 
yes or no question. 
There was an easily correctable error in the attitudes question identified by multiple 
women in that the last scale asking if women were willing to attend or if it was 
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something they felt they had to do was not comparable “…I’m not sure they’re two 
opposites” (A). Additionally, one woman found the scale ‘easy to difficult’ confusing 
“it’s easy to attend. But actually having it done is not without drawbacks. Which sort 
of thing are you trying to…?” (E). This question has now been changed to specify that 
the question is asking about accessibility of the screening service. Similarly, the scale 
about ‘comfortable’ has been changed to specify that it is asking about the physical 
comfort during the mammogram. 
There were twelve items where women identified minor issues with response 
difficulties. Most were easily changed as described in Table 24. The biggest changes 
were changing question thirty-one from a five-point Likert scale to a strongly agree 
to strongly disagree scale because some identified that it was difficult putting a ‘1’ as 
shy as it appeared negative whereas it was not a negative emotion “on question 31 
I’m incredibly shy when it comes to it but I’m circling a 1 as if it’s not important 
whereas it’s incredibly important [I’d prefer an agree to disagree scale]” (H).  The 
issue foreseen with this change is the worry that most women put ‘neither agree nor 
disagree’ but this is the same as entering a ‘3’. This question was also edited to make 
it clearer that I am asking about the experience (or anticipated experience) during 
the actual mammogram rather than the invitation process. 
One woman verbalised her difficulty with reading the numbers of question twenty-
three “I find these numbers quite difficult to read [laughs]” (E) and many commented 
“I wouldn’t know the numbers” (D) or “oh gosh I really don’t know that [re-reads 
question] no I don’t know that at all” (L). One woman made an educated guess but 
admitted as a researcher “I did a presentation yesterday to patients on BC and I 
looked at the stats so I’ll go for B…but that’s a guess” (J). This highlighted a 
fundamental issue with the question that no woman knew the answer and most 
(n=12/13) were guessing. Therefore the question has been changed to explicitly state 
it is asking about overdiagnosis of BC and the answers have been changed to single 
digit options between zero and three which is more consistent with the BCS leaflet 
(63). 
Whilst it did not apply for the participants of the interview, a difficulty was identified 
in questions forty and forty-one about employment status. These questions have 
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now been combined and changed into a ‘tick all that apply’ question to incorporate 
all options for people’s circumstances of employment in order to not alienate 
anybody from the questionnaire. The consequences of this will be discussed in 
Section 6.9 below. 
All recommendations as identified in the transcripts were given consideration. 
However, revision of an item was not based on the number of times the item was 
found to be problematic but the nature of the problem and whether it was deemed 
that it was personal preference or a general issue that would continue to be 
problematic to respondents. Simple changes include the addition of definitions of 
medical terms that are now provided as suggested by many women, particularly 
about the diagnoses and BRCA tests. The numbers of questions have been changed 
to a larger font to aid in transition with skip instructions “It’s just trying to find the 
right bit to go to…” (C). A few women (n=9/13) had difficulty with the interpretation 
of what counted as a condition or illness during questions forty-three and forty-four. 
However, the intention of the question was not to only select certain conditions, and 
in fact the examples were meant as examples. Therefore, these questions have been 
combined and incorporated into a simpler “Do you suffer from…?” and then “in what 
way do they affect you…?” 
Table 23 shows the final questionnaire in an abbreviated format. The full draft 
questionnaire is attached as Appendix 8.4.2 and the final draft questionnaire is 
attached as Appendix 8.4.4. 
5.7 Discussion 
In this chapter I have described how I developed a questionnaire to answer if 
personal demographics, risk of BC or IC are associated with uptake of BCS. 
5.7.2 Questionnaire 
Questionnaire is as a tool to obtain information are considered one of the most 
abused methods in research (407). Many believe it is simple to write a list of 
questions and get answers returned with respondent’s opinions of a service. 
However, to truly gain meaning from a questionnaire study the crucial part is within 
the development phase, which is often overlooked. 
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A questionnaire such as this is investigating multi-dimensions associated with uptake 
of mammography (433). It is advised to make a questionnaire as short as possible to 
ensure maximum response rates. A trade-off exists between breadth and a 
questionnaires comprehensiveness and depth relating to precision of measuring 
each concept (434). This questionnaire remains lengthy due to the number of factors 
that are needed. Each item has been justified for inclusion as elaborated below. 
However, questionnaires are limited. Many potential respondents feel unmotivated 
to complete the questionnaire, especially longer ones. Questions may appear 
irrelevant to some women or may be difficult to interpret. 
The major methodological limitation of a questionnaire is that women may be 
answering a question differently to how the researcher intended. Whilst I have aimed 
to prevent and minimise this, by conducting cognitive interviews, it must remain a 
limitation as there is no way to identify this for each individual respondent. 
5.7.3 Questionnaire development 
The questionnaire was developed following guidelines from previous research (407, 
435). Items were selected and adaptations from scales and questions used in 
published literature were used where possible. A PPI representative formed the first 
step in determining the appropriateness and usefulness of the questionnaire. 
Subsequently cognitive interviews were used to identify any errors or misleading 
questions. 
There was significant debate between the research team and the PPI representative 
about the wording of questions asking about knowledge in the questionnaire. The 
original items were more direct and may have come across as quite strict thus 
increasing the risk of ‘Don’t Know’ answers from respondents. As the knowledge 
section comes on page eight of a lengthy questionnaire, the questions were re-
worded to be friendlier and to reduce the likelihood that respondents might feel 
judged. This meant that, semantically, in the final questionnaire there is a certain 
amount of overlap between assessing knowledge and beliefs about BCS. However, in 
the introductory paragraph to the knowledge questions it does state that we are 
asking about a woman’s knowledge and perception of screening. In addition there is 
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some debate as to whether knowledge and beliefs are interchangeable – you cannot 
believe what you do not know (436). 
By using closed questions, the researcher is limiting the richness of potential data 
from the questionnaire. However, these specific components have been identified as 
key predictors of uptake and are of known importance. Closed ended questions are 
required here for most questions in order to obtain relevant data that can be entered 
into a risk prediction model. 
5.7.4 Cognitive interviews 
The use of cognitive interviews has been discussed and criticised for a long time in 
association with the false environment set-up and the cognitive load on the 
respondent whilst completing the questionnaire (427). Whilst being cognitively 
interviewed, respondents are likely to take more care over their answers than they 
would in reality as described by the ‘Hawthorne effect’ (240). Whilst it is irrelevant 
which answer they select, as the desired outcome of the interview is to re-draft and 
reformat the questionnaire, respondents may feel compelled to answer in a socially 
desirable manner and as such may give untruthful descriptions about their 
interpretation of questions (427). Participants may not feel comfortable being honest 
about the limitations of the questionnaire or about sensitive or threatening 
questions as they are not as anonymous as the final questionnaire would be and they 
are talking directly with researcher (427). Previous literature has also criticised the 
technique as it is non-standardised, situationally artificial (the questionnaire 
respondent would not be interviewed about their answers by the researcher) and 
the analysis can be subjective (240). 
Nevertheless, cognitive interviewing has many advantages that appear to outweigh 
these concerns and it continues to be a useful way of identifying potential problems 
with the questionnaire to redraft the tool for more accurate use ahead of the piloting 
phase. Furthermore it enables a process of checking that all relevant questions are 
asked and that the answer selection is appropriate (437). Being able to cognitively 
test the questionnaire ‘in use’ in a sample population is invaluable. The combination 
of these qualitative results with the validity and reliability testing will ultimately 
create a more substantial, useful questionnaire tool. 
235 
 
5.7.5 Interview outcomes  
Overall, the questionnaire was complimented on its clarity and layout “the 
questionnaire is nicely laid out with good spacing. It’s nice and clear” (K).  However, 
a lot of the questions relied on recall of information that some women struggled with, 
“sometimes it’s just about memory” (C). The general information provided at the 
start of the questionnaire has been edited to be much shorter than the first draft “[I 
didn’t read it as] I’ve assumed that’s included in the participant information sheet” 
(B). The skipping instructions were complimented throughout “it’s good to have it 
right next to the question” (C) so have not been changed. 
Drennan et al. found problems generally arise in five domains. These domains have 
clear similarities and differences to the five categories highlighted via the content 
analysis of my cognitive interviews (240). 
Table 23. Domains of cognitive interview analysis compared with previous research findings. 
Drennen et al. 
domain 
My domain  Definition and discussion 
Linguistic Lexical The researcher over-estimates the 
vocabulary or understanding of the 
participant. This was apparent where 
definitions of terms used were not given on 
the original questionnaire draft. 
Inclusion and 
exclusion 
Sensitivities In an interview or questionnaire setting, a 
respondent may bias an answer to appear 
favourable to the researcher, a term called 
social desirability response bias. Moreover, 
they may not include all relevant 





Cognition This includes recall and temporal 
recollection issues on which my 
questionnaire relies upon a lot. For instance, 
a question asks how many years the woman 
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Drennen et al. 
domain 
My domain  Definition and discussion 
their temporal 
domain too) 
was taking HRT – identifying whether it was 
one year or two may become difficult to 
complete accurately the longer ago it was 
started.  
Dissimilar   Recommendation  This became apparent as a key theme as my 
data is solely about the development of the 
tool and I was very keen to hear suggestions 
and comments about how to improve it. 
Logical  Structure The misunderstanding of conjoining 
questions or instructions. My questionnaire 
used simple and short questions and 
instructions in order to increase likelihood of 
being understood (438) throughout. 
 
 
It was interesting to investigate if it was the same women who had problems recalling 
both age at menstruation and age at menopause. Of the thirteen women, eleven 
struggled or hesitated before recalling the age at which they started their periods, 
often with comments like “difficult just because it’s such a long time ago. I can’t be 
precise but I think it’s about that” (C). Only two women had clear recollection of the 
age “I have a very good memory of that” (M) and “Period information is easily recalled 
– my mum was crying…” (K). Of the ten women that were in menopause, four 
struggled to recall how long ago their last period was. Of the interviewees only two 
struggled with neither question. All women answered the questions. 
5.8 Final draft of questionnaire 
The saliency of a questionnaire, and each item, has an important influence on 
response rates. Therefore, much has been altered in the final draft of the 
questionnaire to limit the negative reactions of potential participants. All action 
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points noted above in Table 24 have been accounted for and minor typographical 
errors changed.  
The questionnaire includes nineteen questions asking about medical factors 
including menopause, menarche and parity as well as previous breast history. Twenty 
questions ask about participant’s knowledge, attitude and behaviour about breast 
cancer and mammography. In the last section, the questionnaire comprises ten 
questions about personal characteristics including demographics like year of birth, 
income and health status. The new draft of the questionnaire is found in Appendix 
8.4.5. 
The next steps for the questionnaire design would be to further evaluate the updated 
questions to ensure no loss of content or meaning has occurred during the re-design 
post-analysis. 
As the questions used here have not been previously used for research in this field, 
the questionnaire has not been evaluated or tested for its reliability yet. That is part 
of the process of developing a useful questionnaire and will be undertaken on this 
tool in the future. 
I did not plan in this PhD to fully test the questionnaire. Some exploration of face (a 
subjective verdict of whether an item makes sense and assesses what it is meant to 
assess) and content (how well a question measures what it is intending to measure) 
validity has been established using the cognitive interviews (439). To complete the 
testing of this questionnaire draft, future research should pilot it using a larger 
number of participants. Further evaluation will seek to establish evidence in support 
of construct validity of the new questionnaire (that is, to confirm that it provides a 
true reflection of the construct under study). Since there is no ‘gold-standard’ for the 
evaluation of this construct, criterion-validity is not possible. 
Data from this pilot phase can then be used to test internal consistency of the 
correlation between questions. The pilot data can also be used to test if the cut-off 
scores are appropriate to be classed as having a ‘positive attitude towards screening’ 
or ‘good knowledge’. Reliability of the questionnaire in repeated tests can also be 
tested using the pilot data. 
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5.9 Strengths and limitations 
To the best of the researcher’s knowledge no questionnaire-based survey has been 
conducted that investigated the effect of personal risk of BC and IC on uptake. 
Previous work has been conducted in the UK using the IBIS risk estimation model 
which has identified it is feasible to incorporate individual risk estimation into the 
NHSBSP (419) and further research is warranted. 
The IBIS model is currently used in practice in the UK for genetic cancer risk 
assessment and counselling for hereditary BC (440). 
A limitation of this work is that it is not solely based on information that came from 
a systematic review of the literature e.g. for informed decision making. This was due 
to time constraints and the nonlinear process of the doctoral research. Future 
research would underpin the questionnaire by ensuring that it is compliant with 
systematic review findings. 
Whilst cognitive interviewing is a useful technique to identify any problems with the 
questionnaire prior to its use with the general population, it may identify problems 
that would not have arisen or may fail to recognise some that will still appear in the 
general population survey phase (237). However it is hoped that these interviews 
have removed or reduced the likelihood of major mistakes being present in the 
survey. 
Interview transcription was conducted immediately after meetings and meant data 
was only collected until it appeared that data saturation had been met. Although this 
is a largely subjective event as new data could have arisen during any interview. By 
the end of the thirteenth interview there had been no new data added that changed 
the results or course of action for three consecutive interviews and minimal new 
information prior to that. 
The ethical approval in place for this research stipulated that recruitment should be 
conducted using personal connections only. Recruiting only from personal 
connections meant that the sample were not from diverse areas of the population 
and demographics. There is a risk of selection bias here as the study group were 
mainly sourced from the university newsletter and are not representative of the 
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target population (441). In hindsight further and/or different ethical approval should 
have been sought to enable recruitment from a larger sample to reflect a wider 
variety of respondents and their opinions. 
A key limitation of this work is the sample used for these cognitive interviews. As 
discussed above, the absence of ethnic minority women or women using a first 
language that is not English is a significant flaw of the cognitive interview tests that 
can hopefully be rectified in future research and testing phases. As well, previous 
research has suggested women who comply with research are more likely to conform 
to suggested health behaviours (442). The presence of this confounding variable 
cannot be overlooked nor prevented. 
Furthermore, nine out of the thirteen participants were women who either regularly 
undertake or are exposed to research in their working environment. One participant 
has previously worked in a bowel cancer screening development team which 
immediately biased her interview as she understood all terms regarding screening. 
The women interviewed often appeared hyperaware of possible selection bias with 
phrases such as “so as a scientist I kind of know what they mean but as a patient or 
lay person I don’t think I would” (J). However, these women continued to contribute 
helpful recommendations and improvements. 
Regardless of the participants’ professions the aim of the cognitive interview phase 
was to obtain a range of knowledge and experiences. These women are all invited to 
participate in the NHSBSP every three years and therefore will be a component of 
the final population the questionnaire will be sent to. Therefore it is not a significant 
hindrance that these women were those who were cognitively interviewed. 
Whilst some may argue that the researcher may introduce subjectivity and bias when 
analysing and presenting qualitative data, I would suggest that being involved and 
responsible at every step of the research process has allowed an in-depth knowledge 
of each interview, and attendant comments, participant feelings and results.  
The employment status question was designed in order to obtain SES information 
about the respondent. However, by changing the question format the answers are 
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not compatible with census information. This may prove challenging with future 
comparative research and should be thoroughly investigated. 
Previous research criticises the use of lengthy questionnaires wherever possible. 
Response rates declined from 70.2% for a two-page questionnaire to 57.1% for a four 
page questionnaire as measured using a questionnaire conducted in Norway (400). 
This is a limitation of administering the questionnaire in paper format. If the 
questionnaire were to be administered online then simple linking techniques could 
dramatically reduce the length for most women. Regardless, despite the 
questionnaire appearing lengthy it only takes between fifteen and thirty minutes to 
complete, depending on how much a woman has a family history of cancer.  
Conclusions 
Furthermore, in combination with the previous quantitative work packages and 
research findings, results from this future questionnaire have the potential to change 
the NHSBSP invitation process.  
This questionnaire could be used to identify whether women are making ICs to 
attend/not attend BCS. It has the potential to be used to identify in which women 
knowledge is lacking or why certain women are not attending. Furthermore it can 
establish if women of high risk of developing BC are attending BCS or not. Importantly 
the questions asked in this questionnaire can be used to estimate a women’s 
likelihood of developing BC and compare this to her current screening attendance 
values and behaviours. Whilst research of this type is in its infancy it will be an 
incredibly important tool in future to establish where tailored risk information or a 
decision aid can be utilised to encourage uptake in those at higher risk and to 
encourage an IC for all with personalised risk information for all women. 
In research, a well-developed version of this questionnaire can be used to explore if 
a new leaflet allows a sufficient understanding and an IC to be made by women in 
mammography screening programme. 
In clinical settings, the results of this questionnaire can be used to identify how best 
these groups could be targeted with tailored invitations and informative materials 
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where appropriate. Some women could also be given longer appointments to ask 
more detailed questions about areas of concern or to achieve an IC where necessary. 
This questionnaire is in its early stages of development. Regardless of the purpose of 
the questionnaire, a concern about the length of the questionnaire remains and non-
response may be high. Further testing and evaluation will seek to reduce the number 
of items with the hope to obtain high levels of acceptability in the target population.  
Regardless, it is likely that those women who do not participate in the questionnaire 
are those who also do not attend BCS appointments. Uptake of the questionnaire 
could be improved with incentives, either financial or not, or it could be improved 
using public awareness campaigns relating to the questionnaire and its aim is to 
provide the ability to make an IC rather than uptake of BSP per se. Ideally, with 
further development the questionnaire can really focus on a relevant, unmet need 
















Chapter 6: Integration, interpretation 
and conclusion 
Introduction 
The aim of this thesis has been to identify predictors of mammography attendance 
both worldwide and in the UK, as well as to develop a questionnaire for future 
investigation into predictors of BCS uptake.  
Chapter two provided an overview of the literature. It provided a summary of 
predictors thought to influence uptake of mammography and showed some patterns 
in attendance explaining the need for the secondary data analysis. The chapter also 
clarified why IC was so important in modern screening policies. 
Chapter three justified the research questions for the thesis and the overall rationale, 
research gap and thesis aims and objectives. Discussion about the contribution to the 
research field was offered. Methodologies that were to be used in the thesis were 
detailed and an overview of the studies provided. 
Chapter four presented the results of a large systematic review of worldwide 
predictors of uptake. Meta-analysis was conducted on the data where quantitative 
data were available, narrative summary was undertaken where not. Data for thirty-
one predictors of uptake were extracted from ninety-one papers. 
Chapter five presented the results of the secondary analysis using data from a South 
West London screening centre. Multilevel modelling was conducted to assess 
predictors of uptake of mammography. 
Chapter six explored the processes involved in the development of a tool to assess 
whether demographics, personal risk of BC and/or IC were predictors of uptake. I 
discussed the methods involved with PPI and cognitive interviews, results and 
outcomes including a final draft which can be found in Appendix 8.4.5. Further 
evaluation and testing of the tool is necessary before use. 
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6.1 Summary of studies 
6.1.1 Systematic Review  
As discussed in Chapter 4, the purpose of the systematic review was to determine 
the predictors of breast screening uptake worldwide. Ninety-one studies were 
included in the systematic review with data analysed quantitatively and narratively. 
The most important findings were that marital status, smoking status, having chronic 
conditions, the number of primary care visits and insurance status were found to be 
statistically significant predictors of uptake. There were non-statistically significant 
differences found in the proportions attending mammography by ethnicity, BMI, age, 
SES, income, housing tenure and education. 
Furthermore, additional predictors were analysed narratively. Unanticipated findings 
from narratively analysed studies included higher rates of reported attendance in 
women who lived in rural areas, those who were victims of abuse or were caregivers. 
These studies may suffer from publication bias and/or other types of error such as a 
subjective analysis by the researcher. Attempt was made to minimise the likelihood 
of this bias by extracting any available data consistently for all articles included in the 
review (not just those analysed using meta-analysis) and all data extracted for the 
review was analysed rather than choosing which data to present. 
As predicted from previous literature, the re-screening analysis showed that women 
who had previously attended were more likely to re-attend BCS. Controversially, 
having a previous false positive result was not significantly associated with uptake. A 
possible explanation for this might be that women react differently to the false 
positive result and the absence of a clear understanding of subsequent attendance 
patterns is a reflection of this. 
 
6.1.2 Routine SW London dataset 
The secondary data analysis aimed to investigate the predictors of mammography 
uptake in more detail using a South West London, UK dataset. This study found 
influential factors including older age and being of a minority ethnicity were 
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negatively associated with uptake but affluence, requiring a special appointment and 
having a previous recall were positively associated with general uptake of BCS. 
As far as first episode attendance is concerned, it was interesting to find that only 
women within IMD deciles six and above were significantly more likely to attend their 
first episode compared with the most deprived women. Again, minority ethnic 
women were significantly less likely to attend and younger women were most likely 
to attend their first episode. Women requiring a special appointment were less likely 
to attend compared to women who did not.  
The study detected some evidence for attendance at BCS having changed over time 
as year was found to be a significant predictor of attendance. Mammography 
attendance patterns have reversed for women requiring a special appointment and 
women with a previous recall, uptake has reduced for all ethnicities except White 
women, and declined for all SES groups and most age groups. 
 
6.1.3 Questionnaire 
This study set out to develop a questionnaire. Key aims were to evaluate if the 
questionnaire was appropriate for women aged between 47 and 73, to assess if there 
were any key questions raised by potential participants and to highlight any potential 
mistakes in the early development phase of the tool. 
The use of a PPI presentative and cognitive interviews with women who were of 
screening age were used to improve the questionnaire. Changes were implemented 
to key questions on topics including menopause, negative consequences of breast 
screening, current health status, employment status and attitudes about screening. 
These were important to ensure the questions were measuring the information 
researchers thought and wanted to obtain. 
There is no doubt that a qualitative approach to exploring what women understand 
by informed choice would have been useful. However, the purpose of this 
questionnaire was not to explore their views and opinions on IC but to design a 
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questionnaire that could be used to explore if they make IC and how this affects their 
uptake pattern of mammography. 
6.2 Integration of study findings 
The purpose of the thesis was to investigate predictors of uptake and determine 
what, if any, were associated with attendance. The main goal of the review was to 
systematically analyse global data and the data analysis aimed to conduct analyses 
of local London uptake data. They are profoundly different populations and multiple 
different screening programmes were included in the systematic review. 
Nevertheless, it was somewhat surprising that the systematic review and the 
secondary data analysis did not produce coherent results as shown in Table 25. A 
possible explanation for the inconsistencies may be because the underlying 
populations as well as the organisations of health services are fundamentally 
different. 
The secondary data analysis did not have identical variables associated with uptake 
and was therefore always likely to find differences. However, a cause of concern 
remains with the discrepancy of results between those variables that were 
considered in both studies – for instance age, ethnicity and IMD/SES. The samples 
are so varied that generalisations would be hard to make anyway. However, the 
discrepancies impact the certainty of any recommendations or conclusions drawn 
from the results of either study as neither can be supported by the other. 
When considering items from the questionnaire, questions were not simply based on 
the results of the previous two studies but also on questions used previously in other, 
similar questionnaires and questions were included for items that were imperative 
for making an IC, as explained in the previous chapter. Ideally, questions about 
demographics would have been based from the results of the studies I conducted. 
However, one of the main reasons for designing the questionnaire was to determine 
if demographics were associated with uptake and therefore this was not too 
concerning. Further to this, previous literature has suggested these factors are 
associated (as described above) so the questionnaire may be able to provide further 
confirmative or contrary evidence. 
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Table 24. Summary of comparisons between review and routine SW London database. n.s. = non-significant 
result. *=significant result at the p<0.001 





Are the results 











Ethnicity Increased for 




White women vs 
Other women 
Yes 
SES Affluent women 
less likely to attend 
(non-significant) 
Affluent women 
more likely to 
attend 
No 
Age Women aged 70 or 
over are less likely 
to attend (non-
significant) 
Women aged 70 
or over are less 
likely to attend 
Yes – but the 
finding was non-
significant in the 
systematic 
review 
Previous recall Re-attendance 
data: women with 
a previous recall 
are less likely to re-
attend (non-
significant) 
Women with a 
previous recall are 








Within the SW London, UK setting, ethnicity, age, SES, previous recall and requiring 
a special appointment were all associated with uptake of BCS. From the systematic 
review, analyses suggest marital status, smoking status, suffering from a chronic 
condition, being uninsured and the number of primary care visits are significantly 
associated with the uptake of BCS. These predictors were useful and were 
incorporated into the development of the questionnaire. 
 
6.3 Thesis strengths and limitations 
Research aims were achieved in that each of my studies were completed.  
The size of the systematic review is a key strength as it includes data from ninety-one 
studies. It followed a published protocol which increases reliability of the results 
(206). Two reviewers were used at all stages of the review and all papers were quality 
appraised. A major strength of the research was that self-report uptake data were 
excluded. 
No studies from the developing world were found. This is unfortunate as that would 
likely have changed the outcomes and/or provided a sub-section analysis of the 
uptake in programmes in those countries. Only papers written in English were 
included in the review and this could account for the lack of studies from a wider 
geographical spread of countries. On the other hand, screening programmes in less 
economically developed countries are rare and perhaps this is the reason why so little 
has been published from these settings. This systematic review only investigated 
organised screening programmes and therefore opportunistic data were removed.  
Furthermore, a significant amount of heterogeneity was found in these analyses. The 
statistical heterogeneity may have been because the samples included in the studies 
were large and therefore estimates, although varied, were very precise. Whilst 
caution should be used when interpreting the results, the amount of heterogeneity 
in the meta-analysis should not necessarily be considered a cause for concern. 
(Heterogeneity existing as a result of different patterns of organisation of breast 
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screening programmes may be a more important problem as discussed in section 
4.6.4). 
As multiple predictors were investigated using some of the same data, a type one 
bias may have been introduced. An attempt was made to reduce this by using a 
Bonferroni correction (260, 261). The review was complicated as it investigated a 
wide variety of different predictors. Nevertheless, it contributes significant 
information to the research field in terms of its breadth and increased understanding 
of the variety of different factors associated with attendance.  
A noteworthy strength of the secondary analysis was the size of the database used. 
There were 915,546 episodes of mammography spanning over seventeen years. A 
key reason for the choice of dataset was its recording of ethnicity data. Whilst this 
was not complete for the dataset it did provide a large proportion of information of 
a variable thought to be strongly associated with mammography uptake. 
The database selection itself could be a source of bias of the analysis and this should 
be considered. SW London was chosen due to its links with a supervisor previously 
associated with this research. Whilst there was no influence imposed by this 
relationship between the screening centre and the researcher, it does appear that a 
wider sample of screening centres could have been more appropriate, provided a 
wider representation of the UK population and allowed further analyses – for 
instance a comparison of results between a local centre and the SW London centre. 
A key limitation remains that data were routinely collected for the screening 
programme and therefore do not contain the entire variable set that I would have 
preferred. If available it would have been important to include variables such as 
marital status, number of children, distance to screening site, car access, other health 
status (such as co-morbidities) or caring status. This would have allowed better 
comparison between the secondary and systematic review studies and would have 
provided a more complete evaluation of associations of uptake in SW London 
dataset. 
Furthermore confounding variables cannot be accounted for, since other predictors 
may influence uptake and remain unidentified. Additionally ethnicity data were 
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missing for a proportion of the women. Whilst this was anticipated it still represents 
a limitation.  
This type of analysis can only provide insight into associations between data rather 
than causation. Whilst we can speculate the cause of any association, the true 
relationship needs further investigation using different research methods. Another 
issue is that the composition of the database does not reflect the composition of the 
England and Wales population. The SW London population invited for and attending 
screening is over-representative of minority ethnic women and this might explain 
why poor uptake results were found when compared with nationally reported 
outcomes. The distribution of SES in the routine SW London database was skewed 
towards affluent women. 
There were two key limitations noted for the questionnaire development study. 
Firstly, the sample used was only obtained via personal connections and as such was 
limited to a sub-group of the population – employment status (the large majority 
were researchers or worked in a research environment) and ethnicity (all were White 
British) and therefore are likely to have similar experiences to draw upon. However, 
sampling is a limitation of any such research and this limitation can be addressed in 
future development of the questionnaire in the pilot phase for instance. In hindsight, 
a different ethical approval would have allowed further cognitive interviews and 
exploration of women’s views from different settings and would have removed the 
limitation of using only personal connections.  
Secondly, the length of the questionnaire is an important limitation as previous 
research has highlighted (400, 443). Despite this, the questionnaire could not be 
made shorter, as layout and white space are important considerations of 
questionnaire design (383). I consider both aspects equally important but if one was 
to be chosen as more influential than the other then layout and white-space would 
need to be compromised in order for the content to remain. 
Whilst the development of this questionnaire is important and is timely as the 
provision of healthcare is moving away from a paternalistic and towards a shared-
decision making framework, more research is needed to address the gaps not 
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explored in this thesis. For instance, the introduction of IC in mammography 
screening is a new concept and as such it would be appropriate to explore the what 
is important for women to enable an IC, and to explore relevance and acceptability 
of this approach with members of the screening target audience. Furthermore, 
questionnaires consistently have low response rates. Research could discover what 
would encourage completion of this questionnaire if it had IC as the end-goal or 
perhaps identify what would make it more acceptable to the target audience prior to 
use in healthcare? Primarily, this questionnaire is only going to be useful to the 
screening programme if individuals are willing to use it.  
6.4 Contribution to knowledge 
Many predictors influence BCS attendance in a complicated matrix as shown in Figure 
60. Indeed, the association between false positive results and likelihood of 
attendance was confusing and remains undeterminable. 
 
Figure 61. Predictors of BCS 
At the time of conducting the research no review existed that examined all predictors 
of BCS attendance. As predictors of attendance are likely to influence mammography 
uptake in a complicated interlinked network, it is important to examine all potential 
factors in one place in order to start to try and understand their relationship to each 
other. This review was important to initiate this process and simultaneously update 
the understanding in research field. 
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Several studies have established that many variables predict uptake of 
mammography. This large study using recent routinely collected data in the UK 
updates previous similar studies (140) and has found that age, ethnicity, requiring a 
special appointment and having a previous recall episode are all significantly 
associated with the uptake of mammography. 
Whilst components of the questionnaire which I designed have been used before in 
different health settings or conditions, the questions have not been used in breast 
screening in the UK (164, 236). This questionnaire and tool to measure IC is an 
innovative project and a tool such as this has not been previously created for breast 
screening. Future research should investigate the acceptability of the questionnaire 
itself which could help drive completion rates. 
As a result of this PhD, research on predictors of mammography attendance has been 
updated both worldwide in my systematic review and in SW London using my 
secondary data analysis. Furthermore the development of a questionnaire to assess 
influence of personal BC risk, demographics and IC on uptake is underway. My PhD 
will directly support future research to identify whether women are making an IC and 
the impact of IC on attendance patterns, allowing us to understand this phenomenon 
better. 
Regardless of its use in a future screening programme, the questionnaire could be 
used also for use in academia. As discussed above, the NHSBSP spent much money 
and time developing and updating the new mammography leaflet only to face 
significant criticism (as displayed in the introduction of the Appendix 8). This 
questionnaire, or questionnaire written from it, could be used to help identify if a 
future leaflet update meets certain criteria – does it provide enough information for 
a women to obtain sufficient knowledge to make an IC, does it provide enough 
information for women to have an attitude to BCS, and does it provide enough 
information for individuals to make IC about their decision to attend or not? This 
would be really important so any future leaflet updates meet ethical criteria (164). 
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6.5 Future research 
Taken together the analyses show that more research is required to evaluate 
predictors associated with uptake of mammography in disparate screening 
programmes across the world. It would be useful to be able to understand predictors 
in relation to the organisation of screening programmes e.g. it was decided not to 
include opportunistic programmes in my systematic review as they are 
fundamentally different from organised screening programmes. No developing 
countries were included in this review and therefore future research should 
investigate uptake in these areas. 
Considerably more work will need to be done to determine the effect of false positive 
results on subsequent re-attendance. As this predictor relied upon re-screening data 
it was not included in the main body of the review and is found instead in Appendix 
8.2. However, the precise mechanism of action is yet to be confirmed and this would 
be a fruitful area and important for future work and would likely involve a review of 
the literature before in-depth qualitative interview methods to establish likely causes 
before wider interpretation and generalisability. 
Previous work has found age, SES, education and housing tenure to be associated 
with uptake (75, 124, 127, 148), however this review found no statistically significant 
association. Further research should be undertaken to explore the effect of these 
predictors on uptake in each particular sub-group of women. 
Following my PhD a repeat investigation of the secondary data analysis of the routine 
SW London dataset should be performed. Ideally, data from all screening centres 
should be obtained to ensure results are generalisable to the entire population rather 
than a subset. It is important to ensure the models fit to different, naïve datasets and 
so further work needs to be done to establish whether the models work. 
Further work also needs to be carried out in the development of the questionnaire 
in order to validate and test the reliability of the tool. Subsequent to this the 
questionnaire needs to be used in research to inform practice so that we can fully 
understand the close links and implications of attitudes, personal BC risk, 
demographics and IC on uptake. 
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In addition, further studies need to be conducted regarding the best type of decision 
aid for potential participants of screening. This decision aid could be personalised 
based on risk or preference in order to ensure that an IC has been made regarding 
mammography attendance. However, the development of a useful decision aid 
cannot be started until the information is gathered and understood about how 
predictors influence attendance. 
 
6.6 Key messages 
For women, the key message that must be made is that many factors are influencing 
uptake and particular attention could be given to highlight the effects of each 
predictor. 
Health practitioners should be advised that the decision to attend mammography is 
personal and that multiple predictors influence this decision. Health practitioners 
should be given the results of this research to explore which women are potentially 
being missed (for instance minority ethnic groups in SW London) to allow for the 
provision of policies to encourage more equitable access. 
Ethically IC is one of the most important considerations for running a screening 
programme and therefore policy should account for this (62, 102). New guidelines 
should be written to represent these new feelings towards the decision following 
practice in Germany (190). In conjunction with further academic research 
investigating decision aids and personalised information, the NHSBSP leaflet should 
be redesigned to incorporate the findings. 
 
Chapter summary 
This chapter has reviewed the research problems addressed in each chapter and 
provided a summary of each study before integrating its findings. The chapter has 
reported the main strengths and limitations found within each study and highlighted 
the contribution this thesis has made to the research field. Future research 
recommendations have been provided based on limitations of the current studies or 
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research problems that either have yet to be resolved or have arisen from conducting 
this body of work. This chapter ends with key messages aimed at women, health 
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Breast Cancer Screening (BCS) 
BCS is a national screening programme to identify the early detection of breast 
cancer in women who are apparently healthy. This is not the same as a programme 
for women known to be at higher risk of BC. In the UK, women aged between 50 and 
70 who are registered at a general practice are invited every three years to attend a 
screening appointment where two x-rays are taken of each breast. The screen is free 
of charge at the point of care and results are sent to the woman within two weeks. 
However, not all screening programmes are identical. In fact, they vary widely 
globally. Only national organised screening programmes are considered here. 
Opportunistic programmes include those who opportunistically screen women when 
they attend healthcare services for reasons other than to receive a mammogram. 
These types of programmes were not examined in this thesis. 
Table 1 shows how different countries have organised their screening programmes. 
Table 25. Screening programme variation in countries included in this thesis. 







   Age 40-49      Age 50+ 
Australia 1991 40-75+ 2 years 2 years 
Belgium 1991-2001 50-69 NA 2 years 
Canada 1988 40-69 1 year 2 years 
Denmark 1991 50-69 NA 2 years 
Finland 1987 50-64 NA 2 years 
France 1989 50-74 NA 2 years 
Germany 2006-7 (full 
coverage by 
2008) 













(extending to 69 
years by 2021) 
NA 2 years 
Israel 1997 50-74 NA 2 years 
Italy 2002 50-69 NA 2 years 
North Korea 2002-2003 40-69 2 years 2 years 
Netherlands 1989 50-74 NA 2 years 
Northern Ireland 1988 50-70 years 
(47-73 years in 
extension trial) 
3 years where 
appropriate 
3 years 
Norway 1996 50-69 NA 2 years 
Portugal 1990 (1997 in 
Alentejo region) 
45-69 2 years 2 years 
Spain 1990 (1995 in 
Catalonia) 
45-69 (50-59 in 
Catalonia) 
2 years (where 
appropriate) 
2 years 
Sweden 1986 40-74 18 months 2 years 
Switzerland 1999 50-69 NA 2 years 
United Kingdom 1988 50-70 years 
(47-73 years in 
extension trial) 
3 years where 
appropriate 
3 years 
United States of 
America 
1995 40-69 1-2 years 1-2 years 
 

















































8.1.1 Eligibility criteria 
Inclusion criteria 
Women routinely invited for mammography screening for breast cancer 
Age variable but relevant for each country screening programme – 90% sample have to be 
within age range for that national programme 
The study must mention attendance at the organised screening programme – either current, 
previous or changes 
Study must mention at least one predictor variable of uptake 
Uptake of mammography has to be reported and separately to CBE/BSE 
Actual attendance for BCS 
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Quantitative study designs, reporting numerical data 
Any country (with a breast cancer screening programme) 
Articles written since 1987 
Written in English 
Humans 
Exclusion criteria 
Case-studies, editorials, letters, commentary, conference abstracts, structured abstracts 
Protocols, ongoing studies 
Qualitative papers 
Systematic reviews and meta-analyses (reference lists will be searched for relevant papers) 
Symptomatic cases of breast cancer screening 
Opportunistic screening 
Diagnostic screening 
Predictors not mentioned 
Uptake not mentioned 
Self-report attendance at mammography/uptake of breast screening (if supported by 
medical records, paper must be included) 
Uptake data must be present for individual predictors 
Subsets/selective samples of the eligible population (ie. sample of non-attenders or 
attenders only, or only specific groups) 
Non-human studies 
Articles written before 1987 
Not written in English 










8.1.2 Search strategies for database searching 
Search strategies 
The following search strategies (shown in the figures below) were applied to each of the six 
databases searched for this review. 
 
Figure 62 Search strategy for Web of Science. Conducted on 05.12.16. 
 
Figure 63. Search strategy for Medline OVID. Conducted on 28.11.16 
 
 
Figure 64. Search strategy for PsycINFO. Conducted on 05.12.16. 
 





Figure 66. Search strategy for Cochrane Library. Conducted on 05.12.16. 
 
Figure 67. Search strategy for Embase. Conducted on 28.11.16. 
8.1.3 Constructs of the Venn diagram 
Table 27 below shows the different individual predictors that comprise the 
overarching constructs used to create the Venn diagram and summary of predictors 
in the systematic review as shown in Table 7 in the main body of the thesis. 
Table 26. Constructs of the Venn diagram 












Body mass index 
Immigration status 
Number of children 
Housing 
Car access 










Fixed or mobile 
screening site 
GP related factors 
(sex, attitude, years 
since graduation) 
Invite type 




Number of chronic 
conditions 
Number of 







Family history of 
breast cancer 










8.1.4 Study Characteristics 
The following characteristics were extracted from papers using the following data extraction sheet.  
 
Figure 68. Data extraction sheet 
Table 27: Studies included in the systematic review. 
SES=socioeconomic status, BMI=body mass index, HRT=hormone replacement therapy, BC=breast cancer. 
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**= data looks at percentages/behaviours of those included in the study so data sums to 100%. E.g. Of the 50 participants, 80% were married who attended. 
†= data includes “rescreening” data that although meets the review criteria, must be analysed separately. 








Summary of main findings 
as reported in the paper 
Ref. 




Netherlands 1067952 Age 
SES 
Year 
↓with increasing age 
↑non-uptake with high 
SES 
↑over time (1998-2005) 
(79) 




Denmark - False positive result ↔remained stable over 
time (1991-2001) 
↔no difference to 
negative test result 
women 
(262) 
Aro** 1999 Cohort 1992 to 
1993 





Perceived BC risk 




↓uptake with serious 
illness 
↑attendance if married 
↔ no apparent trend 
↑non-uptake in low 
income 
↑moderate perceived risk 












Summary of main findings 
as reported in the paper 
Ref. 
pain 
↑uptake and non-uptake 
in occasional BSE group 




↔ no apparent trend 
↑uptake in affluent (high 
SES) 
(133) 






139374 Ethnicity ↓uptake in Pakistani, 
African, Indian and south 
Asian women 
(248) 











Primary care visits 
↓in non-hispanic other 
↑highest in <25 (normal) 
↑commercial/private 
↑non-uptake in low 
income 
↑more healthcare contact 
(263) 









Turkish migrants to 
Germany have ↑uptake 
than non-migrants 












Summary of main findings 
as reported in the paper 
Ref. 















↑at preferred provider 
organisation, ↓medicaid 
(55) 





France 15844 Decision aid vs 
standard 
information 
↑uptake in standard 
information, ↑non-uptake 
in decision aid 
(265) 


















↓with increasing age 
↑Swiss nationals 
↓with increasing distance 
 
↑married women, lowest 
in divorced/separated 

















Summary of main findings 




↑if used <2 years before 
↑ previous negative result 









- Age (14month 
interval) 
Age (15-26 interval) 
↑highest in 60-69yrs 
group 
↑highest in 40-49yrs 
group 
(267) 






Canada 140723 Age ↑in younger women (249) 







Family history BC 
↑in older women 
↑with basic education 
↑married women 
↑2 children (inverse u-
shape) 
↑in those with no family 
history 
(158) 
























Summary of main findings 


















↑with increasing access 
↑no education 
↑routine 






↑with increasing access 
↑no education 
↑routine 
↑if no long-limiting illness 







Denmark 73415 Social class  
Always attender 
Attend all but one 
Copenhagen and Funen 
↑ secretarial 
↔ no general trend 













Summary of main findings 









association with SES 
























↑with family history 
↑with more visits 
 
↑non-obese (very close) 
(268) 




Ireland - False positive  




















Summary of main findings 
as reported in the paper 
Ref. 
TOTAL (all false 
pos) 




Area of residence 












↓in older women 
↑with insurance 
 ↓with education 
↑ in rural areas 
↓all reduced uptake 
Shows same data trends 
as First PNA 
 
↑ in women who do not 
attend (31.8% v 31.7%) 
↑ in women who attend 
 












Summary of main findings 
























Use of own car 
↑ in younger and older 
women 
↑ in never married, 
divorced, widowed 
women 
↑ in urban residence 
↑ in secondary level 
↑ in not employed 
women 
↑with more education 
↓ with good knowledge 




↑ if more than 4 times 
 












Summary of main findings 
as reported in the paper 
Ref. 






382 Intimate partner 
violence 
 – emotional 
– physical and/or 
sexual 
Those with emotional 
abuse were likely to 
attend screening. Those 
with physical and/or 
sexual were less likely to 
attend, only 15.4% 
attended. 
(270) 






24000 Year (round 1 and 
2) 
82.9% attended Round 1 
83.9% attended Round 2 
(271) 













Age (1999)  
Age (2009) 
↑over time for those aged 
55-59, 60-64, 65-69, total. 
↓ for 50-54 yrs 
↑60.6% (2000), 61.9% 
(2008) 
↔ First attendance 























Summary of main findings 
as reported in the paper 
Ref. 
















Indicate effectiveness of 
interventions on screening 













↑rescreening with age 
↑re-uptake with 
American Indian, Alaska 
natives and White women 
(274) 
Hurley 1994 Randomised 
controlled 
trial 
NA Australia 2266 Letter A 
(appointment) 
Letter B (no 
appointment) 
↑attendance first invite 
Majority did not attend 
(275) 




Australia 104876 SES 
Distance 
↓attendance in high SES 
↓with distance to centre 
(276) 




















Summary of main findings 
as reported in the paper 
Ref. 






































































Summary of main findings 
as reported in the paper 
Ref. 











↑11 to 15 yrs education 
↓with number illnesses, 
except 3+chronic = ↑BCS 
(144) 





















BCS does more good 
than harm 
BCS helps live longer 
BCS means fewer 
mastectomies needed 
BCS means better 
chance of a cure if 
have BC 
BCS prevents BC 






















37211 Caregiving status ↑ in carers 1-
19hrs/week 
(282) 










↑ 50-54 yrs 
↑ married women 
↑ owner 
↑ higher SES 
(283) 




Sweden 29915 Year ↓over time (285) 
309 
 













Country of origin 
↓with age 

















27416 Area of residence 75% attended in 
Scotland. More in 
rural than urban. 
(286) 




Korea Variable Year 
Age 
Insurance status 













1859 Chronic Conditions ↑with chronic 
condition 





Makedonov** 2015 Case-control December 
2005 to 
June 2011 
Canada 105665 Physician sex ↑with male 
physician 
(287) 






Sweden 32605 SES ↑in higher SES 
women 
(288) 







253017 False positive ↓reattendance if 
open biopsy rather 
than needle 
sampling or no 
tissue 
(143) 











Number clinic visits 
per year 
In long-term care 
Ambulatory 















History of breast 
biopsy 
↑history of breast 
biopsy 










- Reminder letter type ↑uptake with those 
receiving the 
physician endorsed  
letter 
(290) 




140387 False positive ↓reattendance if 
assessed benign 
rather than assessed 
normal 
(291) 





8805 Number of healthcare 
visits 
Mammography on-site 





↑healthcare visits  
in those with 2-10 
per year 





















Breast biopsy in past 
year 





↑ if no (due) 
↑female 









3083 Standard letter type 
Tailored letter type 
Both letter types had 
best uptake in those 
with previous false 
positive. 62% in 
tailored letter vs 
60% 
(294) 
Moss† 2001 Retrospective 
Cohort 





↑ in younger 
↑↑in those with 
recent screen (<=5 
years) 
(295) 




Norway 20480 Sami group/Age 
Non-sami group/Age 
↑in 60-69 yrs 
↑ in 50-59 yrs 
(296) 






Australia 119502 Indigenous status 





↑ N European 
 




Family history BC 
Clinic type 
↑ in recipients of 
HRT 
↔ no difference 
↑ mobile clinics 























Korea 2511976 Age 
Insurance 
 






↑ for middle age 
groups 
↑ national health 
insurance 
↑ if negative 
 
↑ if previously 
screened 
 
↑ in 2006 than 2005 
(298) 





Israel 1500 Age 
Ethnic origin 
↑ in 65-69 yrs 














Visiting physician in 
the last year 
↑ in those with 10 
to 14 yrs 
↑ in married 



























↑ in 50-54 yrs 
↑married 
↑ high SES 
↑ 2+ cars 
↑house owner 
↑ educated to GCSE 
↑ good health 
↑ rural 
























Australia 3175 Invite type ↑reminder letter at 
6 weeks 
(302) 




Netherlands Variable Age 
Year 
↑ younger women 
↓ time (rounds) 
(303) 





Netherlands 3726 Age ↑younger women (304) 




Belgium 41585 Age 
Nationality 
↑ 50-59 yrs 
↑ Belgium born 
(305) 








48538 False positive ↑ in women aged 
50+ for both true 
negative (at 30 
months) and false 
positive 
(251) 































Family history BC 
Education 







partake in other 
health-care practices 
↑ in younger 
women 
FHx had a variable 
impact 
↑ in less educated 
(306) 




USA 31377 Guideline changes 
Age 
↓after changes 
↑in 50-74 yr olds 
(307) 








↑ younger women 
↑ no qualifications 
↑ lower education 
↑ married 








↑ no long-standing 
illness 
↑ previous smear 
↑ previous 
mammogram 
↑ if previous breast 
exam 
 
Scaf-Klomp 1995 Cohort 1975 to 
1990 
Netherlands 6898 Age ↑ younger women (116) 








↑ in younger 
↑ HRT recipients 
(309) 







Italy 8069 Invite type Majority attend at 
first invite, only 






























↑ in direct access 
letter (n.s.) 
(312) 




































1500 Invite type Combined 
intervention of 
primary physician 
invite + reminder 
postcard had best 
uptake (61.7%) 
(314) 




Canada 57902 Location 
SES 
↑ rural 












Referral by health 
professional 
↑ younger women 
↑ English  
↑ normal previous 
results 
 
↑ previous attendee 
 
↑ referred by health 
professional 





































↑previous attender  
(166) 













rates if women did 
not attend first 
screening invite 


















↑ with higher 
income 
↑ if 1992-1994 
index 
(169) 











↑ younger women 
↑ less educated 
↑ working class 
↑ married women 
↑ good health 
↑ previous smear 














outreach or combined) 
↔ no trend 
↑ outreach 
(317) 




Netherlands 1279982 Nationality 
Time 
↑ in Dutch women 
↑ 2007-2008 
(252) 
Vidal 2014 Cohort June 2011 
to July 
2011 





Easy to reach group 
had higher uptake 
Text reminder had 
lower uptake 
Previously screened 
had higher uptake 
(318) 






Netherlands - Country of birth ↑ in Dutch women (319) 





Denmark - Location 
Age 
Civil status 
Type of citizenship 
Education 
↑ in Funen 







































Williams 1989 Cohort - United 
Kingdom 
450 Intervention type 
Appointment letter 
Open ended invite 
 

























- Guideline changes 
(admin procedure) 




Zidar 2015 Cohort 2011 to 
2012 
Sweden 52541 Age ↑ in younger 
women 
(163) 




Sweden 32732 Age 
Swedish born 
↑ younger women 






8.1.5 Narrative summary 
8.1.5.1 Demographics 
Ethnicity 
From data that could not be combined with the quantitative analysis, minority groups 
repeatedly had lower rates of uptake compared to the majority populations (140, 
141, 299, 321, 329). 
Further papers contributed ethnicity data that could not be meta-analysed. In 2013, 
Ore et al. compared BCS attendance for women born in Israel or other countries. 
Israeli women had the lowest uptake (50.8%) compared with European and American 
(58.8%) or Asian and African (55.0%) (299). Another study in Israel found the odds of 
Arab women attending BCS were 11% lower than non-Arabs, OR 0.89 (0.80, 0.99) 
(321). 
Using name recognition software which assigned each woman to a religio-linguistic 
group, Szczepura et al. investigated attendance and ethnicity to assess its effect by 
proxy on BCS uptake in the UK. Of those believed to be Hindu-Gujarati, the odds of 
attending BCS were not significantly different from non-Asian women. The odds of 
attending BCS were 32% lower for Hindu Other women compared with non-Asian 
women, OR 0.68 (0.56, 0.84); 60% lower for Muslim women compared with non-
Asian women, OR 0.40 (0.35, 0.46); and 21% lower for Sikh women compared with 
non-Asian women, OR 0.79 (0.72, 0.88), p<0.0001 (140).  
Race data were not included in the pooled quantitative analysis as race was defined 
differently in studies. 
Language 
A study in Australia suggested women who spoke a northern European language at 
home were most likely to attend BCS (85.95%). This was closely followed by southern 
European speaking women (82.0%). The language associated with the lowest rate of 




In Canada, those who preferred to speak English were more likely to attend screening 
than those who preferred to speak other languages. Of women preferring English, 
76.94% attending breast screening compared with 59.65% of those speaking another 
language (255).  
Religion 
O’Reilly et al. investigated religion as a predictor of uptake. Results of the large 
population-based study showed that odds of attending were 17% higher for 
Protestant women compared with Catholic women, OR 1.17 (1.11, 1.23) and 28% 
lower for atheists compared with Catholic women, OR 0.72 (0.67, 0.78) (331). 
Nationality 
Attendance appears to be highest among women that are native to the country 
studied (75, 131, 252, 264, 305, 319, 320). 
Lagerlund et al. analysed uptake of BCS with country of origin. Women born in 
Sweden or Nordic countries showed the highest rates of uptake (90.4% and 88% 
respectively) (75). Women born in northern America had the lowest rates of uptake 
within this studied population (73.6%) as did women from ‘other European descent’ 
(79.7%) (75). 
Vermeer et al. investigated attendance in the Netherlands and the effect nationality 
may have. It was found that natives were most likely to attend BCS (81%). Women 
born elsewhere in Europe or other western countries had attendances ranging 
between 65% and 69%. Attendance of women  from non-western countries were 
56% (252). 
Another study conducted in the Netherlands also investigated uptake of BCS by 
country of birth (319). Attendance was 79% (n=572347/724490) for women born in 
the Netherlands. For women born in western countries, attendance ranged from 59% 
to 71%. For women from a non-western country, uptake ranged from 37% to 59%. 
Overall, total attendance was 76% (n=626,936/824,916) (319). 
Pelfrene et al. found that women born in Belgium were more likely to attend BCS 
(22.8%) compared with women born elsewhere (13.5%) (305). Zackrisson et al. also 
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found in Sweden, women born there were more likely to attend screening (68.5%) 
compared with those born elsewhere (51.5%) (131). 
Von Euler-Chelpin et al. showed higher rates of attendance for Danish women 
(54.0%) compared with immigrant or descendant women (40.0%) (320). RR estimates 
comparing never attenders versus always attenders estimated immigrant women 
had a 80% higher risk of being never attenders when compared with native Danish 
women, RR 1.81 (1.64, 2.01). 
Berens et al. investigated uptake of BCS in women of Turkish origin living in Germany. 
Surprisingly, those women with Turkish origin have OR 1.17 (1.14, 1.21) of 
participation in BCS than women without Turkish origin (264). Attendance at BCS by 
women in Germany of Turkish origin was 52.3% (264). 
Insurance 
Data that could not be combined with previous quantitative data on insurance are 
discussed here. In Israel, 51.5% of those who did not have insurance attended BCS 
compared with 70.9% of those who did have insurance (321). 
From a study in the USA, Taylor et al. provided only percentage uptake rather than 
actual numbers who attended. However, 29% of those with Medicaid (free insurance 
for those in need), 36% of those with Medicare (free insurance for those aged over 
65years), 34% of those with commercial insurance and 11% of women without 
insurance attended BCS (315). 
In Korea of those with national health insurance and a premium under 50% (meaning 
they have no out-of-pocket expense to receive mammography), 62.1% attended 
compared with 62.6% attendance of those with a premium over 50% (and therefore 
incur a 10% out-of-pocket expense to receive mammography) (298).  Of those with 
medical aid program, 46.9% attended (298). A different study found lower rates of 
attendance, 21.2% of those with national health insurance and 10.5% in women with 






Papers which only presented percentage data provided insufficient information for 
combining into the quantitative analyses and therefore will be discussed briefly 
below. 
In the late 1990s, two studies found similar rates of uptake across all age groups 
across the UK and USA (292, 308).  This finding was consistent in an intervention 
study conducted in 2003 (317). 
In European studies reporting only percentages, uptake patterns appeared 
inconsistent. Uptake was apparently higher in younger women aged 40 to 49 years 
(22.7%) in Belgium compared with 20.3% in women aged 60 to 69 years (305) and a 
U-shape attendance pattern was observed in Sweden (163). In Italy uptake was found 
to be higher in younger (aged 50-54 years) women before 2000 but higher in older 
(65-69 years) woman after 2005 (7, 272, 444). 
Of papers analysing non-attendance, higher rates were found in older populations in 
the USA where 60.3% of the sampled population did not attend BCS (332). 
SES 
Some studies reporting SES data could not be analysed with the above data as they 
did not provide data on the proportions of those invited who attended. Of those 
studies conducted internationally, uptake was consistently reported as higher in 
higher SES groups from the UK (140, 166), Israel (299, 321) and Sweden (288). Higher 
uptake in higher SES groups was also consistent across studies which used 
employment status and job position as a proxy for SES in Denmark (278), Sweden 
(75), Northern Ireland (283) and Norway (330). 
In the UK, Szczepura et al. conducted a study investigating uptake of mammography 
at different screening rounds (140). Round one information was entered into the 
quantitative analysis. The pattern of uptake across rounds appears consistent 
however with the largest percentages of uptake occurring in those least deprived 
(80.99% compared with 61.39% in round two and 82.18% compared with 67.6% in 
round five) and tapering of attendance over time (140). Vaile et al. also gave rates for 
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rural and provincial uptakes, both of which perhaps surprisingly displayed higher 
uptakes in working class women compared with middle class women (171). 
In Sweden, Matson et al. found 73.6% of high SES women attended screening 
compared with 59.9% of the low SES women (288). 
In the UK, a study reported attendance at breast screening by IMD. It reported that 
of women in the least deprived quintile, 71% (n=1265/1773) attended within three 
weeks of their appointment and 7% (n=118/1773) did not attend. Of the lowest 
quintile and most deprived women, 49% attended (n=1285/2603) and 36% did not 
attend (n=947/2603). Percent of women who opted out (either temporarily or 
permanently) remained fairly constant across all groups and ranged between 4% and 
6% (166). 
Lagerlund et al. (75) found, in Sweden, the highest uptake was in ‘skilled blue collar 
workers’ and ‘intermediate white collar workers’, both with 92.7% uptake. The 
lowest uptake was found in those who were not employed, which did include the 
retired population (82.2%) (75). 
Jensen et al. (278) found in Denmark, of those who attended screening 55.5% were 
employed, 25.1% retired and 12.4% unemployed. Only 0.5% of women screened 
were social welfare recipients (278). A study in Northern Ireland found the highest 
percentages of uptake were in women who were self-employed (78%) compared 
with the lowest in the unemployed group (63.9%) (300, 331). Another study from this 
region found the same low rates of uptake in the unemployed group (50.3%) (283). 
There was insufficient quantitative data to meta-analyse the data for uptake by car 
access (121, 278, 300). O’Reilly et al. found the odds of attending BCS were 26% lower 
amongst women with one car compared to women with two or more, OR 0.74 (0.70, 
0.78) and 63% lower amongst women with no car, OR 0.37 (0.35, 0.39) (300). In 
Portugal, of women who attended screening, 52.2% of women had use of their own 
car compared with 52.5% of non-attenders (121). In Denmark, women without use 






Rodriguez et al. only provided data about attendance of non-smoking women and so 
could not be included in the quantitative analysis. They reported 94% of women 
attending mammography were non-smokers and 90% of non-attenders were non-
smokers (306). 
Co-morbidities 
Meta-analysis was only conducted on three out of the four studies that reported 
primary care visits as a predictor of uptake as McCarthy et al. did not categorise the 
number of visits similarly to the other papers. However McCarthy et al. reported the 
opposite trend (292). They reported lowest rates of uptake (47.7%) in women who 
have had only one visit in the last year compared with 63.5% attendance for women 
who had 2-10 visits and 55.5% attendance for women that have had more than ten 
visits in the last year. 
A study conducted in the University of Alabama also found no significant difference 
between women who were and were not compliant with government 
recommendations to be screened biennially depending on the number of 
comorbidities (289). 
Mental health 
In a randomised controlled trial conducted in Massachusetts, the odds of attending 
for  women who had had depression were 5% lower compared with women without 
a depression diagnosis in the last year, OR 0.95 (0.71, 1.28), p=0.74 (332).  In general, 
women suffering from mental health related chronic conditions appear to have lower 
attendance at BCS compared with other women. Woodhead et al. found that in the 
last three years, 65.7% of women in London without a serious mental illness (SMI) 
attended breast screening. Of women diagnosed with schizophrenia, 55.2% attended 
(OR 0.64 (0.5-0.82)), 50.8% of those with non-organic psychoses attended (OR 0.54 
(0.33-0.87)) and 62.0% of women with bipolar affective disorder attended (OR (0.58-
1.26) not significant) (324). Werneke et al. found that of women receiving enhanced 
care for their mental illness, 34.5% attended BCS (95% CI 27.3, 41.8) and for those 
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diagnosed with psychosis 30.6% attended (17.7, 43.5) (322). This is compared with a 
reference population attendance at breast screening in this study of 57.1% (56.6, 
57.6). However, Merrick et al. found no significant difference in the odds of attending 
BCS based on their depression diagnosis (332). These rates are low and this is 
potentially because only 38.0% of the overall sample had previously attended 
mammography and as shown in this review, previous attendance is associated with 
uptake. However, this study used a sample of only 4,427 women and therefore 
caution should be used in interpreting these results. 
Hospitalisation 
Meguerditchian et al. found no significant difference between attendance of women 
who had and had not been hospitalised in the previous year, OR 0.97 (0.93, 1.02) 
p=0.21 (293). 
A study in the USA found that women in long-term care were less likely to attend 
screening. Only 41.2% of those in long-term healthcare facilities attended screening 
compared with 52% of women not in long-term care (289).  
HRT 
Data on HRT were extracted (141, 309). Groups were defined as never or ever users 
of HRT. There were not enough data to quantitatively analyse this predictor. 
Unadjusted risk ratios estimate Australian women that are using HRT are less likely 
to be non-attenders BCS, RR 0.90 (0.87, 0.93) compared with women who do not use 
HRT (141). Seeley et al. compared uptake of British women who do and do not use 
HRT (309). Women using HRT were found to be significantly more likely than women 
not using HRT to attend mammography (92.7% vs 85.7%, chi-squared=9.0 degrees of 
freedom=1, p<0.01). 
Family history 
Two studies provided data about family history of BC (268, 306). Rodriguez found no 
significant difference in attendance of women with or without family history of BC, 
OR 1.03 (0.62, 1.68) (306). A study from the USA found of women who had family 
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history of BC 76.3% were up to date in mammography compared with 68.6% who 
were up to date but had no family history (268). 
Previous health behaviours 
In Barcelona, 59.5% (n=147) of women who self-reported obtaining a cervical screen 
periodically attended BCS compared with women who did not previously have a 
cervical screening (306). In the States, women who had had a pap smear within the 
last six years had higher odds of attending BCS, OR 7.1 (5.3, 9.5) (289). In the UK, 
92.6% women who reported a previous smear test attended mammography 
compared with 60.7% of those who had not had a smear test (308).  
McCarthy et al. reported on previous visit to gynaecologist: 69.9% (n=575/823) of 
those who had visited a gynaecologist (n=823) and 58.6% (n=3478/5936) of women 
who had not visited the gynaecologist, attended screening (292). 
Data about breast self-examination (BSE) were extracted for the review (125, 306). 
Data were combined into regular (performing BSE at least once a month or more as 
recommended) or women with no regular history of BSE or have never conducted 
BSE. More women who attended BCS reported practising BSE occasionally or 
monthly compared to non-attenders. Of women reporting BSE their OR of attending 
BCS was 1.99 (1.23, 3.23) compared with women who did not practice BSE (125).   
Psychosocial 
Data were extracted about perceived risks of breast cancer (125, 306). 
In Barcelona, 83% of women attending BCS (n=107/129) felt their risk of BC can be 
reduced [by BCS] (306). Those who knew the preventative role of BCS had an OR of 
attending mammography of 2.66 (1.14, 6.18) compared to those who did not (306). 
In a sample of women from Portugal who attended screening 11% had ‘good’ 
knowledge about mammography, 85.7% had ‘poor’ knowledge and 3.4% were 
‘without’ knowledge (121). Of women attending BCS, 73% of women had correct 
knowledge about mammography frequency and 27% did not have the correct 
knowledge about frequency. Of women not attending screening, 48.6% had the 
correct knowledge about frequency compared with 51.4% who did not (121). 
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The results presented by Aro et al. present a more complicated picture. The odds of 
attending BCS were 100% higher for women who believed their risk of BC was 
moderate compared with women who believed their risk to be low, OR 2.0 (1.54, 
2.61). However, the odds of attending were 9% lower for women who believed their 
risk to be high when compared with women who believed their risk is low, OR 0.91 
(0.62, 1.34) although this result is not found to be significant. Finally, the odds of 
attending were 70% higher for women who did not know about their risk of BC 
compared with women who believed their risk to be low, OR 1.70 (1.27, 2.27) (125). 
In Finland Aro et al. (125) recorded women’s expectations of pain. Any expectation 
of pain was predictive of non-attendance with OR 0.69 (0.54, 0.89). 
Kee et al. (281) interviewed six hundred women in the UK to identify attitudes of 
women who attended and did not attend screening. Overall those who believed that 
breast cancer screening does more harm than good had an attendance rate of 27.3% 
compared to a rate of 59.6% for women who believed that breast cancer screening 
does more good than harm.   
Social support 
Jensen et al. investigated the association between social support (as defined by 
frequency of contact, instrumental and emotional support) and attendance at BCS 
(280). Figure 67 below shows the reported social supports felt by women either 
attending or not-attending mammography. As shown, attenders were more likely to 

















Gandhi et al. investigated the effects on BCS of intimate partner violence (IPV) among 
urban minority women (270).  
Of those who were non-victims, 34.5% of women were up-to-date with mammogram 
screening. Of those who were subject to emotional abuse, 53.8% were up-to-date 
with mammogram screening. Of women who were physical and/or sexual abuse 
victims, 15.4% were up-to-date with BCS. The OR of attending mammogram for 
women aged over forty years who were the victims of physical and/or sexual abuse 
was 0.13 (0.02-0.85) compared with victims of emotional abuse only (270). 
Combining all the data presented, of women who suffered any type of abuse, 38.1% 
attended compared with 34.5% of those who suffered no abuse. Of women who 
suffered specifically physical or sexual abuse only 15.4% attended. 
8.1.5.3 Other 
Time 
Data were extracted from four papers which explicitly gave numbers of women who 
attended and did not attend BCS over different time periods, between 1998 and 2008 
Urban-rural 
 Tatla et al. investigated women living in an urban setting and receiving a 
recommendation to attend by a healthcare professional, 75.84% (n=26592/33047) 
attended screening compared with 74.55% (n=6455/33047) attending of women 
who did not receive the recommendation. Of women residing in a rural location and 
receiving the recommendation from a professional, 80.54% (n=7701/10203) 
attended screening compared with 79.73% (n=2502/10203) who had no 
recommendation (255). 
In Northern Ireland, women living in rural settings had the highest rates of 
attendance (80.3%) compared with intermediate (78.0%) and urban (69.0%). The 
study developed a model that adjusted for age, marital status, SES, health status and 




attending mammography were 56% higher among living in an intermediate area, OR 
1.56 (1.47, 1.65), p<0.05 and 54% higher for women living in a rural environment, OR 
1.54 (1.45, 1.64), p<0.05 (300).  
Leung et al. compared the uptake of mammography of women in Australia and 
Scotland. In Australia the higher rates of uptake were found in those residing in urban 
areas (78%) whereas the opposite was true in Scotland where higher rates of uptake 
were found in women living in rural (79%). A logistic regression analysis found in 
Scotland, the odds of attending BCS were 11% higher among women living in a rural 
area compared with those from an urban area, OR 1.11 (1.04, 1.19), p<0.05. A non-
significant difference was found in Australia, OR 1.10 (0.96, 1.25), p>0.05) (286). 
Fleming et al. found highest rates of uptake were observed in women who reside in 
rural areas (51.4%) compared with 28.6% of women who live in a town and 20.0% of 
women who live in a city (168). 
(7, 79, 272, 284, 285, 444). Percentage attendance over time, is presented in Figure 
68. 
 
Figure 70. Percentage of women attending BCS over time. Lim 2010 studied women in Korea which may explain 
the big difference in percentage uptake compared with the other studies that investigated uptake in The 
Netherlands and Sweden. 
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For this section, distance data were merged into close, intermediate and far based 
on the results reported in each study. 
An Australian study examined if uptake was affected by distance to screening site 
and if this varied by SES. Women in the lowest 25% SES group were compared with 
the ‘other’ SES groups. They found for women in the lowest 25% SES, uptake was 
higher in the groups closest to site (12.1% attendance for women within a 3km radius 
of the screening site compared with 8.7% attendance within those travelling 6km or 
more) (276). However, in ‘other’ SES groups, uptake ranged from 8% to 8.1% in the 
furthest and closest groups respectively showing only a small difference (276). 
Hyndman et al. that 12.1% of women attended BCS if they lived within 3km of the 
screening site compared with 8.7% if they lived 6 km from the site (276). Jensen et 
al. found an association between distance to screening site and non-participation 
significant at and above 40km. For women living >40km-60km the prevalence ratio 
of non-attendance was 1.23 (1.15, 1.32) and 1.27 (1.15, 1.40) for women living >60km 
away from the screening site (278). Another Jensen et al. paper investigated a similar 
pattern of non-attendance but data was provided only in association with GP attitude 
to screening and therefore cannot explicitly be extracted (279). 
Type of screening site 
Sites were defined as fixed or mobile clinics with one paper also reporting relocatable 
site data which is approximately similar to mobile. McCarthy et al. studied American 
women. For those who could receive mammography at their usual clinic site without 
having to travel to a new location 63% attended screening (n=2982/4733). This is 
compared with 52.9% (n=1072/2026) attendance at mammography for women that 
had to travel to a new site as they could not obtain mammography at their usual 
clinic site (292). Offman et al. found in the UK that 74.0% of women attended at a 
static screening unit compared with 75.1% of women invited to a mobile site (297). 
O’Bryne et al.  found that women invited to a relocatable site were at higher risk of 
non-attendance than women at a fixed site, RR 1.39 (1.30 1.48) and women invited 






Many different studies found increased uptake in women receiving either invitations 
to attend screening that included a GP signature  (273, 314, 329), a specific 
appointment time  (275), out of hours option (297), supplementary follow up such as 
a reminder letter  (302, 323), tailored information (294) or tailored counselling (317). 
Decision aid vs standard information 
Bourmaud et al. found that of women given a decision aid when deciding whether or 
not to attend BCS they were 9% less likely to attend compared to women in the 
control group, OR 0.91 (0.84, 0.97) (265). 
Invitations 
There was no difference between attendances rates for women receiving a physician-
endorsed invitation letter (47.7%) attended compared to those who received a 
standard facility invitation (46.6%) (329). 
In the UK however women who received a postcard reminder had an odds of 
attending of OR 1.92 (1.36, 2.71) compared with women receiving usual care. 
Women who received both the GP letter and the reminder had an odds ratio for 
attendance of 1.95 (1.38, 2.74) (314). 
Vidal et al. investigated the use of text-message reminders to improve BCS 
participation in Spain (318). The odds of attending BCS were 63% higher amongst 
women in the group who received a text-message reminder compared to those who 
did not, OR 1.63 (1.49, 1.78). More women in the text-message reminder group 
rescheduled their appointment (8.3% compared with 7.0%). Furthermore, less of the 
women in the text-message reminder group attended their rescheduled 
appointment, OR=0.69 (0.49-0.96) (318). 
Hurley et al. investigated the use of a specific appointment time in the invitation. 
They found that 35.1% attended of those receiving a letter with a specific 
appointment time compared with 9.1% who received a letter without the 




Results from Williams et al. established that sending an invitation with an 
appointment time enhances attendance. Of women who were given an appointment 
asked to alter the time if it was not convenient 86.2% attended. The comparison 
group were asked to return a form and list convenient times before being sent an 
appointment, of this group 75.5% attended (323). 
An intervention which provided tailored letters addressing individual barriers to 
attendance increased odds of attending BCS compared to women receiving usual 
care, OR 2.90 (1.59, 5.29). A combined technique which used these letters and a 
motivational interview to discuss barriers and self-help strategies to overcome them 
gave an OR of 2.15 (1.17, 3.94) (317). 
In Australia one letter with an appointment is standard practice. An intervention 
added a reminder letter at six weeks and found odds of attending increased by 61% 
compared with those receiving standard practice letters, OR 1.61 (1.08, 2.40). Adding 
a phone call to this letter gave non-significant results (302). 
In the UK, previous screening history was used to provide a tailored invitation to 
women for mammography. Of those who received the tailored invitation, 62% 
attended compared with 60% of those receiving the standard invitation (294). 
Incentives 
Merrick et al. looked at uptake in groups receiving different incentives in the USA. In 
the women in the control group, 11.9% attended screening. This was similar to those 
receiving a $15 gift card (11.7%). For women receiving a lottery ticket to win $250, 
12.1% attended and in women who had the choice between gift card and a lottery 
option 13.4% attended. However, odd ratio estimates suggest that none of these 
options are statistically different from the control group at the 95% confidence level. 
Additionally the sample included in this study had a mean annual income of over 
$70,000, and 11% reported a depression diagnosis within the last twelve months. It 





Richards et al. compared uptake in control groups to those with a flag in their GP 
notes. For the flag group, if their GP accessed the woman’s notes during the 
screening round, they should discuss mammography with the woman. Only half the 
flags were activated, but 77.7% (n=1000/1287) of women with an activated flag 
attended BCS compared with 54.3% (n=609/1121) attendance of women without an 
activated flag (160). 
In 1987 a health assessment form was introduced to healthcare centres in America 
to improve physicians preventative care discussions and reminders to patients. At 
the study site, 7.3% of patients (n=59/807) completed a mammography screening for 
the two years prior to the health assessment form. Within the two years after the 
health assessment form was introduced, 32.0% (n=333/1040) patients completed a 
mammography screen (325). These women in the ‘before’ part of the study were not 
the same as those in the ‘after’ part and the effects of this study design should be 
considered when evaluating the results. 
8.1.6 Narrative summary of sum to 100% data 
Some studies provided characteristics of attendee or non-attendee population rather 
than attendance rates for the invited population. Those papers will be discussed in 
the section below. 
8.1.6.1 Demographics 
Age 
The data discussed below could not be combined into the quantitative analysis as the 
age groups did not comply with the merged age bandings. Otten et al. (301) found 
for women under fifty years, uptake was highest in the first round of screening 
(87.2%) and tapered to 68.2% in subsequent rounds. This pattern of tapering uptake 
was consistent across all age groups in another paper by Peeters et al.  (301, 303). 
Mayer et al. studied an intervention that compared the effects of a physician 
invitation letter compared with a letter from the screening centre (329). They found 
uptake was higher in older women in the group receiving the facility letter (65.9% in 




higher attendance from younger women in the group receiving the physician letter 
(68.9% and 31.2% respectively) (329). 
Vaile et al. (171) found that inner city women had the lowest uptake rates (76.4% 
and 79.5% for women aged either less than or over fifty-five years respectively) 
compared with women living in provincial (83.6% and 82.3%) or rural habitats (88.3% 
and 88.1%) (171). This data also shows lower uptake in the older age categories. 
McCarthy et al. showed that in the USA uptake was similar across the age categories 
(59.9% and 60%) (292). In 1997, Rutter et al. also found similar uptake rates across 
the ages in the UK (92% and 90.3%) (308). However, these papers both look at limited 
age boundaries, women are categorised either as the ‘younger’ or ‘older’ age groups 
cut off at 65 and 55 respectively rather than more specific age bandings. 
The percent of Belgium women attending screening of those aged between 50 and 
59 years was 24.7% (305). Contrarily, for Swedish women, rates of uptake were 
inconsistent across the age ranges (163). In Italy, Giordano et al. studied attendance 
rates across time for different age bandings (7, 272, 444). Attendance appears to be 
higher for younger women in 2000 (62.8% in women aged 50-54 years compared 
with 54.6% in those aged 65-69 years) (444). However, this pattern changes over 
time, starting in 2005 uptake is higher in the older women (56.4% compared with 
59.1%) and continues until 2008 (58.5% and 60.2% for the same age categories) 
(444). This is somewhat expected as the women aged 50-54 in the initial year analysis 
2000 age with time and will become part of different age cohorts in later analyses. 
However, looking at the total attendance percentages in the studied regions, uptake 
has remained fairly constant over this same time range (60.6% to 60.2% to 61.9%) 
(444). A Swedish study found that in 2002, uptake was highest among those in the 
younger age groups, 40-49 year olds (90.2%), compared with 85.5% in the oldest age 
group, 70-74 year olds (75). In the USA, Merrick et al. found high rates of non-
attendance at BCS within their sample population, ranging from 85.7% in the 40-49 
year old women to 89.7% in the 60-69 year old women (332). 
In a UK study, of those who participated, 41% were over 60 years, 27% aged between 




Some included papers used data that sums to 100%. For instance, a study may have 
selected all women at a particular centre in a certain timeframe and subsequently 
identified which demographical group they belong to. 
Of these papers, a trend of uptake with age was much harder to observe. Uptake in 
different age groups appears dependent on the geographical location. In particular, 
uptake was highest in the younger age groups in the Netherlands (79, 116), Denmark 
(144, 279, 320, 326), Switzerland (266) and Canada (255, 277). On the contrary, two 
included studies showed uptake appears higher in older groups in the UK (133, 158). 
The reproducibility of the Chouliara et al. study is of concern as the sample size was 
very small. In the USA, uptake was higher for older women (267, 268). May et al. 
found variable rates of attendance across age groups, again showing how complex 
the interaction with uptake may be (289). 
However, these patterns stated above need to be analysed with great caution. They 
highlight which women consisted of the study population of which the participants 
either attended or did not. Therefore these patterns may simply be a reflection of 
the underlying populations invited to attend screening.  
There are lots of factors that may influence a woman’s decision to join a study and 
therefore which may bias the results presented in research. Such factors may include 
the required time commitment to the research and availability of the woman, it may 
involve societal pressure to either partake or non-participate, pressure may be 
observed from simple logistical differences such as was the woman invited to 
participate in the research?  
Scaf-Klomp et al. found only being divorced had a significant effect on attendance. 
At round ne, divorced women were significantly less likely to attend breast screening 
OR 0.65 (0.47, 0.90) (116). 
SES 
Wilf-Miron et al. reported only percentages so that specific group totals could not be 
calculated and this study could therefore not be used in the quantitative analysis. 




women studied, those with highest SES were more likely to attend BCS than low SES 
women (72.9% and 64.1% respectively) (321). 
Similarly, Ore et al. only reported uptake percentages and in another Israeli study, 
62.6% high SES women attended breast screening compared with 61.9% and 53.2% 
of medium and low SES women (299).  
Income 
Mayer et al. provided only uptake data and all data sums to 100%, therefore it cannot 
be combined into quantitative analyses as described before. It suggests that the 
majority of women attending BCS (44.1%) are earning more than 40,000USD per 
annum compared with 20.8% of those earning under 20,000USD (329). 
Ethnicity, Nationality and Race 
Mayer et al. also provided only uptake data regarding women’s ethnicity. It suggests 
that the majority of women attending BCS (87.0%) are white women (329).  
Of women who attended BCS in a Danish study, 92.7% were Danish, 1.8% western 
immigrants and 1.5% non-western immigrants (278, 279). However, this could reflect 
the underlying population structure and the women targeted for study participation. 
Another study by the same author has shown that 79.6% of Danish women or women 
of Danish descent attend BCS compared with 62.9% of immigrant women in Denmark 
(326). 
8.1.6.2 Other 
Distance to screening site 
In 2013, St-Jacques et al. investigated the effect of distance to screening site for 
Canadian women (313) which can be found in Figure below. The difference between 
the results of the review and this Canadian paper could be due to the heterogeneity 
included. For instance, distances required to travel in Canada are much greater than 
those in Denmark where much of the review data has been taken from and 
subsequently women may be more willing to travel 12km as it is considered ‘normal’ 
in their society. Additionally, there could be alternative reasons why women who live 




for instance it could be a particularly deprived area of Canada that just happens to 
be closest to the screening site. 
 
Figure 71. Uptake of BCS by distance to screening site in Quebec, Canada Data taken from (313). 
Interventions 
Jean et al. investigated uptake before and after the mailing of a letter intervention to 
women of different ages (277). The difference in uptake between the younger (50-
54) and older (65-69) group before the intervention was 38.2% compared with a 7.9% 
difference afterwards (277).  
In 2003 Valanis et al. found higher rates of uptake (49%) in those targeted with the 
outreach intervention, which consisted of a tailored letter addressing women’s 
barriers to screening and then for those who had not attended initially a tailored 
telephone call at six months, compared with those with in-reach (39%) who received 
a motivational interview to discuss barriers and motivation to seek screening and the 
usual care (38%) (317). Women that received the combined intervention (both the 
in-reach and outreach services) had an uptake of 48% (317). This pattern was 
consistent across age categories, for those aged between 50-64 years their uptake 
was higher (54%, 41%, 38% and 50%) than those aged 65-69 years (30%, 31%, 39%, 
41%) (317). 
In Italy, a study found that the majority of women receiving a letter signed by the GP 






















to be dependent on geographical location (273). Of those who did not attend and 
received a reminder letter from their GP 16.67%, 21.76% and 24.26% attended from 
the respective study locations (273). Of non-attenders receiving a reminder letter 
from the screening centre, 8.91%, 20% and 17.13% attended BCS respectively (273). 
In Australia a study found that of the women receiving letter ‘A’ which contained a 
specific appointment time, 35.1% (n=149/424) attended after the first letter 
compared with 9.1% receiving letter ‘B’ (with no specific appointment time) (275). 
The women were randomly assigned into a follow-up group. Of those assigned to 
receive a follow-up letter, 37.5% of group A still did not attend compared with 60.6% 
of group B (275). 
At baseline of a Canadian study, 83.3% of women were without a mammogram 
history. These women were sent an invitational letter (intervention group). After the 
intervention uptake increased from 7.8% to 23.0% in women aged 65-69 years, 
remained constant for those aged between 55-64 years and decreased from 46% to 
30.9% in those aged 50-54years (277). This shows different interventions affect 
women differently. 
In the United States, a study compared uptake in usual care, a group who received a 
mailed reminder letter (timed to arrive three to five days prior to invite) and a group 
who received a special counselling and education intervention in addition to the 
previous letters. Uptake was 74.5% in the usual care group, 79.7% in the mailed 
reminder and 80.3% in the special intervention group (334).  
A study in the USA compared mammogram return rates by type of letter received. 
Of those receiving a physician endorsed letter, 47.7% returned for a subsequent 
mammogram within one year. Of those receiving a standard facility letter, 46.6% 
returned. Twenty-eight percent of women receiving no letter (control group) 
returned for a subsequent mammogram (329). 
In 1994 Taplin et al. conducted a RCT in the USA investigating the type of invitation 
and uptake of BCS (314). They found that for women invited by the primary physician 
45.6% (n=154/329) attended, for women receiving just a reminder postcard 58.5% 




addition to the reminder postcard attended BCS. These results are compared with 
46.8% (n=154/329) women attended who were assigned to the control/usual care 
group. 
In 2003, Valanis et al. conducted an intervention study comparing eligible women 
aged 50-69 years and their uptake of BCS at twenty-four months. The inreach 
programme ‘reinforced any clinical suggestions and used motivational interviewing 
to discuss barriers and strategies to motivate a decision to seek screening’ (317). The 
outreach programme consisted of a tailored letter addressing barriers to obtaining 
BCS (as identified at a baseline interview) and for women who had not received a 
mammography after six months, they also received a tailored telephone call. Women 
in the combined group received both interventions. Of these women, 38% attended 
in the usual care (control) group, 39% attended of women in the ‘inreach’ group, 49% 
attended of the ‘outreach’ group and 48% attended of the ‘combined’ intervention 
group (317). 
In 1989 Williams et al. compared types of invite letter. Group one received an invite 
with an appointment, of these women 69.7% were screened at first contact and 
13.8% attended following a reminder letter after three weeks (323). Of women in 
group two who received an open ended invitation, 64.2% attended at first contact 
and following the three week reminder a further 9.3% of women attended (323). 
Non-attenders were sent a further appointment letter and 2.7% of group one and 2% 
of group two attended respectively (323). 
In 2013 within the UK, a study found women receiving the standard invite had an 
uptake of 73.2% and 77.1% at static and mobile screening sites respectively. Of 
women receiving the intervention of an invite with an out of office hours for 
appointment option, uptake was 76.4% and 69.1% for women without this option 
(297). In another UK a study found 40.1% of women with a first call invite attend BCS 
compared with 75.6% of women attending their routine recall (135).  
Romaire et al. compared the uptake of mammography after the mailing of different 
types of reminder letters (335). Sixty percent of women receiving a letter with one 




women receiving a birthday letter with three recommendations, 59% attended and 
19% did not. Of women receiving four to eight recommendations 52% attended and 
17% did not. Numbers do not sum to one-hundred here as due to overlap some 
women received both letters and therefore interpretation needs some caution as 
attendance cannot be attributed to one letter or another. 
An Italian study found 35.4% of women (n=2856/8069) attended screening at their 
first invite (310). If women did not attend they were sent a postal reminder and a 
further 7.11% (n=574/8069) of women went for BCS at that stage (310). 
A study in Sweden found future attendance was dependent on her first appointment 
attendance. The likelihood of participation at all future screening rounds was 0.72 if 
a woman attends her first screening at the first invite round. If a women attends her 
first BCS at the second invite round, the likelihood of her attending all future screens 
is 0.62. (316). This study also evaluated the likelihood of not attending following 
rounds if a woman was a non-participant. For women who did not participate in the 
first round, the likelihood of being a permanent non-attender was 0.32 in comparison 
with a woman who attended the first round and then did not attend at the second 
round (0.18 likelihood of being a permanent non-participator). (316). 
 
Other 
In 2009 the US preventative services task force reviewed the evidence and 
recommended women aged 50-74 were only to be screened biennially and women 
younger than fifty were not to be routinely screened (307). This study looked at 
uptake before and after these guideline changes. The number of women who were 
screened in line with US recommendations fell from 62.81% (n=6894/10976) to 
59.38% (n=6518/10976) in those aged less than fifty years. The number of women 
screened in line with the new recommendations were down from 69.73% 
(n=10864/10976) to 60.85% (n=9480/15580) in those aged between 50 and 74 years 
and was down from 30.47% (n=1469/4821) to 11.43% (n=551/4821) in those aged 




Shippee et al. provided adjusted OR estimates for different predictors of adherence 
to BCS health program in America. The results are presented in the table below. 
Table 28. This adjusted model provides predictors of adherence to preventative recommendations for breast 
cancer. *P<0.05. BMI= body mass index. N=873. Chi2=15.060*. BIC=648.176. 
Predictor OR (SE) 
Age 0.999 (0.021) 
BMI 0.977 (0.019) 
Stressors 0.888 (0.109) 
Education 1.210 (0.136) 
Alcohol concerns 0.611 (0.178) 
Current smoker 0.607 (0.252) 
Married 1.904* (0.541) 
Constant 5.997 (8.146) 
 
Meldrum et al. investigated attendances in women who received different invitation 
letters. Of women receiving a standard letter, 60% (n=922/1531) attended compared 
with 62% of women who received a tailored letter (n=956/1552) (294).  
In Canada Madedonov et al. found that compared with women who had a female 
physician, women with a male physician were OR 1.05 (1.02, 1.05) more likely to 
attend mammography screening (287). 
 
8.1.7 Sensitivity analyses 
The following section shows the forest plots of the sensitivity and further sub-group 















Figure 74. Further sub-group analysis within age predictor. UK and Northern Ireland data only. 
 









8.1.8 Data analyses 
8.1.8.1 Forest plots 
Table 29. A summary table indicating forest plot results of the sub-group analysed predictors. 
Predictor (number of 




























































































































































8.1.8.2 Funnel plots 
The plots below indicate the effect of possible publication bias. However, the plots 
could be estimated outside the 95% confidence interval due to large between-studies 
heterogeneity present in these meta-analyses or low quality of studies included 
which can exaggerate some estimates. For this meta-analysis it is likely the 
heterogeneity and low quality of studies causing the asymmetry (445, 446).  
Age 
 
Figure 77. Funnel plot. Points are colour-coded into the age categories. 
Smoking status 
 






Primary care visits 
 
Figure 79. Funnel plot of available primary care visit data 
BMI 















Figure 80. Funnel plot of included marital status data for publication bias. 
Socioeconomic status 
 


























Figure 84. Funnel plot to assess for publication bias within the available housing tenure data 
Education 
 










Figure 86. Funnel plot of available insurance data 
Chronic conditions 
 






8.2 Re-screening data from the Systematic Review 
Introduction 
In the systematic review, reported in the Chapter 4, data from fifteen re-screening 
papers were excluded from the main body of the review. These papers were removed 
from the initial analysis as previous literature has connected outcomes such as 
attendance at previous attendance and previous false positive results with 
subsequent re-attendance at BCS (269, 291, 297, 298, 373). However, those fifteen 
papers provide important information. Once women have attended their first 
screening appointment they all become re-screening attenders or non-attenders and 
predictors of their uptake are as important as predictors of uptake at the first 
appointment. Two predictors in particular are of interest, previous attendance and 
previous false positive results. Therefore it is important that these are included in the 
analysis of the review data in order not to bias the results. 
8.2.1 Methods 
Re-screening refers to any study that used one of the following methods. A study 
may have analysed a cohort of women who had been previously screened and 
predictors of their previous screen (such as attendance or false positive result) were 
used to determine their current uptake or a study may look at adherence or 
compliance rather than specifically uptake. This frequently occurred in American 
studies which assessed if women had met the recommendation for screening such 
as a minimum of two insurance claims made within a three year period. Additionally, 
studies that investigated patterns of attendance such as which women attended 
consistently, or intermittently or delayed attendance (attended at the second round 
rather than at the first invite) were also considered re-screening papers. 
The methods used have previously been described see Chapter 4. Both Review 
Manager 5.3 and Stata 15.1 were used in the meta-analyses of the quantitative data 
where appropriate. Review Manager was used when there were only two sub-
groups. Stata was used where there were three comparison groups such as SES. A 
narrative synthesis has again been used where insufficient data were available to 




Analysis is conducted on the fifteen papers that were analysed separately from the 





8.2.2.1 Study characteristics 
Of the 91 papers included in the final review, 15 papers were identified relating to rescreening and are presented again below. 
Table 31. Re-screening studies identified from the systematic review. 
SES=socioeconomic status, †=re-screening data, **=sum to 100% data 
 






Summary of main 
findings as reported in 
the paper 
Ref. 
Blanchard† 2004 Retrospective 
Cohort 
















Chiarelli† 2003 Retrospective 
Cohort 
July 1990 to 
December 
1995 
Canada 140723 Age ↑in younger women (249) 
Coyle**† 2014 Retrospective 
Cohort 






































Summary of main 
















↑if no long-limiting 
illness 
Fitzpatrick† 2011 Retrospective 
Cohort 
2000 to 2007 Ireland - False positive  




TOTAL (all false 
pos) 















↑rescreening with age 
↑re-uptake with 
American Indian, 
Alaska natives and 
white women 
(274) 




140387 False positive ↓reattendance if 
assessed benign rather 
than assessed normal 
(291) 
Moss† 2001 Retrospective 
Cohort 





↑ in younger 
↑↑in those with 












Summary of main 
findings as reported in 
the paper 
Ref. 





Australia 119502 Indigenous status 




Family history BC 
Clinic type 
↑non-indigenous 
↑ N European 
 
↑ Remote location 
↑ in recipients of HRT 
↔ no difference 
↑ mobile clinics 
(141) 
















Oh† 2011 Retrospective 
Cohort 
2005 to 2008 Korea 2511976 Age 
Insurance 
 






↑ for middle age 
groups 
↑ national health 
insurance 
↑ if negative 
 
↑ if previously 
screened 
 
↑ in 2006 than 2005 
(298) 
Pinckney† 2003 Retrospective 
Cohort 





48538 False positive ↑ in women aged 50+ 
for both true negative 
(at 30 months) and 
false positive 
(251) 









↑ in less affluent 











Summary of main 










Referral by health 
professional 
↑ English  
↑ normal previous 
results 
 
↑ previous attendee 
 
↑ referred by health 
professional 
Ulcickas† 1999 Retrospective 
Cohort 














↑ with higher income 






April 1991 to 
March 1999 
Denmark - Location 
Age 
Civil status 
Type of citizenship 
Education 
↑ in Funen 
↑ younger women 
↑ married 
↑ non-immigrant 
↑ medium education 
(320) 
Woodhead† 2016 Retrospective 
Cohort 
2012 to 2013 United 
Kingdom 
26010 Mental illness ↓ women with mental 
health problems 







Table 32. Quality Assessment Summary Table. QAT Rating key: 1 = STRONG = no weak ratings, 2 = MODERATE = one weak 
rating, 3 = WEAK = two or more weak ratings, NA = withdrawals and dropouts rating not applicable (215). 
Author Year QAT score 
Blanchard† 2004 1 
Chiarelli† 2003 1 
Coyle**† 2014 1 
Fitzpatrick† 2011 1 
Gregory-Mercado† 2007 1 
McCann† 2002 1 
Moss† 2001 1 
O'Byrne† 2000 1 
Offman† 2013 2 
Oh† 2011 1 
Pinckney† 2003 1 
Tatla† 2003 1 
Ulcickas† 1999 1 
von Euler-Chelpin† 2008 1 
Woodhead† 2016 1 
 
8.2.2.2 False positive 
Four studies reported uptake based on prior false positive results (251, 269, 291, 298). There 
was no significant difference in the odds of re-attendance between women who had or had 
not previously had a false positive result, OR 0.54 (95% CI 0.08, 3.62). However the finding is 
heavily influenced by one large study by Oh et al. undertaken in 2011 in North Korea which 
may not be appropriate to combine in this meta-analysis due to the clinical heterogeneity of 
the national screening programmes. 
 
Figure 88. Meta-analysis of available false positive data. FP=false positive. 
All of the studies in the above meta-analysis gave significant odds ratio results. However, the 
combined estimate was not significant. 
Pinckney et al. assessed the odds of attending in general if a woman had had a false positive 




had a false positive result, OR 1.29 (1.20, 1.38) (251). By 30 months, women with a false 
positive index mammogram were 23% more likely to re-attend, OR 1.23 (1.12, 1.35) (251). 
In East Anglia, UK re-attendance was lower for women who had a false positive result. For 
women who were recalled, assessed and found to be normal odds of re-attending were 16% 
lower compared with women who were not assessed, OR 0.84 (0.78, 0.92) and for women 
who were reassessed and diagnosed with a benign breast disease odds of re-attending were 
35% lower, OR 0.65 (0.52, 0.81) (291). 
Fitzpatrick et al. investigated women who previously received false positive results and found 
the rate of rescreening may be dependent on how invasive the investigation was (269). 
Furthermore this effect appears to be associated with age as re-attendance was found to be 
higher in younger age groups. For recalled women who did not undergo tissue sampling, 
uptake rates were between 90.9% and 91.6% (highest uptake in women aged 50-54 years) 
(269). For women who had a core biopsy, rescreening rates were lowest for those aged 55-
59 years (88.4%) (269). For women who experienced an open surgical biopsy, rescreening 
rates were lowest (77.9% for women aged 55-59 years) (269). Furthermore, for recalls (except 
those with no tissue sampling), rescreening was highest in the 50-54 year group (269). 
Oh et al. also found that compared with women who received a true-negative result, odds of 
attending for women who received a false-positive result were 11% lower than for women 
who did not receive a false positive result, OR 0.89 (0.88, 0.90) (298). 
Extracted data that could not be combined into the meta-analysis is narratively presented 
below. 
May et al. found that if women had previously had a breast biopsy the odds of re-attending 
BCS were 110% higher compared with women who had not, OR 2.1 (1.2, 3.5) (289). 
Meguerditchian et al. also found odds of re-attending in the next twelve months were 38% 
higher for women who had had a false positive result, OR 1.38 (1.15, 1.65) (293). However, in 
Canada the opposite was found to be true. The odds of women attending BCS were 51% lower 
if they had had a false positive result, OR 0.49 (0.46, 0.52) (255). 
To summarise May et al. (289) reported a higher rate of attendance for women with previous 




results) in 1999. In contrast in 2013, Maxwell et al. (143) reported very slightly lower 
attendance rates at 90.1% for women with a false positive result compared to 91.1% for 
women without. The programmes are dissimilar however and there is a fourteen year gap 
between data which makes the figures difficult to interpret. 
In contrast with the meta-analytic findings, higher rates of uptake were found in the younger 
population (168, 267, 277, 296, 301, 303, 320). This varied for specific groups, for example 
women experiencing false positive results were more likely to return to screening if they were 
older 60-62 years (91.0%) compared with woman aged 50-54 years (90.4%) (269). Women 
returning for re-screening were more likely to be older, 52% of women aged over 60 years 
attended for re-screening compared with 28% of women aged 40-49 years (274). 
8.2.2.3 Previous attendance 
Data that could be quantitatively analysed were provided about previous attendance pattern 
in four papers (255, 295, 297, 298). Results suggest that the odds of reattendance were 6.05 
times higher in women who had previously attended BCS than those women who had not, 
OR 6.05 (1.44, 25.43). 
 
 
Figure 89. Forest plot of available data for previous attendance 
Tatla et al. found odds of re-attending were 76% more likely in women who had previously 
attended BCS (255). Both Oh et al. (298) and Moss et al. (295) used routine data for their 
analysis and found women who had previously attended were more likely to re-attend but 
found very different effect sizes. Offman et al. were conducting a randomised trial of weekend 
or evening appointments and recording effects on attendance. However, for their data 
analysis any women who needed to rearrange the appointment due to requiring a special 
appointment (likely due to a disability) was removed from the analysis. This may have 





Five studies provided data about women’s previous attendance at BCS that could not be 
combined into the meta-analysis (166, 171, 255, 293, 333). Meguerditchian et al. found if 
women had previously attended, their odds of attending were nearly 4 times higher 
compared with women who had not previously attended, OR 3.94 (3.47, 4.48) (293). In 
Canada, odds of attending BCS were 76% higher for women who had previously attended 
mammography compared with those who had not, OR 1.76 (1.69, 1.84) (255). Taylor-Phillips 
et al. found odds of re-attending were 371% higher amongst women who had previously 
attended BCS compared with those who had not, OR 3.71 (3.49, 4.37) (166). Drosseart et al. 
found that of women who had attended BCS before and invited to re-attend, 94% attended 
both second and third rounds of screening (333). Vaile et al. found of women who had 
previously attended 74.7% re-attended compared with 87.1% of women who had not 
previously attended (171). 
Meguerditchian et al. (293) and Tatla et al. (255) both investigated uptake in Canada. Uptake 
would be expected to be similar across the studies as women can experience similar 
deterrents to attendance such as vast distances. The lowest reported rates of uptake for 
women with previous attendance at mammography were found by Meguerditchian et al.  
60.4% and the highest 79.5% whereas the lowest reported rates of uptake for women without 
previous attendance were reported by Tatla et al. and were 65.2% and the highest 68.8%. 
8.2.2.4 SES 
Three papers contributed data to the meta-analysis of SES and re-attendance (114, 167, 255). 
The sub-group meta-analysis showed no significant difference in the proportions re-attending 





Figure 90. Sub-group meta-analysis of SES data. 
Studies reporting SES as employment status are discussed here. Coyle et al. (114) found 
women who were professional or routine workers were most likely to attend screening 
regularly (28.2% and 39.2% respectively). Women least likely to attend were self-employed 
women (114). Euler-Chelpin et al. found women with secretarial or sales careers were most 
likely to attend all their appointments, 61% in Copenhagen and 79% in Funen (167). 
8.2.3 Discussion 
8.2.3.1 False positive 
No significant difference was found between women who did or who did not have a previous 
false positive result. This result may suggest that women are not deterred by a previous false 
positive result although the effect of a false positive result may depend on many different 
influencing factors. These may include psychosocial aspects such as the level of 
embarrassment or distress a women may feel about the process or structural factors such as 




may (wrongly) feel she got away with something last time (447). The type of recall assessment 
a woman experiences may be important as evidenced by Fitzpatrick et al. (269). Despite the 
difference in age groups, women who underwent tissue sampling, a less invasive procedure, 
had higher odds of re-attending than women undergoing an open biopsy and their odds of 
re-attending were found to be not statistically different from women who had a core biopsy 
(269). 
A large sample (n=5,009,466) of Korean women were used by Oh et al. and they found women 
with a previous false positive result were much less likely to attend BCS, OR 0.07 (0.07, 0.07) 
compared with women without a false positive result (298). However, other papers included 
in this review had much smaller sample sizes and their outcomes were varied. Only one other 
study found a negative influence on uptake of having a false positive result but a much smaller 
effect size, OR 0.82 (0.76, 0.89) (291). There were differences between study locations and 
screening policy. In Korea women were recommended to re-attend in less than three years 
(Korea’s national programme screens women every two years). All studies used retrospective 
databases to analyse uptake patterns except a study in America by Pinckney et al. who 
followed women prospectively through time to identify their re-attendance rate (251). 
Previous research has found mixed results (249, 294, 372, 373, 375, 447) in terms of a possible 
deterrent effect of previous false positive results. It appears that false positive results may 
affect women differently. Caution needs to be taken when interpreting the results as the 
review has included data from Oh et al. which may have been too heterogeneous clinically, 
in terms of the national screening programme, and therefore should have been analysed 
separately. 
8.2.3.2 Previous attendance 
This review adds to a body of literature that suggests that women who have previously 
attended mammography are more likely to attend again. All studies included found that 
women who had previously attended BCS had higher odds of re-attending than those who 
had previously not attended, OR 6.05 (1.44, 25.43). 
Two studies found extreme odds ratios of fifteen and twenty-four. However, both studies 
investigated UK data and the only difference was that one was a randomised trial and one 




Korean women, n=5,009,466 who are recommended to be screened more frequently than in 
the UK. The others investigated previous attendance as a predictor for women in Canada who 
are also screened biennially. 
8.2.3.3 SES 
No significant difference was found between SES groups and the odds of re-attendance. This 
is consistent with my systematic review findings for general uptake where no significant 
difference was found. The women were sampled from Northern Ireland, Denmark and 
Canada (114, 167, 255) and as such represent very different populations. These distinct 
populations likely experience different additional facilitators or barriers to attendance as well 
as other confounding factors associated with uptake of mammography. 
Despite this, the result is consistent with other work such as a previous meta-analysis, 
conducted in 2009, which found mixed yet predominantly positive associations between high 
SES and re-attendance and concluded that the association may be more complex than 
anticipated and warrants further research (448). Regardless, SES inequalities in cancer 
incidence still persist (449). 
Conclusions 
Data about re-screening attendance has provided statistically significant information about 
two key predictors for uptake of breast screening. Receiving a false positive result and 
previously attending mammography have been associated with increased odds of re-
attending future BCS. Additional information about socioeconomic status as a predictor of 
(re)uptake has been evaluated but no significant differences were found in the data available 
which matches the non-significant findings in the main review results.  
In the next chapter I will look at data from a London cohort to identify predictors of uptake in 




8.3 Secondary data study 
 




8.3.1 Ethical approvals 



















































“ Dear Rebecca, 
RE: IRAS 224318 - Confirmation of Capacity and Capability at St George’ University Hospitals NHS 
Foundation Trust 
Full Study Title: Patterns of Mammography attendance 
over time (PaMaT) 
Site PI/LC Dr Louise Wilkinson 
Current Protocol version: V3 16/10/2017 
Latest HRA Approval date: 16/10/2017 
 
This email confirms that St George’s University Hospitals NHS Foundation Trust has the capacity and 
capability to deliver the above referenced study. As per the HRA approval letter dated 16/10/2017, 
neither St. George’s nor Warwick University required the statement of activities or schedule of events 
in this instance. 
St George’s University Hospitals NHS Foundation Trust agrees to start this study on 23/10/2017.  
If you wish to discuss further, please do not hesitate to contact us and local team. 
Please note, in line with the national HRA approvals process, you will no longer receive a NHS R&D 
Approval/Permission letter.  
Kind regards, 
Siân Ellis 
Research Ethics Officer  
Joint Research and Enterprise Office  
St George's, University of London and St. George’s University Hospitals NHS Foundation Trust 
Cranmer Terrace, London, SW17 0RE  
 






8.3.2 Summary of data 
Episodes and appointments data that was inconsistently matched prior to 2000 which was 
subsequently removed from the analysis. 
 
Figure 92. Episodes data without appointments (n=345,301). This is data that matches episodes with women, however there 





8.3.3 Data linkage schematic 
 





8.3.4 Variable summaries 
Table 33. Number of observations within each separate database and the combined final database 
Variable Number in raw database Number in combined database 
Women 406,015 336,717 
Episodes 1,283,671 1,013,928 
Appointments 1,521,309 1,109,034 
 
Table 34. Variable summary table. This summary is for the raw, uncombined datasets. 
Name of Variable (original, 






























values A-Z and 2-9 
 Should match 
with episode and 
appointments 
data 





to link to other 
information 
  Should match 
with 
appointmentdata 
 0 Nothing 
AssociatedGpFullCode 
gpcode 
Registered GP AAA/GGGG    0 Nothing 
AgeAtFoa 
ageatfoa 
























Name of Variable (original, 






























DATE (jan 1991 
onwards) 
 This should be 
BEFORE 
dateapptmade 
1228380 55291 Nothing 
DateApptFirstMade 
dateapptmade 





DATE (jan 1991 
onwards) 
 This should be 
BEFORE dateclinic 




screen was the 
first screening or 
a routine recall 
CA = continued 
assessment 
CD = delayed 
treatment 
CF = follow-up after 
treatment 
CI = interval case 
CR = local recurrance 
F = first call 
G = GP referral 
H = higher risk 
N = non-routine recall 
R = routine recall  
S = self-referral 











R = 716964 
Values should 









episode was the 
incident or 
prevalent screen 
I = incident 
P = prevalent 
XI = xincident 













Name of Variable (original, 


























Is the episode 
(screening 
round) still 






 1283671 0 Nothing 
ReasonEpisodeClosed 
episodeclosed 
What was the 
reason for the 
episode closure. 
AR = randomised out 
BS = being screened 
CP = under care, perm 
CT = under care, temp 
DD = died 
DE = defaulted 
DU = further details 
unavailable 
FB = FPC closed, being 
sx 
FC = FPC closed, 
ceased 
FD = FPC closed, died 
FF = FPC closed, FP69 
FM = FPC closed, 
moved 
FP = FPC closed, prem 
FX = FPC closed, other 
HR =  
MV = moved away 
NA = non-attender 

























If DD or FD, 
woman should 
not be present in 
database again. 




Name of Variable (original, 
























NR = non-responder 
NS = attended not 
screened 
NT = no transport to 
unit 
OP = opted out, 
permanent 
OT = opted out, 
temporary 
R = routine closure 
RS = recently screened 









Did the woman 
attend the 
appointment? 
Y = attended an 
appointment in this 
episode 





 1283671 0 Nothing 
EpisodeAuthorityEndCode 
episodeendcode 
What was the 
reason for the 
closure of the 
appointment? 
BLANK if episode is 
open 
DNA = did not attend 
DNR = did not respond 
PC = premature 
closure  
SC = screening 
complete 
















Name of Variable (original, 
























WC = withdrawn – 
ceased 
WD = withdrawn – 
died 
WF = withdrawn – 
FP69 
WM = withdrawn – 
moved 
WO = withdrawn – 
other 








The series of 
events that 




commas, for example 
“S+,Aabn,H-” 
 
 Blank is not 
screened or 
episode is still 
open. 
S- = screen 
negative 
S+ = screen 
positive (and 
recalled) 
Sabn = screen 
abnormal 
W = core biopsy 
outcome (+-abn) 
C = fine needle 
cytology outcome 
(+-abn) 








Name of Variable (original, 




























Final action in 
episode 












 1283671 0 Nothing 
CancerRegistryCandidate 
cancerregistry 
Was the woman 

































































Name of Variable (original, 




























Which clinic did 
the woman 
attend? 
ZZ111 (variable)   1521309 0 Nothing 
DateOfClinic 
dateclinic 
On what date 
did the woman 
attend? 
DATE (Jan 1991 
onwards) 
 Should be after 
datefirstappt and 
dateapptmade 
1521309 0 Nothing 
Timeslot 
timeclinic 
At what time did 
the clinic run? 
0800 etc  Should be 
between 0815 
and 1945 





A = attended 
B = booked 
D = DNA - no notice 
given 















AW = adverse 
weather 
DE = declined 
EA = equipment 
availability 
HO = holiday 
















Name of Variable (original, 

























PP = postal problems 
RL =  
RS = recently screened 
SI = sickness 
ST = staffing issues 
TA = 
transport/accessibility 
UC =  
WC = work 
commitments 


















Date at which 
woman booked 
or cancelled the 
appointment 
DATE (Jan 1991 
onwards) 
  1521309 0 Nothing 
NotScreened 
notscreened 
Was the woman 
not screened 
Y (if attended but not 
screened) 
N (if screened) 













Qualitative data was 
entered 




Name of Variable (original, 




































Asian or Asian British 
– Bangladeshi 
Asian or Asian British 
– Indian 
Asian or Asian British 
– Pakistani 
Asian or Asian British 
– Other 
Black or Black British – 
African  
Black or Black British – 
Caribbean 
Black - Other 
Mixed – White and 
Asian 
Mixed – White and 
Black 
Mixed – White and 
Caribbean 
Mixed - Other 
Other ethnic groups - 
Chinese 
























This should not 
change over time 




Name of Variable (original, 
























White – Irish 

















   DELETE 
SpecialAppointmentIndicator 
specialappt 











 406015 0 Nothing 
SpecialAppointmentReasons 
specialreason 
What was the 

















Was the woman 
placed on the 
recall status list 
C = ceased 




If N, check woman 
is entered in three 
years? 
406014 1 Nothing 
YOB 
yob 






YOB should only 
be from 1918 
to  






Name of Variable (original, 






























Data used for 
IMD 
   406015 0 Nothing 
LSOAname 
lsoaname 
Date used for 
IMD 
   406015 0 Nothing 
IndexOfMultipleDeprivationRank 
imdrank 
Rank of IMD 1 
To  
32844 




provided for SES 
 
































Table 35. Additional variables used in the dataset 
Variable name What information does 
it provide 
Possible values Frequency of values Missing data? 








attendfirstapptepisode Attended at the first 







Changeattend (attend to not attend) Change in attendance 
(either used to attend 
and now didn’t or 
previously non-attender 






Changeattend (not attend to attend) Change in attendance 
(either used to attend 
and now didn’t or 
previously non-attender 






prevfalsepos Previoulsy had a false 














recalldna Recalled for assessment 






preveprecall Woman has previously 
been recalled for further 










Variable name What information does 
it provide 
Possible values Frequency of values Missing data? 
Immediateprevrecallepisode The episode before 







Attended appointment 1 
Did not attend appointment 1  
Attended appointment 2 
Did not attend appointment 2 
Attended appointment 3 
Did not attend appointment 3 
Attended appointment 4 
Did not attend appointment 4  
Attended appointment 5 
Did not attend appointment 5  
Attended appointment 6 
Did not attend appointment 6  
Attended appointment 7 
Did not attend appointment 7 
Attended appointment 8 
Did not attend appointment 8  
Attended appointment 9 
Did not attend appointment 9 
Attended appointment 10 
Did not attend appointment 10 
Attended appointment 11 
Did not attend appointment 11 
Attended appointment 12 












































































8.3.5 Descriptive statistics 
8.3.5.1 Number of appointments within each episode 
 





Figure 95. Distribution of women's ages for the entire dataset 
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Figure 96. Box plot showing distribution of age separated by attendance status 
Table 36. Number of women who did and did not attend sorted by age category 
Age category Number of 
women 




47-50 102598 58931 43667 57.44 
51-55 305668 177678 127990 58.13 
56-60 261952 154591 107361 59.02 
61-65 215831 126558 89273 58.64 
66-70 117986 75290 42696 63.81 
71-73 6872 4231 2641 61.57 
 






















Figure 98. Distribution of deprivation of all women included in the dataset. IMD=1 is most deprived, IMD=10 is least deprived, 
IMD=N/A is data missing 
Table 37. Raw number of women attending and not attending by IMD decile with attributed percentages 



















6355 0.70 4735 1.07 57.30 
2 49606 5.44 34641 7.81 58.88 
3 92407 6.85 41138 9.28 69.20 
4 91116 9.99 54291 12.24 62.66 
5 75555 8.29 40592 9.15 65.05 
6 106679 11.70 52250 11.78 67.12 
7 97707 10.72 46415 10.47 67.79 
8 124018 13.60 53395 12.04 69.90 
9 180306 19.78 71681 16.16 71.55 
10 (least 
deprived) 
116449 12.77 43368 9.78 72.86 







Figure 99. Box plot showing distribution of IMD separated by attendance status 
 
Figure 100. Number of episodes attended by SES group. 
 













































Table 38. Number and percent of missing ethnicity data per age group. 
Age group Number missing % missing (per age group) 
47-50 57842 38.76 
51-55 139817 31.89 
56-60 103225 27.61 
61-65 94445 31.24 
66-70 41640 24.93 
71-73 2382 22.94 




Figure 102. Distribution of all ethnicities reported in database 
 
Table 39. Number of women who did and did not attend by ethnicity 
Ethnicity Number in each 
group 




Missing 338272 60952 277320 18.02 
Asian – Other 21382 16118 5264 75.38 
Asian – 
Bangladeshi 
1900 1355 545 71.32 
Asian - Indian 26668 20751 5917 77.77 
Asian – Pakistani 8780 6088 2692 69.34 
Black – African 18851 13716 5135 72.76 
Black – Other 1803 1355 448 75.15 




Ethnicity Number in each 
group 




Mixed - Other 3122 2353 769 75.37 
Mixed – White 
and Asian 
3644 2771 873 76.04 
Mixed – White 
and Black African 
1838 1334 504 72.58 
Mixed – White 
and Black 
Caribbean 
3104 2403 701 77.42 
Not stated 52928 39052 13876 73.78 
Other – Other 6675 5050 1625 75.66 
Other – Chinese 8202 6482 1720 79.03 
White - Other 42132 31548 10584 74.88 
White – British 427186 350243 76943 81.99 







Figure 103. Number of episodes attended by ethnicity group. 
8.3.5.5 Special appointment 
 

































Agoraphobia 2 0 2 0 
Breast Implants 1264 848 416 67.09 
Learning difficulties, 
other 
1 1 0 100.00 
Learning difficulties, 
wheelchair user 
1 0 1 0 
Learning difficulties 1373 760 613 55.35 
Other, physical 
restriction 
8 4 4 50.00 
Other, registered 
disabled 
3 3 0 100.00 
Other, wheelchair 
user 
4 4 0 100.00 
Other 2034 1056 978 51.92 
Physical restriction, 
wheelchair user 
27 19 8 70.37 
Physical restriction 976 692 284 70.90 
Registered disabled 300 189 111 63.00 
Social reasons 30 8 22 26.60 
Wheelchair user 1642 1022 620 62.24 
N/A 1006263 594111 412152 59.04 
 
 





Figure 106. Number of episodes attended by special appointment reason group. 
 
8.2.3.6 Attendance by time (year) 
 



















Attendance by special appointment reason























Figure 108. Number of episodes attended by month. 
 



































Attendance by day of the week





Figure 110. Number of episodes attended by time of day categorise into morning or afternoon. 
 
8.3.6 Assumption testing 
 
 
Figure 111. Scatterplot to show association between age at first offered appointment and IMD decile where a value of 1=most 

















Attendance by time of day





Figure 112. Scatterplot to show association between age at first offered appointment and ethnicity. Ethnicity is defined as 
1=asian or asian British – other; 2=asian or asian British – Bangladeshi; 3=asian or asian British – Indian; 4=asian or asian 
British – Pakistani; 5=black or black British – African; 6=black or black British – other; 7=black or black British – Caribbean; 8= 
mixed – other; 9=mixed – white and asian; 10=mixed – white and black African; 11=mixed – white and black Caribbean; 
12=not stated; 13=other ethnic groups – other; 14=other ethnic groups – Chinese; 15=white – other; 16=white – British. 
 
Figure 113. Scatterplot between age at first offered appointment and reason needed for special appointment. Reasons are 
as follows: 1=agoraphobia; 2=implants; 3=learning difficulty, other; 4=learning difficulty, wheelchair user; 5=learning 
difficulty; 6=other, physical restriction; 7=other, registered disabled; 8=other, wheelchair user; 9=other; 10=physical 





Figure 114. Scatterplot to show association between ethnicity and reason for special appointment. Ethnicity is defined as 
1=asian or asian British – other; 2=asian or asian British – Bangladeshi; 3=asian or asian British – Indian; 4=asian or asian 
British – Pakistani; 5=black or black British – African; 6=black or black British – other; 7=black or black British – Caribbean; 8= 
mixed – other; 9=mixed – white and asian; 10=mixed – white and black African; 11=mixed – white and black Caribbean; 
12=not stated; 13=other ethnic groups – other; 14=other ethnic groups – Chinese; 15=white – other; 16=white – British. 
Reasons are as follows: 1=agoraphobia; 2=implants; 3=learning difficulty, other; 4=learning difficulty, wheelchair user; 
5=learning difficulty; 6=other, physical restriction; 7=other, registered disabled; 8=other, wheelchair user; 9=other; 
10=physical restriction, wheelchair user; 11=physical restriction; 12=registered disabled; 13=social reasons; 14=wheelchair 
user. 
 
Figure 115. Scatterplot to show association between IMD decile and ethnicity. For IMD, a value of 1=most deprived and 10= 
least deprived, 11=N/A or missing. Ethnicity is defined as 1=asian or asian British – other; 2=asian or asian British – 
Bangladeshi; 3=asian or asian British – Indian; 4=asian or asian British – Pakistani; 5=black or black British – African; 6=black 
or black British – other; 7=black or black British – Caribbean; 8= mixed – other; 9=mixed – white and asian; 10=mixed – white 
and black African; 11=mixed – white and black Caribbean; 12=not stated; 13=other ethnic groups – other; 14=other ethnic 





Figure 116. Scatterplot to show association between IMD decile and reason for special appointment. For IMD, a value of 
1=most deprived and 10= least deprived, 11=N/A or missing. Reasons are as follows: 1=agoraphobia; 2=implants; 3=learning 
difficulty, other; 4=learning difficulty, wheelchair user; 5=learning difficulty; 6=other, physical restriction; 7=other, registered 
disabled; 8=other, wheelchair user; 9=other; 10=physical restriction, wheelchair user; 11=physical restriction; 12=registered 
disabled; 13=social reasons; 14=wheelchair user. 
Predicting ethnicity missingness 
 
Figure 117. Predicting ethnicity missingness. These three were significantly associated with missing ethnicity data. 
As age increased, the odds of ethnicity data being missing decreased by 11% compared with 
younger women, OR 0.89 (0.88, 0.89), p<0.001. If a woman required a special appointment 




missing decreased by 31%, OR 0.69 (0.66, 0.71), p<0.001. The odds of having missing ethnicity 
data were 46% lower in women with low SES (IMD=1) compared with women of high SES 
(IMD=10), OR 0.56 (0.54, 0.59), p<0.0001.  
 
Predicting IMD missingness 
 
Figure 118. Predicting IMD missingness. These variables were significantly associated with missing IMD data 
As age group increased the likelihood of SES data being missing decreased by 26%, OR 0.74 
(0.64, 0.87), p<0.001. Compared with White women the odds of Indian women having missing 
SES data were 80% lower, OR 0.20 (0.07, 0.53), the odds of Black women having missing data 
were 278% higher, OR 2.78 (1.04, 7.47), and Mixed ethnicity women were 461% more likely 
to have missing data when compared with White women, OR 4.61 (2.52, 8.41) all p<0.001. 
Women requiring a special appointment were not significantly more likely to have SES data 




8.3.7 Multilevel modelling 
 
Figure 119. Odd ratios of socioeconomic status is shown to be a linear effect. However, the odds ratios in table format do not 
appear as linear and consequently SES was kept in the model as a categorical variable. This is most appropriate as IMD does 
not linearly increase or decrease in deprivation anyway. 
 




Using specialreason rather than specialappt gave all non-significant results whereas specialappt on its 
own was significant. 
8.3.7.1 Associations of attendance at any episode 
Table 40. Summary of multilevel model output 
 
 
Figure 121. Cross tabulation of age and ethnicity groups. 
Final model for research question one: melogit attendedonce i.agecategorical i1.specialappt 

















8.3.7.2 Associations of attendance at first episode 
 
 
Figure 123. Cross tabulation of year and attendance at the first appointment within an episode 
 















8.3.7.3 Have influences of attendance changed over time? 
Attended first episode 
Melogit attendedonce c.year || nhscryptic: , or 
 
Figure 126. Year is a significant predictor of attendance 
 
8.4 Questionnaire Study 
This questionnaire has been based on the IBIS risk prediction model. A screenshot of the user 





Figure 127. Screenshot of IBIS risk predictor model 






PARTICIPANT INFORMATION LEAFLET 
Study Title: A questionnaire development study to investigate predictors of uptake of mammography 




We would really value your help in developing this questionnaire. We believe the information 
we will gather as a result of using this questionnaire in practice in the future will enable us 
to improve the understanding of uptake and participation at breast screening, benefitting 
potentially millions of women in the UK. Before you decide whether to take part, you need 




time to read the following information carefully. Feel free to talk to others about the study if 
you wish to discuss any concerns you may have. 
 
Part 1 below tells you more about me, the purpose of the study and what will happen to you 
if you take part. Part 2 gives you more detailed information about the official conduct of the 
study. 
 
Please feel free to ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
PART 1 
Who is organising the study? 
 
My name is Rebecca Crosby. I am a third year PhD student at the University of Warwick. My research 
is investigating factors that may be influencing participation in the breast screening programme. 
My work is funded by a studentship from the NIHR CLAHRC West Midlands initiative. This study will 
contribute to my doctoral qualification in health sciences from Warwick Medical School which I aim 
to finish in September 2018.  
 
What is the study about? 
 
I am developing a questionnaire for future use.  
 
The questionnaire will ask about some of your personal characteristics and some 
background information about your medical history. The questionnaire will also ask about 
your attitude about breast screening and behaviour, such as whether you have been 
screened before. These questions are asked to assess different factors that may influence 
participation at breast screening. These questions may seem very detailed and you may be 
wondering why we need so much information about your family medical background. The 
reason is that one of our ideas is that a woman’s decision to participate in breast screening 
may be affected by her own perceived risk of breast cancer. Anecdotally, we know that 
some women may feel that their own risk of breast cancer may be affected by factors such 
as bodyweight, age of first period, time spent breastfeeding and having female family 
members who have had had cancer etc. Ultimately, we hope information gathered by this 
questionnaire will identify what factors are influencing or deterring women to attend 
mammography. Currently, there is very contradictory evidence which suggests that women 
who perceive their own risk as higher, may be either less likely or more likely to attend 
screening. With better evidence of how women’s own perceived risk affects their decision 
to participate in screening, we hope to be able to target and communicate to women more 





The questionnaire is still being developed and we need to know women’s thoughts on it 
before sending it out as a larger research project. This is where we have asked you for your 
help. 
 
What will happen to the results of the study? 
 
 
Developing this questionnaire is a very important part of my research design as it will improve the 
quality of the final questionnaire used in any future research which rolls-out the questionnaire to 
thousands of women in order to assess factors influencing uptake of breast screening. 
It is vital for us to accurately establish the factors that may influence participation in breast 
screening. We aim to use this information to help reshape the breast screening programme, which 
may result in a better, more personalised approach to targeting and inviting women to breast 
screening. We hope that this will lead to a reduction health inequalities amongst underprivileged 
women 
 
We will present the research findings at relevant conferences and breast screening meetings at 
hospitals responsible for BCS services. Results will be published in appropriate academic journals in 
a timely manner. Any discussion about the development will not include who participated in the 
development process so your participation will be kept confidential. 
If you desire, as part of the development team, you will be sent a copy of the results and outcomes 
of both the development and the final questionnaire at the end of the relevant study phase. 
 
Why should I take part? 
 
It is entirely up to you to decide but we would really value your input and contribution into 
the development of this questionnaire in such an important area of women’s health.  With 
your help, we can make sure the final questionnaire used with potentially thousands of 
women is as good as it possibly can be, giving us the best quality evidence for future 










We will describe the process and go through this information sheet, which we will give you 
to keep. If you choose to participate, we will ask you to sign a consent form to confirm that 
you have agreed to take part. You will be free to withdraw at any time, without giving a 
reason and this will not affect you or your circumstances in any way. 
 
I will give you a copy of the questionnaire for you to complete. However, rather than 
completing this on your own I will ask you to complete something called a ‘cognitive 
interview’. This is simply you answering the questionnaire whilst thinking aloud and 
explaining to me what each question means to you as you read it. I will also ask you to 
explain your thinking about why you are choosing each answer. There are no right or wrong 
answers at this stage and all the information is useful. This should take no longer than 30 
minutes. 
 
At the end of the questionnaire I will ask you one more question ‘is there anything else you 
would like to add about the questionnaire’. This is an opportunity for you to give me any 
more information that might be useful or to point out something I have missed from the 
questionnaire. 
 
We anticipate the whole process (reading the participant information sheet, consenting and 
conducting the cognitive interview) will take approximately one hour of your time. 
 
What are the possible disadvantages of taking part in this study? 
 
Helping with the development of this questionnaire may be uncomfortable for you if you have had 
any negative experiences with the breast health of yourself or someone close to you or you may 
have had a negative breast screening experience in the past. There is no obligation for you to 
complete this questionnaire and you may stop at any time without any issues. 
 
If I witness you becoming distressed at any time I will stop the interview and give you information 
about where you can access help or information about something that is troubling you. 
 









We are asking you to participate in research that will hopefully be used to improve the breast 
screening programme in the future. You are helping to improve my research to ensure the 
questionnaire is useful and gives the best quality information. This may benefit thousands of women 
involved in the breast screening programme in the future. If you want, you will be provided the 
results of the study to keep up to date with what is happening. 
 
Expenses and payments 
 
Unfortunately we are not able to fund any expenses or payments for the completion of this 
cognitive interview. Instead, the cognitive interview will be conducted at a time and place 
convenient for yourself. 
 
 
This concludes Part 1. 
If the information in Part 1 has interested you and you are considering participation, 





What will happen if I change my mind later about being part of the study? 
 
Your participation in this study is entirely voluntary. Any decision you make either now or at any 
point in the future to not participate will not affect you in any way. If you decide to take part in the 
study, we will ask you to sign a consent form, which states that you have given your consent to 
participate. 
 
If you agree to participate, you have the right to withdraw from the study at any time and decline 
any further contact by study staff without affecting you in any way. 
 
Your medical care and invitation to future breast screening appointments will not be affected as 
your involvement in this research is completely confidential. The care you are entitled to will not 
change as a result of participation or non-participation in this research.  
 





This study is covered by the University of Warwick’s insurance and indemnity cover.  If you have an 
issue, please contact the Chief Investigator of the study:  
 
Aileen Clarke, 
Warwick Medical School, 





Telephone: 02476 150189 
 
Who should I contact if I wish to make a complaint? 
 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might have suffered will be fully investigated and addressed.  Please address your complaint to the 
person below, who is a senior University of Warwick official entirely independent of this study: 
   
Head of Research Governance 
Research & Impact Services 
University House 
University of Warwick 
Coventry 
CV4 8UW 
Tel: 024 76 522746 
Email:  researchgovernance@warwick.ac.uk 
 
Will my taking part be kept confidential? 
 
Yes. We will follow strict ethical and legal practice and all information about you will be handled in 
confidence. Data and the informed consent forms will be stored as password protected files on 




returned questionnaires will also be stored for ten years in a locked filing cabinet in a secure office 
that only the research team has access to as per the University of Warwick guidelines. 
All questionnaires and interviews will be completed confidentially.  
 
Who has reviewed the study? 
 
This study has been reviewed and given favourable opinion by the University of Warwick’s 
Biomedical and Scientific Research Ethics Committee (BSREC): REGO-2017-2118. Approval was 
granted on the 3rd January 2018.   
 
What if I want more information about the study? 
 
If you have any questions about any aspect of the study, or your participation in it, not answered 







Warwick Medical School, 





Telephone: 02476 574785 
 
 
Chief Investigator and Academic Supervisor 
 
Aileen Clarke 









Telephone: 02476 150189 
 
 







8.4.2 Questionnaire (original) 
A. Personal risk of breast cancer 
In this section the questions asked are specific to your medical history. Please answer as carefully 
and accurately as you can so your personal risk of breast cancer can be calculated. 
1. How tall are you without shoes? (metric or imperial) ______________ 
 
2. How much do you weigh unclothed? (metric or imperial) ____________ 
 
3. Have you given birth? (please circle) 
a. Yes (please continue) 
b. No (please go to question 6) 
 
4. How old were you at the first birth? _________________ (years) 
 
5. How old were you when you started your first period? __________ (years) 
 
6. Are you still having regular periods? (please circle) 




b. No (please continue) 
 
7. Have your periods completely stopped? (please circle) 
a. Yes (please continue) 
b. No (please go to question 14) 
 
8. How old were you when you went through the menopause? ____________ (years) 
 
9. Have you ever used hormone replacement therapy (HRT)? 
a. Yes (please continue) 
b. No (please go to question 14) 
 
10. When did you use HRT? (please circle) 
a. 5 or more years ago 
b. Less than 5 years ago 
c. Current user 
 
11. How long did you use HRT for in total? __________ years 
 
12. Have you been previously diagnosed with a breast disease? (please circle) 
a. Yes (please continue) 
b. No (please go to question 8) 
 
13. What have you been diagnosed with? (please tick all that apply) 
a. Prior biopsy conducted, result unknown 
b. Hyperplasia (not atypia) 
c. Atypical hyperplasia) 
d. Lobular carcinoma in situ (LCIS) 
e. Ovarian cancer 
 
14. Have any relatives been diagnosed with ovarian cancer? 
a. Yes (please continue) 





15. If you answered yes, please complete the table below identifying which relatives were 
diagnosed with ovarian cancer and at what age? (please complete for all relatives that this applies) 
Family Member  Diagnosed with 
Ovarian cancer? 
(yes/no) 
At what age?  
(years) 
Mother   
Sister(s) 









Paternal Grandmother   
Maternal Grandmother   
Paternal aunt(s) 

















For the below relatives please provide detail on your family linkage. For example a cousin could be 
described as “paternal cousin”.  
Half-sister(s) 














16. Have any relatives been diagnosed with breast cancer? 
a. Yes (please continue) 





17. If you answered yes, please complete the table below identifying which relatives were 
diagnosed with breast cancer, at what age and if this cancer was present in both breasts 
(bilateral)? (please complete for all relatives that this applies) 
Family Member Diagnosed with 
Breast Cancer? 
At what age? Was this 
bilateral breast 
cancer? 
Mother    
Sister(s) 









Paternal Grandmother    
Maternal Grandmother    
Paternal aunt(s) 




   
Maternal aunt(s) 




   
Daughter(s) 




   
For the below relatives please provide detail on your family linkage. For 
example a cousin could be described as “paternal cousin”.  
 
Half sister(s) 
Please use a new line for 
each half sister 
   
Affected cousin(s) 
Please use a new line for 
each cousin 
 
   
Affected niece(s) 
Please use a new line for 
each niece 
 
   
 





a. Yes (please continue) 
b. No (please go to question 20) 
c. Don’t know 
 
19. If you know the results, please indicate below.  
Family Member Negative result BRCA1 positive BRCA2 positive 
Individual (you)    
Father    
Mother    
Sister(s) 
Please use a new line for each 
sister 
 
   
Daughter(s) 
Please use a new line for each 
daughter 
 
   
Paternal Grandmother    
Maternal Grandmother    
Paternal aunt    
Maternal aunt    
 
B. Informed Choice 
The questions asked in this section are based on research conducted in Sydney, Australia by Mathieu 
and colleagues. 
Knowledge  
This part of the questionnaire is asking about your knowledge about breast screening. You will not 
be judged by right or wrong answers and your healthcare will not be affected. 
1. What is screening used for? (please circle) 
a. To test what is wrong with unhealthy people 
b. To find illnesses in currently healthy people 
c. To determine who deserves treatment and who does not 
d. Don’t know 
 
2. What is a screening mammogram? (please circle) 
a. Detects if cancer is present in those who have a lump in their breast 
b. Checks for signs of breast cancer in healthy women 





3. Does every woman with a ‘positive’ mammogram result have breast cancer? (please circle) 
a. Yes 
b. No 
c. Don’t know 
 
4. What does it mean if a woman receives a ‘negative’ mammogram result? (please circle) 
a. She will not get cancer in the future 
b. The mammogram did not work 
c. She does not have cancer that can be detected at the moment 
d. Don’t know 
 
5. Which groups have the highest rates of breast cancer detected? (please circle) 
a. Women who attend screening 
b. Women who do not attend screening 
c. Don’t know 
 
6. Some women are diagnosed with a cancer that never would have caused her harm. How 





e. Other _________ (please specify) 
f. Don’t know 
 
7. Are there negative consequences of breast screening? 
a. Yes 
b. No 
c. Don’t know 
 
8. Out of 100 women aged 50 or over who are invited to screening in the UK each year, how 











h. Other _____________ (please specify) 
i. Don’t know 
 
9. Is breast screening compulsory? (please circle) 
a. Yes  
b. No 
c. Don’t know 
Attitudes 
Your thoughts about the screening test will be measured now.  
For the following statements below please circle a number from 1 to 5 on the scale that best describes 
how you feel at the moment. Please read the scale for each question. 
For example in question 1(a) if you thought having the screening test would be very useful, you would 
circle 1. If you thought it was a worthless thing you would circle 5. If you did not have a strong opinion 
either way you would circle 3. 
 
1. For me, having a mammogram for breast cancer will be: 
Useful 1 2 3 4 5 Worthless 
Beneficial 1 2 3 4 5 Harmful 
Essential 1 2 3 4 5 Inappropriate 
Good thing 1 2 3 4 5 Bad thing 
Not 
embarrassing 
1 2 3 4 5 Embarrassing 






1 2 3 4 5 Something I 
have to do 
 
2. Please only complete this question if you have attended a mammogram appointment 
before.  
 
For me, when I receive a mammogram I feel: 
 
Comfortable 1 2 3 4 5 Uncomfortable 
No pain 1 2 3 4 5 Pain  
Healthy 1 2 3 4 5 Unhealthy 
Not 
embarrassed 
1 2 3 4 5 Embarrassed 
  
 




1 2 3 4 5 6 7 Very likely 
 




1 2 3 4 5 6 7 Very likely 
 
Behaviour 













This section will be asking some questions about you. This is so that we can recognise which group of 
the population you belong to. Remember this questionnaire is anonymous and your answers cannot 
be linked back to you so please be as accurate as you can. 
1. What is your date of birth? __ __ / __ __ / __ __ __ __ (DD/MM/YYYY)  
 
2. What is your postcode? __ __ __ __    __ __ __ 
 
3. How would you describe your ethnicity? (please circle) 
a. White British 
b. White Other 
c. White and Black Caribbean 
d. White and Black African 
e. White and Asian 





k. Asian other (please specify) _____________ 
l. African 
m. Caribbean 
n. Black other (please specify) _____________ 
o. Other (please specify) _________________ 
 
4. How would you describe yourself?  (please circle) 
a. Single 
b. Cohabiting with partner 




5. In which of these ways does your household occupy your accommodation? (please circle) 
a. Owned 




c. Pay part rent part mortgage (shared ownership) 
d. Rent it 




6. What is the highest level of education you have completed? (please circle) 
a. University or college equivalent 
b. Intermediate between secondary level and university (e.g. technical training) 
c. Secondary school 
d. Primary school only (or less) 
 
7. Which of these descriptions applies to you for the last seven days? (please circle) 
a. In paid employment or self-employed 
b. Permanently unable to work due to long-term sickness or disability 
c. Retired 
d. Looking after home and/or family 
e. Never had work or been employed 
f. Other (please specify) _____________________ 
If you circled answer (e) please proceed to question 7. 
8. How would you describe your last employment role? (please circle) 
a. Managerial and professional occupations 
b. Intermediate occupations 
c. Small employers and own account workers 
d. Lower supervisory and technical occupations 
e. Semi-routine and routine occupations 
f. Other (please specify) ______________________ 
g. Unknown  
 
9. How much does your household take home each year? (please circle) 
a. Up to £15,000 
b. £15,001 to £25,000 
c. £25,001 to £35,000 




e. £45,001 to £55,000 
f. More than £55,001 
g. Prefer not to say 
h. Unknown 
 
10. Do you consider to have any conditions or illnesses that affect you? (please circle) 
a. Yes (please continue) 
b. No (please go to question 12) 
 
11. Do any of your conditions or illnesses affect you in the any of the following areas (please tick all 
that apply) 
a. Vision (for example blindness or partial sight)  
b. Hearing (for example deafness or partial hearing) 
c. Mobility (for example walking short distances or climbing stairs) 
d. Dexterity (for example lifting and carrying objects or using a computer) 
e. Learning or understanding or concentrating 
f. Memory  
g. Mental health (for example depression, schizophrenia or anxiety) 
h. Stamina or breathing or fatigue 
i. Socially or behaviourally (for example autism, attention deficit disorder or 
Asperger’s syndrome) 
j. Other (please specify) _________________ 
k. Would prefer not to say 
 
8.4.3 Questionnaire (post PPI) 
Thank you for agreeing to participate in this questionnaire study. The following questions will ask a 
number of detailed questions about your and your family’s medical history. 
These questions are asked to assess different factors that may influence participation at breast 
screening. These questions may seem very detailed and you may be wondering why we need so much 
information about your family medical background. The reason is that one of our ideas is that a 
woman’s decision to participate in breast screening may be affected by her own perceived risk of 




may be affected by factors such as bodyweight, age of first period, giving birth and having female 
family members who have had had cancer. Hence, we ask a number of detailed questions in these 
areas. Not everything that we ask are about risk factors of cancer.  
Your answers are anonymous and will be kept confidential. Your answers will be used in the future 
research that may influence the breast screening programme. We appreciate you helping with our 
research and would like to thank you in advance for your time taken to complete this questionnaire. 
Medical factors that may influence uptake 
In this section the questions asked are specific to your medical history. Some, but not all, are risk 
factors associated with cancer. Please answer as carefully and accurately as you can. However, if you 
do not know exactly, please estimate where you can. 
1. How tall are you without shoes? ______________cm or _____ft______inches 
 
2. How much do you weigh unclothed? ______kg or _____stone ____pounds 
 
3. Have you given birth? (please tick one answer) 
a. Yes (please continue)  
b. No (please go to question 5) 
 
4. How old were you at the birth of your first child? _________________ (years) 
 
5. How old were you when your first period started? ________________ (years) 
 
6. When was your last period (i.e. no monthly bleeding)? (please tick one answer) 
a. Last month (please go to question 11) 
b. Up to six months ago 
c. Six months to one year ago 
d. 1 year ago 
e. 1-2 years ago 
f. 2-5 years ago 
g. More than 5 years ago 
h. Don’t know 
 
7. How old were you when you started to go through the menopause? 





8. Have you ever used hormone replacement therapy (HRT)? (please tick one answer) 
a. Yes (please continue) 
b. No (please go to question 11) 
 
9. When did you last use hormone replacement therapy? (please tick one answer) 
a. 5 or more years ago 
b. Within the last five years 
c. I am a current user 
 
10. How long did you use hormone replacement therapy for in total? ___________ years 
 
11. Have you previously been diagnosed with any of the following? (please tick all that apply) 
a. Prior biopsy conducted, result unknown 
b. Hyperplasia (not atypical) 
c. Atypical hyperplasia 
d. Lobular carcinoma in situ (LCIS) 
e. Breast cancer 
f. Ductal carcinoma in situ (DCIS) 
g. No 
For this questionnaire, we’re only interested in blood relatives (not people related to you by marriage). 
We are also only interested in the medical history of your female relatives. 
12. Have any blood relatives been diagnosed with breast cancer? (please tick one answer) 
c. Yes (please continue)  
d. No (please go to question 14)  
 
13. If you answered yes, we need some more specific information about how the relative with a 
breast cancer diagnosis is related to you. Please complete the table below to your best ability 
identifying which relatives were diagnosed with breast cancer, at what age and if this cancer 
was present in both breasts (bilateral)? It would be really useful to be as accurate as you can. 




estimate her decade for instance if she was about 53 years old you would enter 50 years, if 
she was about 58 you would enter 60 years. (please complete for all relatives that this applies) 
 
Family Member Diagnosed with 
Breast Cancer? 
(yes/no) 
At what age? (years) Was this 
bilateral breast 
cancer? (yes/no) 
Mother    
Sister(s) 











   
Maternal Grandmother 
(mother’s mother) 
   
Paternal aunt(s) (father’s 
sister) 




   
Maternal aunt(s) (mother’s 
sister) 




   
Daughter(s) 




   
For the below relatives please provide detail on your family linkage.   
Please use a new line for 





   
Please use a new line for 









Please use a new line for 





   
 
14. Have you or anyone in your family been genetically tested for BRCA1 or BRCA2 genes? (please 
tick one answer) 
a. Yes (please continue)  
b. No (please go to question 16) 
c. Don’t know (please go to question 16) 
 
 
15. If you know the results, please indicate them below. Please remember, we are only 
interested in your blood relatives. 
Family Member Negative result BRCA1 positive BRCA2 positive 
Individual (you)    
Father    
Mother    
Sister(s) 
Please use a new line for each 
sister 
 
   
Daughter(s) 
Please use a new line for each 
daughter 
 
   
Paternal Grandmother (father’s 
mother) 
   
Maternal Grandmother 
(mother’s mother) 
   
Paternal aunt (father’s sister)    
Maternal aunt (mother’s sister)    
 
16. Have any relatives been diagnosed with ovarian cancer? (please tick one answer) 
a. Yes (please continue) 




17. If you answered yes, we need some more specific information about how the diagnosis is 




were diagnosed with ovarian cancer and at what age? It would be really useful to be as 
accurate as you can. However if you cannot remember how old your family member was at 
diagnosis please estimate her decade for instance if she was about 53 years old you would 
enter 50 years, if she was about 58 you would enter 60 years. (please complete for all relatives that this 
applies) 
 
For this questionnaire, we’re only interested in blood relatives (not people related to you by 
marriage). 
Family Member  Diagnosed with 
Ovarian cancer? 
(yes/no) 
At what age?  
(years) 
Mother   
Sister(s) 









Paternal Grandmother (your 
fathers mother) 
  









Maternal aunt(s) (your mothers 
sister) 











For the below relatives please provide detail on your family linkage.  

























Knowledge, attitudes and behaviour  
The questions asked in this section are based on previous research which indicates that a woman’s   
knowledge, attitudes and behaviour towards screening may be factors that could influence 
participation in screening. Please remember we are not testing you and your answers will not affect 
any healthcare you are receiving. 
This part of the questionnaire is asking about your background knowledge and perceptions about 
breast screening. You will not be judged by right or wrong answers. 
To help you complete the next part of the questionnaire, a ‘mammogram’ is the term used for the x-
ray taken during the breast screening appointment. 
18. What do you think screening is used for? (please tick one answer) 
d. To test what is wrong with unhealthy people 
e. To find illnesses in currently healthy people 
f. To determine who deserves treatment and who does not 
g. Don’t know 
 
19. What do you think a screening mammogram is for? (please tick one answer) 
a. Detects if cancer is present in those who have a lump in their breast 
b. Checks for signs of breast cancer in healthy women 
c. Don’t know 
  
20. Do you believe every woman with a ‘positive’ mammogram result has breast cancer? (please 
tick one answer) 
a. Yes 
b. No 





21. What do you think it means if a woman receives a ‘negative’ mammogram result? (please tick 
one answer)  
a. She will not get cancer in the future 
b. The mammogram did not work 
c. She does not have cancer that can be detected at the moment 
d. Don’t know 
 
22. Which groups do you believe have the highest rates of breast cancer detection? (please tick one 
answer) 
a. Women who attend screening 
b. Women who do not attend screening 
c. Don’t know 
 
23. Some women are diagnosed with a cancer that never would have caused her harm. How 





e. Other _________ (please specify) 
f. Don’t know 
 
 
24. Do you think there are negative consequences of breast screening? (please tick one answer) 
a. Yes 
b. No 
c. Don’t know 
 
25. Out of 100 women aged 50 or over who are invited to screening in the UK each year, how 
many people do you think are told they need more tests and later find out they do not have 









f. More than 10 
g. Don’t know 
 
26. Do you think breast screening is compulsory? (please tick one answer) 
a. Yes  
b. No 










We will now ask a number of questions to capture your thoughts about the mammogram and the 
experience. 
For the following statements below please circle a number from 1 to 5 on the scale that best describes 
how you feel at the moment. Please read the scale for each question. 
For example in the first part if you thought having the screening test would be very useful, you would 
circle 5. If you thought it was a worthless thing you would circle 1. If you did not have a strong opinion 
either way you would circle 3. 
 
27. Even if you have not had a mammogram before please answer how you feel about the idea 
of having one.  
For me, having a mammogram for breast cancer will be: 
Worthless 1 2 3 4 5 Useful 
Harmful to 
health 





Not necessary 1 2 3 4 5 Essential 
Will be a bad 
thing 
1 2 3 4 5 Will be a good 
thing 
Embarrassing 1 2 3 4 5 Not embarrassing 
Difficult 1 2 3 4 5 Easy 
Something I 
feel I have to 
do 
1 2 3 4 5 I’d be willing to 
go 
 
28. Have you ever had a mammogram? (please tick one answer) 
c. Yes 
d. No (please go to question 32) 
 
29.  Have you attended a previous breast screening appointment within the last three years? 




30. Have you ever done the following? (please tick all that apply) 
a. Delayed or re-scheduled a breast screening appointment 
b. Permanently withdrawn from the breast screening programme 
c. Other (please specify) 
______________________________________________________ 
d. None of the above 
 
31. Please only complete this question if you have attended a mammogram appointment 
before.  
 
For me, when I receive a mammogram I feel: 
 
Uncomfortable 1 2 3 4 5 Comfortable 
Pain 1 2 3 4 5 No pain 




Shy 1 2 3 4 5 Not shy 
  




1 2 3 4 5 6 7 Very likely 
 











This section will be asking some questions about you. This is so that we can recognise which group of 
the population you belong to. Remember this questionnaire is anonymous and your answers cannot 
be linked back to you in any way so please be as accurate as you can. 
34. What is your date of birth? __ __ / __ __ / __ __ __ __  (DD/MM/YYYY)  
 
35. What is your postcode? __ __ __ __    __ __ __ 
 
36. How would you describe your ethnicity? (please tick one answer) 
l. White British 
m. White Other 
n. White and Black Caribbean 
o. White and Black African 
p. White and Asian 








v. Asian other (please specify) _____________ 
w. African 
x. Caribbean 
y. Black other (please specify) _____________ 
z. Other (please specify) _________________ 
 
37. How would you describe yourself?  (please tick one answer) 
a. Single 
b. Cohabiting with partner 
c. Married or civil partnered 
d. Divorced 
e. Widowed 
38. Your household is defined as anyone you live with and share a joint budget. In which of 
these ways do you or your household occupy your accommodation? (please tick one answer) 
a. Own outright 
b. Bought with a mortgage or loan 
c. Pay part rent part mortgage (shared ownership)  
d. Renting 
e. Living rent free 
f. Squatting 
g. Homeless 
h. Contribute to expenses in someone else’s house  
(For example living in parent’s or friend’s house) 
 
39. What is the highest level of education you have completed? (please tick one answer) 
a. University 
b. Intermediate between secondary level and university  
(e.g. technical training or college) 
c. Secondary school 
d. Primary school only (or less) 
 
40. Which of these descriptions applies to you for the last seven days? (please circle) 




b. Permanently unable to work due to long-term  
sickness or disability 
c. Retired 
d. Looking after home and/or family 
e. Never had work or been employed (please go to question 42) 





If you circled answer (e) please proceed to question 42. 
41. Which option best describes your last employment role? (please tick one answer) 
a. Self-employed 
b. Salaried employment 
c. Zero hour contract work 
d. Short term contract work 
e. Other (please specify) ______________________ 
 
42. How much does your household take home each year? Your household is defined as anyone 





43. Do you consider yourself as having any conditions or illnesses that affect you? (please tick one 
answer) 
a. Up to £15,000  
b. £15,001 to £25,000  
c. £25,001 to £35,000  
d. £35,001 to £45,000  
e. £45,001 to £55,000  
f. More than £55,001  
g. Prefer not to say  





a. Yes (please continue to question 44) 





44. Do any of your conditions or illnesses affect you in any of the following areas? (please tick all that 
apply) 
a. Vision (for example blindness or partial sight)   
b. Hearing (for example deafness or partial hearing)  
c. Mobility (for example walking short distances or climbing stairs)  
d. Dexterity (for example lifting and carrying objects or using a computer)  
e. Learning or understanding or concentrating  
f. Memory   
g. Mental health (for example depression, schizophrenia or anxiety)  
h. Stamina or breathing or fatigue  
i. Socially or behaviourally (for example autism, attention deficit disorder or 
Asperger’s syndrome) 
 
j. Other (please specify) _________________  





















Thank you for taking the time to complete 
this questionnaire and send it back to us, it is 
really appreciated and your answers will be 


















8.4.5 Final draft questionnaire 
Predictors of Attendance. A questionnaire development study. 
Thank you for agreeing to participate in this study. It should take you no more than 15 
minutes. 
Your answers will be kept confidential. Your answers will be used in future research. The 
results of this research may influence the breast screening programme. We appreciate you 
helping with our research and would like to thank you in advance for your time taken to 
complete this questionnaire. 
The following questions will ask about your and your family’s medical history to assess factors 
that may influence participation at breast screening. Not everything we ask is about risk 
factors of cancer. They are designed to identify factors that might influence participation at 
breast screening 
Medical factors that may influence uptake 
In this section the questions asked are specific to your medical history. Some, but not all, are 
risk factors associated with cancer. Please answer as carefully and accurately as you can. If 
you do not know exactly, please estimate where you can. 
 
1. How tall are you without shoes? ______________cm or _____ft______inches 
 
2. How much do you weigh unclothed? ______kg or _____stone ____pounds 
 
3. Have you given birth? (please tick one answer) 
a. Yes (please go to question 4)  
b. No (please go to question 5) 
 
4. How old were you at the birth of your first child (or twins)? ______________ (years) 
 







6. When was your last period (i.e. monthly bleeding)? (please tick one answer) 
a. Last month (please go to question 13) 
b. One to five months ago 
c. Six months to one year ago 
d. 1-2 years ago 
e. 3-5 years ago 
f. More than 5 years ago 
g. Don’t know 
 
7. Was this monthly bleed hormone induced (i.e. because you take hormone replacement 
therapy)? 
a. Yes 
b. No  
 
8. How old were you when you started to go through the menopause? Menopause is 
defined as when there has been no menstrual periods for 12 months consecutively and 
no other cause is identified.                                           
_______________________ (years) 
 
9. Would you describe yourself as peri-menopausal? This is defined as a time where you 
experience menopause-like symptoms but have had a menstrual period within the last 
12 months. 
a. Yes  
b. No  
 
10. Have you ever used hormone replacement therapy (HRT)? (please tick one answer) 
a. Yes (please go to question 11) 
b. No (please go to question 13) 






11. When did you last use hormone replacement therapy? (please tick one answer) 
a. 5 or more years ago 
b. Within the last five years 
c. I am a current user 
 
12. How long did you use hormone replacement therapy for in total?  
a. 1-2 months 
b. 3-6 months 
c. 7-12 months 
d. 1 year 
e. 2 years 
f. 3 years 
g. 4 years 
h. 5+ years 
 
13. Have you previously been diagnosed with any of the following? (please tick all that apply) 
a. Prior breast biopsy conducted, result unknown 
b. Hyperplasia (not atypical) (an increase in number of cells in the breast, it can occur naturally 
and is not cancer) 
c. Atypical hyperplasia (the cells in the breast increase in number and also develop in an 
unusual pattern or shape) 
d. Lobular carcinoma in situ (LCIS) (an area of abnormal cell growth that increases a person’s 
risk of developing invasive breast cancer later in life) 
e. Breast cancer  
f. Ductal carcinoma in situ (DCIS) (the cells in the lining of the duct of the breast tissue have 
started to turn into cancer cells. These cells have not started to spread into the surrounding 
breast tissue) 




For this questionnaire, we are only interested in blood relatives (not people related to you by 
marriage). 
14. Have any blood relatives been diagnosed with breast cancer? (please tick one answer) 
e. Yes (please go to question 15)  
f. No (please go to question 16)  
 
15. If you answered yes, we need some more specific information about how the relative with 
a breast cancer diagnosis is related to you. Please complete the table below as best you 
can identifying which relatives were diagnosed with breast cancer, at what age and if this 
cancer was present in both breasts? If you cannot remember how old your family member 
was at diagnosis please estimate to the nearest decade. For example, if she was about 53 
years old enter 50 years, if she was about 58 enter 60 years. (please complete for all relatives that 
this applies to) 




At what age? (years) Was this breast 
cancer in both 
breasts? 
(yes/no) 
Mother    
Father    
Sister(s) 









   
   
Brother(s)    
   
Paternal Grandmother 
(father’s mother) 
   
Maternal Grandmother 
(mother’s mother) 
   
Paternal aunt(s) (father’s 
sister) 
Please use a new line for 
each aunt 
   
   






   
Maternal aunt(s) 
(mother’s sister) 




   
   
   
   
Daughter(s) 




   
   
   
   
For the below relatives please provide detail on your family linkage.   
Please use a new line for 





   
   
   
   
Please use a new line for 





   
   
   
   
Please use a new line for 





   
   
   
   
   
 
16. Have you or anyone in your family been genetically tested for BRCA1 or BRCA2 genes? 
(please tick one answer) 
d. Yes (please go to question 17)  
e. No (please go to question 18) 
Please only tick this if you are certain 







17.  If you know the results, please indicate them below. Please remember, we are only 
interested in your blood relatives. 
 
Family Member Negative result BRCA1 positive BRCA2 positive 
You    
Father    
Mother    
Sister(s) 
Please use a new line for 
each sister 
 
   
   
   
Daughter(s) 
Please use a new line for 
each daughter 
 
   
   
   
Paternal Grandmother 
(father’s mother) 
   
Maternal Grandmother 
(mother’s mother) 
   
Paternal aunt (father’s sister)    
   
   
   
Maternal aunt (mother’s 
sister) 
   
   
   
   
 
 
18. Have any of your relatives been diagnosed with ovarian cancer? (please tick one answer) 
a. Yes (please go to question 19) 











19. If you answered yes, we need some more specific information about how the person with 
the diagnosis is related to you. Please complete the table below as best you can identifying 
which relatives were diagnosed with ovarian cancer and at what age. If you cannot 
remember how old your family member was at diagnosis please estimate to the nearest 
decade for example, if she was about 53 years old enter 50 years, if she was about 58 
enter 60 years.  (please complete for all relatives that this applies) 
For this questionnaire, we’re only interested in blood relatives (not people related to 
you by marriage). 
Family Member  Diagnosed with 
ovarian cancer? 
(yes/no) 
At what age?  
(years) 
Mother   
Sister(s) 






Paternal Grandmother (your 
fathers mother) 
  












Maternal aunt(s) (your mothers 
sister) 

















For the below relatives please provide detail on your family linkage.  






















Knowledge, attitudes and behaviour  
The questions asked in this section are based on previous research which indicates that a 
woman’s knowledge, attitudes and behaviour towards screening might influence her 
participation in screening. Please remember we are not testing you and your answers will not 
affect any healthcare you are receiving. 
This part of the questionnaire is asking about your current knowledge and perceptions about 
breast screening. You will not be judged by right or wrong answers. 
To help you complete the next part of the questionnaire, a ‘mammogram’ is the term used 
for the x-ray taken during the breast screening appointment. 
20. What do you think population screening programme is used for? (please tick one answer) 
h. To test what is wrong with unhealthy people 
i. To identify increased risk of disease in apparently healthy people 
j. To determine who requires treatment and who does not 
k. Don’t know 
 
21. What do you think the population breast screening programme is for? (please tick one answer) 
d. Detects if cancer is present in those who have a lump in their breast 
e. Checks for signs of breast cancer in healthy women 
f. Both a and b 






22. Do you believe every woman with a ‘positive’ mammogram result has breast cancer? 
(please tick one answer) 
d. Yes 
e. No 
f. Don’t know 
 
23. What do you think it means if a woman receives a ‘negative’ mammogram result? (please 
tick one answer)  
e. She will not get cancer in the future 
f. The mammogram did not work 
g. To the best of the screener’s knowledge, she does not have cancer that can be 
detected at the moment but it may still be present 
h. She does not have cancer 
i. Don’t know 
 
24. Which groups do you believe have the highest rates of breast cancer? (please tick one answer) 
d. Women who attend screening 
e. Women who do not attend screening 
f. Don’t know 
 
25. Some women are diagnosed with a breast cancer that never would have caused her 
harm. For every one women who has her life saved from breast cancer how many 
women are believed to be overdiagnosed with a cancer that would never have become 





k. Other _________ (please specify) 






26. Do you think there are negative consequences of breast screening? (please tick one answer) 
d. Yes – there are negative consequences (please go to question 27) 
e. No – there are no negative consequences (please go to question 28) 
f. Don’t know 









29. Out of 100 women aged 50 or over who are invited to screening in the UK each year, 
how many do you think have further tests but later find out they do not have cancer? 






m. 11 or more 
n. Don’t know 




31. Do you think there is a legal requirement to attend breast screening? (please tick one answer) 
d. Yes  
e. No 




The following questions are about views and experience of mammograms 
For the following statements below please circle a number from 1 to 5 on the scale that best 
describes how you feel at the moment. Please read the scale for each question. 
For example in the first part if you thought having the screening test would be very useful, 
you would circle 5. If you thought it was a worthless thing you would circle 1. If you did not 
have a strong opinion either way you would circle 3. 
 
32. Even if you have not had a mammogram before please answer how you feel about the 
idea of having one.  
For me, having a mammogram for breast cancer will be: 
Worthless 1 2 3 4 5 Useful 
Beneficial to 
health 
1 2 3 4 5 Harmful to 
health 
Not necessary 1 2 3 4 5 Essential 
Will be a good 
thing 
1 2 3 4 5 Will be a bad 
thing 




1 2 3 4 5 Easy to access 
Something I 
feel I have to 
do 
1 2 3 4 5 Something I 
don’t feel I 
have to do 
 
33. Have you ever had a mammogram? (please tick one answer) 
e. Yes (please go to question 35) 
f. No (please got to question 34) 
 
34. Why did you not attend?  
a. Inconvenient time 
b. Inconvenient location 
c. I don’t want to be screened 
d.  I’m embarrassed or shy 










36. Have you ever done the following? (please tick all that apply) 
e. Delayed or re-scheduled a breast screening appointment 
f. Permanently withdrawn from the breast screening programme 
g. None of the above 
 
 
37. Please circle the statement you agree with most for the following statements: 
 
If you have had a mammogram before please complete this question answering “For 
me, when I have a mammogram I feel…” 
 
If you have not had a mammogram before, please complete this question answering 










































38. In the next five years, how likely do you think it is that you will be diagnosed with breast 






1 2 3 4 5 6 7 Very 
likely 
 
39. How likely do you think it is that you will develop breast cancer (or breast cancer will 




1 2 3 4 5 6 7 Very 
likely 
         
Personal Characteristics 
This section will be asking some questions about you. This is so that we can recognise which 
group of the population you belong to. Remember this questionnaire is anonymous and your 
answers cannot be linked back to you in any way so please be as accurate as you can. 
40. What is your year of birth? __ __ __ __  (YYYY)  
 
41. What is the first part of your postcode? __ __ __ __    
 
42. How would you describe your ethnicity? (please tick one answer) 
aa. White British 
bb. White Other 
cc. White and Black Caribbean 
dd. White and Black African 













43. How would you describe yourself?  (please tick one answer) 
f. Single 
g. Cohabiting with partner 
h. Married or civil partnered 
i. Divorced 
j. Widowed 
k. In a relationship, not cohabiting 
 
44. How would you describe your living arrangements? (please tick one answer) 
i. Own outright 
j. Bought with a mortgage or other loan 
k. Pay part rent part mortgage (shared ownership)  
l. Renting 
m. Living rent free 
n. Squatting 
o. Homeless 
p. Contribute to expenses in someone else’s house  
(For example living in parent’s or friend’s house) 
 
45. What is the highest level of education you have completed? (please tick one answer) 
e. University 
f. Intermediate between secondary level and university  
(e.g. technical training or college) 
g. Secondary school 











46. How would you describe your current employment status? (please tick all that apply) 
g. Full time work (35 hours or more every seven days) 
h. Part time work (less than 35 hours every seven days) 
i. Self-employed 
j. In education full time 
k. In education part time 
l. Permanently unable to work due to long-term sickness or disability 
m. Retired completely 
n. Working intermittently 
o. Looking after home and/or family 
p. Never had work or been employed 
q. Other (please specify) _____________________ 
 
47. How much does your household take home each year after tax? Your household is 















i. Up to £15,000  
j. £15,001 to £25,000  
k. £25,001 to £35,000  
l. £35,001 to £45,000  
m. £45,001 to £55,000  
n. More than £55,001  
o. Prefer not to say  




48. Do you suffer from any conditions or illnesses in any of the following areas? The 
following are examples only and are not the only conditions we are interested in. (please 
tick all that apply) 
l. Vision (e.g. blindness or partial sight that cannot be corrected by reading glasses)   
m. Hearing (e.g. deafness or partial hearing)  
n. Mobility (e.g. walking short distances or climbing stairs)  
o. Dexterity (e.g. lifting and carrying objects or using a computer)  
p. Learning or understanding or concentrating  
q. Memory   
r. Mental health (e.g. depression, schizophrenia or anxiety)  
s. Stamina or breathing or fatigue  
t. Socially or behaviourally (e.g. autism, attention deficit disorder or Asperger’s 
syndrome) 
 
u. Other (please specify) _________________  
v. Would prefer not to say  
 
49. In what areas do the conditions you mentioned before affect you? (please tick all that apply) 
 
a. Home life 
b. Work life 
c. Daily activities 
d. Social life 











Thank you for taking the time to complete 
this questionnaire and send it back to us, 
it is really appreciated and your answers 
will be very useful for our research. 
 
Please return this questionnaire to: 
Farmhouse 
University of Warwick 
Coventry 
CV4 7AJ 
 
 
 
 
 
 
 
